

A P P L I C A T I O N

for

UNITED STATES LETTERS PATENT

on

COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINES

By

Lin Yu

Qing Dong

Fabrice Pierre

Edcon Chang

Henk Lang

Yong Qin

Yunfeng Fang

Mark Hansen

Maurizio Pellecchia

Sheets of Drawings: 22

Docket No: P-TB 4648

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER: EL 856980209 US

DATE OF DEPOSIT: February 21, 2002

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER
37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE, AND IS
ADDRESSED TO: COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231.

KIMBERLY J. PRIOR
(TYPED OR PRINTED NAME OR PERSON MAILING PAPER OR FEE)

Kimberly J. Prior
(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Attorneys

CAMPBELL & FLORES LLP

4370 La Jolla Village Drive, Suite 700

San Diego, California 92122

USPTO CUSTOMER NO. 23601

20020221 686T800T

COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINESBACKGROUND OF THE INVENTIONFIELD OF THE INVENTION

5 The present invention relates generally to
receptor/ligand interactions and to combinatorial
libraries of ligand compounds. The present invention
also relates to the manufacture of thiazolidinediones and
rhodanines and combinatorial libraries containing such
compounds.

BACKGROUND INFORMATION

10 Two general approaches have traditionally been
used for drug discovery: screening for lead compounds and
structure-based drug design. Both of these approaches
are laborious and time-consuming and often produce
15 compounds that lack the desired affinity or specificity.

20 Screening for lead compounds involves
generating a pool of candidate compounds, often using
combinatorial chemistry approaches in which compounds are
synthesized by combining chemical groups to generate a
large number of diverse candidate compounds that bind to
the target or that inhibit binding to the target. The
candidate compounds are screened with a drug target of
interest to identify lead compounds that bind to the

target or inhibit binding to the target. However, the screening process to identify a lead compound can be laborious and time consuming.

Structure-based drug design is an alternative approach to identifying drug candidates. Structure-based drug design uses three-dimensional structural data of the drug target as a template to model compounds that bind to the drug target and alter its activity. The compounds identified as potential drug candidates using structural modeling are used as lead compounds for the development of drug candidates that exhibit a desired activity toward the drug target.

Identifying compounds using structure-based drug design can be advantageous when compared to the screening approach in that modifications to the compound can often be predicted by modeling studies. However, obtaining structures of relevant drug targets and of drug targets complexed with test compounds is extremely time-consuming and laborious, often taking years to accomplish. The long time period required to obtain structural information useful for developing drug candidates is particularly limiting with regard to the growing number of newly discovered genes, which are potential drug targets, identified in genomics studies.

Despite the time-consuming and laborious nature of these approaches to drug discovery, both screening for lead compounds and structure-based drug design have led to the identification of a number of useful drugs, such

20250922 10081989 023402

as receptor agonists and antagonists. However, many of the drugs identified by these approaches have unwanted toxicity or side effects. Therefore, there is a need in the art for drugs that have high specificity and reduced toxicity. For example, in addition to binding to the drug target in a pathogenic organism or cancer cell, in some cases the drug also binds to an analogous protein in the patient being treated with the drug, which can result in toxic or unwanted side effects. Therefore, drugs that have high affinity and specificity for a target are particularly useful because administration of a more specific drug at lower dosages will minimize toxicity and side effects.

In addition to drug toxicity and side effects, a number of drugs that were previously highly effective for treating certain diseases have become less effective during prolonged clinical use due to the development of resistance. Drug resistance has become increasingly problematic, particularly with regard to administration of antibiotics. A number of pathogenic organisms have become resistant to several drugs due to prolonged clinical use and, in some cases, have become almost totally resistant to currently available drugs. Furthermore, certain types of cancer develop resistance to cancer therapeutic agents. Therefore, drugs that are refractile to the development of resistance would be particularly desirable for treatment of a variety of diseases.

10081989-022102

One approach to developing such drugs is to find compounds that bind to a target protein such as a receptor or enzyme. When such a target protein has two adjacent binding sites, it is especially useful to find "bi-ligand" drugs that can bind at both sites simultaneously. However, the rapid identification of bi-ligand drugs having the optimum combination of affinity and specificity has been difficult. Bi-ligand drug candidates have been identified using rational drug design, but previous methods are time-consuming and require a precise knowledge of structural features of the receptor. Recent advances in nuclear magnetic spectroscopy (NMR) have allowed the determination of the three-dimensional interactions between a ligand and a receptor in a few instances. However, these efforts have been limited by the size of the receptor and can take years to map and analyze the complete structure of the complexes of receptor and ligand.

Thus, there exists a need for compounds that bind to multiple members of a receptor family. There is also a need for receptor bi-ligands containing such compounds coupled to ligands having a high specificity for the receptor.

There is a further need in the art for methods of preparing such compounds and bi-ligands. There is also a need in the art for methods of preparing combinatorial libraries of the bi-ligands and methods of screening these libraries to find bi-ligands that interact with a drug target with improved affinity and/or


specificity. The present invention satisfies these needs and provides related advantages as well.

SUMMARY OF THE INVENTION

The present invention provides compounds that function as mimics to a natural common ligand for a receptor family. These compounds interact with a conserved binding site on multiple receptors within the receptor family.

In one aspect, the present invention provides compounds that are common ligand mimics for NAD. NAD is a natural common ligand for many oxidoreductases. Thus, compounds of the invention that are common ligand mimics for NAD interact selectively with conserved sites on oxidoreductases.


In one embodiment, the present invention provides compounds of Formula I,



wherein R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOalkyl, CONR₁₀R₁₁, C(O)R₁₂, OH, Oalkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂,


5

10'



15

20



5 wherein R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR₁₀R₁₁, OH, OAlkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂, SO₂NR₁₀R₁₁, S(O)₂R₁₂, NH₂, NHR₁₂, NR₁₀R₁₁, NHCOR₁₂, NR₁₀COR₁₂, N₃, NO₂, PH₃, PH₂R₁₂, H₂PO₄, H₂PO₃, H₂PO₂, HPO₄R₁₂, PO₂R₁₁R₁₂, CN, or X. R_{10} , R_{11} ,
10 and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together with the nitrogen to which they are attached can be joined to form a heterocyclic ring.

In a second aspect, the present invention
15 provides methods for preparing compounds of Formula I. These methods generally comprise two steps. In the first step of each method, a furaldehyde intermediate is formed. In the second step, the furaldehyde intermediate is reacted either with 2,4-thiazolidinedione to form a
20 compound of Formula II or with rhodanine to form a compound of Formula III.

In a third aspect, the present invention provides bi-ligands containing a common ligand mimic and a specificity ligand which interact with distinct sites
25 on a receptor. In one embodiment, the present invention

provides bi-ligands that are the reaction products of compounds of Formula I with specificity ligands. In another embodiment, the invention provides bi-ligands containing the reaction products of compounds of Formula II with specificity ligands. In yet another embodiment, the invention provides bi-ligands that are reaction products of compounds of Formula III and specificity ligands. In yet another aspect, the invention provides methods for preparing bi-ligands that are reaction products of the common ligand mimics of general Formulas I, II, and III and a pyridine dicarboxylate specificity ligand.

The present invention further provides combinatorial libraries containing one or more common ligand variants of the compounds of the invention. In one embodiment, the combinatorial libraries of the invention contain one or more common ligand variants of the compounds of Formula I. In other embodiments, the combinatorial libraries of the invention contain one or more common ligand variants of the compounds of Formula II or Formula III.

The present invention also provides combinatorial libraries comprised of one or more bi-ligands that are reaction products of common ligand mimics and specificity ligands. In one embodiment, such combinatorial libraries contain one or more bi-ligands that are the reaction product of compounds of Formula I and specificity ligands. In another embodiment, such combinatorial libraries contain one or more bi-ligands

that are the reaction product of compounds of Formula II and specificity ligands. In still another embodiment, such combinatorial libraries contain one or more bi-ligands that are the reaction product of compounds of Formula III and specificity ligands.

The present invention also provides methods for producing and screening combinatorial libraries of bi-ligands for binding to a receptor and families of such receptors.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows Scheme 1 for the synthesis of thiazolidinedione compounds of Formula II where R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOalkyl, CONR₁₀R₁₁, C(O)R₁₂, OH, Oalkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂, SO₂NR₁₀R₁₁, S(O)₂R₁₂, NH₂, NHR₁₂, NR₁₀R₁₁, NHCOR₁₂, NR₁₀COR₁₂, N₃, NO₂, PH₃, PH₂R₁₂, H₂PO₄, H₂PO₃, H₂PO₂, HPO₄R₁₂, PO₂R₁₁R₁₂, CN, or X. R_{10} , R_{11} , and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together with the nitrogen to which they are attached can be joined to form a heterocyclic ring. The reaction steps are as follows: (a) an aminobenzoic acid and 2-furaldehyde are reacted in the presence of HNO₂ and CuCl₂/CuCl to form a furaldehyde intermediate; (b) the furaldehyde intermediate is reacted with 2,4-thiazolidinedione, while heating, to form the corresponding thiazolidinedione.

Figure 2 shows Scheme 1 for the synthesis of rhodanine compounds of Formula III where R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR₁₀R₁₁, C(O)R₁₂, OH, OAlkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂, SO₂NR₁₀R₁₁, S(O)₂R₁₂, NH₂, NHR₁₂, NR₁₀R₁₁, NHCOR₁₂, NR₁₀COR₁₂, N₃, NO₂, PH₃, PH₂R₁₂, H₂PO₄, H₂PO₃, H₂PO₂, HPO₄R₁₂, PO₂R₁₁R₁₂, CN, or X. R_{10} , R_{11} , and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together with the nitrogen to which they are attached can be joined to form a heterocyclic ring.. The reaction steps are as follows: (a) an aminobenzoic acid and 2-furaldehyde are reacted in the presence of HNO₂ and CuCl₂/CuCl to form a furaldehyde intermediate; (b) the furaldehyde intermediate is reacted with rhodanine, while heating, to form the corresponding rhodanine compound.

Figure 3 shows Scheme 2 for the synthesis of thiazolidinedione compounds of Formula II where R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR₁₀R₁₁, C(O)R₁₂, OH, OAlkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂, SO₂NR₁₀R₁₁, S(O)₂R₁₂, NH₂, NHR₁₂, NR₁₀R₁₁, NHCOR₁₂, NR₁₀COR₁₂, N₃, NO₂, PH₃, PH₂R₁₂, H₂PO₄, H₂PO₃, H₂PO₂, HPO₄R₁₂, PO₂R₁₁R₁₂, CN, or X. R_{10} , R_{11} , and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together with the nitrogen to which they are attached can be joined to form a heterocyclic ring. The reaction steps are as follows: (a) a halobenzoate and 5-trimethylstannanyl-furan-2-carbaldehyde are reacted in the presence of Pd(PPh₃)₄ to form a furaldehyde

intermediate; (b) the furaldehyde intermediate is reacted with 2,4-thiazolidinedione while heating, to form the corresponding thiazolidinedione.

Figure 4 shows Scheme 2 for the synthesis of rhodanine compounds of Formula III where R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR₁₀R₁₁, C(O)R₁₂, OH, OAlkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂, SO₂NR₁₀R₁₁, S(O)₂R₁₂, NH₂, NHR₁₂, NR₁₀R₁₁, NHCOR₁₂, NR₁₀COR₁₂, N₃, NO₂, PH₃, PH₂R₁₂, H₂PO₄, H₂PO₃, H₂PO₂, HPO₄R₁₂, PO₂R₁₁R₁₂, CN, or X. R_{10} , R_{11} , and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together with the nitrogen to which they are attached can be joined to form a heterocyclic ring. The reaction steps are as follows: (a) a halobenzoate and 5-trimethylstannanyl-furan-2-carbaldehyde are reacted in the presence of Pd(PPh₃)₄ to form a furaldehyde intermediate; (b) the furaldehyde intermediate is reacted with rhodanine, while heating, to form the corresponding rhodanine compound.

Figure 5 shows Scheme 3 for the synthesis of thiazolidinedione compounds of Formula II where R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR₁₀R₁₁, C(O)R₁₂, OH, OAlkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂, SO₂NR₁₀R₁₁, S(O)₂R₁₂, NH₂, NHR₁₂, NR₁₀R₁₁, NHCOR₁₂, NR₁₀COR₁₂, N₃, NO₂, PH₃, PH₂R₁₂, H₂PO₄, H₂PO₃, H₂PO₂, HPO₄R₁₂, PO₂R₁₁R₁₂, CN, or X. R_{10} , R_{11} , and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together

with the nitrogen to which they are attached can be joined to form a heterocyclic ring. The reaction steps are as follows: (a) a halofuraldehyde and phenylboronic acid are reacted in the presence of $\text{Pd}(\text{PPh}_3)_4$ to form a furaldehyde intermediate; (b) the furaldehyde intermediate is reacted with 2,4-thiazolidinedione, while heating, to form the corresponding thiazolidinedione.

Figure 6 shows Scheme 3 for the synthesis of rhodanine compounds of Formula III where R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH , COOAlkyl , $\text{CONR}_{10}\text{R}_{11}$, $\text{C}(\text{O})\text{R}_{12}$, OH , OAlkyl , OAc , SH , SR_{12} , SO_3H , $\text{S}(\text{O})\text{R}_{12}$, $\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{S}(\text{O})_2\text{R}_{12}$, NH_2 , NHR_{12} , $\text{NR}_{10}\text{R}_{11}$, NHCOR_{12} , $\text{NR}_{10}\text{COR}_{12}$, N_3 , NO_2 , PH_3 , PH_2R_{12} , H_2PO_4 , H_2PO_3 , H_2PO_2 , $\text{HPO}_4\text{R}_{12}$, $\text{PO}_2\text{R}_{11}\text{R}_{12}$, CN , or X . R_{10} , R_{11} , and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together with the nitrogen to which they are attached can be joined to form a heterocyclic ring. The reaction steps are as follows: (a) a halofuraldehyde and phenylboronic acid are reacted in the presence of $\text{Pd}(\text{PPh}_3)_4$ to form a furaldehyde intermediate; (b) the furaldehyde intermediate is reacted with rhodanine, while heating, to form the corresponding rhodanine compound.

Figure 7 shows Scheme 4 for modification of substituents attached to the common ligand mimics of the invention.

Figure 8 shows Scheme 5 for modification of substituents attached to the common ligand mimics of the invention.

Figure 9 shows Scheme 6 for modification of substituents attached to the common ligand mimics of the invention.

Figure 10 shows Scheme 7 for the preparation of common ligand mimics of the present invention containing linker molecules.

Figure 11 shows Scheme 8 for the preparation of common ligand mimics of the present invention containing linker molecules.

Figures 12a-c show various reaction schemes by which combinatorial libraries of the present invention can be made. Figure 12a shows the reaction scheme for reaction of common ligand mimics of the present invention having a carboxylic acid group with an amine in the presence of hydroxybenzotriazole (HOBt). Figure 12b shows the reaction of common ligand mimics of the invention having an amine terminal amide substituent with a carboxylic acid in the presence of HOBt. Figure 12c shows the reaction scheme for reaction of common ligand mimics of the invention having an amine terminal amide substituent with an isocyanate or thioisocyanate.

Figure 13 shows a reaction scheme by which combinatorial libraries of the present invention can be made employing amines. The reaction steps are as follows: (a) reacting a halopyridine with a thiol in the presence of DBU under microwave irradiation to form a thiopyridine; (b) reacting the thiopyridine with LiOH to free the acid group; (c) adding diverse elements to the resulting acid through formation of an amide bond, catalyzed by HOBt resin; (d) treating the amide with TFA in DCE to remove the Boc-protecting group; and (e) reacting the pyridine derivative with a common ligand mimic of the invention to yield bi-ligand libraries of the invention.

Figure 14 shows a reaction scheme by which combinatorial libraries of the present invention can be made employing alkyl halides. The reaction steps are as follows: (a) mixing 4-mercaptobenzoic acid and an alkylhalide in CH_3CN ; (b) adding Et_3N resin to the mixture; (c) reacting the product of step (b) with HOBt resin; and (d) adding a common ligand mimic of the present invention.

Figure 15 shows Scheme 9 for the synthesis of bi-ligands containing thiazolidinedione common ligand mimics and pyridine dicarboxylate specificity ligands.

Figure 16 shows the results of an oxidoreductase enzymatic panel study of selected thiazolidinedione compounds of the invention.

Figure 17 shows the results of an enzymatic panel study of selected thiazolidinedione compounds of the invention.

Figure 18 shows the results of an
5 oxidoreductase assay of selected bi-ligands of the invention.

Figures 19a-c show the names and corresponding structures for exemplified thiazolidinedione and rhodanine common ligand mimics of the invention.

10 Figure 20 shows examples of bi-ligands of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to bi-ligands and the development of combinatorial libraries associated
15 with these bi-ligands. The invention can be used advantageously to develop bi-ligands that bind to two distinct sites on a receptor, a common site and a specificity site. Tailoring of the two portions of the bi-ligand provides optimal binding characteristics.
20 These optimal binding characteristics provide increased diversity within a library, while simultaneously focusing the library on a particular receptor family or a particular member of a receptor family. The two portions of the bi-ligand, a common ligand mimic and a specificity

10001989-02402

ligand act synergistically to provide higher affinity and/or specificity than either ligand alone.

5 The technology of the present invention can be applied across receptor families or can be used to screen for specific members of a family. For example, the present invention can be used to screen libraries for common ligand mimics that bind to any oxidoreductase. Alternatively, the present invention can be used to screen for a particular oxidoreductase that will bind a particular specificity ligand.

10 The present invention provides common ligand mimics that bind selectively to a conserved site on a receptor. The compounds advantageously can be used to develop combinatorial libraries of bi-ligands more efficiently than conventional methods. The present invention takes advantage of NMR spectroscopy to identify the interactions between the common ligand mimic and the receptor, which allows for improved tailoring of the ligand to the receptor.

20 The present invention also provides bi-ligands containing these common ligand mimics. The bi-ligands of the invention contain a common ligand mimic coupled to a specificity ligand. These bi-ligands provide the ability to tailor the affinity and/or specificity of the ligands to the binding sites on the receptor.

25 The present invention further provides combinatorial libraries containing bi-ligands of the

10081989-0210

invention as well as formation of such libraries from the common ligand mimics of the invention. These libraries provide an enhanced number of bi-ligands that bind multiple members of a receptor family than is provided with standard combinatorial techniques due to specific positioning of the specificity ligand on the common ligand mimic. Optimal positioning of the specificity ligand can be determined through NMR studies of the receptor and the common ligand mimic to be employed.

The present invention also provides methods for the preparation of two categories of common ligand mimics useful in the present invention and methods for the preparation of bi-ligands containing these common ligand mimics. In general, such methods involve formation of a furaldehyde intermediate followed by reaction of the intermediate with 2,4-thiazolidinedione or rhodanine. The present invention also provides methods for modification of the common ligand mimics to form additional common ligand mimics having different bi-ligand directing/binding substituents to yield enhanced specificity and potency. The common ligand mimics can be used to create bi-ligands having improved affinity, improved specificity, or both. These and other aspects of the invention are described below.

The present invention provides common ligand mimics. As used herein, the term "ligand" refers to a molecule that can selectively bind to a receptor. The term "selectively" means that the binding interaction is detectable over non-specific interactions as measured by

10081989 "022102"
a quantifiable assay. A ligand can be essentially any
type of molecule such as an amino acid, peptide,
polypeptide, nucleic acid, carbohydrate, lipid, or small
organic compound. The term ligand refers both to a
5 molecule capable of binding to a receptor and to a
portion of such a molecule, if that portion of a molecule
is capable of binding to a receptor. For example, a bi-
ligand, which contains a common ligand and specificity
ligand, is considered a ligand, as would the common
10 ligand and specificity ligand portions since they can
bind to a conserved site and specificity site,
respectively. As used herein, the term "ligand" excludes
a single atom, for example, a metal atom. Derivatives,
analogues, and mimetic compounds also are included within
15 the definition of this term. These derivatives,
analogues and mimetic compounds include those containing
metals or other inorganic molecules, so long as the metal
or inorganic molecule is covalently attached to the
ligand in such a manner that the dissociation constant of
20 the metal from the ligand is less than 10^{-14} M. A ligand
can be multi-partite, comprising multiple ligands capable
of binding to different sites on one or more receptors,
such as a bi-ligand. The ligand components of a multi-
partite ligand can be joined together directly, for
25 example, through functional groups on the individual
ligand components or can be joined together indirectly,
for example, through an expansion linker.

As used herein, the term "common ligand" refers
to a ligand that binds to a conserved site on receptors
30 in a receptor family. A "natural common ligand" refers

to a ligand that is found in nature and binds to a common site on receptors in a receptor family. As used herein, a "common ligand mimic (CLM)" refers to a common ligand that has structural and/or functional similarities to a natural common ligand but is not naturally occurring. Thus, a common ligand mimic can be a modified natural common ligand, for example, an analogue or derivative of a natural common ligand. A common ligand mimic also can be a synthetic compound or a portion of a synthetic compound that is structurally similar to a natural common ligand.

As used herein, a "common ligand variant" refers to a derivative of a common ligand. A common ligand variant has structural and/or functional similarities to a parent common ligand. A common ligand variant differs from another variant, including the parent common ligand, by at least one atom. For example, as with NAD and NADH, the reduced and oxidized forms differ by an atom and are therefore considered to be variants of each other. A common ligand variant includes reactive forms of a common ligand mimic, such as an anion or cation of the common ligand mimic. As used herein, the term "reactive form" refers to a form of a compound that can react with another compound to form a chemical bond, such as an ionic or covalent bond. For example, where the common ligand mimic is an acid of the form ROOH or an ester of the form ROOR', the common ligand variant can be ROO⁻.

As used herein, the term "conserved site" on a receptor refers to a site that has structural and/or functional characteristics common to members of a receptor family. A conserved site contains amino acid residues sufficient for activity and/or function of the receptor that are accessible to binding of a natural common ligand. For example, the amino acid residues sufficient for activity and/or function of a receptor that is an enzyme can be amino acid residues in a substrate binding site of the enzyme. Also, the conserved site in an enzyme that binds a cofactor or coenzyme can be amino acid residues that bind the cofactor or coenzyme.

As used herein, the term "receptor" refers to a polypeptide that is capable of selectively binding a ligand. The function or activity of a receptor can be enzymatic activity or ligand binding. Receptors can include, for example, enzymes such as kinases, dehydrogenases, oxidoreductases, GTPases, carboxyl transferases, acyl transferases, decarboxylases, transaminases, racemases, methyl transferases, formyl transferases, and α -ketodecarboxylases.

Furthermore, the receptor can be a functional fragment or modified form of the entire polypeptide so long as the receptor exhibits selective binding to a ligand. A functional fragment of a receptor is a fragment exhibiting binding to a common ligand and a specificity ligand. As used herein, the term "enzyme"

refers to a molecule that carries out a catalytic reaction by converting a substrate to a product.

Enzymes can be classified based on Enzyme Commission (EC) nomenclature recommended by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB) (see, for example, www.expasy.ch/sprot/enzyme.html) (which is incorporated herein by reference). For example, oxidoreductases are classified as oxidoreductases acting on the CH-OH group of donors with NAD^+ or NADP^+ as an acceptor (EC 1.1.1); oxidoreductases acting on the aldehyde or oxo group of donors with NAD^+ or NADP^+ as an acceptor (EC 1.2.1); oxidoreductases acting on the CH-CH group of donors with NAD^+ or NADP^+ as an acceptor (EC 1.3.1); oxidoreductases acting on the CH-NH₂ group of donors with NAD^+ or NADP^+ as an acceptor (EC 1.4.1); oxidoreductases acting on the CH-NH group of donors with NAD^+ or NADP^+ as an acceptor (EC 1.5.1); oxidoreductases acting on NADH or NADPH (EC 1.6); and oxidoreductases acting on NADH or NADPH with NAD^+ or NADP^+ as an acceptor (EC 1.6.1).

Additional oxidoreductases include oxidoreductases acting on a sulfur group of donors with NAD^+ or NADP^+ as an acceptor (EC 1.8.1); oxidoreductases acting on diphenols and related substances as donors with NAD^+ or NADP^+ as an acceptor (EC 1.10.1); oxidoreductases acting on hydrogen as donor with NAD^+ or NADP^+ as an acceptor (EC 1.12.1); oxidoreductases acting on paired donors with incorporation of molecular oxygen with NADH

or NADPH as one donor and incorporation of two atoms (EC 1.14.12) and with NADH or NADPH as one donor and incorporation of one atom (EC 1.14.13); oxidoreductases oxidizing metal ions with NAD^+ or NADP^+ as an acceptor (EC 1.16.1); oxidoreductases acting on $-\text{CH}_2$ groups with NAD^+ or NADP^+ as an acceptor (EC 1.17.1); and oxidoreductases acting on reduced ferredoxin as donor, with NAD^+ or NADP^+ as an acceptor (EC 1.18.1).

Enzymes can also bind coenzymes or cofactors such as nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), thiamine pyrophosphate, flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), pyridoxal phosphate, coenzyme A, and tetrahydrofolate or other cofactors or substrates such as ATP, GTP and S-adenosyl methionine (SAM). In addition, enzymes that bind newly identified cofactors or enzymes can also be receptors.

As used herein, the term "receptor family" refers to a group of two or more receptors that share a common, recognizable amino acid motif. A motif in a related family of receptors occurs because certain amino acid residues, or residues having similar chemical characteristics, are required for the structure, function and/or activity of the receptor and are, therefore, conserved between members of the receptor family. Methods of identifying related members of a receptor family are well known to those skilled in the art and include sequence alignment algorithms and identification of conserved patterns or motifs in a group of

polypeptides, which are described in more detail below. Members of a receptor family also can be identified by determination of binding to a common ligand.

In another aspect, the present invention provides bi-ligands that contain a common ligand mimic as described above and a specificity ligand. As used herein, the term "bi-ligand" refers to a ligand comprising two ligands that bind to independent sites on a receptor. One of the ligands of a bi-ligand is a specificity ligand capable of binding to a site that is specific for a given member of a receptor family when joined to a common ligand. The second ligand of a bi-ligand is a common ligand mimic that binds to a conserved site in a receptor family. The common ligand mimic and specificity ligand are bonded together. Bonding of the two ligands can be direct or indirect, such as through a linking molecule or group. A depiction of exemplary bi-ligands is shown in Figure 20.

As used herein the term "specificity" refers to the ability of a ligand to differentially bind to one receptor over another receptor in the same receptor family. The differential binding of a particular ligand to a receptor is measurably higher than the binding of the ligand to at least one other receptor in the same receptor family. A ligand having specificity for a receptor refers to a ligand exhibiting specific binding that is at least two-fold higher for one receptor over another receptor in the same receptor family.

As used herein, the term "specificity ligand" refers to a ligand that binds to a specificity site on a receptor. A specificity ligand can bind to a specificity site as an isolated molecule or can bind to a specificity site when attached to a common ligand, as in a bi-ligand. When a specificity ligand is part of a bi-ligand, the specificity ligand can bind to a specificity site that is proximal to a conserved site on a receptor.


As used herein, the term "specificity site" refers to a site on a receptor that provides the binding site for a ligand exhibiting specificity for a receptor. A specificity site on a receptor imparts molecular properties that distinguish the receptor from other receptors in the same receptor family. For example, if the receptor is an enzyme, the specificity site can be a substrate binding site that distinguishes two members of a receptor family which exhibit substrate specificity. A substrate specificity site can be exploited as a potential binding site for the identification of a ligand that has specificity for one receptor over another member of the same receptor family. A specificity site is distinct from the common ligand binding site in that the natural common ligand does not bind to the specificity site.

As used herein, the term "linker" refers to a chemical group that can be attached to either the common ligand or the specificity ligand of a bi-ligand. The linker provides the functional groups through which the common ligand mimic and specificity ligand are indirectly

bound to one another. The linker can be a simple functional group, such as COOH, NH₂, OH, or the like. Alternatively, the linker can be a complex chemical group containing one or more unsaturation, one or more substituent, and/or one or more heterocyclic atom. Nonlimiting examples of complex linkers are depicted in Tables 6 to 12.

The present invention provides common ligand mimics that are common mimics of NAD and combinatorial libraries containing these common ligand mimics. For example, in one embodiment, compounds of the invention are ligands for conserved sites on dehydrogenases and reductases. Examples of such receptors include, but are not limited to, HMG CoA reductase (HMGCoAR), inosine-5'-monophosphate dehydrogenase (IMPDH), 1-deoxy-D-xylulose-5-phosphate reductase (DOXPR), dihydrodipicolinate reductase (DHPR), dihydrofolate reductase (DHFR), 3-isopropylmalate (IPMDH), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), aldose reductase (AR), alcohol dehydrogenase (ADH), and lactate dehydrogenase (LDH), and enoyl ACP reductase.

The present invention also provides compounds and combinatorial libraries of compounds of the formula:



FORMULA I

5 wherein R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOalkyl, CONR₁₀R₁₁, C(O)R₁₂, OH, Oalkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂, SO₂NR₁₀R₁₁, S(O)₂R₁₂, NH₂, NHR₁₂, NR₁₀R₁₁, NHCOR₁₂, NR₁₀COR₁₂, N₃, NO₂, PH₃, PH₂R₁₂, H₂PO₄, H₂PO₃, H₂PO₂, HPO₄R₁₂, PO₂R₁₁R₁₂,
 10 CN, or X. R_9 is an oxygen, sulfur, or nitrogen atom, where the nitrogen atom can be substituted, e.g. NR₁₂. R_{10} , R_{11} , and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together with the nitrogen to which they are attached can
 15 be joined to form a heterocyclic ring.

As used herein, "alkyl" means a carbon chain having from one to twenty carbon atoms. The alkyl group of the present invention can be straight chain or branched. It can be unsubstituted or can be substituted.
 20 When substituted, the alkyl group can have up to ten substituent groups, such as COOH, COOalkyl, CONR₁₀R₁₁, C(O)R₁₂, OH, Oalkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂, SO₂NR₁₀R₁₁, S(O)₂R₁₂, NH₂, NHR₁₂, NR₁₀R₁₁, NHCOR₁₂, NR₁₀COR₁₂, N₃, NO₂, PH₃, PH₂R₁₂, H₂PO₄, H₂PO₃, H₂PO₂, HPO₄R₁₂, PO₂R₁₁R₁₂,
 25 CN, or X, =O, CR₁₀R₁₁, aryl, heterocycle and the like. In

such instances, R_{10} , R_{11} , and R_{12} each independently can be, for example, hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together with the carbon or nitrogen atom to which they are attached can be joined to form a ring.

Additionally, the alkyl group present in the compounds of the invention, whether substituted or unsubstituted, can have one or more of its carbon atoms replaced by a heterocyclic atom, such as an oxygen, nitrogen, or sulfur atom. For example, alkyl as used herein includes groups such as $(OCH_2CH_2)_n$ or $(OCH_2CH_2CH_2)_n$, where n has a value such that there are twenty or less carbon atoms in the alkyl group. Similar compounds having alkyl groups containing a nitrogen or sulfur atom are also encompassed by the present invention.

As used herein "alkenyl" means an unsaturated alkyl groups as defined above, where the unsaturation is in the form of a double bond. The alkenyl groups of the present invention can have one or more unsaturations. Nonlimiting examples of such groups include $CH=CH_2$, $CH_2CH_2CH=CHCH_2CH_3$, and $CH_2CH=CHCH_3$. As used herein "alkynyl" means an unsaturated alkyl group as defined above, where the unsaturation is in the form of a triple bond. Alkynyl groups of the present invention can include one or more unsaturations. Nonlimiting examples of such groups include $C\equiv CH$, $CH_2CH_2C\equiv CCH_2CH_3$, and $CH_2C\equiv CCH_3$.

The compounds of the present invention can include compounds in which R_1 to R_8 each independently are complex substituents containing one or more unsaturation, one or more substituent, and/or one or more heterocyclic atom. These complex substituents are also referred to herein as "linkers" or "expansion linkers." Nonlimiting examples of complex substituents that can be used in the present invention are presented in Tables 6 to 12.

As used herein, "aromatic group" refers to a group that has a planar ring with $4n+2$ pi-electrons, where n is a positive integer. The term "aryl" as used herein denotes a nonheterocyclic aromatic compound or group. For example, a benzene ring or naphthalene ring.

As used herein, "heterocyclic group" or "heterocycle" refers to an aromatic compound or group containing one or more heterocyclic atom. Nonlimiting examples of heterocyclic atoms that can be present in the heterocyclic groups of the invention include nitrogen, oxygen and sulfur. In general, heterocycles of the present invention will have from five to seven atoms and can be substituted or unsubstituted. When substituted, substituents include, for example, those groups provided for R_1 to R_8 . Nonlimiting examples of heterocyclic groups of the invention include pyrroles, pyrazoles, imidazoles, pyridines, pyrimidines, pyridazines, pyrazines, triazines, furans, oxazoles, thiazoles, thiophenes, diazoles, triazoles, tetrazoles, oxadiazoles, thiodiazoles, and fused heterocyclic rings, for example, indoles, benzofurans, benzothiophenes, benzoimidazoles,

benzodiazoles, benzotriazoles, benzotetrazoles, and quinolines.

As used herein, the variable "X" indicates a halogen atom. Halogens suitable for use in the present invention include chlorine, fluorine, iodine, and bromine, with bromine being particularly useful. As used herein, "Ac" denotes an acyl group. Suitable acyl groups can have, for example, an alkyl, alkenyl, alkynyl, aromatic, or heterocyclic group as defined above attached to the carbonyl group.

The phenyl ring in Formula I can be substituted with one or multiple substituents. Variation in the substitution on the phenyl ring provides compounds that allow for addition of a specificity ligand to directed sites on the phenyl ring. Direction of the specificity ligand improves the ease and efficiency of manufacture of combinatorial libraries containing bi-ligands having the common ligand mimic bound to a specificity ligand.

In one embodiment of the invention, only one of R_1 to R_5 is a substituent other than hydrogen. In such instances, R_1 to R_5 independently can be, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOalkyl, CONR₁₀R₁₁, C(O)R₁₂, OH, Oalkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂, SO₂NR₁₀R₁₁, S(O)₂R₁₂, NH₂, NHR₁₂, NR₁₀R₁₁, NHCOR₁₂, NR₁₀COR₁₂, N₃, NO₂, PH₃, PH₂R₁₂, H₂PO₄, H₂PO₃, H₂PO₂, HPO₄R₁₂, PO₂R₁₁R₁₂, CN, or X, where R₁₀, R₁₁, and R₁₂ are as defined in Formula I. For example, R_1 to R_5 independently can be an amide, a hydroxy group, a thiol group, or an acid group, such as a

carboxylic acid. Additionally, R_1 to R_5 independently can be any of the complex substituents provided in Tables 6 to 12. When compounds of the invention contain an active hydroxy group, they also can be present in the form of an ether or ester, for example, an alkyl ether or alkyl ester. Thus, the invention encompasses compounds in which R_1 to R_5 can be an OAlkyl group or a COOAlkyl group. Non-limiting examples of OAlkyl groups include OMe (OCH_3), OEt (OCH_2CH_3), OPr ($\text{OCH}_2\text{CH}_2\text{CH}_3$), and the like. Non-limiting examples of COOAlkyl groups include COOMe, COOEt, COOPr, COOBu, COO-tBu, and the like.

In another embodiment, two or more of R_1 to R_5 are substituents other than hydrogen. In such instances, the substituent groups can be the same or different. For example, the phenyl ring of the compounds can be substituted with two OAlkyl groups, such as two OMe groups or one OMe group and one OPr group. Alternatively, the phenyl ring of the compounds can be substituted with an OH group and either a COOH or COOAlkyl group. Any combination of the above listed substituents for R_1 to R_5 , including complex substituents such as those in Tables 6 to 12, is contemplated by the present invention. Similarly, where the compounds of the invention contain three or more substituents any combination of R_1 to R_5 is encompassed by the invention.

Similarly, the furan ring in Formula I can be substituted with one or two substituents. In one embodiment of the invention, only one of R_6 or R_7 is a substituent other than hydrogen. In such instances, R_6

or R_7 can be alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, $\text{CONR}_{10}\text{R}_{11}$, $\text{C}(\text{O})\text{R}_{12}$, OH, OAlkyl, OAc, SH, SR_{12} , SO_3H , $\text{S}(\text{O})\text{R}_{12}$, $\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{S}(\text{O})_2\text{R}_{12}$, NH_2 , NHR_{12} , $\text{NR}_{10}\text{R}_{11}$, NHCOR_{12} , $\text{NR}_{10}\text{COR}_{12}$, N_3 , NO_2 , PH_3 , PH_2R_{12} , H_2PO_4 , H_2PO_3 , H_2PO_2 , $\text{HPO}_4\text{R}_{12}$, $\text{PO}_2\text{R}_{11}\text{R}_{12}$, CN, or X, where R_{10} , R_{11} , and R_{12} are as defined in Formula I. When R_6 or R_7 contains an active hydroxy group, it also can be present in the form of an ether or ester, for example, an alkyl ether or alkyl ester. Thus, the invention encompasses compounds in which R_6 and R_7 can be an OAlkyl group or a COOAlkyl group.

In another embodiment, both of R_6 and R_7 are substituents other than hydrogen. In such instances, the substituent groups can be the same or different. Any combination of the above listed substituents for R_6 to R_7 , including complex substituents such as those in Tables 6 to 12, is contemplated by the present invention.


Likewise, the substituent R_8 attached to the carbon atom between the furan and thiazolidinedone rings can be either hydrogen or a substituent other than hydrogen. Where R_8 is a substituent other than hydrogen, it can be alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, $\text{CONR}_{10}\text{R}_{11}$, $\text{C}(\text{O})\text{R}_{12}$, OH, OAlkyl, OAc, SH, SR_{12} , SO_3H , $\text{S}(\text{O})\text{R}_{12}$, $\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{S}(\text{O})_2\text{R}_{12}$, NH_2 , NHR_{12} , $\text{NR}_{10}\text{R}_{11}$, NHCOR_{12} , $\text{NR}_{10}\text{COR}_{12}$, N_3 , NO_2 , PH_3 , PH_2R_{12} , H_2PO_4 , H_2PO_3 , H_2PO_2 , $\text{HPO}_4\text{R}_{12}$, $\text{PO}_2\text{R}_{11}\text{R}_{12}$, CN, or X, where R_{10} , R_{11} , and R_{12} are as defined in Formula I. When R_8 contains an active hydroxy group, it also can be present in the form of an ether or ester, for example, an alkyl ether or alkyl ester. Thus,

the invention encompasses compounds in which R₈ can be an OAlkyl group or a COOAlkyl group. The present invention further encompasses compounds in which R₈ is a complex substituent such as those provided in Tables 6 to 12.

5 In one aspect, the invention provides compounds in which R₁ to R₈ are not all hydrogen. In other words, the invention includes compounds in which at least one of R₁ to R₈ is a substituent other than hydrogen.

10 Compounds having complex substituents are encompassed by the invention. The following formulas are representative of such compounds. In each of the formula, any combination of the variables listed can exist. Nonlimiting examples of thiazolidinedione compounds corresponding to formulas Ia to Ik and IIa to 15 IIk are provided in Tables 6 to 12. However, it is understood that the invention also encompasses corresponding rhodanine compounds in accordance with formulas Ia to Ik and IIIa to IIIk. The compounds represented in Tables 6 to 12 are only examples of 20 compounds of the invention and are not intended to be all-inclusive. One having ordinary skill in the art would readily recognize other compounds within the scope of formula I which are also part of the invention.

25 In one embodiment, the invention provides compounds and combinatorial libraries of compounds having formula Ia




Formula Ia

5 wherein R_9 is O, S, or NR_{12} . R_6 , R_7 , and R_8 each independently are as defined above. D is alkylene, alkenylene, alkynylene, aryl, or heterocycle; Y is OH, NHR_{12} , SR_{12} , $COOH$, SO_2OH , X, CN, $C(O)R_{12}$, N_3 , $CONH_2$, $C\equiv CH$, or $CH=CH_2$; and R_9 is S, O, or NR_{12} . R_{12} is hydrogen,
10 alkyl, alkenyl, alkynyl, aryl, or heterocycle.

As used herein, the terms "alkylene," "alkenylene," and "alkynylene" refer to alkyl, alkenyl, and alkynyl groups as defined above in which one additional atom has been removed such that the group is
15 divalent. Nonlimiting examples of such groups include $-CH_2CH_2CH_2-$, $-CH_2CH=CHCH_2-$, and $-CH_2C\equiv CCH_2-$.


In a second embodiment, the invention provides compounds and combinatorial libraries of compounds having formula Ib



Formula Ib

5 wherein R_9 is O, S, or NR_{12} , and Y is OH, NHR_{12} , SR_{12} , $COOH$, SO_2OH , X, CN, $C(O)R_{12}$, N_3 , $CONH_2$, $CONHR_{12}$, $C\equiv CH$, or $CH=CH_2$. R_{12} is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle. R_6 , R_7 , and R_8 each independently are as defined above.

10 In another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula Ic




Formula Ic

15 wherein R_9 is O, S, or NR_{12} . R_6 , R_7 , and R_8 each independently are as defined above. E is O, S, NR_{12} , $CR_{11}C_{12}$, $CONR_{12}$, SO_2NR_{12} , $NR_{11}CONR_{12}$, $NR_{11}CNHNR_{12}$, $NR_{12}COO$,

$C\equiv C$, or $CH=CH$. Y is OH, NHR_{12} , SH, COOH, SO_2OH , X, CN, $C(O)R_{12}$, N_3 , $CONH_2$, $CONHR_{12}$, $C\equiv CH$, or $CH=CH_2$; and n is an integer between 0 and 5, inclusive. R_{11} and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


In yet another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula Id



Formula Id

wherein R_9 is O, S, or NR_{12} . R_6 , R_7 , and R_8 each independently are as defined above. E and F each independently are O, S, NR_{12} , $CR_{11}C_{12}$, $CONR_{12}$, SO_2NR_{12} , $NR_{11}CONR_{12}$, $NR_{11}CNHNR_{12}$, $NR_{12}COO$, $C\equiv C$, or $CH=CH$. Y is OH, NHR_{12} , SH, COOH, SO_2OH , X, CN, $C(O)R_{12}$, N_3 , $CONH_2$, $CONHR_{12}$, $C\equiv CH$, or $CH=CH_2$; and n is an integer between 0 and 5, inclusive. R_{11} and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


In a further embodiment, the invention provides compounds and combinatorial libraries of compounds having formula Ie



Formula Ie

wherein R_9 is O, S, or NR_{12} . R_6 , R_7 , and R_8 each independently are as defined above. E is O, S, NR_{12} , $CR_{11}C_{12}$, $CONR_{12}$, SO_2NR_{12} , $NR_{11}CONR_{12}$, $NR_{11}CNHNR_{12}$, $NR_{12}COO$, $C\equiv C$, or $CH=CH$. Y is OH, NHR_{12} , SH, COOH, SO_2OH , X, CN, $C(O)R_{12}$, N_3 , $CONH_2$, $CONHR_{12}$, $C\equiv CH$, or $CH=CH_2$; and n is an integer between 0 and 5, inclusive. R, R_{11} , R_{12} , and R_{13} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


In another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula If



Formula If

- 5 wherein R_9 is O, S, or NR_{12} . R_6 , R_7 , and R_8 each independently are as defined above. E and F each independently are O, S, NR_{12} , $CR_{11}C_{12}$, $CONR_{12}$, SO_2NR_{12} , $NR_{11}CONR_{12}$, $NR_{11}CNHNR_{12}$, $NR_{12}COO$, $C\equiv C$, or $CH=CH$. Y is OH, NHR_{12} , SH, COOH, SO_2OH , X, CN, $C(O)R_{12}$, N_3 , $CONH_2$, $CONHR_{12}$, $C\equiv CH$, or $CH=CH_2$; and n is an integer between 0 and 5, inclusive. R_{11} and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.
- 10


- In yet another embodiment, the invention provides compounds and combinatorial libraries of
- 15 compounds having formula Ig



Formula Ig

wherein R_9 is O, S, or NR_{12} . R_6 , R_7 , and R_8 each independently are as defined above. E is O, S, NR_{12} , $CR_{11}C_{12}$, $CONR_{12}$, SO_2NR_{12} , $NR_{11}CONR_{12}$, $NR_{11}CNHNR_{12}$, $NR_{12}COO$, $C\equiv C$, or $CH=CH$. Each F independently is O, S, NR_{12} , $CR_{11}R_{12}$, $CONR_{12}$, $NR_{11}CONR_{12}$, $NR_{11}CNHNR_{12}$, $NR_{12}COO$, $C=C$, or $CH=CH$. Y is OH, NHR_{12} , SH, COOH, SO_2OH , X, CN, $C(O)R_{12}$, N_3 , $CONH_2$, $CONHR_{12}$, $C\equiv CH$, or $CH=CH_2$; and n is an integer between 0 and 5, inclusive. R_{11} and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.

In a further embodiment, the invention provides compounds and combinatorial libraries of compounds having formula Ih




Formula Ih

wherein R_9 is O, S, or NR_{12} . R_6 , R_7 , and R_8 each independently are as defined above. E is O, S, NR_{12} , $CR_{11}C_{12}$, $CONR_{12}$, SO_2NR_{12} , $NR_{11}CONR_{12}$, $NR_{11}CNHNR_{12}$, $NR_{12}COO$, $C\equiv C$, or $CH=CH$. Each F independently is O, S, NR_{12} , $CR_{11}R_{12}$, $CONR_{12}$, $NR_{11}CONR_{12}$, $NR_{11}CNHNR_{12}$, $NR_{12}COO$, $C=C$, or $CH=CH$. Y is OH, NHR_{12} , SH, COOH, SO_2OH , X, CN, $C(O)R_{12}$, N_3 , $CONH_2$, $CONHR_{12}$, $C\equiv CH$, or $CH=CH_2$; and n is an integer

between 0 and 5, inclusive. R_{11} and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


In another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula Ii



Formula Ii

wherein E is CH_2 , $\text{CH}_2\text{CH}_2\text{OCH}$, or $\text{CH}_2\text{CH}_2\text{SCH}$ and n is an integer between 1 and 10, inclusive. In certain embodiments of the invention, when n is greater than 4, E is $\text{CH}_2\text{CH}_2\text{OCH}$ or $\text{CH}_2\text{CH}_2\text{SCH}$. R_9 is O, S, or NR_{12} . R_6 , R_7 , and R_8 each independently are as defined above.


In another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula Ij



Formula Ij

5 wherein E is CH₂, CH₂CH₂OCH, or CH₂CH₂SCH and n is an integer between 1 and 10, inclusive. In certain embodiments of the invention, when n is greater than 4, E is CH₂CH₂OCH or CH₂CH₂SCH. R₉ is O, S, or NR₁₂. R₆, R₇, and R₈ each independently are as defined above.


10 In another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula Ik



Formula Ik

15 wherein R₆, R₇, and R₈ each independently are as defined above.

In one aspect, the invention provides compounds and combinatorial libraries of compounds having the formula




FORMULA II

wherein R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOalkyl, CONR₁₀R₁₁, C(O)R₁₂, OH, Oalkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂, SO₂NR₁₀R₁₁, S(O)₂R₁₂, NR₁₂, NHR₁₂, NR₁₀R₁₁, NHCOR₁₂, NR₁₀COR₁₂, N₃, NO₂, PH₃, PH₂R₁₂, H₂PO₄, H₂PO₃, H₂PO₂, HPO₄R₁₂, PO₂R₁₁R₁₂, CN, or X. R_{10} , R_{11} , and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together with the nitrogen to which they are attached can be joined to form a heterocyclic ring. Such compounds include all manner of combinations for R_1 to R_8 as discussed above with regard to compounds of Formula I. Exemplified compounds of this formula include, but are not limited to, 4-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]benzoic acid; 3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]benzoic acid; 5-[5-(4-hydroxy-phenyl)-furan-2-ylmethylene]-thiazolidine-2,4-dione; 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-

benzoic acid methyl ester; 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoic acid; N-{3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]phenyl}acetamide; and 5-[5-(3,4-dimethoxy-phenyl)-furan-2-ylmethylene]-thiazolidine-2,4-dione.

In one embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIa


10



Formula IIa

wherein D is alkylene, alkenylene, alkynylene, aryl, or heterocycle, and Y is OH, NHR_{12} , SH, COOH, SO_2OH , X, CN, N_3 , CONH_2 , CONHR_{12} , $\text{C}\equiv\text{CH}$, or $\text{CH}=\text{CH}_2$. R_{12} is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


In a second embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIb



Formula IIb

wherein Y is OH, NHR_{12} , SH, COOH , SO_2OH , X, CN, N_3 , CONH_2 , CONHR_{12} , $\text{C}\equiv\text{CH}$, or $\text{CH}=\text{CH}_2$. R_{12} is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


In another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIc



Formula IIc

wherein E is O, S, NR_{12} , $\text{CR}_{11}\text{C}_{12}$, CONR_{12} , $\text{SO}_2\text{NR}_{12}$, $\text{NR}_{11}\text{CONR}_{12}$, $\text{NR}_{11}\text{CNHNR}_{12}$, NR_{12}COO , $\text{C}\equiv\text{C}$, or $\text{CH}=\text{CH}$. Y is OH, NHR_{12} , SH, COOH , SO_2OH , X, CN, N_3 , CONH_2 , CONHR_{12} , $\text{C}\equiv\text{CH}$, or $\text{CH}=\text{CH}_2$;


In yet another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIId



10

15

In a further embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIe



In another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula II_f




Formula IIf

wherein E and F each independently are O, S, NR₁₂, CR₁₁C₁₂, CONR₁₂, SO₂NR₁₂, NR₁₁CONR₁₂, NR₁₁CNHNr₁₂, NR₁₂COO, C≡C, or

CH=CH. Y is OH, NHR₁₂, SH, COOH, SO₂OH, X, CN, N₃, CONH₂, CONHR₁₂, C≡CH, or CH=CH₂; and n is an integer between 0 and 5, inclusive. R₁₁ and R₁₂ each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


5 In yet another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIg



10 Formula IIg

wherein E is O, S, NR₁₂, CR₁₁C₁₂, CONR₁₂, SO₂NR₁₂, NR₁₁CONR₁₂, NR₁₁CNHNHNR₁₂, NR₁₂COO, C=C, or CH=CH. Each F independently is O, S, NR₁₂, CR₁₁R₁₂, CONR₁₂, NR₁₁CONR₁₂, NR₁₁CNHNHNR₁₂,
 15 NR₁₂COO, C=C, or CH=CH. Y is OH, NHR₁₂, SH, COOH, SO₂OH, X, CN, N₃, CONH₂, CONHR₁₂, C≡CH, or CH=CH₂; and n is an integer between 0 and 5, inclusive. R₁₁ and R₁₂ each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


20 In a further embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIh



Formula IIh

5 wherein E is O, S, NR₁₂, CR₁₁C₁₂, CONR₁₂, SO₂NR₁₂, NR₁₁CONR₁₂,
 NR₁₁CNHNHNR₁₂, NR₁₂COO, C≡C, or CH=CH. Each F independently
 is O, S, NR₁₂, CR₁₁R₁₂, CONR₁₂, NR₁₁CONR₁₂, NR₁₁CNHNHNR₁₂,
 NR₁₂COO, C=C, or CH=CH. Y is OH, NHR₁₂, SH, COOH, SO₂OH,
 X, CN, N₃, CONH₂, CONHR₁₂, C≡CH, or CH=CH₂; and n is an
 10 integer between 0 and 5, inclusive. R₁₁ and R₁₂ each
 independently are hydrogen, alkyl, alkenyl, alkynyl,
 aryl, or heterocycle.


In another embodiment, the invention provides
 compounds and combinatorial libraries of compounds having
 15 formula IIIi



Formula IIIi

wherein E is CH_2 , $\text{CH}_2\text{CH}_2\text{OCH}$, or $\text{CH}_2\text{CH}_2\text{SCH}$ and n is an integer between 1 and 10, inclusive. In certain embodiments of the invention, when n is greater than 4, E is $\text{CH}_2\text{CH}_2\text{OCH}$ or $\text{CH}_2\text{CH}_2\text{SCH}$.


5 In another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIj



10 Formula IIj

wherein E is CH_2 , $\text{CH}_2\text{CH}_2\text{OCH}$, or $\text{CH}_2\text{CH}_2\text{SCH}$ and n is an integer between 1 and 10, inclusive. In certain embodiments of the invention, when n is greater than 4, E is $\text{CH}_2\text{CH}_2\text{OCH}$ or $\text{CH}_2\text{CH}_2\text{SCH}$.


15 In another embodiment, invention provides compounds and combinatorial libraries of compounds having formula IIk



Formula IIk

5

In another aspect, the invention provides




FORMULA III

- 10 wherein R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH , COOalkyl , $\text{CONR}_{10}\text{R}_{11}$, C(O)R_{12} , OH , Oalkyl , OAc , SH , SR_{12} , SO_3H , S(O)R_{12} , $\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{S(O)}_2\text{R}_{12}$, NH_2 , NHR_{12} , $\text{NR}_{10}\text{R}_{11}$, NHCOR_{12} , NO_2 , PH_3 , PH_2R_{12} , H_2PO_4 , H_2PO_3 , H_2PO_2 , $\text{HPO}_4\text{R}_{12}$, $\text{PO}_2\text{R}_{11}\text{R}_{12}$, CN , or X .
- 15 R_{10} , R_{11} , and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together with the nitrogen to which they are attached can be joined to form a heterocyclic ring. Such compounds include all manner of combinations for R_1 to R_8 as
- 20 discussed above with regard to compounds of Formula I. Exemplified compounds of this formula include, but are

not limited to, 4-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]benzoic acid; 3-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]benzoic acid; 5-[5-(4-hydroxy-phenyl)-furan-2-ylmethylene]-2-thioxo-thiazolidin-4-one; 2-hydroxy-5-[5-(4-oxo-2-thioxo-thiazolidine-5-ylidenemethyl)-furan-2-yl]-2-benzoic acid methyl ester; 2-hydroxy-5-[5-(4-oxo-2-thioxo-thiazolidine-5-ylidenemethyl)-furan-2-yl]-2-benzoic acid; N-{3-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]phenyl}acetamide; and 5-[5-(3,4-dimethoxy-phenyl)-furan-2-ylmethylene]-2-thioxo-thiazolidin-4-one.


In one embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIIa



Formula IIIa

wherein D is alkylene, alkenylene, alkynylene, aryl, or heterocycle; and Y is OH, NHR_{12} , SH, COOH, SO_2OH , X, CN, N_3 , CONH_2 , $\text{C}\equiv\text{CH}$, or $\text{CH}=\text{CH}_2$. R_{12} is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


In a second embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIIb



Formula IIIb

wherein, and Y is OH, NHR_{12} , SH, COOH, SO_2OH , X, CN, N_3 , CONH_2 , CONHR_{12} , $\text{C}\equiv\text{CH}$, or $\text{CH}=\text{CH}_2$. R_{12} is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle


In another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIIc



Formula IIIc

wherein E is O, S, NR₁₂, CR₁₁C₁₂, CONR₁₂, SO₂NR₁₂, NR₁₁CONR₁₂, NR₁₁CNHNHNR₁₂, NR₁₂COO, C≡C, or CH=CH. Y is OH, NHR₁₂, SH, COOH, SO₂OH, X, CN, N₃, CONH₂, CONHR₁₂, C≡CH, or CH=CH₂; and n is an integer between 0 and 5, inclusive. R₁₁ and R₁₂ each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


In yet another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIIId



Formula IIIId

wherein E and F each independently are O, S, NR₁₂, CR₁₁C₁₂, CONR₁₂, SO₂NR₁₂, NR₁₁CONR₁₂, NR₁₁CNHNHNR₁₂, NR₁₂COO, C≡C, or CH=CH. Y is OH, NHR₁₂, SH, COOH, SO₂OH, X, CN, N₃, CONH₂, CONHR₁₂, C≡CH, or CH=CH₂; and n is an integer between 0 and 5, inclusive. R₁₁ and R₁₂ each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


In a further embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIIe



Formula IIIe

5 wherein E is O, S, NR₁₂, CR₁₁C₁₂, CONR₁₂, SO₂NR₁₂, NR₁₁CONR₁₂,
 NR₁₁CNHNHNR₁₂, NR₁₂COO, C≡C, or CH=CH. Y is OH, NHR₁₂, SH,
 COOH, SO₂OH, X, CN, N₃, CONH₂, CONHR₁₂, C≡CH, or CH=CH₂;
 and n is an integer between 0 and 5, inclusive. R, R₁₁,
 R₁₂, and R₁₃ each independently are hydrogen, alkyl,
 10 alkenyl, alkynyl, aryl, or heterocycle.

In another embodiment, the invention provides
 compounds and combinatorial libraries of compounds having
 formula IIIf




Formula IIIf

15 wherein E and F each independently are O, S, NR₁₂, CR₁₁C₁₂,
 CONR₁₂, SO₂NR₁₂, NR₁₁CONR₁₂, NR₁₁CNHNHNR₁₂, NR₁₂COO, C≡C, or

CH=CH. Y is OH, NHR₁₂, SH, COOH, SO₂OH, X, CN, N₃, CONH₂, CONHR₁₂, C≡CH, or CH=CH₂; and n is an integer between 0 and 5, inclusive. R₁₁ and R₁₂ each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


5 In yet another embodiment, invention provides compounds and combinatorial libraries of compounds having formula IIIg



10 Formula IIIg

wherein E is O, S, NR₁₂, CR₁₁C₁₂, CONR₁₂, SO₂NR₁₂, NR₁₁CONR₁₂, NR₁₁CNHNHNR₁₂, NR₁₂COO, C=C, or CH=CH. Each F independently is O, S, NR₁₂, CR₁₁R₁₂, CONR₁₂, NR₁₁CONR₁₂, NR₁₁CNHNHNR₁₂,
 15 NR₁₂COO, C=C, or CH=CH. Y is OH, NHR₁₂, SH, COOH, SO₂OH, X, CN, N₃, CONH₂, CONHR₁₂, C≡CH, or CH=CH₂; and n is an integer between 0 and 5, inclusive. R₁₁ and R₁₂ each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle.


20 In a further embodiment, invention provides compounds and combinatorial libraries of compounds having formula IIIh



Formula IIIh

5 wherein E is O, S, NR₁₂, CR₁₁C₁₂, CONR₁₂, SO₂NR₁₂, NR₁₁CONR₁₂,
 NR₁₁CNHNHNR₁₂, NR₁₂COO, C≡C, or CH=CH. Each F independently
 is O, S, NR₁₂, CR₁₁R₁₂, CONR₁₂, NR₁₁CONR₁₂, NR₁₁CNHNHNR₁₂,
 NR₁₂COO, C=C, or CH=CH. Y is OH, NHR₁₂, SH, COOH, SO₂OH,
 X, CN, N₃, CONH₂, CONHR₁₂, C≡CH, or CH=CH₂; and n is an
 10 integer between 0 and 5, inclusive. R₁₁ and R₁₂ each
 independently are hydrogen, alkyl, alkenyl, alkynyl,
 aryl, or heterocycle.


In another embodiment, the invention provides
 compounds and combinatorial libraries of compounds having
 15 formula IIIi



Formula IIIi

wherein E is CH_2 , $\text{CH}_2\text{CH}_2\text{OCH}$, or $\text{CH}_2\text{CH}_2\text{SCH}$ and n is an integer between 1 and 10, inclusive. In certain embodiments, when n is greater than 4, E is $\text{CH}_2\text{CH}_2\text{OCH}$ or $\text{CH}_2\text{CH}_2\text{SCH}$.


5 In another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIIj



10 Formula IIIj

wherein E is CH_2 , $\text{CH}_2\text{CH}_2\text{OCH}$, or $\text{CH}_2\text{CH}_2\text{SCH}$ and n is an integer between 1 and 10, inclusive. In certain embodiments, when n is greater than 4, E is $\text{CH}_2\text{CH}_2\text{OCH}$ or $\text{CH}_2\text{CH}_2\text{SCH}$.

15 In another embodiment, the invention provides compounds and combinatorial libraries of compounds having formula IIIk



Formula IIIk

5 One or more of the compounds of the invention,
 even within a given library, can be present as a salt.
 The term "salt" encompasses those salts that form within
 the carboxylate anions and amine nitrogens and includes
 salts formed with the organic and inorganic anions and
 10 cations discussed below. Furthermore, the term includes
 salts that form by standard acid-based reactions with
 basic groups (such as amino groups) and organic or
 inorganic acids. Such acids include, hydrochloric,
 hydrofluoric, trifluoroacetic, sulfuric, phosphoric,
 15 acetic, succinic, citric, lactic, maleic, fumaric,
 glutaric, phthalic, tartaric, lauric, stearic,
 salicyclic, methanesulfonic, benzenesulfonic, sorbic,
 picric, benzoic, cinnamic, and like acids.

The term "organic or inorganic cation" refers
 20 to counter-ions for the carboxylate anion of a
 carboxylate salt. The counter-ions are chosen from the
 sodium, potassium, barium, aluminum, and calcium);
 ammonium and organic cations, such as mono-, di-, and
 tri-alkyl amines. Examples of suitable alkyl amines
 25 include, but are not limited to, trimethylamine,

201220-022102

cyclohexylamine, dibenzylamine, bis(2-hydroxyethyl)
amine, and the like. See for example "Pharmaceutical
Salts," Berge et al., *J. Pharm. Sci.*, 66:1-19 (1977),
which is incorporated herein by reference. Other cations
5 encompassed by the above term include the protonated form
of procaine, quinine, and N-methylglucosamine, and the
protonated forms of basic amino acids such as glycine,
ornithine, histidine, phenylglycine, lysine, and
arginine. Furthermore, any zwitterionic form of the
10 instant compounds formed by a carboxylic acid and an
amino group is referred to by this term. For example, a
cation for a carboxylate anion will exist when a position
is substituted by a (quarternary ammonium)methyl group.

The compounds of the invention can also exist
15 as solvates and hydrates. Thus, these compounds can
crystallize with, for example, waters of hydration, or
one, a number of, or any fraction thereof, of molecules
of the mother liquor solvent. The solvates and hydrates
of such compounds are included within the scope of this
20 invention.

One or more compounds of the invention, even
when in a library, can be in the biologically active
ester form. Such as the non-toxic, metabolically-labile,
ester-form. Such esters induce increased blood levels
25 and prolong efficacy of the corresponding nonesterified
forms of the compounds. Ester groups which can be used
include the lower alkoxymethyl groups, for example,
methoxymethyl, ethoxymethyl, isopropoxymethyl and the
like; the $-(C_1-C_{12})$ alkoxyethyl groups, for example,

methoxyethyl, ethoxyethyl, propoxyethyl, isopropoxyethyl and the like; the $-(C_1-C_{10})$ alkylthiomethyl groups, for example, methylthiomethyl, ethylthiomethyl, isopropylmethyl and the like; and the acyloxymethyl groups, for example, pivaloyloxymethyl, pivaloyloxyethyl, acetoxymethyl, and acetoxyethyl. Salts, solvates, hydrates, biologically active esters of the compounds of the invention are common ligand variants of the compounds as defined above.


10 In another aspect, the present invention provides bi-ligands that contain a common ligand mimic as described above and a specificity ligand. In the bi-ligands of the invention, the common ligand mimic and the specificity ligand can be attached directly or
15 indirectly. The common ligand mimic and specificity ligand are attached via a covalent bond formed from the reaction of one or more functional groups on the common ligand mimic with one or more functional groups on the specificity ligand. Direct attachment of the individual
20 ligands in the bi-ligand can occur through reaction of simple functional groups on the ligands. Indirect attachment of the individual ligands in the bi-ligand can occur through a linker molecule. Such linkers include those provided in Tables 6 to 12. These linkers bind to
25 each of the common ligand mimic and the specificity ligand through functional groups on the linker and the individual ligands. Some of the common ligand mimics of the present invention having substituents which include linker molecules, e.g. the common ligand mimics of Tables
30 6 to 12. Tailoring of the specific type and length of

20081989 "022102

the linker attaching the common ligand mimic and
specificity ligand allows tailoring of the bi-ligand to
optimize binding of the common ligand mimic to a
conservative site on the receptor and binding of the
5 specificity ligand to a specificity site on the receptor.

The present invention provides specificity
ligands that are specific for NAD receptors and
combinatorial libraries containing these specificity
ligands. For example, in one embodiment, compounds of
10 the invention are ligands for specificity sites on
dehydrogenases and reductases like those described above.

In another embodiment of the present invention,
the specificity ligand is a compound having formula



FORMULA IV

Specificity ligands, such as that of Formula IV can also
20 exist as salts, or in other reactive forms.

Bi-ligands of the invention can be bi-ligands for any receptor. In one embodiment, the bi-ligand is a bi-ligand that binds an oxidoreductase. In another embodiment, bi-ligands of the present invention comprise a thiazolidinedione or rhodanine compound as a common ligand mimic and a specificity ligand. For example, bi-ligands of the invention can contain a common ligand mimic of Formula I coupled to a specificity ligand. Alternatively, bi-ligands of the invention can contain a common ligand mimic of Formula II or Formula III coupled to a specificity ligand. The specificity ligand can be any specificity ligand, for example a ligand that binds to a specificity site on an oxidoreductase. In such an embodiment, the specificity ligand can be a pyridine dicarboxylate. Examples of particular bi-ligands that fall within the invention are provided in Figure 20.

The compounds of the present invention can be produced by any feasible method. For example, the compounds of the present invention can be produced by the following methods. Generally, these methods include the formation of an intermediate compound, followed by reaction of the intermediate with either 2,4-thiazolidinedione or rhodanine to form the final product.

The invention provides several methods for preparation of intermediates of the invention. Tailoring of each of these methods to produce a particular compound within the scope of the invention is within the level of skill of the ordinary artisan.

In one aspect, as shown in Figures 1 and 2, the present invention provides a method for the manufacture of an intermediate compound by reaction with 2-furaldehyde. For example, furanyl benzoic acid derivatives, such as 4-(5-formyl-furan-2-yl)-benzoic acid or 3-(5-formyl-furan-2-yl)-benzoic acid, can be prepared by this method.

Where the intermediate is a furanyl benzoic acid, the method provides reaction of an aminobenzoic acid, such as 4-aminobenzoic acid or 3-aminobenzoic acid, with a 2-furaldehyde in water or in acetone. The reaction is conducted in the presence of nitrous acid and a copper catalyst. In one embodiment, the nitrous acid is formed *in situ* from the reaction of HCl, such as 12M HCl, and a nitrate, such as sodium nitrate (NaNO_2). In such an embodiment, the HCl can be mixed with the aminobenzoic acid initially to form a suspension. This reaction is exothermic, and, thus, the suspension can be cooled to maintain a desirable reaction temperature. Once the suspension is cooled, for example, to a temperature of about 1°C , a solution of NaNO_2 in water can be added to the suspension in small amounts so that the temperature of the suspension is maintained, for example at a temperature of between about 5°C and 10°C .

The copper catalyst employed in the reaction can be, for example, a $\text{CuCl}_2/\text{CuCl}$ catalyst. In one embodiment, $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ in water is added to the aminobenzoic acid/HCl suspension, followed by addition of a solution of 2-furaldehyde in acetone. The 2-

furaldehyde can be pre-cooled, for instance by placing it in an ice bath, prior to addition to the suspension.

CuCl is then added to the mixture in small portions, resulting in foaming of the mixture and precipitation of the desired intermediate compound. The CuCl can be added in small amounts over a period of time. For instance, the CuCl can be added over a period of time of about 10 to 60 minutes, for example, over a period of about 10 minutes. Because this reaction is exothermic, it is advantageous, but not necessary, to maintain the reaction mixture in an ice bath to control the reaction temperature.

The reaction mixture can be removed from the ice bath, and the internal temperature of the mixture allowed to rise. Additional amounts of CuCl can be added to the mixture. The mixture is then stirred at room temperature of a period of time, such as about 10 to 20 hours, for example, about 16 hours.

The resulting brown precipitate can then be filtered, washed with water, and dried. The product can be dried by conventional methods. For example, drying conveniently can be accomplished through lyophilization of the washed precipitate. The furaldehyde intermediate produced by this method can be used in subsequent reactions without further purification. However, if desired, purification can be carried out by any conventional means, for example, by recrystallization in ethanol.

In one embodiment of the invention, 4-aminobenzoic acid is employed in the present method to produce the compound 4-(5-formyl-furan-2-yl)benzoic acid which can subsequently be employed in the methods of the invention to form 4-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]benzoic acid or 4-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]benzoic acid. Examples 1 and 8 further describe preparation of these compounds.

In another embodiment, 3-aminobenzoic acid is employed in the present process to produce the compound 4(5-formyl-furan-2-yl)benzoic acid which can subsequently be employed in the methods of the invention to form 3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]benzoic acid or 3-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]benzoic acid. Examples 2 and 9 further describe preparation of these compounds.

In another embodiment, this method of the invention can be employed to form additional intermediate compounds by reacting additional starting materials with 2-furaldehyde. One example of another group of intermediate compounds that can be formed by this method is furan-2-carbaldehydes. For example, when 4-hydroxybenzoic acid is employed as the starting material in the method, 5-(4-hydroxy-phenyl)-furan-2-carbaldehyde is produced. This intermediate can subsequently be employed to form 5-[5-(4-hydroxy-phenyl)-furan-2-ylmethylene]-thiazolidine-2,4-dione or 5-[5-(4-hydroxy-phenyl)-furan-2-ylmethylene]-2-thioxo-thiazolidin-4-one.

Examples 3 and 10 further describe preparation of these compounds.

In another aspect, as shown in Figures 3 and 4, the present invention provides a method for the manufacture of methyl ester intermediates. In this method, a benzene derivative, such as a halobenzene, is reacted with 5-trimethylstannanyl-furan-2-carbaldehyde in the presence of tetrakis(triphenylphosphine)palladium ($\text{Pd}(\text{PPh}_3)_4$) in a solvent under an inert atmosphere. Suitable halobenzenes include, for example, bromobenzenes and iodobenzenes, such as 4-bromobenzoate. Suitable solvents for use in the reaction include, but are not limited to, tetrahydrofuran, dimethylformamide, dimethyl ether, and dioxane. For example, the reaction can be performed in dimethylformamide (DMF) under a nitrogen (N_2) atmosphere. The reaction mixture is heated to a temperature of between about 50 and 100°C for a period of time of about 4 to 40 hours. For example, the reaction mixture can be heated to a temperature of about 60°C for a period of about 30 hours.

The solution is then dried, for example, by evaporating under reduced pressure. If desired, the intermediate compound then can be purified by chromatography. Examples 4 and 11 further describe preparation of these compounds.

The 5-trimethylstannanyl-furan-2-carbaldehyde used in the above method can be prepared by any known method. In one embodiment of the present invention, this

compound also can be prepared according to the following method.

A solution of 4-methylpiperidine in a solvent, such as THF, is formed at temperature of about -60 to about -100°C under an inert atmosphere. For instance, the solution can be formed at a temperature of about -78°C under a nitrogen atmosphere. Butyl lithium (BuLi) in hexane is then added to the solution, followed by the addition of 2-furaldehyde.

While maintaining the reaction temperature, another portion of BuLi is added to the reaction mixture. The mixture is then allowed to warm to a temperature of about -10 to -40°C and stirred for a period of about 1 to 10 hours. For example, the reaction mixture can be warmed to a temperature of about -20°C and stirred for a period of about 5 hours.

The reaction mixture is then cooled again to a temperature of about -60 to -100°C, for example -78°C, and added to a solution of Me_3SnCl in the same solvent.

The reaction mixture is then allowed to warm gradually to room temperature and stirred overnight.

The reaction is then quenched, for example, by adding cold brine or cold water, followed by extraction with ethyl acetate or dichloromethane. The extracted organic phase then can be dried and concentrated using conventional methods. If desired, the product can be purified by chromatography or by any other suitable

means. This process for the manufacture of 5-trimethylstannanyl-furan-2-carbaldehyde is further described in Examples 4 and 11.

In an additional aspect, as shown in Figures 5 and 6, the present invention provides a method for the manufacture of intermediate compounds from a bromofuraldehyde and a phenylboronic acid. In accordance with this method, the bromofuraldehyde and the phenylboronic acid are mixed with tetrakis(triphenylphosphine)palladium, a salt, dioxane, and deionized water. Suitable salts for use in this reaction include, but are not limited to, sodium carbonate, potassium carbonate, and sodium bicarbonate. The solution is then deoxygenated, for example, with nitrogen. Following deoxygenation, the mixture is heated to a temperature of about 50 to 100°C for a period of about 4 to 24 hours. For instance, the mixture can be heated to a temperature of about 90°C for a period of about 10 hours.

The reaction mixture is then cooled to room temperature. The product then can be recovered by pouring the reaction mixture onto a silica gel column and eluting with a mixture of ethyl acetate and hexane.

In one embodiment, 4-bromofuraldehyde and 3-acetamidophenylboronic acid are employed in the present method to produce the compound N-[3-(5-formyl-furan-2-yl)phenyl]acetamide which can subsequently be employed in the methods of the invention to form N-{3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]phenyl}acetamide

In another embodiment, 3,4-dimethoxyphenyl-
boronic acid and 5-bromo-2-furaldehyde are employed in
the present method to produce the compound 5-(3,4-
dimethoxyphenyl)-2-furaldehyde which can subsequently be
employed in the methods of the invention to form 5-[5-
(3,4-dimethoxy-phenyl)-furan-2-ylmethylene]-thiazolidine-
2,4-dione or 5-[5-(3,4-dimethoxy-phenyl)furan-2-
ylmethylene]-2-thioxo-thiazolidin-4-one. Examples 7 and
13 further describe preparation of these compounds.

20 Such compounds can be formed by reacting the intermediate compound with 2,4-thiazolidinedione in a solvent, such as ethanol. The intermediate compound can be used in its crude form or can be purified, as by chromatography, prior to its use.

25 Piperidine is added to the mixture, and the resulting suspension is heated to a temperature of about

50 to 100°C, while stirring, for a period of about 1 to 12 hours. For example, the suspension can be heated to a temperature of about 70°C for a period of about 5 hours.

10081989-022102
The mixture is then cooled with ice, resulting
5 in formation of a yellow precipitate. The precipitate
can be filtered and washed, for example, with ethyl
acetate and ether. To remove any residual piperidine,
the crude product can be suspended in aqueous HCl and
placed in an ultrasound bath for a period of about 10
10 minutes. The resulting product can be filtered and dried
in a conventional manner, for example, by lyophilization.
Examples 1 through 7 further describe preparation of
thiazolidinedione compounds.

In another aspect, as shown in Figures 8 to 13,
15 the present invention provides methods for the
preparation of rhodanine compounds.

Such compounds can be formed by reacting an
intermediate compound formed by the methods of the
invention described above with rhodanine in a solvent,
20 such as ethanol. It may be desirable to perform this
reaction in the presence of a catalyst, for example,
piperidine. The mixture can be stirred, under microwave
irradiation, for a period of time of about 60 to 1000
seconds at a temperature of about 50 to 200°C. For
25 instance, the mixture can be stirred for a period of time
of about 300 seconds at 160°C, while stirring under
microwave irradiation.


The reaction mixture is then cooled to room temperature, forming the product as a precipitate. The precipitate can be filtered, washed, for example, with ethyl acetate and ether, and dried, for example, *in vacuo*. Examples 8 through 13 further describe preparation of rhodanine compounds.

When the intermediate compound formed by the methods of the invention is a benzoic acid methyl ester, it may be desirable to convert the methyl ester to the corresponding benzoic acid. In such instances, the present invention provides a method by which this conversion can occur. The methyl ester intermediate is suspended in a solvent, such as methanol or a methanol/THF mixture. A solution of LiOH in water is then added to the solution. The reaction mixture is stirred at room temperature for a period of time of about 1 to 30 hours. For example, the reaction can be stirred at room temperature for a period of about 20 hours.

The solution is then acidified to a pH of about 1 and quickly extracted. The solution can be acidified, for example, with a solution of citric acid or 2N HCl. Extraction of the product can be accomplished with ethyl acetate or dichloromethane.

The extracted organic layers can then be dried, for example, over MgSO_4 . If desired, the resulting benzoic acid can be filtered and concentrated *in vacuo*. Examples 5 and 12 further describe conversion of benzoic acid methyl esters to the corresponding benzoic acid.

The methods of the present invention now will be described in terms of specific embodiments for the preparation of a compound of formula I



wherein R_1 to R_8 each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR₁₀R₁₁, C(O)R₁₂, OH, OAlkyl, OAc, SH, SR₁₂, SO₃H, S(O)R₁₂, SO₂NR₁₀R₁₁, S(O)₂R₁₂, NH₂, NHR₁₂, NR₁₀R₁₁, NHCOR₁₂, N₃, NO₂, PH₃, PH₂R₁₂, H₂PO₄, H₂PO₃, H₂PO₂, HPO₄R₁₂, PO₂R₁₁R₁₂, CN, or X. R_9 is O, S, or NR₁₂; and R_{10} , R_{11} , and R_{12} each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R_{10} and R_{11} together with the nitrogen to which they are attached can be joined to form a heterocyclic ring. These embodiments exemplify the invention and do not limit the scope of the invention.

In one embodiment, the method involves reacting an aminobenzoic acid, such as 4-aminobenzoic acid or 3-aminobenzoic acid, with a 2-furaldehyde in the presence of nitrous acid and a copper catalyst to form a 5-formyl-furan-2-ylbenzonic acid intermediate. The 5-formyl-furan-2-yl-benzonic acid intermediate then is reacted

with either 2,4-thiazolidinedione or rhodanine to form the corresponding thiazolidinedione or rhodanine derivative.

The nitrous acid employed in the reaction can be formed *in situ* by addition of a nitrate, such as sodium nitrate. The copper catalyst used in the invention can be, for example, a $\text{CuCl}_2/\text{CuCl}$ catalyst. In some embodiments, the reaction mixture is heated to a temperature of about 70°C to about 95°C , for example, to a temperature of about 70°C . Alternatively, the mixture can be heated to about 160°C with irradiation.

In another embodiment, the method of the invention comprises reacting a bromobenzoate, such as 2-hydroxy-5-bromobenzoate, 5-trimethylstannanyl-furan-2-carbaldehyde, and $\text{Pd}(\text{PPh}_3)_4$ in a solvent, such as dimethylformamide, under an inert atmosphere, such as nitrogen, to form a 5-formyl-furan-2-ylbenzonic acid methyl ester intermediate. The 5-formyl-furan-2-ylbenzonic acid methyl ester intermediate formed in the reaction can be used to prepare the thiazolidinedione or rhodanine derivatives without additional manipulation. However, in some instances, it may be desirable to purify the intermediate. In such instances, the intermediate can be purified by chromatography.

The methyl ester intermediate is then heated with either 2,4-thiazolidinedione or rhodanine to form the corresponding thiazolidinedione or rhodanine derivative. The reaction mixture is heated, for example,

to a temperature of about 70°C to about 95°C, more particularly to a temperature of 90°C.

In one embodiment, the 5-trimethylstannanyl-furan-2-carbaldehyde employed in the reaction is formed by reacting 4-methylpiperidine and 2-furaldehyde in a solvent, such as tetrahydrofuran, under an inert atmosphere, such as nitrogen, in the presence of BuLi at a temperature of about -60 to -100°C. The mixture is stirred while allowing it to warm to a temperature of about -10 to -40°C. Then, the reaction mixture is cooled again to a temperature of about -60 to -100°C, followed by addition of a solution of Me₃SnCl and by warming of the reaction temperature under agitation. Next, the reaction is quenched with cold brine, and the 5-trimethylstannanyl-furan-2-carbaldehyde is extracted in the organic phase with EtOAc and, optionally, is dried.

The 5-trimethylstannanyl-furan-2-carbaldehyde can be used in the method of the invention without additional manipulation. However, in some instances, it may be desirable to purify the compound prior to use. In such instances, the 5-trimethylstannanyl-furan-2-carbaldehyde can be purified by, for example, chromatography.

In another embodiment, the method of the invention comprises reacting a bromobenzoate, such as 2-hydroxy-5-bromobenzoate, 5-trimethylstannanyl-furan-2-carbaldehyde, and Pd(PPh₃)₄ in a solvent, such as methanol or a mixture of methanol and tetrahydrofuran, under an

inert atmosphere, such as nitrogen, to form a 5-formyl-furan-2-ylbenzonic acid methyl ester intermediate. The 5-formyl-furan-2-ylbenzonic acid methyl ester intermediate formed in the reaction can be used to
5 prepare the thiazolidinedione or rhodanine derivatives without additional manipulation. However, in some instances, it may be desirable to purify the intermediate. In such instances, the intermediate can be purified by chromatography.

10 The 5-formyl-furan-2-ylbenzonic acid methyl ester intermediate is heated with either 2,4-thiazolidinedione or rhodanine to form the corresponding thiazolidinedione or rhodanine derivative. This derivative is then suspended in a solution of LiOH in a
15 solvent. The suspension is stirred for a period of about 2 to 40 hours, and the pH of the mixture is adjusted to about pH 1, followed by extraction of the product with EtOAc. The product optionally is dried over MgSO_4 . If desired, the final thiazolidinedione methyl ester or
20 rhodanine methyl ester can be purified prior to conversion to the corresponding benzoic acid.

In yet another embodiment, the method of the invention comprises forming a mixture 4-bromofuraldehyde, a phenylboronic acid, such as 3-acetamidophenylboronic
25 acid or 3,4-dimethoxy-phenylboronic acid, and $\text{Pd}(\text{PPh}_3)_4$ in the presence of dioxane, D.I. water, and sodium carbonate.

The mixture is then deoxygenated, for example with N₂, and heated for a period of about 5 to 12 hours to form a furaldehyde intermediate compound. The reaction mixture is then cooled to room temperature and poured over a silica gel column from which the furaldehyde intermediate compound is eluted, for example, with a 1:1 mixture of EtoAc/Hexane. The furaldehyde intermediate is then heated, for example, to a temperature of about 50 to 100°C with either 2,4-thiazolidinedione or rhodanine to form the corresponding thiazolidinedione or rhodanine derivative.

Any of the thiazolidinedione or rhodanine compounds of the present invention can be made by the methods described above. Where it is necessary to add or modify substituents attached to the compounds, for example substituents on the phenyl or furan rings of the present invention, such modification are within the level of skill of an ordinary artisan in view of the present disclosure.

Common ligand mimics of the present invention containing linkers can be prepared from less complex common ligand mimics of the invention by conventional methods. These common ligand mimics can also be prepared by the following methods.

As shown in Figure 7, a common ligand mimic of the present invention containing a carboxylic acid group is dissolved in a solvent, such as dimethylformamide or tetrahydrofuran. The compound is then reacted with 1,1'-

carbonyldiimidazole in tetrahydrofuran at a temperature of about 40 to 80°C, for example, 40 to 50°C. The reaction mixture is agitated for a period of time of about 20 to 120 minutes, for example 20 minutes.

5 The mixture is then covered and refrigerated for a period of time at a temperature of about -20 to 10°C. For example the reaction mixture can be refrigerated overnight at a temperature of about -10°C. The precipitate can then be collected by filtration and
10 washed with THF to form an intermediate compound.

 The intermediate compound is then placed in a mixture of DMF and THF. Boc protected diamines (t-butyl carbamate protected diamines) are added to the mixture, and the mixture is heated to a temperature of about 40 to
15 80°C for a period of about 1 to 5 hours, followed by evaporation of the solvent, for example, under reduced pressure. For example, the mixture can be heated at a temperature of about 65°C for a period of about 1 hour.

 Next, a solution of 50% trifluoroacetic acid in
20 dichloroethane (100 ml) is added to the precipitate and reacted for a period of about 10 to 40 minutes, followed by evaporation of the remaining solvent. For example, the mixture can be reacted for a period of about 10 minutes, followed by evaporation of extra solvent. The
25 precipitate can then be dissolved in a solvent, such as DMF, by heating. The solution is cooled to room temperature, and a Na₂CO₃ solution added. When a precipitate forms, it is filtered. If necessary,

20220929 10:03:19

additional solvent and water can be added. The final product can then be washed with a mixture of water and alcohol, such as water and MeOH, and then dried. This method is described further in Example 19.

5 As shown in Figure 8, common ligand mimics of the invention also can be prepared by the following method. The compounds 4-bromophenethylamine and NaHCO_3 are suspended in aqueous acetone at a temperature of about -10 to 10°C , for example 0°C . A solution of di-
10 tert-butyldicarbonate acetone then is added dropwise to the solution, which is stirred at room temperature for a period of time. For example, the solution can be stirred overnight at room temperature.

15 The reaction then can be poured into water and extracted with ethyl acetate. The extracts then can be dried by conventional means, for example with MgSO_4 , and concentrated to provide a powder of an intermediate compound.

20 Next, a mixture of the intermediate product, 5-trimethylstannanyl-2-furaldehyde, and tetrakis(triphenylphosphine)palladium is formed in a solvent, such as DMF. The mixture is then heated to a temperature of about 50 to 90°C for a period of about 20 to 30 hours. For example, the mixture can be heated to a
25 temperature of about 60°C for a period of about 24 hours. The reaction mixture then is concentrated under reduce pressure, and the residue purified by chromatography, for

example using an extractant of EtOAc/Hexanes to provide an intermediate furaldehyde.

5 A solution of the intermediate furaldehyde, 2,4-thiazolidinedione, and ethanolamine is formed in a solvent, such as dioxane. The solution is then heated to reflux for a period of about 2 to 3 days. For example, the solution can be heated to reflux for a period of about 3 days. The reaction mixture is concentrated, and the resulting residue triturated several times with ethyl acetate. The precipitate is then collected by filtration to provide the desired common ligand mimic. This method is further described in Example 20.

As shown in Figure 9, common ligand mimics of the invention can also be prepared by the following method. The compounds 2-formylfuran-5-boronic acid, 5-bromonicotinic acid, and sodium carbonate (262 mg, 2.48 mmol) are added to a mixture of solvent and water, for example a mixture of dioxane, water, ethanol, and DMF. Dichlorobis(triphenylphosphine)palladium is added to the mixture, and the mixture heated to a temperature of about 80 to 100°C for a period of about 12 to 18 hours. For example, the mixture can be heated to a temperature of about 90°C for a period of about 15 hours. Another portion of dichlorobis(triphenyl-phosphine)palladium and 2-formylfuran-5-boronic acid can be added to the reaction mixture, if necessary, and the reaction again stirred, for example overnight at room temperature.

Volatiles then were removed *in vacuo*, and the residue diluted with water, followed by extraction with ethyl acetate. Combined organic layers then can be dried by conventional methods, for example over Mg_2SO_4 , followed by filtration and concentration *in vacuo*. The crude product can be purified by flash chromatography, for example with a $\text{CH}_2\text{Cl}_2/\text{MeOH}$ mixture, to provide an intermediate nicotinic acid.

The intermediate nicotinic acid and 2,4-thiazolidinedione then are mixed in ethanol. Piperidine is added dropwise, and the reaction mixture stirred at a temperature of about 60 to 80°C for a period of about 1 to 6 hours. For example, 1 to 5 drops of piperidine can be added, and the reaction stirred at a temperature of about 70°C for a period of about 36 hours.

The resulting precipitate can be collected on filter paper using a Büchner funnel and washed with ethyl acetate, followed by ethyl ether to give the desired product. This method is further described in Examples 21 and 22.

Bi-ligands of the present invention can be produced by any feasible method. For example, the compounds of the present invention can be produced by the following methods. These methods are exemplified using a common ligand mimic or Formula I and a pyridine dicarboxylate specificity ligand. However, one having ordinary skill in the art will appreciate that variations in such methods can be employed to produce bi-ligands

having other common ligand mimics or other specificity ligands.

As shown in Figure 15, a common ligand mimic of the invention, such as a thiazolidinedione or rhodanine compound of Formula I can be reacted in the presence of HOBT·H₂O. Suitable solvents include dimethylformamide, tetrahydrofuran, and dichloromethane. For example, the reaction of 4-(2-amino-ethylsulfanyl)-pyridine-2,6-dicarboxylic acid dimethyl ester can be performed in dimethylformamide with the addition of (HOBT·H₂O). Triethylamine and 1-dimethylaminopropyl-3-ethylcarbodiimide (EDCI) are then added to the mixture. The reaction is then stirred at room temperature for a period of about 2 to 40 hours. For example, the reaction can be stirred at room temperature for a period of about 24 hours.

The reaction precipitate is collected and washed in a mixture of solvent, hydrochloric acid, and methanol. Then, the recovered solid can be suspended in a mixture of alcohol, base, and water, such as a methanol, LiOH, and water mixture. This solution is stirred at room temperature for a period of about 1 to 24 hours until it is homogenous. The solution is then acidified, for example with citric acid or aqueous 2N HCl. The resulting precipitated product can then be filtered, washed with water, and dried.

As used herein, a "combinatorial library" is an intentionally created collection of differing molecules

that can be prepared by the means provided below or otherwise and screened for biological activity in a variety of formats (e.g., libraries of soluble molecules, libraries of compounds attached to resin beads, silica chips or other solid supports). A "combinatorial library," as defined above, involves successive rounds of chemical syntheses based on a common starting structure. The combinatorial libraries can be screened in any variety of assays, such as those detailed below as well as others useful for assessing their biological activity. The combinatorial libraries will generally have at least one active compound and are generally prepared such that the compounds are in equimolar quantities.

Compounds described in previous work that are not taught as part of a collection of compounds or not taught as intended for use as part of such a collection are not part of a "combinatorial library" of the invention. In addition, compounds that are in an unintentional or undesired mixture are not part of a "combinatorial library" of the invention.

The present invention provides combinatorial libraries containing two or more compounds. The present invention also provides combinatorial libraries containing three, four, or five or more compounds. The present invention further provides combinatorial libraries that can contain ten or more compounds, for example, fifty or more compounds. If desired, the combinatorial libraries of the invention can contain 100,000 or more, or even 1,000,000 or more, compounds.

In one embodiment, the present invention provides combinatorial libraries containing common ligand variants of compounds of Formula I. These common ligand variants are active forms of the compounds of Formula I that are capable of binding to a specificity ligand to form a bi-ligand. For example, where one of R_1 to R_8 is a COOH or COOAlkyl group, the common ligand variant can be a compound containing the group COO^- . Common ligand variants of the invention include common ligand mimics in which the substituents on the compounds are complex ligands such as those attached to the compounds listed in Tables 6 to 12.

In another embodiment, the present invention provides combinatorial libraries containing bi-ligands of the invention. The bi-ligands are the reaction product of a common ligand mimic and a specificity ligand which interact with distinct sites on a single receptor. For example, the common ligand mimic can be one or more common ligand mimics for NAD which binds to a conserved site on a dehydrogenase, like ADH. In such a bi-ligand, the specificity ligand is one or more ligands which bind a specificity site on ADH.

Such combinatorial libraries can contain bi-ligands having a single common ligand mimic bonded to multiple specificity ligands. Alternatively, the combinatorial libraries can contain bi-ligands having a single specificity ligand bonded to multiple common ligand mimics. In another aspect, the combinatorial

libraries can contain multiple common ligand mimics and multiple specificity ligands for one or more receptors.

The use of a common ligand mimic of the invention to produce the combinatorial library allows generation of combinatorial libraries having improved affinity and/or specificity. Selection and tailoring of the substituents on the common ligand mimic also allows for production of combinatorial libraries in a more efficient manner than heretofore possible.

Bi-ligand libraries of the invention can be prepared in a variety of different ways. For example, two methods employing a resin, such as HOBt resin, carbodiimide resin, or DIEA (diisopropyl-diisamine) resin, can be used to form bi-ligand libraries. In one such method, bi-ligand libraries can be prepared via direct coupling of amines to common ligand mimics of the invention having a carboxylic acid group.

As shown in Figure 12a, bi-ligand libraries can be prepared in the following manner. HOBt resin is swelled in a dry solvent, such as a mixture of dry THF and dry DMF, and added to a solution of a common ligand mimic of the invention that is dissolved in a solvent, such as a mixture of DMF and DIC. The solution is shaken at room temperature overnight and then washed with 3x dry DMF and 3x dry THF. The resin is added to a solution of an amine in a solvent, for example dry DMF. The mixture is shaken again at room temperature overnight. The resin then can be filtered and washed with solvent, and the

filtrate can be collected and vacuum dried to provide bi-ligands of the invention. Nonlimiting examples of amines useful for the preparation of bi-ligand libraries include those in Table 1.

5

TABLE 1

cyclopropylamine	nipecotamide	3-chloro-p-anisidine
isopropylamine	1-(3-aminopropyl)pyrrolidine	5-amino-1-naphthol
N,N-diethyl-N'-methylethylenediamine	2-(2-aminoethyl)-1-methylpyrrolidine	2-amino-5,6-dimethyl-benzimidazole
N-(3-aminopropyl)-N-methylaniline	2-(aminomethyl)-1-ethylpyrrolidine	N,N-diethyl-p-phenylenediamine
hydroxylamine hydrochloride	N-(2-aminoethyl)-piperidine	1-(2-pyridyl)piperazine
cyclobutylamine	4-(2-aminoethyl)morpholine	4-pentylaniline
N-methylallylamine	propylamine	pyrrolidine
3-pyrroline	2-(aminomethyl)benzimidazole	1-phenylpiperazine
diethylamine	ethyl 3-aminobutyrate	4-butoxyaniline
isobutylamine	5-aminoindan	2,3-dimethoxybenzylamine
N-butylamine	trans-2-phenylcyclopropylamine	2,4-dimethoxybenzylamine
N-methylpropylamine	3-phenyl-1-propylamine	3,5-dimethoxybenzylamine
sec-butylamine	beta-methylphenethylamine	ethyl 4-aminobutyrate
2-methoxyethylamine	N-methylphenethylamine	1-cyclohexylpiperazine
4-amino-1,2,4-triazole	p-isopropylaniline	4-piperidinopiperidine
cyclopentylamine	3-aminobenzamide	2-amino-5-chlorobenzoxazole
ethyl 4-amino-1-piperidinecarboxylate	N,N-dimethyl-1,4-phenylenediamine	2-amino-5-trifluoromethyl-1,3,4-thiadiazole
morpholine	N-(4-pyridylmethyl)ethylamine	2-aminobiphenyl
1-ethylpropylamine	4-aminobenzamide	3-aminobiphenyl
neopentylamine	3,4-(methylenedioxy)-aniline	N-undecylamine
N-ethylisopropylamine	4-hydroxybenzamide	piperidine
N-methylbutylamine	6-aminonicotinamide	4-cyclohexylaniline
2-amino-1-methoxypropane	4-fluorophenethylamine hydrochloride	2-(trifluoromethyl)benzylamine
3-methoxypropylamine	3-amino-4-methylbenzyl alcohol	2,4-dimethyl-6-aminophenol
thiazolidine	3-methoxybenzylamine	2,4-dichlorobenzylamine

3-amino-1,2,4-triazine	4-ethoxyaniline	3,4-dichlorobenzylamine
furfurylamine	4-methoxy-2-methylaniline	4-aminoquinoline
diallylamine	4-methoxybenzylamine	4-(methylthio)aniline
2-methylpiperidine	m-phenetidine	1-benzylpiperazine
3-methylpiperidine	5-amino-2-methoxyphenol	4-piperidino aniline
4-methylpiperidine	tyramine	4-(trifluoromethoxy)-aniline
cyclohexylamine	2-fluorophenethylamine	4-hexylaniline
hexamethyleneimine	3-fluorophenethylamine	4-amino-2,6-dichlorophenol
1-aminopiperidine	3-(methylthio)aniline	4-morpholinoaniline
2-amino-4-methoxy-6-methylpyrimidine	(3S)-(+)-1-benzyl-3-aminopyrrolidine	N-(2-aminoethyl)-N-ethyl-m-toluidine
tetrahydrofurfurylamine	1-methylpiperazine	4-chlorobenzylamine
1,3-dimethylbutylamine	3,3,5-trimethylcyclohexylamine	1-(2-furoyl)piperazine
dipropylamine	2-chlorobenzylamine	1-(2-fluorophenyl)piperazine
4-aminomorpholine	3-chlorobenzylamine	1-(4-fluorophenyl)piperazine
N-(3'-aminopropyl)-2-pyrrolidinone	4-aminophenylacetic acid ethyl ester	2-(3,4-dimethoxyphenyl)ethylamine
3-dimethylaminopropylamine	N-acetylenediamine	2-amino-fluorene
N-isopropylethylenediamine	2,4-difluorobenzylamine	3,4,5-trimethoxyaniline
o-toluidine	N-phenyl-p-phenylenediamine	4-aminodiphenylmethane
1-aminonaphthalene	2,6-difluorobenzylamine	aminodiphenylmethane
5-amino-1-pentanol	3,4-difluorobenzylamine	2,5-difluorobenzylamine
3-ethoxypropylamine	2-(aminomethyl)-1,3-dioxolane	3-phenoxyaniline
3-(methylthio)propylamine	2-aminonaphthalene	4-phenoxyaniline
benzylamine	p-phenetidine hydrochloride	1-(3-chlorophenyl)piperazine
m-toluidine	8-aminoquinoline	4-amino-1-benzylpiperidine
3-fluoroaniline	N-(3-aminopropyl)morpholine	4-aminohippuric acid
p-toluidine	7-amino-4-methylcoumarin	2-amino-9-fluorenone
1-amino-5,6,7,8-tetrahydronaphthalene	4-piperidone monohydrate hydrochloride	2-methyl-1-(3-methylphenyl)piperazine
2-(aminomethyl)pyridine	2-amino-1-methylbenzimidazole	3,4,5-trimethoxybenzylamine
3-(aminomethyl)pyridine	4-phenylbutylamine	2,2-diphenylethylamine
4-(aminomethyl)pyridine	4-amino-N-methylphthalimide	3-benzoyloxyaniline
1,2,3,4-tetrahydro-1-naphthylamine	4-(2-aminoethyl)benzene sulfonamide	4-amino-4'-methyl-diphenylether
2-amino-4-methylbenzothiazole	N-propylcyclopropanemethylamine	1-methyl-3-phenylpropylamine
2-thiophenemethylamine	4-tert-butylaniline	exo-2-aminonorborene
2-methylcyclohexylamine	4'-aminoacetanilide	1,4-benzodioxan-5-amine
3,5-dimethylpiperidine	N-(4-aminobenzoyl)-beta-alanine	piperonylamine
4-methylcyclohexylamine	methyl 3-amino-benzoate	5-phenoxy-o-anisidine
N-isopropyl-N-phenyl-p-	2-methoxy-N-phenyl-1,4-	4-amino-4'-

10061989.022102

phenylenediamine	phenylenediamine	chlorodiphenylether
cyclohexanemethylamine	2-ethoxybenzylamine	1-piperonylpiperazine
heptamethyleneimine	2-methoxyphenethylamine	4-amino-4'-methoxystilbene
1-(4-nitrophenyl)piperazine	4-isopropoxyaniline	cycloheptylamine
1-piperazinecarboxaldehyde	4-methoxyphenethylamine	(-)-cis-myrtanylamine
2-amino-4-methylthiazole	3,5-dimethoxyaniline	4-(4-nitrophenoxy)-aniline
1,3,3-trimethyl-6-azabicyclo[3,2,1]octane	alpha-(cyanoimino)-3,4-dichlorophenethylamine	4-amino-4'-nitrodiphenylsulfide
1-methylhomopiperazine	1-ethylpiperazine	2-amino-7-bromofluorene
N-(2-aminoethyl)pyrrolidine	4-tert-butylcyclohexylamine	2-(3-chlorophenyl)ethylamine
2-amino-5-phenyl-1,3,4-thiadiazole sulfate	2-amino-4,5,6,7-tetrahydrobenzo(b)thiophene-3-carbonitrile	(1R,2S)-(+)-cis-1-amino-2-indanol
1-amino-4-methylpiperazine	2-(4-chlorophenyl)ethylamine	n-undecylamine
2-heptylamine	1-(3-aminopropyl)-2-pipecoline	2,6-dimethylmorpholine
N, N, N'-trimethyl-1,3-propanediamine	4-amino-2,2,6,6-tetramethylpiperidine	d(+)-alpha-methylbenzylamine
N-methylhexylamine	ethyl nipecotate	dl-1-amino-2-propanol
1-(3-aminopropyl)-4-methyl-piperazine	N,N-dimethyl-N'-ethylethylenediamine	dl-alpha-methylbenzylamine
3-aminobenzyl alcohol	N, N-diethylethylenediamine	o-anisidine
(R)-(+)-2-amino-3-phenylpropanol	2-(furfurylthio) ethylamine	3-amino-4-methylbenzyl alcohol
2-(2-aminoethyl)-1,3-dioxolane	2,3-dimethylcyclohexylamine	3-amino-5,5-dimethyl-2-cyclohexen-1-one
6-amino-1-hexanol	N-methyl-b-alaninenitrile	3-aminophenol
3-isopropoxypropylamine	1-methyl-4-(methylamino)piperidine	(R)-(+)-1-phenylpropylamine
2-methylbenzylamine	1-amino-2-butanol	2-piperidineethanol
(R)-1-(4-methylphenyl)ethylamine	2-amino-2-methyl-1-propanol	2,3-dimethyl-4-aminophenol
3-methylbenzylamine	4-amino-1-butanol	1-aminoindan
4-methylbenzylamine	3-(ethylamino)propionitrile	phenethylamine
N-methylbenzylamine	4-hydroxypiperidine	3,4-dimethylaniline
(+/-)-2-amino-1-butanol	N-(2-hydroxyethyl)piperazine	1-naphthalene methylamine
2-(2-aminoethyl)pyridine	S(+)-1-cyclohexylethylamine	2-aminophenethyl alcohol
6-amino-m-cresol	4-aminophenol	decylamine
m-anisidine	2-ethylpiperidine	4-aminophenethyl alcohol
p-anisidine	N-methylcyclohexylamine	diethanolamine
methyl 4-aminobenzoate	3-piperidinemethanol	2-(methylthio)aniline
5-amino-o-cresol	2,4-dimethylaniline	4-amino-2-chlorophenol
4-fluorobenzylamine	2,5-dimethylaniline	dibenzylamine
1-(3-aminopropyl)-imidazole	6'-amino-3',4'-(methylene-dioxy)acetophenone	2-(aminomethyl)-5-methylpyrazine
2-(1-cyclohexenyl)ethylamine	3-amino-4-hydroxybenzoic acid	(R)-(+)-1-(4-methoxyphenyl)ethylamine
2, (2-thienyl)ethylamine	(1R, 2S)-1-amino-2-indanol	4-ethynylaniline
1-(3,4-dichlorophenyl)piperazine	N-(4-amino-2-chlorophenyl)morpholine	1(-)-2-amino-3-phenyl-1-propanol
1-acetyl-piperazine	N-benzyl-2-phenylethylamine	5-tert-butyl-o-anisidine

isonipecotamide	5-phenyl-o-anisidine	4-amino salicylic acid
2-amino-m-cresol	cyclooctylamine	2,4-dimethoxyaniline
2-methoxy-6-methylaniline	3-hydroxytyramine hydrobromide	4-amino-3-hydroxybenzoic acid
2-aminonorbornane hydrochloride	2-[2-(aminomethyl)phenylthio]benzyl alcohol	1-amino-2-methylnaphthalene
5-aminoindazole	2-amino-1,3-propanediol	3-amino-5-phenylpyrazole
5-aminobenzotriazole	3-amino-1,2-propanediol	veratrylamine
methyl 4-aminobutyrate hydrochloride	3-bromobenzylamine hydrochloride	3-amino-1-phenyl-2-pyrazolin-5-one
2-chloro-4,6-dimethylaniline	1-(2-methoxyphenyl)piperazine hydrochloride	5-amino-1-methyl-3-(thien-2-yl)pyrazole
(1S,2S)-(+) -2-amino-1-phenyl-1,3-propanediol	4-benzyloxyaniline hydrochloride	3,5-bis(trifluoromethyl)-benzylamine
2-bromobenzylamine hydrochloride	(S) - (+) -2-amino-3-cyclohexyl-1-propanol HCl	3-aminopyrrolidine dihydrochloride
N-(4-methoxyphenyl)-p-phenylenediamine hydrochloride		2-piperidinemethanol

In another of such methods, bi-ligand libraries can be prepared by reacting carboxylic acids to common ligand mimics of the present invention having an amine or amide containing substituent.

5 As shown in Figure 12b, bi-ligand libraries of the invention can also be prepared in the following manner. HOBt resin is swelled a dry solvent, such as dry THF, and added to a solution of a carboxylic acid in a solvent, such as a mixture of dry DMF and DIC. The solution is shaken at room temperature overnight and then washed with 3x dry DMF and 1x dry THF. The resin is added to a solution of a common ligand mimic of the invention in a solvent, for example dry DMF. The solution is again shaken at room temperature overnight. 10 The resin then can be filtered and washed with solvent, followed by collection and vacuum drying of the filtrate to provide bi-ligands of the invention. Nonlimiting examples of carboxylic acids useful for the preparation of bi-ligand libraries include those in Table 2.

TABLE 2

acetic acid	5-Bromonicotinic acid	4-Chlorobenzoic acid
4-Chloro-3-nitrobenzoic acid	4-(3-Hydroxyphenoxy)benzoic Acid	4-Biphenylcarboxylic acid
N-Acetyl glycine	3,5-Dihydroxybenzoic acid	2-Bromobenzoic acid
Propionic acid	2,4-Dihydroxybenzoic acid	3-Bromobenzoic acid
Crotonic acid	2,3-Dihydroxybenzoic acid	4-Bromobenzoic acid
4-pentenoic acid	2-Chloro-5-nitrobenzoic acid	4-Phenoxybenzoic acid
methacrylic acid	6-Mercaptonicotinic acid	4-Mercaptobenzoic acid
Pyruvic acid	Cyclohexanepropionic acid	acrylic acid
3-Hydroxy-2-methyl-4-quinolinecarboxylic acid	1-(4-Chlorophenyl)-1-cyclopropanecarboxylic acid	4-Hydroxy-3-(morpholino-methyl)benzoic acid
n-butyric acid	3-Chlorobenzoic acid	isobutyric acid
methoxyacetic acid	2-Chlorobenzoic acid	3-Indolebutyric acid
mercaptoacetic acid	5-Nitro-2-furoic acid	2,6-Difluorobenzoic acid
2,3-Difluorobenzoic acid	6-Chloronicotinic acid	Ethoxyacetic acid
trans-2,3-dimethylacrylic acid	1,4-Dihydroxy-2-napthoic acid	3,7-Dihydroxy-2-napthoic acid
Cyclobutanecarboxylic acid	2-methylcyclopropane carboxylic acid	2-Chloro-4-nitrobenzoic acid
cyclopropanecarboxylic acid	4-(4-Hydroxyphenoxy)benzoic Acid	9H-Fluorene-9-carboxylic acid
2-ketobutyric acid	3,5-Difluorobenzoic acid	Pentafluorobenzoic acid
Isovaleric acid	2,4-Difluorobenzoic acid	Indole-5-carboxylic acid
Trimethylacetic acid 99%	3,4,5-Trimethoxybenzoic acid	3-Nitrobenzoic acid
3-methoxypropionic acid	Indole-2-carboxylic acid	3-Phenoxybenzoic acid
3-Hydroxybutyric acid	2-benzofurancarboxylic acid	4-Phenylbutyric acid
4,8-Dihydroxyquinoline-2-carboxylic acid	2,3,4-Trimethoxybenzoic acid	3-(3,4-Dimethoxyphenyl) propionic acid
(Methylthio)acetic acid	indazole-3-carboxylic acid	3-chloropropionic acid
Pyrrole-2-carboxylic acid	Benzotriazole-5-carboxylic acid	3-bromo-4-methylbenzoic acid
4-Aminobenzoic acid	Indoline-2-carboxylic acid	3-Bromophenylacetic acid
5-Acetylsalicylic acid	Pentafluoropropionic acid	4-bromophenylacetic acid
2-Furoic acid	4-acetylbenzoic acid	2-Iodobenzoic acid
Cyclopentanecarboxylic acid	5-Norbornene-2,3-dicarboxylic acid monomethyl ester	9-Flourenone-2-carboxylic acid
trans-3-Hexenoic acid 97%	3-(5-Nitro-2-furyl)acrylic Acid	xanthene-9-carboxylic acid
Piperonylic acid	4-Carboxyphenylboronic acid	3-Benzoylbenzoic acid
2-tetrahydrofuroic acid	4-Dimethylaminobenzoic acid	4-benzoylbenzoic acid
2-Phenoxybenzoic acid	3-Dimethylaminobenzoic acid	2-Butynoic acid
Tetrahydro-3-furoic acid	3-Methoxyphenylacetic acid	2-Hydroxyisobutyric acid
hexanoic acid	4-Ethoxybenzoic acid	2,4-Hexadienoic acid
2-Ethylbutyric acid	4-methoxyphenylacetic acid	(Ethylthio)acetic acid
DL-3-Methylvaleric acid, 97%	(alpha, alpha, alpha-tetrafluoro-p-tolyl)acetic acid	1-Cyclohexene-1-carboxylic acid
Tert-Butylacetic acid, 98%	1,4-Benzodioxan-2-carboxylic acid	2-Phenoxymethylbenzoic Acid
1-Acetyl piperidine-4-carboxylic acid	(R) - (-) - 5-oxo-2-tetrahydro-furancarboxylic	2-hydroxy-2-methylbutyric acid

	acid	
Vanillic acid	2,6-Dichloronicotinic acid	3-Allyloxypropionic acid
Benzoic acid	5-Methoxysalicylic acid	5-Methylhexanoic acid
Picolinic acid, 99%	(4-Pyridylthio)acetic acid	2-Aminonicotinic acid
Nicotinic acid	2-(Methylthio)nicotinic acid	6-Methylpicolinic acid
2-Pyrazinecarboxylic acid	1-Methyl-1-cyclohexanecarboxylic acid	2-Ethyl-2-hydroxybutyric acid
1-methyl-2-pyrrolicarboxylic acid	2-Hydroxy-6-methylpyridine-3-carboxylic acid	3-Cyclohexenecarboxylic acid
1-Isoquinolinecarboxylic acid	(R)-(+)-3-Methylsuccinic acid -1-monomethyl ester	2-Hydroxyphenylacetic acid
4-butylbenzoic acid	Quinoline-4-carboxylic acid	2,6-Dimethylbenzoic acid
2-Thiophenecarboxylic acid	1H-Indole-3-acetic acid	Thiophene-3-carboxylic acid
5-Fluoroindole-2-carboxylic acid	5-Hydroxy-2-indolecarboxylic acid	2-(n-Propylthio)nicotinic acid
(S)-(-)-2-Pyrrolidone-5-carboxylic acid	(R)-(-)-4-Methylglutaric acid 1-monomethyl ester	DL-2-Hydroxy-4-(methylthio)butyric acid
Itaconic acid monoethyl ester	5-methylisoxazole-4-carboxylic acid	2-Amino-6-fluorobenzoic acid
m-Toluic acid	4-Acetamidobenzoic acid	2-Mercaptonicotinic acid
p-Toluic acid	4-Aminosalicylic acid	6-Methylnicotinic acid
2-Methylnicotinic acid	3-Acetamidobenzoic acid	2,5-Difluorobenzoic acid
3-aminobenzoic acid	Succinamic acid	o-Toluic acid
2-Chloroisonicotinic acid	2-(4-Fluorobenzoyl)benzoic acid	2-Fluorophenylacetic acid
3-Hydroxybenzoic acid	3,4-Dimethoxybenzoic acid	2-Acetylbenzoic acid
4-Hydroxybenzoic acid	3,5-Dimethoxybenzoic acid	4-chlorosalicylic acid
2,5-Dimethoxybenzoic acid	3-(3,4-Dihydroxyphenyl)propionic acid	1-Phenyl-1-cyclopropane carboxylic acid
5-Norbornene-2-carboxylic acid	5-Methyl-2-pyrazinecarboxylic acid	2,5-Dimethylphenylacetic acid
(2-n-Butoxyethoxy)acetic Acid	3-Hydroxy-4-nitrobenzoic acid	2,4,6-Trimethylbenzoic acid
5-Bromofuroic acid	5-Nitrosalicylic acid	2-Ethoxybenzoic acid
6-Hydroxynicotinic acid	4-Chloro-o-anisic acid	Salicylic acid
2-Methoxyphenylacetic acid	3-Chloro-4-hydroxyphenylacetic acid	3-Methyl-2-thiophenecarboxylic acid
2,4-Difluorophenylacetic acid	trans-4-n-propylcyclohexane carboxylic acid	2-Amino-5-chlorobenzoic acid
2-Chloro-6-methyl-3-pyridinecarboxylic acid	2-Hydroxyquinoline-4-carboxylic acid	O-Chlorophenylacetic acid
4-Fluorobenzoic acid	3-indolepropionic acid	4-Octyloxybenzoic acid
3-Fluorobenzoic acid	2-Amino-4-chlorobenzoic acid	5-Bromofuroic acid
alpha, alpha, alpha-trifluoro-p-toluic acid	Alpha, Alpha, Alpha-Trifluoro-o-toluic acid	Alpha, Alpha, Alpha-Trifluoro-m-toluic acid
2-Thiopheneacetic acid	2,5-Dimethyl-3-furoic acid	(+/-)-Citronellic acid
3-Thiopheneacetic acid	Chromone-2-carboxylic acid	2-Fluorobenzoic acid
5-Bromo-2,4-dihydroxybenzoic acid monohydrate	2-[(4S)-2,2-Dimethyl-5-oxo-1,3-dioxolane-4-yl]acetic acid	2,5-Difluorophenylacetic acid
(R)-(+)-2-Benzyloxypropionic acid	3-Hydroxy-2-quinoxalinecarboxylic acid	2,4,5-Trifluorobenzoic acid
4-cyanobenzoic acid	Coumarin-3-carboxylic acid	2-Chloronicotinic acid
3-Cyanobenzoic acid	2,4-Dichlorobenzoic acid	2-Chloro-6-fluorobenzoic acid

		acid
phthalide-3-acetic acid	2,5-Dichlorobenzoic acid	3-indoleglyoxylic acid
2,5-Dimethylphenoxy acetic acid	5-Methoxyindole-2-carboxylic acid	2,3,4-Trifluorobenzoic acid
2,5-Dimethylbenzoic acid	2,6-Dichlorobenzoic acid	4-Isobutylbenzoic acid
3,4-Dimethylbenzoic acid	3,4-Dichlorobenzoic acid	1-Naphthoic acid
p-Tolylacetic acid	2,3-Dichlorobenzoic acid	m-Tolylacetic acid
4-acetylphenoxyacetic acid	2,4-Dimethylphenoxyacetic acid	2,4-Dimethoxybenzoic acid
2,4-Dimethylbenzoic acid	(-)-2-oxo-4-thiazolidinecarboxylic acid	1-Adamantanecarboxylic acid
3,5-Dimethylbenzoic acid	2,3-Dimethylphenoxyacetic acid	2-Amino-5-nitrobenzoic acid
2-Bromoacrylic acid	3-Methylhippuric acid	3,5-Dichlorobenzoic acid
3-(3-pyridyl)propionic acid	4-(4-methoxyphenyl)butyric acid	2,3-Dimethoxybenzoic acid
1-Hydroxy-2-naphthoic acid	2-(4-Hydroxyphenoxy) propionic acid	2-(allylthio)nicotinic acid
3-methylsalicylic acid	N,N-dimethylsuccinamic acid	2-(Ethylthio)nicotinic acid
P-Anisic acid	2-Methylhippuric acid	6-bromohexanoic acid
o-Anisic acid	5-Chloroindole-2-carboxylic acid	Itaconic acid mono-n-butyl ester
4-Nitrophenoxyacetic acid	trans-4-n-Butylcyclohexane carboxylic acid	2-(4-Chlorophenyl)-2-methylpropionic acid
5-methylsalicylic acid	Rhodanine-N-acetic acid	2-Chloromandelic acid
6-Hydroxy-1-naphthoic acid	2-Chloro-4,5-difluorobenzoic acid	2-Biphenylcarboxylic acid
3,5-dimethoxy-4-methylbenzoic acid	2,3,4,5-Tetrafluorobenzoic acid	4-Bromo-2-fluorocinnamic acid
1-Adamantaneacetic acid	2-Chloro-4-fluorophenylacetic acid	1-Naphthaleneacetic acid
Cyclopentylacetic acid	(2,5-Dimethoxyphenyl)acetic acid	2-Chloro-4-fluorocinnamic acid
1-Phenylcyclopentane carboxylic acid	2-(4-Chlorophenoxy)-2-methylpropionic acid	Cyclohexanecarboxylic acid
1-(p-Tolyl)-1-cyclopentanecarboxylic acid	(2S)-4-(1,3-Dioxoisindolin-2-yl)-2-hydroxy butanoic acid	2,6-Dichloro-5-fluoropyridine-3-carboxylic acid
2,6-Dichlorophenylacetic acid	(4-Chlorophenylthio) acetic acid	3-Hydroxy-7-methoxy-2-naphthoic acid
(-)-Camphanic acid	2,3-Diphenylpropionic acid	DL-2-Methylbutyric acid
2-Amino-5-bromobenzoic acid	Beta-(4-Methylbenzyl) mercaptopropionic acid	Rhodanine-3-propionic acid
2,5-Dimethoxy cinnamic acid	2,5-Dichlorophenylthio glycolic acid	trans-2-Methyl-2-pentenoic acid
trans-2-Pentenoic acid	(-)-Camphanic acid	2-Methyl-3-furoic acid
Valeric acid	mono-Ethyl malonate	trans-2-hexenoic acid
3-(2-benzothiazolylthio) propionic acid	2-Chloro-6-fluorophenylacetic acid	4-Benzyloxyphenylacetic acid
2,4-Dichlorophenylacetic acid	5-Bromo-2-fluorocinnamic acid	4-(4-tert-butylphenyl)benzoic acid
(+/-)-2-(6-Methoxy-2-naphthyl)propionic acid	2-(carboxymethylthio)-4,6-dimethylpyridine monohydrate	1-Piperidinepropionic acid
3-Cyclopentylpropionic acid	(2-Benzothiazolylthio)acetic acid	Alpha-Methylcinnamic acid

201220"68612001

	acid	
2-Ethoxynaphthoic acid	DL-Lactic acid	2-Methylhexanoic acid
trans-3-Furanacrylic acid	1-(4-Methoxyphenyl)-1-cyclopentanecarboxylic acid	3-Hydroxy-2-pyridine-carboxylic acid
2,3-Dichlorophenoxy acetic acid	2,4-Dichlorophenoxy acetic acid	3-Mercaptoisobutyric Acid
5-Fluoro-2-methylbenzoic acid	(3,4-Dimethoxyphenyl)acetic acid	2-Thiopheneglyoxylic acid
(2-Napthoxy)-acetic acid	o-Tolylacetic acid	2-Hydroxyoctanoic acid
Urocanic acid	Hydrocinnamic acid	N-Acetyl-L-proline
DL-Mandelic acid	DL-2-Phenylpropionic acid	N-Methyl-maleamic acid
Coumalic acid	4-(Methylamino)benzoic acid	3,4-Difluorobenzoic acid
4-Methyl-1-cyclohexane carboxylic acid	Tetrahydro-2,2-dimethyl-5-oxo-3-furancarboxylic acid	DL-2-phenoxypropionic acid
m-Anisic acid	3-Hydroxyphenylacetic acid	Indole-3-carboxylic acid
Cyclohexylacetic acid	Phenoxyacetic acid	3-Fluorocinnamic acid
Cycloheptanecarboxylic acid	3-Amino-1H-1,2,4-triazole-5-carboxylic acid	3-Fluoro-4-methylbenzoic acid
2-Octynoic acid	trans-Styrylacetic acid	2-Methylcinnamic acid
2-Propylpentanoic acid	3-Fluorophenylacetic acid	4-Acetylbutyric acid
2-Methylheptanoic acid	Furylacrylic acid	Phenylpyruvic acid
Octanoic acid	Thiosalicylic acid	mono-Ethyl succinate
3-(2-Thienyl)acrylic acid	Alpha-Methylhydrocinnamic acid	Alpha-Fluorocinnamic acid
mono-Methyl glutarate	3-(2-Thienyl)propanoic acid	3-Phenoxypropionic acid
trans-3-(3-Pyridyl)acrylic acid	trans-3-(3-Thienyl)acrylic acid	3,4-(Methylenedioxy)phenylacetic acid
3-Noradamantane carboxylic acid	4-Acetyl-3,5-dimethyl-2-pyrrolecarboxylic acid	3-(2-Hydroxyphenyl)propionic acid
2-Nitrobenzoic acid	DL-Atrolactic acid	4-Methylsalicylic acid
4-(Dimethylamino)butyric acid hydrochloride	2-Methyl-1H-benzimidazole-5-carboxylic acid	3-Fluoro-4-methoxybenzoic acid
3-Chloro-4-hydroxybenzoic acid	4-(Dimethylamino)phenylacetic acid	3,4-Difluorocinnamic acid
DL-3-Phenyllactic acid	3-Benzoylpropionic acid	Homovanillic acid
2-Methyl-terephthalic acid	3-(Diethylamino)propionic acid hydrochloride	3-(4-Methylbenzoyl)propionic acid
4-(2-Thienyl)butyric acid	3,4-Dihydro-2,2-dimethyl-4-oxo-2H-pyran-6-carboxylic acid	Cyclohexanepentanoic acid
Cyclohexanebutyric acid	mono-Methyl phthalate	Undecanoic acid
3-Chlorophenylacetic acid	3,5-Difluorophenylacetic acid	6-Hydroxy-2-naphthoic acid
3-Benzoylacrylic acid	4-Amino-2-chlorobenzoic acid	3-Indoleacrylic acid
3-Amino-4-chlorobenzoic acid	4-(4-Methylphenyl)butyric acid	3-Hydroxy-2-naphthoic acid
3,4-Difluorophenylacetic acid	3-(4-Methoxyphenyl)propionic acid	2-Hydroxy-1-naphthoic acid
2,5-Dimethylphenoxy acetic acid	trans-3-(4-Methylbenzoyl)acrylic acid	5-Methyl-2-nitrobenzoic acid
3-Quinolinecarboxylic acid	3-(2-Methoxyphenyl)propionic acid	3,5-Dimethyl-p-anisic acid
Decanoic acid	2-Naphthoic acid	4-Benzoylbutyric acid
5-Chlorosalicylic acid	Quinaldic acid	N-Methylhippuric acid
3-(3-Methoxyphenyl)	5-Nitrothiophene-2-	4-(Diethylamino) benzoic

propionic acid	carboxylic acid	acid
2-Methyl-6-nitrobenzoic acid	Alpha,Alpha,Alpha-2-Tetrafluoro-p-toloic acid	N,N-Dimethyl-1-phenylalanine
Ibuprofen	2-Nitrophenylacetic acid	4-Benzyloxybutyric acid
3-Pyridylacetic acid	2-Methyl-5-nitrobenzoic acid	Diethylphosphonoacetic acid
2-Oxo-6-pentyl-2H-pyran-3-carboxylic acid	mono-Methyl cis-5-norbornene -endo-2,3-dicarboxylate	2-Methyl-3-nitrobenzoic acid
DL-2-(3-Chlorophenoxy) propionic acid	3,5-Dichloro-4-hydroxybenzoic acid	trans-2-Chloro-fluorocinnamic acid
5-Bromo-2-thiophenecarboxylic acid	DL-4-Hydroxy-3-methoxymandelic acid	
3,4-Diethoxybenzoic acid	Alpha-Phenyl-o-toluic acid	Diphenylacetic acid
5-Bromosalicylic Acid	Adipic acid monoethyl ester	Syringic acid
3,5-Dichloroanthranilic acid	trans-2,4-Dimethoxycinnamic acid	4-(4-Hydroxyphenyl) benzoic Acid
Alpha-Phenylcinnamic acid	trans-2,3-dimethoxycinnamic acid	3-(Phenylsulfonyl) propionic acid
3,3-Diphenylpropionic acid	(s)-(-)-2-[(Phenylamino) carbonyloxy]propionic acid	3-(Trifluoromethyl) cinnamic acid
Cyclohexylphenylacetic acid	4-(3-Methyl-5-oxo-2-pyrazoline-1-yl)benzoic acid	3,4-Dimethoxycinnamic acid
4-(Trifluoromethyl) mandelic acid	Pentafluorophenoxyacetic acid	Trans-2,4-Dichlorocinnamic acid
2-Nitrophenylpyruvic acid	Alpha-Phenylcyclopentane acetic acid	3,4-Dichlorophenylacetic acid
4-(Hexyloxy)benzoic acid	4-Butoxyphenylacetic acid	4-Bromocinnamic acid
7-Hydroxycoumarin-4-acetic acid	3-(3,4,5-Trimethoxyphenyl) propionic acid	2-Chloro-5-(methylthio)benzoic acid
1,3-dioxo-2-isoindolineacetic acid	1,4-dihydro-1-ethyl-7-methyl -4-oxo-1,8-naphthyridine-3-carboxylic acid	2-Phenylmercapto methylbenzoic acid
Anthracene-9-carboxylic acid	3,4,5-Trimethoxyphenylacetic acid	3-Bromo-4-fluorocinnamic acid
p-Bromophenoxyacetic acid	4-Butoxyphenylacetic acid	N-Carbobenzyloxy-L-proline
(Phenylthio)acetic acid	4-Benzyloxybenzoic acid	3-Phenylbutyric acid
7-Chloro-4-hydroxy-3-quinolinecarboxylic acid	gamma-Oxo-(1,1'-biphenyl)-4-butanoic acid	3,4,5-Triethoxybenzoic acid
Acridine-9-carboxylic acid hydrate	2-Ethoxycarbonylamino-3-phenyl-propionic acid	3,5-Di-tert-butyl-4-hydroxybenzoic acid
2-Cyclopentene-1-acetic acid	3,4,5-Trimethoxycinnamic acid	3-(BOC-amino)benzoic acid
4-Methoxysalicylic acid	4-Fluorocinnamic acid	4,5-Dibromo-2-furoic acid
2-Hydroxynicotinic acid	4-Bromo-3,5-dihydroxybenzoic acid	5-Phenylvaleric acid
4-Pentynoic acid	4-Ethoxybenzoic acid	4-Acetoxybenzoic acid
3,3-Dimethylacrylic acid	Dicyclohexylacetic acid	3-Acetoxybenzoic acid
4-Methoxy-2-methylbenzoic acid	cis-2-(2-Thiophenecarbonyl)-1-cyclohexanecarboxylic acid	4-Methyl-3-nitrobenzoic acid
4-Methylvaleric acid	(2-Methylphenoxy)acetic acid	4-Isopropoxybenzoic acid

20250222 100199

3,3,3-Trifluoropropionic acid	(4-Methylphenoxy)acetic acid	4-Nitrophenylacetic acid
2-Methyl-1-cyclohexane carboxylic acid	2,2,3,3-Tetramethyl cyclopropanecarboxylic acid	3-Methyl-1-cyclohexane carboxylic acid
4-Amino-3-nitrobenzoic acid	5-Methyl-2-thiophenecarboxylic acid	4-Methoxyphenoxyacetic acid
3-Methoxysalicylic acid	4-Fluorophenylacetic acid	2-Phenoxybutyric acid
3,5-Dimethoxy-4-hydroxycinnamic acid	(R)-(-)-2,2-Dimethyl-5-oxo-1,3-dioxolane-4-acetic acid	4-Hydroxymandelic acid monohydrate
(2-Methoxyphenoxy)acetic acid	2,2-Dichloro-1-methylcyclopropanecarboxylic acid	4-Hydroxyphenylacetic acid
2-Ethylbenzoic acid	4-Fluorophenoxyacetic acid	4-tert-Butylbenzoic acid
5-Fluoro-2-methoxybenzoic acid	(R)-(+)-2-(4-Hydroxyphenoxy)-propionic acid	2,6-Dimethoxynicotinic acid
2-Carboxyethylphosphonic acid	4-Hydroxy-3-nitrobenzoic acid	3,4-Difluorohydro cinnamic acid
4-Hydroxy-3-methoxy benzoic acid	3-Chloro-2-methylbenzoic acid	2-Chloro-4-fluorobenzoic acid
4-Fluoro-3-methylbenzoic acid	2-Chloro-6-methylnicotinic acid	4-Chlorophenoxyacetic acid
3-Fluoro-2-methylbenzoic acid	2,2-Bis(hydroxymethyl) butyric acid	5-Chloro-2-methoxybenzoic acid
5-Amino-4-methyl-cyclohexa-1,5-diene-1,4-dicarboxylic acid	(2,2-Dimethyl-5-[2,5-dimethylphenoxy]-pentanoic acid)	(Alpha, Alpha, Alpha-Trifluoro-m-tolyl)acetic acid
4-Methoxycyclohexane carboxylic acid	1-Methylindole-3-carboxylic acid	(R)-(-)-3-Chloromandelic acid
4-Propylbenzoic acid	4-Chlorophenylacetic acid	4-Bromomandelic acid
2-Methoxy-4-(methylthio)-benzoic acid	4-Oxo-4H-1-benzopyran-2-carboxylic acid	2-Mercapto-4-methyl-5-thiazoleacetic acid
2-(Trifluoromethyl) cinnamic acid	4-Methoxy-3-nitrobenzoic acid	3,4-Dichlorocinnamic acid
3-Methylcyclohexane carboxylic acid	4-Methoxy-2-quinolinecarboxylic acid	5-Methoxy-2-methyl-3-indoleacetic acid
2-(4-Nitrophenyl) propionic acid	4-(4-Methoxyphenyl)butyric acid	4-Carboxybenzene sulfonamide
2-Hydroxy-5-(1H-pyrrol-1-yl)-benzoic acid	3-Chloro-4-hydroxyphenylacetic acid	5-Chloro-2-nitrobenzoic acid
2-Methyl-3-indoleacetic acid	2-Fluoro-3(trifluoromethyl)-benzoic acid	4-Amino-5-chloro-2-methoxybenzoic acid
4-Chloro-2-fluorocinnamic acid	2-(2-Nitrophenoxy)acetic acid	3-Acetoxy-2-methylbenzoic acid
2,4,6-Trichlorobenzoic acid	3,4-Dichlorophenoxyacetic acid	2-Bibenzylcarboxylic acid
2-Chloro-5-(trifluoromethyl)benzoic acid	(S)-(+)-6-Methoxy-alpha-methyl-2-naphthalenacetic acid	4-(3,4-Dimethoxyphenyl)-butyric acid
4-Ethylbiphenyl-4'-carboxylic acid	2-Bromo-5-methoxybenzoic acid	5-Bromo-2-chlorobenzoic acid
3,5-Dinitro-p-toluic acid	1-Methyl-2-nitroterephthalate	1-Methyl-3-indoleacetic acid
4-Pentylbenzoic acid	4-n-Heptyloxybenzoic acid	4-Biphenylacetic acid

Over 5450 compounds have been made using this process employing the amines and carboxylic acids listed in Tables 1 and 2.

Alternatively, bi-ligand libraries of the
5 invention can be built through the direct reaction of isocyanates or thioisocyanates using a combination of solid phase chemistry and solution phase chemistry.

As shown in Figure 12c, bi-ligand libraries of
the invention can further be prepared in the following
10 manner. A solution of an isocyanate or thioisocyanate and a common ligand mimic of the invention is formed in a solvent, such as DMSO. The isocyanate and common ligand mimic are allowed to react overnight, followed by the addition of aminomethylated polystyrene Resin
15 (NovaBiochem, Cat. No. 01-64-0383). This mixture is then shaken at room temperature for a period of time, for example about 4 hours. The resin then can be filtered and dried under reduced pressure to yield the desired product. Nonlimiting examples of isocyanates and
20 thioisocyanates are provided in Table 3.

10081989-022102

Table 3

allyl isocyanate	3-chloro-4-methylphenyl isocyanate
N-propyl isocyanate	1-naphthyl isocyanate
pentyl isocyanate	3-chloro-4-fluorophenyl isocyanate
phenyl isocyanate	2,6-diethylphenyl isocyanate
m-tolyl isocyanate	1-adamantyl isocyanate
p-tolyl isocyanate	2-methyl-4-nitrophenyl isocyanate
o-tolyl isocyanate	2-methyl-5-nitrophenyl isocyanate
benzyl isocyanate	2-methyl-3-nitrophenyl isocyanate
4-fluorophenyl isocyanate	4-methyl-2-nitrophenyl isocyanate
heptyl isocyanate	4-methyl-3-nitrophenyl isocyanate
3-cyanophenyl isocyanate	2,4-dimethoxyphenyl isocyanate
2,6-dimethylphenyl isocyanate	2,5-dimethoxyphenyl isocyanate
2-ethylphenyl isocyanate	2-fluoro-5-nitrophenyl isocyanate
2,5-dimethylphenyl isocyanate	4-fluoro-3-nitrophenyl isocyanate
2,4-dimethylphenyl isocyanate	5-chloro-2-methoxyphenyl isocyanate
3,4-dimethylphenyl isocyanate	ethyl-6-isocyanatohexanoate
4-ethylphenyl isocyanate	4-(trifluoromethyl)phenyl isocyanate
3-ethylphenyl isocyanate	3-(trifluoromethyl)phenyl isocyanate
2,3-dimethylphenyl isocyanate	2-(trifluoromethyl)phenyl isocyanate
2-methoxyphenyl isocyanate	3,4-dichlorophenyl isocyanate
3-methoxyphenyl isocyanate	2,4-dichlorophenyl isocyanate
4-methoxyphenyl isocyanate	3,5-dichlorophenyl isocyanate
5-chloro-3-methylphenyl isocyanate	2,3-dichlorophenyl isocyanate
2-chlorophenyl isocyanate	trichloroacetyl isocyanate
3-chlorophenyl isocyanate	ethyl-4-isocyanatobenzoate
2,4-difluorophenyl isocyanate	Isopropyl isocyanate
3,4-difluorophenyl isocyanate	Butyl isocyanate
2,6-difluorophenyl isocyanate	cyclopentyl isocyanate
butyl isocyanatoacetate	cyclohexyl isocyanate
trans-2-phenylcyclopropyl isocyanate	o-tolyl isocyanate
trichloromethyl isocyanate	3-fluorophenyl isocyanate
3-acetylphenyl isocyanate	2-fluorophenyl isocyanate
4-acetylphenyl isocyanate	ethyl 3-isocyanatopropionate
2-isopropylphenyl isocyanate	4-methylbenzyl isocyanate
2-ethyl-6-methylphenyl isocyanate	phenethyl isocyanate
2,4,6-trimethylphenyl isocyanate	3-fluorobenzyl isocyanate
4-ethoxyphenyl isocyanate	4-fluorobenzyl isocyanate
2-methoxy-5-methylphenyl isocyanate	3-fluoro-4-methylphenyl isocyanate
2-ethoxyphenyl isocyanate	2,4-difluorophenyl isocyanate
4-methoxy-2-methylphenyl isocyanate	3,4-difluorophenyl isocyanate
4-methoxybenzyl isocyanate	2,6-difluorophenyl isocyanate
2-nitrophenyl isocyanate	3,5-difluorophenyl isocyanate
4-nitrophenyl isocyanate	octyl isocyanate
3-nitrophenyl isocyanate	1,1,3,3-tetramethylbutyl isocyanate

10081989-022102

4-(methylthio)phenyl isocyanate	trans-2-phenylcyclopropyl isocyanate
2-(methylthio)phenyl isocyanate	trichloromethyl isocyanate
5-chloro-2-methylphenyl isocyanate	4-isopropylphenyl isocyanate
4-chloro-2-methylphenyl isocyanate	propyl isothiocyanate
2-isopropyl-6-methylphenyl isocyanate	3,4-(methylenedioxy)phenyl isocyanate
2-chloro-6-methylphenyl isocyanate	2-chloro-5-methylphenyl isocyanate
3-chloro-2-methylphenyl isocyanate	2-chlorobenzyl isocyanate
isobutyl isothiocyanate	3-chloro-4-fluorophenyl isocyanate
tert-butyl isothiocyanate	2,6-diethylphenyl isocyanate
N-butyl isothiocyanate	4-N-butylphenyl isocyanate
2-methoxyethyl isothiocyanate	methyl-4-isocyanato-benzoate
N-amyl isothiocyanate	3-carbomethoxyphenyl isocyanate
3-methoxypropyl isothiocyanate	methyl-2-isocyanatobenzoate
phenyl isothiocyanate	1-adamantyl isocyanate
cyclohexyl isothiocyanate	2-methyl-4-nitrophenyl isocyanate
2-tetrahydrofurfuryl isothiocyanate	2-methyl-5-nitrophenyl isocyanate
o-tolyl isothiocyanate	2-methyl-3-nitrophenyl isocyanate
benzyl isothiocyanate	4-methyl-2-nitrophenyl isocyanate
m-tolyl isothiocyanate	4-methyl-3-nitrophenyl isocyanate
4-fluorophenyl isothiocyanate	diethoxyphosphinyl isocyanate
2-fluorophenyl isothiocyanate	2,4-dimethoxyphenyl isocyanate
3-fluorophenyl isothiocyanate	2,5-dimethoxyphenyl isocyanate
heptyl isothiocyanate	3,4-dimethoxyphenyl isocyanate
ethyl 3-isothiocyanatopropionate	2-fluoro-5-nitrophenyl isocyanate
ethyl 2-isothiocyanatopropionate	4-fluoro-3-nitrophenyl isocyanate
4-cyanophenyl isothiocyanate	benzenesulphonyl isocyanate
2-ethylphenyl isothiocyanate	5-chloro-2-methoxyphenyl isocyanate
2,6-dimethylphenyl isothiocyanate	3-chloro-4-methoxyphenyl isocyanate
2-phenylethyl isothiocyanate	ethyl-6-isocyanatohexanoate
2,4-dimethylphenyl isothiocyanate	4-(trifluoromethyl)phenyl isocyanate
4-methylbenzyl isothiocyanate	3-(trifluoromethyl)phenyl isocyanate
2-phenylethyl isothiocyanate	2-(trifluoromethyl)phenyl isocyanate
3-methoxyphenyl isothiocyanate	2-(trifluoromethyl)phenyl isocyanate
2-methoxyphenyl isothiocyanate	3,4-dichlorophenyl isocyanate
4-methoxyphenyl isothiocyanate	2,6-dichlorophenyl isocyanate
4-chlorophenyl isothiocyanate	2,4-dichlorophenyl isocyanate
2-chlorophenyl isothiocyanate	2,5-dichlorophenyl isocyanate
3-chlorophenyl isothiocyanate	3,5-dichlorophenyl isocyanate
2,4-difluorophenyl isothiocyanate	2,3-dichlorophenyl isocyanate
2-morpholinoethyl isothiocyanate	trichloroacetyl isocyanate
3-acetylphenyl isothiocyanate	2-ethyl-6-isopropylphenyl isocyanate
4-isopropylphenyl isothiocyanate	ethyl-3-isocyanatobenzoate
2-isopropylphenyl isothiocyanate	ethyl-4-isocyanatobenzoate
4-(dimethylamino)phenyl isothiocyanate	2-isopropyl-6-methylphenyl isocyanate
4-ethoxyphenyl isothiocyanate	ethyl-2-isocyanatobenzoate

10081989.022102

4-methoxybenzyl isothiocyanate	4-butoxyphenyl isocyanate
3-nitrophenyl isothiocyanate	2-methoxy-5-nitrophenyl isocyanate
4-nitrophenyl isothiocyanate	2-biphenylisocyanate
2-(methylthio)phenyl isothiocyanate	4-biphenyl isocyanate
3-(methylthio)phenyl isothiocyanate	p-toluenesulphonyl isocyanate
4-(methylthio)phenyl isothiocyanate	o-toluenesulphonyl isocyanate
1-naphthyl isothiocyanate	undecyl isocyanate
2-chlorobenzyl isothiocyanate	2-bromophenyl isocyanate
4-chlorobenzyl isothiocyanate	3-bromophenyl isocyanate
3-chloro-4-methylphenyl isothiocyanate	4,5-dimethyl-2-nitrophenyl isocyanate
4-chloro-2-methylphenyl isothiocyanate	5-chloro-2-methylphenyl isothiocyanate
4-bromophenyl isocyanate	2-chloro-4-nitrophenyl isocyanate
3-morpholinopropyl isothiocyanate	2-chloro-5-nitrophenyl isocyanate
4-N-butylphenyl isothiocyanate	4-chloro-2-nitrophenyl isocyanate
allyl isothiocyanate	ethyl isothiocyanate
2-methoxycarbonylphenyl isothiocyanate	2-chloro-6-methylphenyl isothiocyanate
1-adamantyl isothiocyanate	isopropyl isothiocyanate
4-methyl-2-nitrophenyl isothiocyanate	4-chloro-3-nitrophenyl isothiocyanate
3,4-dimethoxyphenyl isothiocyanate	3-bromophenyl isothiocyanate
2,5-dimethoxyphenyl isothiocyanate	2-bromophenyl isothiocyanate
2,4-dimethoxyphenyl isothiocyanate	2,6-diisopropylphenyl isothiocyanate
5-chloro-2-methoxyphenyl isothiocyanate	2-(3,4-dimethoxyphenyl)ethyl isothiocyanate
2-(trifluoromethyl)phenyl isothiocyanate	4-bromo-2-methylphenyl isothiocyanate
4-(trifluoromethyl)phenyl isothiocyanate	2-bromo-4-methylphenyl isothiocyanate
2,6-dichlorophenyl isothiocyanate	cyclododecyl isothiocyanate
2,3-dichlorophenyl isothiocyanate	4-phenylazophenyl isothiocyanate ¹¹¹
3,5-dichlorophenyl isothiocyanate	4-diethylaminophenyl isothiocyanate
4-methoxy-2-nitrophenyl isothiocyanate	

Bi-ligand libraries of the invention can also be made by the reaction sequence provided in Figure 13, using Boc-protected amines. As shown in Figure 13, bi-ligand libraries of the present invention can be prepared in the following manner. A mixture of DBU, a

5 halopyridine and a thiol is formed in a solvent, such as dioxane. The reaction mixture then is agitated under microwave irradiation at a temperature of 150 to 170°C for a period of about 30 to 40 minutes. For example, the

reaction mixture is agitated under microwave irradiation at a temperature of about 170°C for a period of about 40 minutes. The solvent can be removed from the mixture and the resultant oil residue subjected to a column to
5 provide the desired intermediate compound.

The intermediate compound then can be suspended in a mixture of water and alcohol, for example a mixture of water and methanol. Lithium hydroxide is added to the solution, which then is refluxed for a period of about 1
10 to 2 hours, for example a period of about 2 hours. Solvent can be removed from the reaction mixture, and the residue dissolved in water. Dilute hydrochloric acid is added dropwise, forming a white precipitate.

The white precipitate is dissolved in a
15 solvent, such as a mixture of dry DMF and DIC. HOBt resin, swelled in a solvent, such as dry THF, is then added to the solution, which is shaken at room temperature overnight. The resin then is washed with 3x dry DMF and 2x dry THF and added to a solution of an
20 amine dissolved in a solvent, such as dry DMF. The mixture can be shaken at room temperature overnight, followed by filtration and washing in solvent of the Boc protected intermediate, which then can be collected and vacuum dried.

25 The Boc-protected intermediate is then dissolved in a solvent mixture, for example a mixture of TFA and dichloroethane. The mixture is then shaken at room temperature for a period of about 15 to 20 minutes,

for example a period of about 20 minutes. Solvent can be removed from the mixture to form a deBoc intermediate.

5 HOBt resin, swelled in a solvent, such as a mixture of dry THF and dry DMF, is added to a solution of a common ligand mimic of the present invention, dissolved in a solvent, such as a mixture of dry DMF and DIC. This solution then is shaken at room temperature overnight and washed with 3x dry DMF and 3x dry THF.

10 The resin mixture then can be added to a solution of the deBoc intermediate in a solvent, such as dry THF. The mixture can be shaken at room temperature overnight, followed by filtration and washing of the resin in a solvent, such as dry DMF. The filtrate then can be collected and vacuum dried to provide bi-ligands
15 of the invention. Nonlimiting examples of amines that are useful in this method include those provided in Table 4.

20120222 10:22:22

Table 4

Cyclopropylamine	2-methoxyethylamine
Isopropylamine	3-amino-1-propanol
Propylamine	DL-1-amino-2-propanol
ethanolamine	N-Methyl-b-alaninenitrile
3-pyrroline	4-amino-4H-1,2,4-triazole
Hydroxylamine	cyclopentylamine
N-Methylallylamine	Piperidine
Cyclobutylamine	morpholine
Pyrrolidine	1-Ethylpropylamine
Diethylamine	Neopentylamine
isobutylamine	N-ethylisopropylamine
N-butylamine	N-Methylbutylamine
N-Methylpropylamine	2-Aminopyridine
sec-Butylamine	3-Aminopyridine
Tert-butylamine	furfurylamine
3-methoxypropylamine	3-Amino-5-methylpyrazole
(+/-)-2-amino-1-butanol	diallylamine
2-amino-1-methoxypropane	3-(ethylamino)propionitrile
4-amino-1-butanol	2-methylpiperidine
1-AMINO-2-BUTANOL	3-methylpiperidine
2-amino-2-methyl-1-propanol	4-methylpiperidine
Thiazolidine	cyclohexylamine
2-amino-1,3-propanediol	hexamethyleneimine
3-amino-1,2-propanediol	Methylpiperazine
Aniline	1-aminopiperidine
N-acetyleneethylenediamine	4-hydroxypiperidine
4-aminomorpholine	Tetrahydrofurfurylamine
3-dimethylaminopropylamine	1,3-Dimethylbutylamine
N-Isopropylethylenediamine	dipropylamine
4-Amino Butyric Acid	cycloheptylamine
5-Amino-1-pentanol	3-Fluoroaniline
3-ethoxypropylamine	4-fluoroaniline
diethanolamine	exo-2-aminobornane
3-(methylthio)propylamine	2-thiophenemethylamine
m-toluidine	2-ethylpiperidine
O-Toluidine	2-methylcyclohexylamine
p-Toluidine	3,5-dimethylpiperidine
2-(Aminomethyl)pyridine	4-methylcyclohexylamine
3-(aminomethyl)pyridine	glycinamide hydrochloride
4-(aminomethyl)pyridine	benzylamine

20250929 10081929.022102

Over 560 compounds have been made by this process employing the amines provided in Table 4.

Bi-ligand libraries of the invention can also be built using alkyl halides following the reaction scheme depicted in Figure 14. As shown in Figure 14, bi-ligands libraries of the invention can be prepared in the following manner. A mixture of 4-mercaptobenzoic acid and an alkyl bromide is formed in a solvent, such as CH_3CN . Triethylamine resin (Fluka) then is added to the mixture, which is shaken at room temperature overnight. The resin can be filtered and washed with solvent, followed by collection and vacuum drying.

Next, the filtrate is dissolved in a solvent, such as a mixture of dry DMF and DIC. HOBt resin, swelled in a solvent, such as dry THF, is added to the solution. The solution then is shaken at room temperature overnight and washed with 3x dry DMF and 2x dry THF. The resin then is added to a common ligand mimic of the invention, which has been dissolved in a solvent, such as dry DMF. The solution is shaken at room temperature overnight. The resin then can be filtered and washed with solvent. The filtrate can be collected and vacuum dried to provide bi-ligands of the invention. Nonlimiting examples of alkylhalides useful in this method are provided in Table 5.

TABLE 5

Bromoethane	4-Bromo-1-butene
Propargyl bromide	3-Bromo-2-methylpropene
Bromoacetonitrile	1-Bromobutane
Allyl bromide	2-Bromobutane
2-Bromopropane	2-Bromoacetamide
1-Bromopropane	Cyclopentyl bromide
1-Bromo-2-butyne	4-Bromo-2-methyl-2-butene
3-Bromopropionitrile	5-Bromo-1-pentene
2-Bromopropionitrile	Methyl 4-bromocrotonate
(Bromomethyl)cyclopropane	Methyl bromoacetate
Crotyl bromide remainder 3-bromo-1-butene	2-(Bromomethyl)tetrahydro-2H-pyran
Bromomethyl acetate	2-Bromopropionamide
2-Bromo-1,1,1-trifluoroethane	Ethyl 3-bromopropionate
Cyclohexyl Bromide	Alpha-Bromo-p-xylene
1-Bromohexane	alpha-Bromo-o-xylene
Methyl DL-2-bromopropionate	Alpha-Bromo-m-xylene
2-Bromoethyl acetate	(2-Bromoethyl)benzene
6-Bromohexanenitrile	3-Bromo-1,1,1-trifluoroacetone
(Bromomethyl)cyclohexane	4-Bromobutyl acetate
Alpha-Bromo-m-tolunitrile	tert-Butyl bromoacetate

Over 240 compounds have been made using this process employing the alkyl halides listed in Table 5.

The present invention is based on the development of bi-ligands that bind to two independent sites on a receptor. The combination of two ligands into a single molecule allows both ligands to simultaneously bind to the receptor and thus can provide synergistically higher affinity than either ligand alone (Dempsey and Snell, Biochemistry 2:1414-1419 (1963); and Radzicka and Wolfenden, Methods Enzymol. 249:284-303 (1995), each of which is incorporated herein by reference). The generation of libraries of bi-ligands focused for binding to a receptor family or a particular receptor in a receptor family has been described previously (see WO 99/60404, which is incorporated herein by reference).

The common ligand mimics of the present invention allow for increased diversity of bi-ligand libraries while simultaneously preserving the ability to focus a library for binding to a receptor family.

5 As described previously (see WO 99/60404), when developing bi-ligands having binding activity for a receptor family, it is generally desirable to use a common ligand having relatively modest binding activity, for example, mM to μ M binding activity. This binding
10 activity is increased when combined with a specificity ligand.

 The common ligand mimic can be modified through the addition of substituents, which can also be called expansion linkers. Substitution of the common ligand
15 mimic allows for tailoring of the bi-ligand by directing the attachment location of the specificity ligand on the common ligand mimic. Tailoring of the bi-ligand in this manner provides optimal binding of the common ligand mimic to the conserved site on the receptor and of the
20 specificity ligand to the specificity site on the same receptor. Through such tailoring, libraries having improved diversity and improved receptor binding can be produced. The bi-ligands contained in such libraries also exhibit improved affinity and/or specificity.

25 A number of formats for generating combinatorial libraries are well known in the art, for example soluble libraries, compounds attached to resin beads, silica chips or other solid supports. As an

10081989.022102

example, the "split resin approach" can be used, as described in U.S. Patent No. 5,010,175 to Rutter and in Gallop et al., J. Med. Chem., 37:1233-1251 (1994), incorporated by reference herein.

5 Methods for generating libraries of bi-ligands having diversity at the specificity ligand position have been described previously (see WO 99/60404, WO 00/75364, and US 6,333,149 which issued December 25, 2001). A library of bi-ligands is generated so that the binding
10 affinity of the common ligand mimic and the specificity ligand can synergistically contribute to the binding interactions of the bi-ligand with a receptor having the respective conserved site and specificity site. Thus, the bi-ligands are generated with the specificity ligand
15 and common ligand mimic oriented so that they can simultaneously bind to the specificity site and conserved site, respectively, of a receptor.

 The present invention also provides methods of screening combinatorial libraries of bi-ligands
20 comprising one or more common ligand mimic bound to a variety of specificity ligands and identification of bi-ligands having binding activity for the receptor. Thus, the present invention provides methods for generating a library of bi-ligands suitable for screening a particular
25 member of a receptor family as well as other members of a receptor family.

 Development of combinatorial libraries of bi-ligands of the invention begins with selection of a

10081989-02402

receptor family. Methods for determining that two receptors are in the same family, and thus constitute a receptor family, are well known in the art. For example, one method for determining if two receptors are related is BLAST, Basic Local Alignment Search Tool, available on the National Center for Biotechnology Information web page (www.ncbi.nlm.gov/BLAST/) (which is incorporated herein by reference) and modified BLAST protocols. A second resource for identifying members of a receptor family is PROSITE, available at ExpASy (www.expasy.ch/sprot/prosite.html) (which is incorporated herein by reference). A third resource for identifying members of a receptor family is Structural Classification of Proteins (SCOP) available at SCOP (scop.mrc-lmb.cam.ac.uk/scop/) (which is incorporated herein by reference).

Once a receptor family has been identified, the next step in development of bi-ligands involves determining whether there is a natural common ligand that binds at least two members of the receptor family, and preferably to several or most members of the receptor family. In some cases, a natural common ligand for the identified receptor family is already known. For example, it is known that dehydrogenases bind to dinucleotides such as NAD or NADP. Therefore, NAD or NADP are natural common ligands to a number of dehydrogenase family members. Similarly, all kinases bind ATP, and, thus, ATP is a natural common ligand to kinases.

After a receptor family has been selected, at least two receptors in the receptor family are selected as receptors for identifying useful common ligand mimics. Selection criteria depend upon the specific use of the bi-ligands to be produced. Once common ligand mimics are identified, these compounds are screened for binding affinity to the receptor family.

Those common ligand mimics having the most desirable binding activity then can be modified by adding substituents that are useful for the attachment and orientation of a specificity ligand. For example, in the present invention, thiazolidinedione and rhodanine were determined to be common ligand mimics for NAD. These compounds can be modified, for example, by the addition of substituents to the phenyl ring. For example, the phenyl ring can be substituted with a COOH group, two OMe groups, or an NHAc group. These groups provide attachment points for the specificity ligand. Substituents added to the phenyl ring can also act as blocking groups to prevent attachment of a specificity ligand at a particular site or can act to orient the specificity ligand in a particular manner to improve binding of the bi-ligand to the receptor.

Methods of screening for common ligand mimics and bi-ligands containing the common ligand mimics are well known in the art. For example, a receptor can be incubated in the presence of a known ligand and one or more potential common ligand mimics. In some cases, the natural common ligand has an intrinsic property that is

useful for detecting whether the natural common ligand is bound. For example, the natural common ligand for dehydrogenases, NAD, has intrinsic fluorescence.

Therefore, increased fluorescence in the presence of potential common ligand mimics due to displacement of NAD can be used to detect competition for binding of NAD to a target NAD binding receptor (Li and Lin, Eur. J. Biochem. 235:180-186 (1996); and Ambroziak and Pietruszko, Biochemistry 28:5367-5373 (1989), each of which is incorporated herein by reference).

In other cases, when the natural common ligand does not have an intrinsic property useful for detecting ligand binding, the known ligand can be labeled with a detectable moiety. For example, the natural common ligand for kinases, ATP, can be radiolabeled with ^{32}P , and the displacement of radioactive ATP from an ATP binding receptor in the presence of potential common ligand mimics can be used to detect additional common ligand mimics. Any detectable moiety, for example a radioactive or fluorescent label, can be added to the known ligand so long as the labeled known ligand can bind to a receptor having a conserved site. Similarly, a radioactive or fluorescent moiety can be added to NAD or a derivative thereof to facilitate screening of the NAD common ligand mimics and for bi-ligands of the invention.

The pool of potential common ligand mimics screened for competitive binding with a natural common ligand can be a broad range of compounds of various structures. However, the pool of potential ligands can

2025-03-20 10:22:10

also be focused on compounds that are more likely to bind to a conserved site in a receptor family. For example, a pool of candidate common ligand mimics can be chosen based on structural similarities to the natural common
5 ligand.

Thiazolidinedione and rhodanine were identified as common ligand mimics of NAD by first determining the three-dimensional structure of NAD, the natural common ligand, and searching commercially available databases of
10 commercially available molecules such as the Available Chemicals Directory (MDL Information Systems, Inc.; San Leandro CA) to identify potential common ligands having similar shape or electrochemical properties to NAD. Methods for identifying molecules having similar
15 structure are well known in the art and are commercially available (Doucet and Weber, in Computer-Aided Molecular Design: Theory and Applications, Academic Press, San Diego CA (1996), which is incorporated herein by reference; software is available from Molecular
20 Simulations, Inc., San Diego CA). Furthermore, if structural information is available for the conserved site in the receptor, particularly with a known ligand bound, compounds that fit the conserved site can be identified through computational methods (Blundell,
25 Nature 384 Supp:23-26 (1996), which is incorporated herein by reference). These methods also can be used to screen for specificity ligands and bi-ligands of the invention.

10081969-022102

Once a library of bi-ligands is generated, the library can be screened for binding activity to a receptor in a corresponding receptor family. Methods of screening for binding activity that are well known in the art can be used to test for binding activity.

The common ligand mimics and bi-ligands of the present invention can be screened, for example, by the following methods. Screening can be performed through kinetic assays that evaluate the ability of the common ligand mimic or bi-ligand to react with the receptor. For example, where the receptor is and reductase or dehydrogenase for which NAD is a natural common ligand, compounds of the invention can be assayed for their ability to oxidize NADH or NADPH or for their ability to reduce NAD⁺. Such assays are described more fully in Examples 23 through 25.

Examples

Starting materials were obtained from commercial suppliers and used without further purification. ¹H NMR spectra were acquired on a Bruker Avance 300 spectrometer at 300 MHz for ¹H NMR and 75 MHz for ¹³C NMR. Chemical shifts are recorded in parts per million (δ) relative to TMS (δ = 0.0 ppm) for ¹H or to the residual signal of deuterated solvents (chloroform, δ = 7.25 ppm for ¹H; δ = 77.0 ppm for ¹³C). Coupling constant *J* is reported in Hz. Chromatography was performed on silica gel with ethyl acetate/hexane as elutant unless otherwise noted. Mass spectra were recorded on LCQ from Finnigan.

EXAMPLE 1

Preparation of 4-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 5a)

5 This example describes the synthesis of thiazolidinedione compounds following the scheme shown in Figure 1. Compound numbers correspond to those in the figure.

Step a: Formation of 4-(5-formyl-furan-2-yl)-benzoic acid (compound 3a)

10 The compound 4-aminobenzoic acid (compound 1, 60.0 g, 0.438 mol) was suspended in 100 ml of water. The solution was stirred while HCl 12M (225 ml) was added. The resulting suspension was stirred for about 10 minutes and then cooled to 1°C. A solution of NaNO₂ (30.2 g, 15 0.438 mol) in 200 ml of water was added to the mixture in small portions while maintaining the temperature between 5°C and 10°C. Addition of the NaNO₂ was accomplished over a time period of approximately 30 minutes. The reaction mixture was stirred at 5°C for an additional 30 minutes 20 while adding another 300 ml of water. The mixture remained a suspension.

A solution of CuCl₂·2H₂O (7.5 g, 0.044 mol) in 300 ml of water was added, followed by a pre-cooled solution of 2-furaldehyde (compound 2, 36 ml, 0.435 mol) 25 in 50 ml of acetone. While stirring, CuCl (1.8 g, 0.018

mol) was added in small portions over a period of time of 10 minutes, which resulted in foaming and precipitation of 4-(5-formyl-furan-2-yl)-benzoic acid (compound 3a).

The ice bath was removed and the mixture stirred for 30 minutes. During this period, the internal temperature rose from 5°C to 15°C. An additional amount of CuCl (500 mg, 5 mmol) was added, and the mixture stirred for 20 minutes. This addition of CuCl resulted in a rise in the internal temperature of the suspension to 20°C.

An additional amount of CuCl (500 mg, 5 mmol) was then added, and the mixture stirred at room temperature for 16 hours. The resulting brown precipitate was filtered, thoroughly washed with water, and lyophilized. The compound 4-(5-formyl-furan-2-yl)-benzoic acid (compound 5a) was obtained as a brown powder (73.2g, 77% mass yield). The purity of the material was about 70-80% according to NMR. The compound was employed in step b without further purification. However, a small amount of the compound was purified by recrystallization in ethanol. The results of the NMR analysis of the product follow.

^1H NMR (300 MHz, DMSO- d_6): δ 7.31 (d, J = 3.5, 1H), 7.66 (d, J = 3.5, 1H), 7.82 (d, J = 8.0, 2H), 8.00 (d, J = 8.0, 2H), 9.62 (s, 1H).

Step b: Formation of 4-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 5a)

Crude 4-(5-formyl-furan-2-yl)-benzoic acid (compound 3a, 30.2 g, about 0.140 mol) and 2,4-thiazolidinedione (compound 4, 18.0 g, 0.154 mol) were mixed in 500 ml of ethanol in a 1L flask equipped with a magnetic stirring bar. Piperidine (2.8 ml, 0.028 mol) was added, and the resulting suspension was heated at 70°C for 5 hours while stirring. The mixture was then cooled with ice, and the yellow precipitate was filtered off and washed with a mixture of ethyl acetate and ether.

The crude product was suspended in 100 ml of aqueous HCl 0.1N and placed in an ultrasound bath for 10 minutes to eliminate any residual piperidine (about 10%). The product was then filtered and dried by lyophilization to provide the compound 4-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 5a) as a nice yellow orange powder (16.95 g, 38%). The product was analyzed by NMR with the following results.

^1H NMR (300 MHz, DMSO- d_6): δ 7.24 (d, J = 3.6, 1H), 7.40 (d, J = 3.6, 1H), 7.63 (s, 1H), 7.89 (d, J = 8.2, 2H), 8.06 (d, J = 8.3, 2H); ^{13}C NMR (75.5 MHz, DMSO- d_6): δ 111.46, 117.67, 120.87, 121.06, 124.03, 130.18, 130.40, 132.36, 149.68, 155.58, 166.75, 166.92, 168.57; MS m/z 316 (M+1).

EXAMPLE 2

Preparation of 3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 5b)

5 This example describes the synthesis of thiazolidinedione compounds following the reaction scheme shown in Figure 1. Compound numbers correspond to those in the figure.

Step a: Formation of 3-(5-formyl-furan-2-yl)-benzoic acid (compound 3b)

10 The compound 3-(5-formyl-furan-2-yl)-benzoic acid (compound 3b) was prepared from 3-(5-formyl-furan-2-yl)-benzoic acid (compound 1) following the procedure in step a of Example 1. The compound was prepared in 69% yield and analyzed by NMR with the following results.

15 ^1H NMR (300 MHz, DMSO- d_6): δ 7.42 (d, $J = 3.43$, 1H), 7.63-7.69 (m, 2H), 8.01 (d, $J = 7.6$, 1H), 8.13 (d, $J = 7.7$, 1H), 8.40 (s, 1H), 9.66 (s, 1H); MS: m/z 217 ($M+1$).

Step b: Formation of 3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid
20 (compound 5b)

Crude 3-(5-formyl-furan-2-yl)-benzoic acid (compound 3b, 35.0 g, 0.162mol) and 2,4-thiazolidinedione (compound 4, 22.8 g, 0.195 mol) were mixed in 500 ml of

20190909 0922102

ethanol in a 1L flask equipped with a magnetic stirring bar. Piperidine (1.6 ml, 0.0162 mol) was added to the mixture through syringe, and the suspension was heated at 70°C for 5 hours while stirring.

5 The mixture was cooled with ice, and the yellow precipitate was collected and washed with a mixture of ethyl acetate and ether. The crude product was suspended in 100 ml of aqueous HCl (0.1N) and placed in an ultrasound bath for 10 minutes to eliminate residual
10 piperidine (about 10%). The compound was filtered and lyophilized to obtain a yellow-orange powder (18.51 g, 36%). The product was analyzed by NMR with the following results.

¹H NMR (300 MHz, DMSO-*d*₆): δ 7.22 (d, *J* = 3.4, 1H), 7.39
15 (d, *J* = 3.4, 1H), 7.63 (s, 1H), 7.66 (t, *J* = 7.8, 1H),
7.96 (d, *J* = 7.3, 1H), 8.05 (d, *J* = 7.7, 1H), 8.37 (s, 1H); ¹³C NMR (75.5 MHz, DMSO-*d*₆): δ 110.31, 117.72,
120.81, 120.86, 124.64, 128.22, 129.16, 129.39, 129.64,
131.82, 149.24, 155.68, 166.78, 167.26, 168.76; MS *m/z*
20 316 (M).

EXAMPLE 3

Preparation of 5-[5-(4-hydroxy-phenyl)-furan-2-ylmethylene]-thiazolidine-2,4-dione (compound 5c)

25 This example describes the synthesis of thiazolidinedione compounds following the reaction scheme

shown in Figure 1. Compound numbers correspond to those in the figure.

Step a: Formation of 5-(4-hydroxy-phenyl)-furan-2-carbaldehyde (compound 3c)

5 The compound 5-(4-hydroxy-phenyl)-furan-2-carbaldehyde (compound 3c) was prepared following the procedure in step (a) of Example 1. The compound was prepared in 83% yield and analyzed with the following results.

10 ^1H NMR (300 MHz, DMSO- d_6): δ 6.89 (d, J = 8.5, 2H), 7.07 (d, J = 3.6, 1H), 7.61 (d, J = 3.6, 1H), 7.71 (d, J = 8.5, 2H), 9.53 (s, 1H), 10.03 (br. s., 1H); MS m/z 189 (M+1).

15 Step b: Formation of 5-[5-(4-hydroxy-phenyl)-furan-2-ylmethylene]-thiazolidine-2,4-dione (compound 5c)

The compound 5-[5-(4-hydroxy-phenyl)-furan-2-ylmethylene]-thiazolidine-2,4-dione (compound 5c) was prepared following the procedure in step b of Example 1.

20 The compound was prepared in 78% yield and analyzed with NMR with the following results. ^1H NMR (300 MHz, CD_3OD): δ 6.85 (d, J = 3.7, 1H), 6.89 - 6.92 (m, 2H), 7.03 (d, J = 3.7, 1H), 7.58 (s, 1H), 7.64 - 7.68 (m, 1H).

EXAMPLE 4

Preparation of 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoic acid methyl ester (compound 5d)

5 This example describes the synthesis of thiazolidinedione compounds following the reaction scheme shown in Figure 3. Compound numbers correspond to those in the figure.

10 Step a: Formation of 5-trimethylstannanyl-furan-2-carbaldehyde (compound 9)

15 A solution of butyl lithium (BuLi; 105 mmol, 2.5 M in hexanes) was added to a solution of 4-methylpiperidine (10.00 g, 100 mmol) in 50 ml of tetrahydrofuran (THF) under N₂ at -78°C, followed by the addition of 2-furaldehyde (8.73 g, 91 mmol). The solution was kept at -78°C for 15 minutes, and then another portion of BuLi (105 mmol, 2.5 M solution in hexane) was added. The reaction mixture was allowed to warm to -20°C and was stirred for 5 hours.

20 The solution was cooled to -78°C and then added to a solution of Me₃SnCl (100 mmol, 1M solution in THF). The mixture was allowed to warm gradually to room temperature and then stirred overnight. The reaction was quenched by adding 150 ml of cold brine and extracted

2012220-022402

with EtOAc (3 x 100 ml). The combined organic phase was dried and concentrated.

Chromatography (EtOAc/Hexane 20:1) afforded 20.7 g (88.5%) of 5-trimethylstannanyl-furan-2-carbaldehyde. The product was analyzed by NMR as follows:

^1H NMR (300 MHz, CDCl_3) δ 0.41 (s, 9H), 6.74 (d, $J = 3.7$, 1H), 7.25 (d, $J = 3.6$, 1H), 9.67 (s, 1H); MS m/z 261 (M+1).

10 Step b: Formation of 5-(5-formyl-furan-2-yl)-2-hydroxybenzoic acid methyl ester (compound 3d)

The 5-trimethylstannanyl-furan-2-carbaldehyde (compound 9, 2.60 g, 10 mmol), methyl 2-hydroxy-5-bromobenzoate (compound 8, 2.30 g, 10 mmol), and
15 tetrakis(triphenylphosphine)palladium ($\text{Pd}(\text{PPh}_3)_4$; 0.577g, 1 mmol) in 25 ml of dimethylformamide (DMF) was heated to 60°C under N_2 atmosphere for 30 hours. The solution was evaporated to dryness under reduced pressure, and the residue was purified by chromatography (EtOAc/hexane 1:1)
20 to give 2.13 g (86.2%) of methyl 5-(5-formyl-furan-2-yl)-2-hydroxybenzoic acid methyl ester. NMR analysis of the product provided the following:

^1H NMR (300 MHz, CDCl_3) δ 4.03 (s, 3H), 6.78 (d, $J = 3.2$, 1H), 7.10 (d, $J = 8.8$, 1H), 7.27 (s, 1H), 7.34 (d, $J =$

2.2, 1H), 7.92 (d, $J = 8.6$, 1H), 8.36 (s, 1H), 9.64 (s, 1H), 11.03 (s, 1H); MS m/z 247 ($M+1$).

Step c: Formation of 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoic acid methyl ester (compound 5d)

The compound 5-(5-formyl-furan-2-yl)-2-hydroxy-benzoic acid methyl ester (compound 3d, 872 mg, 3.54 mmol) and 2,4-thiazolidinedione (compound 4, 539 mg, 4.60 mmol) were suspended in 25 ml of ethanol. Five drops of piperidine were added, and the mixture was heated to 70°C for 5 hours. The mixture was then cooled to room temperature overnight. The bright orange precipitate that formed was collected on a fritted filter to give 1.1 g (90%) 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoic acid methyl ester (compound 5d). NMR analysis of the product provided the following data:

^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 3.93 (s, 3H), 7.14 (d, $J = 8.7$, 1H), 7.19 (m, 2H), 7.61 (s, 1H), 7.92 (d, $J = 8.7$, 2.3, 1H), 8.16 (d, $J = 2.3$, 1H), 10.71 (s, 1H).

EXAMPLE 5

Preparation of 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoic acid (5e)

This example describes conversion of
5 thiazolidinedione benzoic acid methyl esters to the
corresponding thiazolidinedione benzoic acids following
the reaction scheme shown in Figures 1 through 3.

The compound 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoic acid methyl
10 ester (compound 5d, 500 mg, 1.45 mmol) was suspended in
methanol. A solution of LiOH (800 mg, 16.7 mmol) in 8 ml
of H₂O was added. The reaction mixture was stirred at
room temperature for 20 hours. The clear solution was
then acidified with 2N HCl to pH 1 and quickly extracted
15 three times with EtOAc. The combined organic layers were
dried over MgSO₄, filtered, and concentrated in vacuo to
give 450 mg (94%) of 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoic acid
(compound 5e). NMR analysis showed the following:

20 ¹H NMR (300 MHz, DMSO-d₆): δ 6.76 (d, J = 8.5, 1H), 6.96
(d, J = 3.7, 1H), 7.14 (d, J = 3.7, 1H), 7.54 (s, 1H),
7.63 (dd, J = 8.5, 2.4, 1H), 8.14 (d, J = 2.4, 1H).

10031989-022102

EXAMPLE 6

Preparation of N-{3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-phenyl}-acetamide (compound 5f)

5 This example describes the synthesis of thiazolidinedione compounds following the reaction scheme shown in Figure 5. Compound numbers correspond to those in the figures.

10 Step a: Formation of N-[3-(5-formyl-furan-2-yl)-phenyl]-acetamide (compound 3f)

15 A mixture of 5-bromofuraldehyde (compound 11, 219 mg, 1.25 mmol), 3-acetamidophenylboronic acid (compound 10a, 291 mg, 1.63 mmol), Pd(PPh₃)₄ (72 mg, 0.062 mmol), sodium carbonate (345 mg, 3.25 mmol), dioxane (8 ml), and D. I. water (1ml) was deoxygenated with nitrogen (N₂). The mixture was then heated at 90°C for 10 hours and cooled to room temperature. The cooled mixture was poured onto a silica gel column and eluted with EtOAc / Hexane (1:1). The compound N-[3-(5-formyl-furan-2-yl)-phenyl]-acetamide (compound 3f, 290 mg, 1.26 mmol, 100%)
20 was obtained as a white solid. NMR analysis of the product gave the following:

¹H NMR (300 MHz, Acetone-d₆): δ 2.13 (s, 3H), 7.10 (d, J = 3.7, 1H), 7.39-7.44 (m, 1H), 7.53 (d, J = 3.7, 1H), 7.53

- 7.58 (m, 1H), 7.74 - 7.77 (m, 1H), 7.48 (d, $J = 1.7$, 1H), 9.67 (s, 1H).

Step b: Formation of N-{3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-phenyl}-acetamide
(compound 5f)

The compound N-{3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-phenyl}-acetamide (compound 5f) from N-[3-(5-formyl-furan-2-yl)-phenyl]-acetamide (compound 3f) was prepared following the procedure in step b of Example 1. The compound was obtained in 90% yield, and NMR analysis gave the following:

^1H NMR (300 MHz, DMSO- d_6): δ 2.08 (s, 3H), 7.18 (d, $J = 3.7$, 1H), 7.22 (d, $J = 3.7$, 1H), 7.39 - 7.59 (m, 3H), 7.62 (s, 1H), 8.08 (s, 1H).

EXAMPLE 7

Preparation of 5-[5-(3,4-dimethoxy-phenyl)-furan-2-yl-methylene]-thiazolidine-2,4-dione (compound 5g)

This example describes the synthesis of thiazolidinedione compounds following the reaction scheme show in Figure 5. Compound numbers correspond to those in the figure.

Step a: Formation of 5-(3,4-Dimethoxyphenyl)-2-furaldehyde (compound 3g)

The compound 5-(3,4-dimethoxyphenyl)-2-furaldehyde (compound 3g) was prepared from 3,4-dimethoxyphenylboronic acid (compound 10b) and 5-bromo-2-furaldehyde following the procedure in step a of Example 6. The compound was obtained in 90% yield, and NMR analysis gave the following:

¹H NMR (300 MHz, CDCl₃) δ 3.92 (m, 3H), 3.95 (s, 3H), 6.73 (d, *J* = 3.8, 1H), 6.92 (d, *J* = 8.4, 1H), 7.30 (m, 2H), 7.40 (dd, *J* = 2.0, 8.4, 1H), 9.59 (s, 1H); MS *m/z* 233 (M+1).

Step b: Formation of 5-[5-(3,4-dimethoxy-phenyl)-furan-2-yl-methylene]-thiazolidine-2,4-dione (compound 5g)

The compound 5-[5-(3,4-dimethoxy-phenyl)-furan-2-ylmethylene]-thiazolidine-2,4-dione (compound 5g) was prepared from 5-(3,4-dimethoxyphenyl)-2-furaldehyde (compound 3g) following the procedure in step b of Example 1. The product was obtained in 94% yield, and NMR analysis showed the following:

¹H NMR (300 MHz, CDCl₃) δ 3.95 (s, 3H), 3.99 (s, 1H), 6.79 (d, *J* = 3.9, 1H), 6.91 (d, *J* = 3.8, 1H), 6.98 (d, *J* = 8.4, 1H), 7.28 (s, 1H), 7.35 (dd, *J* = 8.4, 1.9, 1H), 7.62 (s, 1H); MS *m/z* 332 (M+1).

EXAMPLE 8

Preparation of 4-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 7a)

5 This example describes the synthesis of rhodanine compounds following the reaction scheme shown in Figure 2. The compound numbers correspond to those in the figure.

20 The compound 4-(5-formyl-furan-2-yl)-benzoic acid (compound 3a, 412 mg, 1.91 mmol), rhodanine (compound 6, 279 mg, 2.09 mmol), and piperidine (38 μ l, 0.384 mmol) were placed in 5 ml of ethanol in a vial. The mixture was stirred under microwave irradiation for 300 seconds at 160°C. The mixture was then cooled to room temperature, and the obtained orange precipitate was filtered, washed with a mixture of ethyl acetate and ether, and dried *in vacuo* to provide 4-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid as an orange powder (compound 7a, 477 mg, 75% yield). NMR analysis of the product provided the following:

^1H NMR (300 MHz, DMSO- d_6): δ 7.34 (d, J = 3.3, 1H), 7.45 (d, J = 3.2, 1H), 7.52 (s, 1H), 7.93 (d, J = 8.2, 2H) and 8.08 (d, J = 8.0, 2H); MS: m/z 332 (M+1).

EXAMPLE 9

Preparation of 3-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 7b)

5 This example describes the synthesis of rhodanine compounds following the reaction scheme of Figure 2. Compound numbers correspond to those in the figure.

20T22D"686TE00T
10 The compound 3-(5-formyl-furan-2-yl)-benzoic acid (compound 3b, 3.45 mmol), rhodanine (compound 6, 460 mg, 3.45 mmol), water (15 ml), and ethanolamine (21 μ l, 0.35 mmol) were placed in a flask. The suspension was stirred at 90°C for 3 hours. After cooling to room temperature, the resulting orange precipitate was filtered and dried *in vacuo* to give 3-[5-(4-oxo-2-thioxo-
15 thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 7b, 573 mg, 50% yield). NMR analysis of the product revealed:

^1H NMR (300 MHz, DMSO- d_6): δ 7.31 (d, J = 3.6, 1H), 7.43 (d, J = 3.6, 1H), 7.50 (s, 1H), 7.69 (t, J = 7.8, 1H),
20 7.97 (d, J = 7.7, 1H), 8.07 (d, J = 7.8, 1H), 8.38 (s, 1H).

EXAMPLE 10

Preparation of 5-[5-(4-hydroxy-phenyl)-furan-2-ylmethylene]-2-thioxo-thiazolidin-4-one (compound 7c)

5 This example describes the synthesis of rhodanine compounds following the reaction scheme of Figure 2. Compound numbers correspond to those in the figure.

10 The compound 5-[5-(4-hydroxy-phenyl)-furan-2-ylmethylene]-2-thioxo-thiazolidin-4-one (compound 7c) was prepared from 5-(4-hydroxy-phenyl)-furan-2-carbaldehyde (compound 3c) following the procedure in step b of Example 1. The compound was prepared in 81% yield. NMR analysis provided the following:

15 ^1H NMR (300 MHz, Acetone- d_6): δ 7.00 - 7.03 (m, 3H), 7.24 - 7.25 (m, 1H), 7.46 (s, 1H), 7.77 - 7.79 (m, 2H).

EXAMPLE 11

Preparation of 2-hydroxy-5-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid methyl ester (compound 7d)

20 This example describes the synthesis of rhodanine compounds following the reaction scheme shown in Figure 4. Compound numbers correspond to those in the figure.

The compound 2-hydroxy-5-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid methyl ester (compound 7d) was prepared from 5-(5-formyl-furan-2-yl)-2-hydroxy-benzoic acid methyl ester (compound 3d) following the procedure in Example 9. The compound was prepared in 83% yield. NMR analysis revealed the following:

^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 3.94 (s, 3H), 7.18 (d, J = 8.7, 1H), 7.23 (d, J = 3.5, 1H), 7.30 (d, J = 3.5, 1H), 7.50 (s, 1H), 7.97 (dd, J = 8.7, 1.9, 1H) and 8.26 (d, J = 1.9, 1H).

EXAMPLE 12

Preparation of 2-hydroxy-5-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 7e)

This example describes conversion of rhodanine benzoic acid methyl esters to the corresponding rhodanine benzoic acids.

The compound 2-hydroxy-5-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid methyl ester (compound 7d, 36 mg, 0.10 mmol) was suspended in methanol (0.5 ml) and THF (0.25 ml). A solution of LiOH (57 mg, 2.38 mmol) in H_2O (0.25 ml) was added. The reaction mixture was stirred at room temperature for 20 hours. The resulting clear solution

was then acidified with 2N HCl to pH = 1 and was quickly extracted three times with EtOAc. The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo to give 2-hydroxy-5-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 7e, 27 mg, 0.078 mmol, 78%). The product was analyzed by NMR to provide the following:

¹H NMR (300 MHz, CD₃OD): δ 6.88 (d, J = 3.7, 1H), 6.96 (d, J = 8.6, 1H), 7.07 (d, J = 3.7, 1H), 7.37 (s, 1H), 7.79 (dd, J = 8.6, 2.1, 1H), 8.33 (d, J = 2.1, 1H). MS (ESI negative mode): m/z 346 (M-1).

EXAMPLE 13

Preparation of 5-[5-(3,4-dimethoxy-phenyl)-furan-2-ylmethylene]-2-thioxo-thiazolidin-4-one (compound 7f)

This example describes the synthesis of rhodanine compounds following the reaction scheme show in Figure 6. Compound numbers correspond to those in the figure.

Step a: Formation of 5-(3,4-dimethoxyphenyl)-2-furaldehyde (7f)

A solution of 3,4-dimethoxyphenylboronic acid (compound 10b, 0.945 g, 5.2 mmol), 5-bromo-2-furaldehyde (0.696 g, 4 mmol), Pd(PPh₃)₄ (0.231 g, 0.2 mmol) and Na₂CO₃ (1.270 g, 12 mmol) in a mixture of 20 ml of water

and dioxane (1:10) was heated under N₂ at reflux overnight. The reaction mixture was concentrated, and the residue was purified by chromatography (EtOAc/hexanes 1:3) to give 5-(3,4-Dimethoxyphenyl)-2-furaldehyde (0.823 g, 90 %). The product was analyzed by NMR to give the following:

¹H NMR (300 MHz, CDCl₃) δ 3.92 (m, 3H), 3.95 (s, 3H), 6.73 (d, *J* = 3.8, 1H), 6.92 (d, *J* = 8.4, 1H), 7.30 (m, 2H), 7.40 (dd, *J* = 8.4, 2.0, 1H), 9.59 (s, 1H); MS *m/z* 233 (M+1).

Step b: Formation of 5-[5-(3,4-dimethoxy-phenyl)-furan-2-ylmethylene]-2-thioxo-thiazolidin-4-one (compound 7f)

A solution of 5-(3,4-dimethoxyphenyl)-2-furaldehyde (compound 3f, 100 mg, 0.43 mmol), rhodanine (compound 6, 75 mg, 0.64 mmol), and ethanolamine (26 μl, 0.43 mmol) in a mixture of 1 ml of AcOH and 5 ml of dioxane was heated at reflux for 3 hours. Concentration and recrystallization from ethanol afforded the coupling product 5-[5-(3,4-dimethoxy-phenyl)-furan-2-ylmethylene]-2-thioxo-thiazolidin-4-one (compound 7f, 81 mg, 93%). NMR analysis provided:

¹H NMR (300 MHz, CDCl₃) δ 3.93 (s, 3H), 4.01 (s, 3H), 6.77 (d, *J* = 3.8, 1H), 6.99 (m, 2H), 7.28 (m, 2H), 7.42 (s, 1H); MS *m/z* 347 (M+1).

EXAMPLE 14

Preparation of 4-(2-{4-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoylamino}-ethylsufanyl)-pyridine-2,6-dicarboxylic acid (compound 13a)

5 This example describes the synthesis of bi-ligands of the invention following the reaction scheme show in Figure 15. Compound numbers correspond to those in the figure.

10 The compound 4-amino-pyridine-2,6-dicarboxylic acid dimethyl ester (compound 12, free base, 75 mg, 0.277 mmol), 4-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 5a, 87 mg, 0.276 mg) and HOBt·H₂O (51 mg, 0.333 mmol) were dissolved in DMF (1ml). Triethylamine (46 µl, 0.331mmol) and 1-
15 dimethylaminopropyl-3-ethyl-carbodiimide (EDCI) (70 mg, 0.333 mmol) were added to the mixture which was then stirred at room temperature for 24 hours. The resulting precipitate (52.4 mg) was collected on a funnel and washed with DMF, aqueous 0.5N HCl, and MeOH.

20 Next, 48.2 mg of the solid was suspended in a mixture of MeOH (0.5 ml) and water (0.5 ml), followed by the addition of LiOH (14 mg, 0.585 mmol). The solution was then stirred at room temperature for 1.5 hours until homogenous. The homogenous solution was acidified with
25 aqueous 2N HCl, and the resulting precipitate was filtered, washed with water, and dried. The reaction

afforded a bright yellow solid: 4-(2-{4-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoylamino}-ethylsufanyl)-pyridine-2,6-dicarboxylic acid (compound 13a, 41.5 mg, 30%).

- 5 ^1H NMR (300 MHz, DMSO- d_6): δ 3.42 (m, 2H), 3.60 (m, 2H), 7.26 (d, J = 3.6, 1H), 7.41 (d, J = 3.5, 1H), 7.67 (s, 1H), 7.89 (d, J = 8.3, 2H), 7.95 (d, J = 8.4, 2H), 8.08 (s, 2H), 8.85 (br. t., 1H); MS m/z 540 ($M+1$).

EXAMPLE 15

- 10 Preparation of 4-(2-{4-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoylamino}-ethylsulfanyl)-pyridine-2,6-dicarboxylic acid (compound 13b)

- 15 This example describes the synthesis of bi-ligands of the invention following the reaction scheme shown in Figure 15. Compound numbers correspond to those in the figure.

- 20 The compound 4-amino-pyridine-2,6-dicarboxylic acid dimethyl ester (compound 12, HCl salt, 84 mg, 0.275 mmol), 4-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 7a, 91 mg, 0.275 mmol) and HOBT·H₂O (51 mg, 0.333 mmol) were dissolved in DMF (1 ml). Triethylamine (0.11 ml, 0.79 mmol) and EDCI (0.329 mmol) were added to the mixture, followed by stirring at room temperature for 24 hours.

Four drops of concentrated HCl were added to the mixture and induced formation of a precipitate (159 mg), which was filtered, washed with aqueous 0.1N HCl, and dried *in vacuo*. Then, 111 mg of this compound were placed in a mixture of water (0.5 ml) and MeOH (0.5 ml). LiOH (40 mg, 1.67 mmol) was added to the mixture which was stirred at room temperature for 2 hours.

The lithium salt of the expected compound precipitated from the solution and was isolated by filtration. The salt was dissolved in warm water (about 40°C) and precipitated by addition of aqueous 2N HCl. The precipitate was filtered and dried *in vacuo* to give 4-(2-{4-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoylamino}-ethylsulfanyl)-pyridine-2,6-dicarboxylic acid as a red powder (compound 13b, 41 mg, 38%).

^1H NMR (300 MHz, DMSO- d_6): δ 3.54 (br. t., 2H), 3.60 (br. t., 2H), 7.35 (d, $J = 3.5$, 1H), 7.44 (d, $J = 3.5$, 1H), 7.54 (s, 1H), 7.91 (d, $J = 8.2$, 2H), 7.99 (d, $J = 8.3$, 2H), 8.08 (s, 2H), 8.87 (br. t., 1H); MS m/z 556 (M+1).

EXAMPLE 16

Preparation of 4-(2-{3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoylamino}-ethylsulfanyl)-pyridine-2,6-dicarboxylic acid (13c)

5 This example describes the synthesis of bi-ligands of the invention following the reaction scheme shown in Figure 15. Compound numbers correspond to the numbers in the figure.

10 The compound 4-amino-pyridine-2,6-dicarboxylic acid dimethyl ester (compound 12, HCl salt, 100 mg, 0.326 mmol), 3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 5b, 103 mg, 0.327 mmol) and HOBt·H₂O (60 mg, 0.392 mmol) were dissolved in DMF (1 ml). Triethylamine (0.14 ml, 1.01 mmol) and EDCI
15 (75 mg, 0.391 mmol) were added to the mixture which was then stirred at room temperature for 2.5 days. The resulting solid (73 mg) was collected on a funnel, washed with aqueous 0.5N HCl and dried.

20 The product (63 mg) was suspended in a mixture of water (0.5 ml) and MeOH (0.5 ml), followed by the addition of LiOH (20 mg, 0.84 mmol). The mixture was then stirred at room temperature for 1.5 hours. Water was added, and the compound was precipitated by acidification with aqueous 2N HCl. After drying in
25 vacuo, we obtained pure 4-(2-{3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoylamino}-

ethylsulfanyl)-pyridine-2,6-dicarboxylic acid was obtained as a yellow powder (compound 13c, 49 mg, 32%).

¹H NMR (300 MHz, DMSO-d₆): δ 3.62 (br. m., 2H) and one signal overlapped by water at 3.44, 7.25 (d, *J* = 3.5, 1H), 7.33 (d, *J* = 3.5, 1H), 7.62 (t, *J* = 7.8, 1H), 7.67 (s, 1H), 7.81 (d, *J* = 7.7, 1H), 7.95 (d, *J* = 7.7, 1H), 8.08 (s, 2H), 8.24 (s, 1H), 8.91 (br. t., 1H); MS *m/z* 540 (M+1).

EXAMPLE 17

Preparation of 4-(2-{3-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoylamino}-ethylsulfanyl)-pyridine-2,6-dicarboxylic acid (13d)

This example describes the synthesis of bi-ligands of the invention following the reaction scheme of Figure 15. Compound numbers correspond to those in the figure.

The compound 4-amino-pyridine-2,6-dicarboxylic acid dimethyl ester (compound 12, free base, 80 mg, 0.296 mmol), 3-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl-furan-2-yl)-benzoic acid (compound 7b, 98 mg, 0.296 mmol) and HOBt·H₂O (54 mg, 0.353 mmol) were dissolved in DMF (1 ml). Triethylamine (49 l, 0.352 mmol) and EDCI (72 mg, 0.375 mmol) were added to the solution which was then stirred at room temperature for 30 hours. The resulting

orange precipitate (95 mg) was filtered, washed with DMF and aqueous 0.5N HCl, and dried.

The compound (88.2 mg) was suspended in a mixture of water (1 ml) and MeOH (1 ml), followed by the addition of LiOH (25 mg, 1.05 mmol). The solution was then stirred at room temperature for 2.5 hours, and the solution was acidified with aqueous 2N HCl. The resulting solid was filtered and washed with water. After drying 4-(2-{3-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoylamino}-ethylsulfanyl)-pyridine-2,6-dicarboxylic acid (compound 13d, 65 mg, 42%) was obtained as a red powder.

¹H NMR (300 MHz, DMSO-*d*₆): δ 3.63 (m, 2H) and one signal overlapped by water at 3.39, 7.35 (s, 2H), 7.55 (s, 1H), 7.63 (t, *J* = 7.7, 1H), 7.82 (d, *J* = 7.7, 1H), 7.97 (d, *J* = 7.7, 1H), 8.08 (s, 2H), 8.27 (s, 1H), 8.93 (br. t., *J* = 5.1, 1H); MS *m/z* 556 (*M*+1).

EXAMPLE 18

Preparation of 4-(2-{5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoylamino}-ethylsulfanyl)-pyridine-2,6-dicarboxylic acid (compound 13f)

This examples describes the synthesisi of bi-ligands of the invention following the reaction scheme

shown in Figure 15. Compound numbers correspond to those in the figure.

10084939.D22102
The compound 4-amino-pyridine-2,6-dicarboxylic acid dimethyl ester (compound 12, free base, 73 mg, 0.270 mmol), 5-[5-(2,4-dioxo-thiazolidin-5-ylidene methyl)-furan-2-yl]-2-hydroxy-benzoic acid (compound 5e, 89 mg, 0.269 mmol) and HOBt·H₂O (49 mg, 0.320 mmol) were dissolved in DMF (1 ml). Triethylamine (45 l, 0.324 mmol) and EDCI (62 mg, 0.323 mmol) were added to the mixture which was then stirred at room temperature for 30 hours. The reaction was acidified with HCl, inducing formation of an orange precipitate that was isolated by filtration.

The isolated compound was purified by flash chromatography (SiO₂, MeOH 5% to 7.5% in dichloromethane) and suspended in a mixture of MeOH (0.5 ml) and water (0.5 ml). LiOH (15 mg) was added to the mixture which was then stirred for 2 hours at room temperature to form a homogenous solution. The homogenous solution was then acidified by aqueous 2N HCl. The resulting compound was filtered and purified by preparative HPLC to give a reddish powder: 4-(2-{5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoylamino}-ethylsulfanyl)-pyridine-2,6-dicarboxylic acid (compound 13f, 16.1 mg, 15% yield).

¹H NMR (300 MHz, DMSO-*d*₆): δ 3.66 (m, 2H) and signal overlapped by water at 3.37, 7.10 (m, 2H), 7.22 (d, *J* = 3.0, 1H), 7.63 (s, 1H), 7.81 (d, *J* = 8.1, 1H), 8.11 (s,

2H), 8.24 (s, 1H), 9.12 (br. t., 1H); MS m/z 468 (M+H-2CO₂).

EXAMPLE 19

Preparation of Common Ligand Mimics having Amide Linkers

5 This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 7. Compound numbers correspond to the numbers in the figure.

10 In a 500 ml round-bottom flask, compound 5 (6.3 g, 20 mM) was dissolved in dry DMF (120 ml) by heating. The solution was cooled to a temperature of 40 to 50°C. THF (ca 150 ml) and 1,1'-carbonyldiimidazole (4.5 g) were added to the solution. After shaking for 20 minutes, the flask was capped and refrigerated overnight at -10 °C.

15 The precipitate was collected by filtration and washed with THF to provide intermediate compound 14 (5.3-6.0g).

20 A mixture of dry DMF (30 ml) and dry THF (80 ml) was prepared in a 250 ml flask. Intermediate compound 14 (5.3-6.0g) was added to the mixture. Boc protected diamines (1.2 eq) were added to the mixture which then was heated at a temperature of 65°C for a period of 1 hour. By this time, the undissolved solid had dissolved, and a clear solution was obtained. The solvent was then evaporated under reduced pressure.

20250922 10:04:59

A solution of 50% trifluoroacetic acid in dichloroethane (100 ml) was added and reacted for 10 minutes. Extra solvent was evaporated, resulting in a yellow solid. The yellow solid was then dissolved in 40 to 50 ml of DMF by heating. The solution was cooled to room temperature, and a Na_2CO_3 solution (150-200 ml, 5%) was added. When a yellow precipitate formed, it was filtered. Otherwise, more DMF solvent was evaporated, and more water was added. The yellow solid, compound 16, was washed with a mixture of water and MeOH and then dried to provide 5 to 5.5 g of product 16.

Compound 16a (CLM-3-COOH, $n = 0$); MW calcd 357.38, found: MW 358.02;
Compound 16b (CLM-3-COOH, $n = 1$), MW calcd 371.41, found: MW 372.05;
Compound 16c (CLM-3-COOH, $n = 2$), MW calcd 385.44, found: MW 386.10;
Compound 16d (CLM-4-COOH, $n = 0$); MW calcd 357.38, found: MW 358.02;
Compound 16e (CLM-4-COOH, $n = 1$), MW calcd 371.41, found: MW 372.05;
Compound 16f (CLM-4-COOH, $n = 2$), MW calcd 385.44, found: MW 386.10.

EXAMPLE 20

Preparation of 5-(4-N-Boc-aminoethylphenyl)-2-((2,4-thiazolidinedion-5-yl)methylene)furan

5 This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 8.

Step a: Formation of N-Boc-4-bromophenethylamine

10 The compound 4-bromophenethylamine (50 g, 0.180 mol) and NaHCO₃ (15.12 g, 0.480 mol) were suspended in 300 ml of aqueous acetone (5% water) at a temperature of 0°C. A solution of di-tert-butylidicarbonate (38.80 g, 0.180 mol) in 50 ml of acetone was added dropwise to the solution. The solution was then stirred overnight at room temperature.

15 The reaction mixture was poured into 200 ml of water and extracted with ethyl acetate (2 × 250 ml). The extracts were dried with MgSO₄ and concentrated to give a white powder (53.8 g, 98.9%) that was pure enough for the next step.

20 ¹H NMR (CDCl₃) δ 7.77 (d, J = 8.9 Hz, 2 H), 7.08 (d, J = 8.5 Hz, 2 H), 3.36 (m, 2 H), 2.73 (m, 2 H), 1.44 (s, 9 H) ppm. MS (M+1⁺) 303.

20160227-022102

Step b: Formation of 5-(4-N-Boc-aminoethylphenyl)-2-furaldehyde

A mixture of N-Boc-4-bromophenethylamine (95.0 g, 0.314 mol), 5-trimethylstannanyl-2-furaldehyde (94.3 g, 0.330 mol), and tetrakis(triphenylphosphine)palladium (17.3 g, 0.016 mol) in 300 ml of DMF was heated to a temperature of 60°C for a period of 24 hours. The reaction mixture was concentrated under reduce pressure, and the residue was purified by chromatography (EtOAc/Hexanes 5:1) to give 83.0 (83.9%) of 5-(4-N-Boc-aminoethylphenyl)-2-furaldehyde.

^1H NMR (CDCl_3) δ 9.65 (s, 1 H), 7.79 (d, J = 8.1 Hz, 2 H), 7.30 (m, 3 H), 6.82 (d, J = 3.5 Hz, 1 H), 3.41 (m, 2 H), 2.85 (m, 2 H), 1.44 (s, 9 H) ppm. MS ($\text{M}+1^+$) 316.

Step c: Formation of 5-(4-N-Boc-aminoethylphenyl)-2-((2,4-thiazolidinedion-5-yl)methylene)furan

A solution of 5-(4-N-Boc-aminoethylphenyl)-2-furaldehyde (25.0 g, 0.079 mol), 2,4-thiazolidinedione (9.3 g, 0.079 mol), and ethanolamine (0.5 g, 0.005 mol) in 100 ml of dioxane was heated to reflux for 3 days. The reaction mixture was concentrated, and the resultant residue was triturated several times with ethyl acetate. The precipitates were collected by filtration to give 23.5 g (72.0%) of 5-(4-N-Boc-aminoethylphenyl)-2-((2,4-thiazolidinedion-5-yl)methylene)furan.

¹H NMR (CDCl₃) δ 7.74 (d, J = 6.6 Hz, 2 H), 7.63 (d, J = 2.2 Hz, 1 H), 7.35 (d, J = 6.7 Hz, 2 H), 7.22 (d, J = 2.0 Hz, 2 H), 6.90 (t, J = 3.9 Hz, 1 H), 3.13 (m, 2 H), 2.73 (m, 2 H), 1.35 (s, 9 H) ppm. MS (M+1⁺) 314.

5

EXAMPLE 21

Preparation of 5-[5-(2,4-dioxothiazolidin-5-ylidenemethyl)-furan-2-yl]-nicotinic acid (compound 20a)

10 This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 9. Compound numbers correspond to the numbers in the figure.

Step a: Preparation of 5-(5-formylfuran-2-yl)-nicotinic acid (compound 19a)

15 The compounds 2-formylfuran-5-boronic acid (compound 17, 289 mg, 2.06 mmol), 5-bromonicotinic acid (compound 18a, 500 mg, 2.48 mmol) and sodium carbonate (262 mg, 2.48 mmol) were added to a mixture of dioxane (10 ml), water (5 ml), ethanol (4 ml), and DMF (0.5 ml). Dichlorobis(triphenylphosphine)palladium (87 mg, 0.12
20 mmol) was added to the mixture, and the mixture was heated to a temperature of 90°C for 15 hours. Volatiles were removed *in vacuo*, and the residue was diluted with water, followed by extraction with ethyl acetate. Combined organic layers were dried over Mg₂SO₄, filtered,
25 and concentrated *in vacuo*. The crude product was

purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 10:1) to give 5-(5-formylfuran-2-yl)-nicotinic acid (compound 19a, 250 mg, 47%).

^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.70 (d, $J = 3.0$, 1H), 7.57 (d, $J = 3.0$, 1H), 8.59 (s, 1H), 9.06 (s, 1H), 9.28 (s, 1H), 9.67 (s, 1H); ^{13}C NMR (300 MHz, $\text{DMSO}-d_6$) δ 110.9, 124.9, 127.4, 132.3, 149.4, 150.4, 152.4, 154.5, 165.8.

Step b: 5-[5-(2,4-dioxothiazolidin-5-ylidenemethyl)-furan-2-yl]-nicotinic acid (compound 20a)

10 The compounds 5-(5-formylfuran-2-yl)-nicotinic acid (compound 19a, 78.1 mg, 0.360 mmol) and 2,4-thiazolidinedione (63.2 mg, 0.539 mmol) were mixed in ethanol (5 ml). Piperidine (2 drops) was added, and the reaction was stirred at a temperature of 70°C for a
15 period of 36 hours. The resulting orange precipitate was collected on filter paper using a Büchner funnel. The solid was washed with ethyl acetate, followed by ethyl ether, to give pure 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-nicotinic acid (compound 20a,
20 95 mg, 84%).

^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.18 (d, $J = 3.6$, 1H), 7.54 (d, $J = 3.6$, 1H), 7.56 (s, 1H), 8.56 (s, 1H), 9.02 (s, 1H), 9.22 (d, $J = 1.4$, 1H); MS m/z 317.15 ($M+1$).

EXAMPLE 22

Preparation of 5-[5-(2,4-dioxothiazolidin-5-ylidenemethyl)-furan-2-yl]-N-(3-hydroxypropyl)-nicotinamide (compound 20b)

5 This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 9. Compound numbers correspond to the numbers in the figure.

10 Step a: Formation of 5-(5-formylfuran-2-yl)-N-(3-hydroxypropyl)-nicotinamide (compound 19b)

15 The compounds 2-formylfuran-5-boronic acid (compound 17, 225 mg, 1.61 mmol), 5-bromo-N-(3-hydroxypropyl)-nicotinamide (compound 18b, 530 mg, 1.93 mmol) and sodium carbonate (205 mg, 1.93 mmol) were added to a mixture of dioxane (7 ml), water (3 ml), ethanol (2 ml) and DMF (0.4 ml). Dichlorobis(triphenylphosphine) palladium (67.8 mg, 0.0966 mmol) was added, and the reaction was heated to a temperature of 80°C for 5 hours.

20 Another portion of dichlorobis(triphenylphosphine)palladium (67.8 mg, 0.0966 mmol) and 2-formylfuran-5-boronic acid (compound 17, 23 mg, 0.19 mmol) was added to the reaction mixture, which was then stirred overnight at room temperature. Volatiles were removed *in vacuo*, and the residue was diluted with

saturated NaHCO₃ solution, followed by extraction with ethyl acetate.

Combined organic layers were dried over Mg₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified by flash chromatography (EtOAc/MeOH, 9:1) to give 5-(5-formylfuran-2-yl)-N-(3-hydroxypropyl)-nicotinamide (compound 19b, 358 mg, 81.2%).

¹H NMR (300 MHz, MeOH-*d*₃) δ 1.88 (m, 2H), 3.52 (m, 2H), 3.69 (m, 2H), 7.24 (d, *J* = 3.8, 1H), 7.51 (d, *J* = 3.8, 1H), 8.53 (m, 1H), 8.91 (d, *J* = 1.7, 1H), 9.06 (d, *J* = 1.7, 1H), 9.62 (s, 1H); ¹³C NMR (300 MHz, MeOH-*d*₃) δ 33.2, 38.5, 60.7, 111.5, 125.3, 126.9, 132.1, 132.5, 139.3, 149.1, 149.5, 154.4, 156.4, 167.1; MS *m/z* 374.2 (M+1).

Step b: Formation of 5-[5-(2,4-dioxothiazolidin-5-ylidenemethyl)-furan-2-yl]-N-(3-hydroxypropyl)-nicotinamide (compound 20b)

The compounds 5-(5-formylfuran-2-yl)-N-(3-hydroxypropyl)-nicotinamide (compound 19b, 123 mg, 0.448 mmol) and 2,4-thiazolidinedione (64.2 mg, 0.493 mmol) were mixed in ethanol (5 ml). Piperidine (1 drop) was added, and the reaction was stirred at a temperature of 70°C for a period of 2 hours. The resulting orange precipitate was collected on filter paper using a Büchner funnel. The solid was washed with ethyl acetate, followed by ethyl ether, to give pure 5-[5-(2,4-


Dioxothiazolidin-5-ylidenemethyl)-furan-2-yl]-N-(3-hydroxypropyl)-nicotinamide (compound 20b, 115 mg, 76%).

¹H NMR (300 MHz, DMSO-*d*₆) δ 1.71 (dt, *J* = 6.7, 6.7, 2H), 3.37 (m, 2H), 3.48 (m, 2H), 4.49 (bs, 1H), 7.28 (d, *J* = 3.7, 1H), 7.48 (d, *J* = 3.7, 1H), 7.68 (s, 1H), 8.50 (m, 1H), 8.76 (m, 1H), 8.96 (d, *J* = 1.8, 1H), 9.13 (d, *J* = 2.0, 1H); ¹³C NMR (300 MHz, DMSO-*d*₆) δ 32.3, 36.7, 58.5, 111.6, 117.6, 120.6, 121.4, 124.7, 130.1, 130.5, 149.9, 153.3, 164.2, 167.0, 168.4.

10 Examples of compounds which can be produced by the methods described in Examples 19 to 22 include those in Tables 6 to 12.

201220-68678001


TABLE 6



	Y		Y		Y		Y		Y
1	OH	2	OH	3	OH	4	OH	5	OH
1	SH	2	SH	3	SH	4	SH	5	SH
1	COOH	2	COOH	3	COOH	4	COOH	5	COOH
1	SO ₂ H	2	SO ₂ H	3	SO ₂ H	4	SO ₂ H	5	SO ₂ H
1	Cl	2	Cl	3	Cl	4	Cl	5	Cl
1	Br	2	Br	3	Br	4	Br	5	Br
1	I	2	I	3	I	4	I	5	I
1	F	2	F	3	F	4	F	5	F
1	CN	2	CN	3	CN	4	CN	5	CN
1	N ₃	2	N ₃	3	N ₃	4	N ₃	5	N ₃
1	CONH ₂	2	CONH ₂	3	CONH ₂	4	CONH ₂	5	CONH ₂
1	CH=CH ₂	2	CH=CH ₂	3	CH=CH ₂	4	CH=CH ₂	5	CH=CH ₂
1	C≡CH	2	C≡CH	3	C≡CH	4	C≡CH	5	C≡CH
1	NH ₂	2	NH ₂	3	NH ₂	4	NH ₂	5	NH ₂
1	NHR	2	NHR	3	NHR	4	NHR	5	NHR
1	COH	2	COH	3	COH	4	COH	5	COH
1	COR	2	COR	3	COR	4	COR	5	COR

R= alkyl, alkenyl, alkynyl, aryl, or heterocycle

TABLE 7



n	E	Y	n	E	Y	N	E	Y	n	E	Y
0	O	OH	0	S	OH	0	NH	OH	0	NR	OH
0	O	SH	0	S	SH	0	NH	SH	0	NR	SH
0	O	COOH	0	S	COOH	0	NH	COOH	0	NR	COOH
0	O	SO ₂ H	0	S	SO ₂ H	0	NH	SO ₂ H	0	NR	SO ₂ H
0	O	Cl	0	S	Cl	0	NH	Cl	0	NR	Cl
0	O	Br	0	S	Br	0	NH	Br	0	NR	Br
0	O	I	0	S	I	0	NH	I	0	NR	I
0	O	F	0	S	F	0	NH	F	0	NR	F
0	O	CN	0	S	CN	0	NH	CN	0	NR	CN
0	O	N ₃	0	S	N ₃	0	NH	N ₃	0	NR	N ₃
0	O	CONH ₂	0	S	CONH ₂	0	NH	CONH ₂	0	NR	CONH ₂
0	O	CH=CH ₂	0	S	CH=CH ₂	0	NH	CH=CH ₂	0	NR	CH=CH ₂
0	O	C≡CH	0	S	C≡CH	0	NH	C≡CH	0	NR	C≡CH
0	O	NH ₂	0	S	NH ₂	0	NH	NH ₂	0	NR	NH ₂
0	O	NHR	0	S	NHR	0	NH	NHR	0	NR	NHR
0	O	COH	0	S	COH	0	NH	COH	0	NR	COH
0	O	COR	0	S	COR	0	NH	COR	0	NR	COR
0	CH ₂	OH	0	COR ₁ R ₂	OH	0	CONH	OH	0	CONR	OH
0	CH ₂	SH	0	COR ₁ R ₂	SH	0	CONH	SH	0	CONR	SH
0	CH ₂	COOH	0	COR ₁ R ₂	COOH	0	CONH	COOH	0	CONR	COOH

0	CH ₂	SO ₂ H	0	COR ₁ R ₂	SO ₂ H	0	CONH	SO ₂ H	0	CONR	SO ₂ H
0	CH ₂	Cl	0	COR ₁ R ₂	Cl	0	CONH	Cl	0	CONR	Cl
0	CH ₂	Br	0	COR ₁ R ₂	Br	0	CONH	Br	0	CONR	Br
0	CH ₂	I	0	COR ₁ R ₂	I	0	CONH	I	0	CONR	I
0	CH ₂	F	0	COR ₁ R ₂	F	0	CONH	F	0	CONR	F
0	CH ₂	CN	0	COR ₁ R ₂	CN	0	CONH	CN	0	CONR	CN
0	CH ₂	N ₃	0	COR ₁ R ₂	N ₃	0	CONH	N ₃	0	CONR	N ₃
0	CH ₂	CONH ₂	0	COR ₁ R ₂	CONH ₂	0	CONH	CONH ₂	0	CONR	CONH ₂
0	CH ₂	CH=CH ₂	0	COR ₁ R ₂	CH=CH ₂	0	CONH	CH=CH ₂	0	CONR	CH=CH ₂
0	CH ₂	C≡CH	0	COR ₁ R ₂	C≡CH	0	CONH	C≡CH	0	CONR	C≡CH
0	CH ₂	NH ₂	0	COR ₁ R ₂	NH ₂	0	CONH	NH ₂	0	CONR	NH ₂
0	CH ₂	NHR	0	COR ₁ R ₂	NHR	0	CONH	NHR	0	CONR	NHR
0	CH ₂	COH	0	COR ₁ R ₂	COH	0	CONH	COH	0	CONR	COH
0	CH ₂	COR	0	COR ₁ R ₂	COR	0	CONH	COR	0	CONR	COR
0	SO ₂ NH	OH	0	SO ₂ NR	OH	0	NHCONH	OH	0	NRCONR	OH
0	SO ₂ NH	SH	0	SO ₂ NR	SH	0	NHCONH	SH	0	NRCONR	SH
0	SO ₂ NH	COOH	0	SO ₂ NR	COOH	0	NHCONH	COOH	0	NRCONR	COOH
0	SO ₂ NH	SO ₂ H	0	SO ₂ NR	SO ₂ H	0	NHCONH	SO ₂ H	0	NRCONR	SO ₂ H
0	SO ₂ NH	Cl	0	SO ₂ NR	Cl	0	NHCONH	Cl	0	NRCONR	Cl
0	SO ₂ NH	Br	0	SO ₂ NR	Br	0	NHCONH	Br	0	NRCONR	Br
0	SO ₂ NH	I	0	SO ₂ NR	I	0	NHCONH	I	0	NRCONR	I
0	SO ₂ NH	F	0	SO ₂ NR	F	0	NHCONH	F	0	NRCONR	F
0	SO ₂ NH	CN	0	SO ₂ NR	CN	0	NHCONH	CN	0	NRCONR	CN
0	SO ₂ NH	N ₃	0	SO ₂ NR	N ₃	0	NHCONH	N ₃	0	NRCONR	N ₃
0	SO ₂ NH	CONH ₂	0	SO ₂ NR	CONH ₂	0	NHCONH	CONH ₂	0	NRCONR	CONH ₂
0	SO ₂ NH	CH=CH ₂	0	SO ₂ NR	CH=CH ₂	0	NHCONH	CH=CH ₂	0	NRCONR	CH=CH ₂
0	SO ₂ NH	C≡CH	0	SO ₂ NR	C≡CH	0	NHCONH	C≡CH	0	NRCONR	C≡CH
0	SO ₂ NH	NH ₂	0	SO ₂ NR	NH ₂	0	NHCONH	NH ₂	0	NRCONR	NH ₂
0	SO ₂ NH	NHR	0	SO ₂ NR	NHR	0	NHCONH	NHR	0	NRCONR	NHR
0	SO ₂ NH	COH	0	SO ₂ NR	COH	0	NHCONH	COH	0	NRCONR	COH
0	SO ₂ NH	COR	0	SO ₂ NR	COR	0	NHCONH	COR	0	NRCONR	COR
0	NHCNHNH	OH	0	NRCNHNH	OH	0	NHCOO	OH	0	NRCOO	OH
0	NHCNHNH	SH	0	NRCNHNH	SH	0	NHCOO	SH	0	NRCOO	SH
0	NHCNHNH	COOH	0	NRCNHNH	COOH	0	NHCOO	COOH	0	NRCOO	COOH
0	NHCNHNH	SO ₂ H	0	NRCNHNH	SO ₂ H	0	NHCOO	SO ₂ H	0	NRCOO	SO ₂ H
0	NHCNHNH	Cl	0	NRCNHNH	Cl	0	NHCOO	Cl	0	NRCOO	Cl
0	NHCNHNH	Br	0	NRCNHNH	Br	0	NHCOO	Br	0	NRCOO	Br
0	NHCNHNH	I	0	NRCNHNH	I	0	NHCOO	I	0	NRCOO	I

0	NHCNHNH	F	0	NRCNHNH	F	0	NHCOO	F	0	NRCOO	F
0	NHCNHNH	CN	0	NRCNHNH	CN	0	NHCOO	CN	0	NRCOO	CN
0	NHCNHNH	N ₃	0	NRCNHNH	N ₃	0	NHCOO	N ₃	0	NRCOO	N ₃
0	NHCNHNH	CONH ₂	0	NRCNHNH	CONH ₂	0	NHCOO	CONH ₂	0	NRCOO	CONH ₂
0	NHCNHNH	CH=CH ₂	0	NRCNHNH	CH=CH ₂	0	NHCOO	CH=CH ₂	0	NRCOO	CH=CH ₂
0	NHCNHNH	CC≡H	0	NRCNHNH	C≡CH	0	NHCOO	C≡CH	0	NRCOO	C≡CH
0	NHCNHNH	NH ₂	0	NRCNHNH	NH ₂	0	NHCOO	NH ₂	0	NRCOO	NH ₂
0	NHCNHNH	NHR	0	NRCNHNH	NHR	0	NHCOO	NHR	0	NRCOO	NHR
0	NHCNHNH	COH	0	NRCNHNH	COH	0	NHCOO	COH	0	NRCOO	COH
0	NHCNHNH	COR	0	NRCNHNH	COR	0	NHCOO	COR	0	NRCOO	COR
0	C≡C	OH	0	CH ₂ =CH ₂	OH	1	O	OH	1	S	OH
0	C≡C	SH	0	CH ₂ =CH ₂	SH	1	O	SH	1	S	SH
0	C≡C	COOH	0	CH ₂ =CH ₂	COOH	1	O	COOH	1	S	COOH
0	C≡C	SO ₂ H	0	CH ₂ =CH ₂	SO ₂ H	1	O	SO ₂ H	1	S	SO ₂ H
0	C≡C	Cl	0	CH ₂ =CH ₂	Cl	1	O	Cl	1	S	Cl
0	C≡C	Br	0	CH ₂ =CH ₂	Br	1	O	Br	1	S	Br
0	C≡C	I	0	CH ₂ =CH ₂	I	1	O	I	1	S	I
0	C≡C	F	0	CH ₂ =CH ₂	F	1	O	F	1	S	F
0	C≡C	CN	0	CH ₂ =CH ₂	CN	1	O	CN	1	S	CN
0	C≡C	N ₃	0	CH ₂ =CH ₂	N ₃	1	O	N ₃	1	S	N ₃
0	C≡C	CONH ₂	0	CH ₂ =CH ₂	CONH ₂	1	O	CONH ₂	1	S	CONH ₂
0	C≡C	CH=CH ₂	0	CH ₂ =CH ₂	CH=CH ₂	1	O	CH=CH ₂	1	S	CH=CH ₂
0	C≡C	C≡CH	0	CH ₂ =CH ₂	C≡CH	1	O	C≡CH	1	S	C≡CH
0	C≡C	NH ₂	0	CH ₂ =CH ₂	NH ₂	1	O	NH ₂	1	S	NH ₂
0	C≡C	NHR	0	CH ₂ =CH ₂	NHR	1	O	NHR	1	S	NHR
0	C≡C	COH	0	CH ₂ =CH ₂	COH	1	O	COH	1	S	COH
0	C≡C	COR	0	CH ₂ =CH ₂	COR	1	O	COR	1	S	COR
1	NH	OH	1	NR	OH	1	CH ₂	OH	1	COR ₁ R ₂	OH
1	NH	SH	1	NR	SH	1	CH ₂	SH	1	COR ₁ R ₂	SH
1	NH	COOH	1	NR	COOH	1	CH ₂	COOH	1	COR ₁ R ₂	COOH
1	NH	SO ₂ H	1	NR	SO ₂ H	1	CH ₂	SO ₂ H	1	COR ₁ R ₂	SO ₂ H
1	NH	Cl	1	NR	Cl	1	CH ₂	Cl	1	COR ₁ R ₂	Cl
1	NH	Br	1	NR	Br	1	CH ₂	Br	1	COR ₁ R ₂	Br
1	NH	I	1	NR	I	1	CH ₂	I	1	COR ₁ R ₂	I
1	NH	F	1	NR	F	1	CH ₂	F	1	COR ₁ R ₂	F
1	NH	CN	1	NR	CN	1	CH ₂	CN	1	COR ₁ R ₂	CN

1	NH	N ₃	1	NR	N ₃	1	CH ₂	N ₃	1	COR ₁ R ₂	N ₃
1	NH	CONH ₂	1	NR	CONH ₂	1	CH ₂	CONH ₂	1	COR ₁ R ₂	CONH ₂
1	NH	CH=CH ₂	1	NR	CH=CH ₂	1	CH ₂	CH=CH ₂	1	COR ₁ R ₂	CH=CH ₂
1	NH	C≡CH	1	NR	C≡CH	1	CH ₂	C≡CH	1	COR ₁ R ₂	C≡CH
1	NH	NH ₂	1	NR	NH ₂	1	CH ₂	NH ₂	1	COR ₁ R ₂	NH ₂
1	NH	NHR	1	NR	NHR	1	CH ₂	NHR	1	COR ₁ R ₂	NHR
1	NH	COH	1	NR	COH	1	CH ₂	COH	1	COR ₁ R ₂	COH
1	NH	COR	1	NR	COR	1	CH ₂	COR	1	COR ₁ R ₂	COR
1	CONH	OH	1	CONR	OH	1	SO ₂ NH	OH	1	SO ₂ NR	OH
1	CONH	SH	1	CONR	SH	1	SO ₂ NH	SH	1	SO ₂ NR	SH
1	CONH	COOH	1	CONR	COOH	1	SO ₂ NH	COOH	1	SO ₂ NR	COOH
1	CONH	SO ₂ H	1	CONR	SO ₂ H	1	SO ₂ NH	SO ₂ H	1	SO ₂ NR	SO ₂ H
1	CONH	Cl	1	CONR	Cl	1	SO ₂ NH	Cl	1	SO ₂ NR	Cl
1	CONH	Br	1	CONR	Br	1	SO ₂ NH	Br	1	SO ₂ NR	Br
1	CONH	I	1	CONR	I	1	SO ₂ NH	I	1	SO ₂ NR	I
1	CONH	F	1	CONR	F	1	SO ₂ NH	F	1	SO ₂ NR	F
1	CONH	CN	1	CONR	CN	1	SO ₂ NH	CN	1	SO ₂ NR	CN
1	CONH	N ₃	1	CONR	N ₃	1	SO ₂ NH	N ₃	1	SO ₂ NR	N ₃
1	CONH	CONH ₂	1	CONR	CONH ₂	1	SO ₂ NH	CONH ₂	1	SO ₂ NR	CONH ₂
1	CONH	CH=CH ₂	1	CONR	CH=CH ₂	1	SO ₂ NH	CH=CH ₂	1	SO ₂ NR	CH=CH ₂
1	CONH	C≡CH	1	CONR	C≡CH	1	SO ₂ NH	C≡CH	1	SO ₂ NR	C≡CH
1	CONH	NH ₂	1	CONR	NH ₂	1	SO ₂ NH	NH ₂	1	SO ₂ NR	NH ₂
1	CONH	NHR	1	CONR	NHR	1	SO ₂ NH	NHR	1	SO ₂ NR	NHR
1	CONH	COH	1	CONR	COH	1	SO ₂ NH	COH	1	SO ₂ NR	COH
1	CONH	COR	1	CONR	COR	1	SO ₂ NH	COR	1	SO ₂ NR	COR
1	NHCONH	OH	1	NRCONR	OH	1	NHCNHNH	OH	1	NRCNHNH	OH
1	NHCONH	SH	1	NRCONR	SH	1	NHCNHNH	SH	1	NRCNHNH	SH
1	NHCONH	COOH	1	NRCONR	COOH	1	NHCNHNH	COOH	1	NRCNHNH	COOH
1	NHCONH	SO ₂ H	1	NRCONR	SO ₂ H	1	NHCNHNH	SO ₂ H	1	NRCNHNH	SO ₂ H
1	NHCONH	Cl	1	NRCONR	Cl	1	NHCNHNH	Cl	1	NRCNHNH	Cl
1	NHCONH	Br	1	NRCONR	Br	1	NHCNHNH	Br	1	NRCNHNH	Br
1	NHCONH	I	1	NRCONR	I	1	NHCNHNH	I	1	NRCNHNH	I
1	NHCONH	F	1	NRCONR	F	1	NHCNHNH	F	1	NRCNHNH	F
1	NHCONH	CN	1	NRCONR	CN	1	NHCNHNH	CN	1	NRCNHNH	CN
1	NHCONH	N ₃	1	NRCONR	N ₃	1	NHCNHNH	N ₃	1	NRCNHNH	N ₃
1	NHCONH	CONH ₂	1	NRCONR	CONH ₂	1	NHCNHNH	CONH ₂	1	NRCNHNH	CONH ₂
1	NHCONH	CH=CH ₂	1	NRCONR	CH=CH ₂	1	NHCNHNH	CH=CH ₂	1	NRCNHNH	CH=CH ₂
1	NHCONH	C≡CH	1	NRCONR	C≡CH	1	NHCNHNH	C≡CH	1	NRCNHNH	C≡CH

1	NHCONH	NH ₂	1	NRCONR	NH ₂	1	NHCNHNH	NH ₂	1	NRCNHNH	NH ₂
1	NHCONH	NHR	1	NRCONR	NHR	1	NHCNHNH	NHR	1	NRCNHNH	NHR
1	NHCONH	COH	1	NRCONR	COH	1	NHCNHNH	COH	1	NRCNHNH	COH
1	NHCONH	COR	1	NRCONR	COR	1	NHCNHNH	COR	1	NRCNHNH	COR
1	NHCOO	OH	1	NRCOO	OH	1	C≡C	OH	1	CH=CH ₂	OH
1	NHCOO	SH	1	NRCOO	SH	1	C≡C	SH	1	CH=CH ₂	SH
1	NHCOO	COOH	1	NRCOO	COOH	1	C≡C	COOH	1	CH=CH ₂	COOH
1	NHCOO	SO ₂ H	1	NRCOO	SO ₂ H	1	C≡C	SO ₂ H	1	CH=CH ₂	SO ₂ H
1	NHCOO	Cl	1	NRCOO	Cl	1	C≡C	Cl	1	CH=CH ₂	Cl
1	NHCOO	Br	1	NRCOO	Br	1	C≡C	Br	1	CH=CH ₂	Br
1	NHCOO	I	1	NRCOO	I	1	C≡C	I	1	CH=CH ₂	I
1	NHCOO	F	1	NRCOO	F	1	C≡C	F	1	CH=CH ₂	F
1	NHCOO	CN	1	NRCOO	CN	1	C≡C	CN	1	CH=CH ₂	CN
1	NHCOO	N ₃	1	NRCOO	N ₃	1	C≡C	N ₃	1	CH=CH ₂	N ₃
1	NHCOO	CONH ₂	1	NRCOO	CONH ₂	1	C≡C	CONH ₂	1	CH=CH ₂	CONH ₂
1	NHCOO	CH=CH ₂	1	NRCOO	CH=CH ₂	1	C≡C	CH=CH ₂	1	CH=CH ₂	CH=CH ₂
1	NHCOO	C≡CH	1	NRCOO	C≡CH	1	C≡C	CCH	1	CH=CH ₂	CCH
1	NHCOO	NH ₂	1	NRCOO	NH ₂	1	C≡C	NH ₂	1	CH=CH ₂	NH ₂
1	NHCOO	NHR	1	NRCOO	NHR	1	C≡C	NHR	1	CH=CH ₂	NHR
1	NHCOO	COH	1	NRCOO	COH	1	C≡C	COH	1	CH=CH ₂	COH
1	NHCOO	COR	1	NRCOO	COR	1	C≡C	COR	1	CH=CH ₂	COR
2	O	OH	2	S	OH	2	NH	OH	2	NR	OH
2	O	SH	2	S	SH	2	NH	SH	2	NR	SH
2	O	COOH	2	S	COOH	2	NH	COOH	2	NR	COOH
2	O	SO ₂ H	2	S	SO ₂ H	2	NH	SO ₂ H	2	NR	SO ₂ H
2	O	Cl	2	S	Cl	2	NH	Cl	2	NR	Cl
2	O	Br	2	S	Br	2	NH	Br	2	NR	Br
2	O	I	2	S	I	2	NH	I	2	NR	I
2	O	F	2	S	F	2	NH	F	2	NR	F
2	O	CN	2	S	CN	2	NH	CN	2	NR	CN
2	O	N ₃	2	S	N ₃	2	NH	N ₃	2	NR	N ₃
2	O	CONH ₂	2	S	CONH ₂	2	NH	CONH ₂	2	NR	CONH ₂
2	O	CH=CH ₂	2	S	CH=CH ₂	2	NH	CH=CH ₂	2	NR	CH=CH ₂
2	O	C≡CH	2	S	C≡CH	2	NH	C≡CH	2	NR	C≡CH
2	O	NH ₂	2	S	NH ₂	2	NH	NH ₂	2	NR	NH ₂
2	O	NHR	2	S	NHR	2	NH	NHR	2	NR	NHR

2	O	COH	2	S	COH	2	NH	COH	2	NR	COH
2	O	COR	2	S	COR	2	NH	COR	2	NR	COR
2	CH ₂	OH	2	COR ₁ R ₂	OH	2	CONH	OH	2	CONR	OH
2	CH ₂	SH	2	COR ₁ R ₂	SH	2	CONH	SH	2	CONR	SH
2	CH ₂	COOH	2	COR ₁ R ₂	COOH	2	CONH	COOH	2	CONR	COOH
2	CH ₂	SO ₂ H	2	COR ₁ R ₂	SO ₂ H	2	CONH	SO ₂ H	2	CONR	SO ₂ H
2	CH ₂	Cl	2	COR ₁ R ₂	Cl	2	CONH	Cl	2	CONR	Cl
2	CH ₂	Br	2	COR ₁ R ₂	Br	2	CONH	Br	2	CONR	Br
2	CH ₂	I	2	COR ₁ R ₂	I	2	CONH	I	2	CONR	I
2	CH ₂	F	2	COR ₁ R ₂	F	2	CONH	F	2	CONR	F
2	CH ₂	CN	2	COR ₁ R ₂	CN	2	CONH	CN	2	CONR	CN
2	CH ₂	N ₃	2	COR ₁ R ₂	N ₃	2	CONH	N ₃	2	CONR	N ₃
2	CH ₂	CONH ₂	2	COR ₁ R ₂	CONH ₂	2	CONH	CONH ₂	2	CONR	CONH ₂
2	CH ₂	CH=CH ₂	2	COR ₁ R ₂	CH=CH ₂	2	CONH	CH=CH ₂	2	CONR	CH=CH ₂
2	CH ₂	C≡CH	2	COR ₁ R ₂	C≡CH	2	CONH	C≡CH	2	CONR	C≡CH
2	CH ₂	NH ₂	2	COR ₁ R ₂	NH ₂	2	CONH	NH ₂	2	CONR	NH ₂
2	CH ₂	NHR	2	COR ₁ R ₂	NHR	2	CONH	NHR	2	CONR	NHR
2	CH ₂	COH	2	COR ₁ R ₂	COH	2	CONH	COH	2	CONR	COH
2	CH ₂	COR	2	COR ₁ R ₂	COR	2	CONH	COR	2	CONR	COR
2	SO ₂ NH	OH	2	SO ₂ NR	OH	2	NHCONH	OH	2	NRCONR	OH
2	SO ₂ NH	SH	2	SO ₂ NR	SH	2	NHCONH	SH	2	NRCONR	SH
2	SO ₂ NH	COOH	2	SO ₂ NR	COOH	2	NHCONH	COOH	2	NRCONR	COOH
2	SO ₂ NH	SO ₂ H	2	SO ₂ NR	SO ₂ H	2	NHCONH	SO ₂ H	2	NRCONR	SO ₂ H
2	SO ₂ NH	Cl	2	SO ₂ NR	Cl	2	NHCONH	Cl	2	NRCONR	Cl
2	SO ₂ NH	Br	2	SO ₂ NR	Br	2	NHCONH	Br	2	NRCONR	Br
2	SO ₂ NH	I	2	SO ₂ NR	I	2	NHCONH	I	2	NRCONR	I
2	SO ₂ NH	F	2	SO ₂ NR	F	2	NHCONH	F	2	NRCONR	F
2	SO ₂ NH	CN	2	SO ₂ NR	CN	2	NHCONH	CN	2	NRCONR	CN
2	SO ₂ NH	N ₃	2	SO ₂ NR	N ₃	2	NHCONH	N ₃	2	NRCONR	N ₃
2	SO ₂ NH	CONH ₂	2	SO ₂ NR	CONH ₂	2	NHCONH	CONH ₂	2	NRCONR	CONH ₂
2	SO ₂ NH	CH=CH ₂	2	SO ₂ NR	CH=CH ₂	2	NHCONH	CH=CH ₂	2	NRCONR	CH=CH ₂
2	SO ₂ NH	C≡CH	2	SO ₂ NR	C≡CH	2	NHCONH	C≡CH	2	NRCONR	C≡CH
2	SO ₂ NH	NH ₂	2	SO ₂ NR	NH ₂	2	NHCONH	NH ₂	2	NRCONR	NH ₂
2	SO ₂ NH	NHR	2	SO ₂ NR	NHR	2	NHCONH	NHR	2	NRCONR	NHR
2	SO ₂ NH	COH	2	SO ₂ NR	COH	2	NHCONH	COH	2	NRCONR	COH
2	SO ₂ NH	COR	2	SO ₂ NR	COR	2	NHCONH	COR	2	NRCONR	COR
2	NHCNHNH	OH	2	NRCNHNH	OH	2	NHCOO	OH	2	NRCOO	OH
2	NHCNHNH	SH	2	NRCNHNH	SH	2	NHCOO	SH	2	NRCOO	SH

2	NHCNHNH	COOH	2	NRCNHNH	COOH	2	NHCOO	COOH	2	NRCOO	COOH
2	NHCNHNH	SO ₂ H	2	NRCNHNH	SO ₂ H	2	NHCOO	SO ₂ H	2	NRCOO	SO ₂ H
2	NHCNHNH	Cl	2	NRCNHNH	Cl	2	NHCOO	Cl	2	NRCOO	Cl
2	NHCNHNH	Br	2	NRCNHNH	Br	2	NHCOO	Br	2	NRCOO	Br
2	NHCNHNH	I	2	NRCNHNH	I	2	NHCOO	I	2	NRCOO	I
2	NHCNHNH	F	2	NRCNHNH	F	2	NHCOO	F	2	NRCOO	F
2	NHCNHNH	CN	2	NRCNHNH	CN	2	NHCOO	CN	2	NRCOO	CN
2	NHCNHNH	N ₃	2	NRCNHNH	N ₃	2	NHCOO	N ₃	2	NRCOO	N ₃
2	NHCNHNH	CONH ₂	2	NRCNHNH	CONH ₂	2	NHCOO	CONH ₂	2	NRCOO	CONH ₂
2	NHCNHNH	CH=CH ₂	2	NRCNHNH	CH=CH ₂	2	NHCOO	CH=CH ₂	2	NRCOO	CH=CH ₂
2	NHCNHNH	CCH	2	NRCNHNH	C≡CH	2	NHCOO	C≡CH	2	NRCOO	C≡CH
2	NHCNHNH	NH ₂	2	NRCNHNH	NH ₂	2	NHCOO	NH ₂	2	NRCOO	NH ₂
2	NHCNHNH	NHR	2	NRCNHNH	NHR	2	NHCOO	NHR	2	NRCOO	NHR
2	NHCNHNH	COH	2	NRCNHNH	COH	2	NHCOO	COH	2	NRCOO	COH
2	NHCNHNH	COR	2	NRCNHNH	COR	2	NHCOO	COR	2	NRCOO	COR
2	C≡C	OH	2	CH ₂ =CH ₂	OH	3	O	OH	3	S	OH
2	C≡C	SH	2	CH ₂ =CH ₂	SH	3	O	SH	3	S	SH
2	C≡C	COOH	2	CH ₂ =CH ₂	COOH	3	O	COOH	3	S	COOH
2	C≡C	SO ₂ H	2	CH ₂ =CH ₂	SO ₂ H	3	O	SO ₂ H	3	S	SO ₂ H
2	C≡C	Cl	2	CH ₂ =CH ₂	Cl	3	O	Cl	3	S	Cl
2	C≡C	Br	2	CH ₂ =CH ₂	Br	3	O	Br	3	S	Br
2	C≡C	I	2	CH ₂ =CH ₂	I	3	O	I	3	S	I
2	C≡C	F	2	CH ₂ =CH ₂	F	3	O	F	3	S	F
2	C≡C	CN	2	CH ₂ =CH ₂	CN	3	O	CN	3	S	CN
2	C≡C	N ₃	2	CH ₂ =CH ₂	N ₃	3	O	N ₃	3	S	N ₃
2	C≡C	CONH ₂	2	CH ₂ =CH ₂	CONH ₂	3	O	CONH ₂	3	S	CONH ₂
2	C≡C	CH=CH ₂	2	CH ₂ =CH ₂	CH=CH ₂	3	O	CH=CH ₂	3	S	CH=CH ₂
2	C≡C	C≡CH	2	CH ₂ =CH ₂	C≡CH	3	O	C≡CH	3	S	C≡CH
2	C≡C	NH ₂	2	CH ₂ =CH ₂	NH ₂	3	O	NH ₂	3	S	NH ₂
2	C≡C	NHR	2	CH ₂ =CH ₂	NHR	3	O	NHR	3	S	NHR
2	C≡C	COH	2	CH ₂ =CH ₂	COH	3	O	COH	3	S	COH
2	C≡C	COR	2	CH ₂ =CH ₂	COR	3	O	COR	3	S	COR
3	NH	OH	3	NR	OH	3	CH ₂	OH	3	COR ₁ R ₂	OH
3	NH	SH	3	NR	SH	3	CH ₂	SH	3	COR ₁ R ₂	SH
3	NH	COOH	3	NR	COOH	3	CH ₂	COOH	3	COR ₁ R ₂	COOH
3	NH	SO ₂ H	3	NR	SO ₂ H	3	CH ₂	SO ₂ H	3	COR ₁ R ₂	SO ₂ H

3	NH	Cl	3	NR	Cl	3	CH ₂	Cl	3	COR ₁ R ₂	Cl
3	NH	Br	3	NR	Br	3	CH ₂	Br	3	COR ₁ R ₂	Br
3	NH	I	3	NR	I	3	CH ₂	I	3	COR ₁ R ₂	I
3	NH	F	3	NR	F	3	CH ₂	F	3	COR ₁ R ₂	F
3	NH	CN	3	NR	CN	3	CH ₂	CN	3	COR ₁ R ₂	CN
3	NH	N ₃	3	NR	N ₃	3	CH ₂	N ₃	3	COR ₁ R ₂	N ₃
3	NH	CONH ₂	3	NR	CONH ₂	3	CH ₂	CONH ₂	3	COR ₁ R ₂	CONH ₂
3	NH	CH=CH ₂	3	NR	CH=CH ₂	3	CH ₂	CH=CH ₂	3	COR ₁ R ₂	CH=CH ₂
3	NH	C≡CH	3	NR	C≡CH	3	CH ₂	C≡CH	3	COR ₁ R ₂	C≡CH
3	NH	NH ₂	3	NR	NH ₂	3	CH ₂	NH ₂	3	COR ₁ R ₂	NH ₂
3	NH	NHR	3	NR	NHR	3	CH ₂	NHR	3	COR ₁ R ₂	NHR
3	NH	COH	3	NR	COH	3	CH ₂	COH	3	COR ₁ R ₂	COH
3	NH	COR	3	NR	COR	3	CH ₂	COR	3	COR ₁ R ₂	COR
3	CONH	OH	3	CONR	OH	3	SO ₂ NH	OH	3	SO ₂ NR	OH
3	CONH	SH	3	CONR	SH	3	SO ₂ NH	SH	3	SO ₂ NR	SH
3	CONH	COOH	3	CONR	COOH	3	SO ₂ NH	COOH	3	SO ₂ NR	COOH
3	CONH	SO ₂ H	3	CONR	SO ₂ H	3	SO ₂ NH	SO ₂ H	3	SO ₂ NR	SO ₂ H
3	CONH	Cl	3	CONR	Cl	3	SO ₂ NH	Cl	3	SO ₂ NR	Cl
3	CONH	Br	3	CONR	Br	3	SO ₂ NH	Br	3	SO ₂ NR	Br
3	CONH	I	3	CONR	I	3	SO ₂ NH	I	3	SO ₂ NR	I
3	CONH	F	3	CONR	F	3	SO ₂ NH	F	3	SO ₂ NR	F
3	CONH	CN	3	CONR	CN	3	SO ₂ NH	CN	3	SO ₂ NR	CN
3	CONH	N ₃	3	CONR	N ₃	3	SO ₂ NH	N ₃	3	SO ₂ NR	N ₃
3	CONH	CONH ₂	3	CONR	CONH ₂	3	SO ₂ NH	CONH ₂	3	SO ₂ NR	CONH ₂
3	CONH	CH=CH ₂	3	CONR	CH=CH ₂	3	SO ₂ NH	CH=CH ₂	3	SO ₂ NR	CH=CH ₂
3	CONH	C≡CH	3	CONR	C≡CH	3	SO ₂ NH	C≡CH	3	SO ₂ NR	C≡CH
3	CONH	NH ₂	3	CONR	NH ₂	3	SO ₂ NH	NH ₂	3	SO ₂ NR	NH ₂
3	CONH	NHR	3	CONR	NHR	3	SO ₂ NH	NHR	3	SO ₂ NR	NHR
3	CONH	COH	3	CONR	COH	3	SO ₂ NH	COH	3	SO ₂ NR	COH
3	CONH	COR	3	CONR	COR	3	SO ₂ NH	COR	3	SO ₂ NR	COR
3	NHCONH	OH	3	NRCONR	OH	3	NHCNHNH	OH	3	NRCNHNH	OH
3	NHCONH	SH	3	NRCONR	SH	3	NHCNHNH	SH	3	NRCNHNH	SH
3	NHCONH	COOH	3	NRCONR	COOH	3	NHCNHNH	COOH	3	NRCNHNH	COOH
3	NHCONH	SO ₂ H	3	NRCONR	SO ₂ H	3	NHCNHNH	SO ₂ H	3	NRCNHNH	SO ₂ H
3	NHCONH	Cl	3	NRCONR	Cl	3	NHCNHNH	Cl	3	NRCNHNH	Cl
3	NHCONH	Br	3	NRCONR	Br	3	NHCNHNH	Br	3	NRCNHNH	Br
3	NHCONH	I	3	NRCONR	I	3	NHCNHNH	I	3	NRCNHNH	I
3	NHCONH	F	3	NRCONR	F	3	NHCNHNH	F	3	NRCNHNH	F

3	NHCONH	CN	3	NRCONR	CN	3	NHCNHNH	CN	3	NRCNHNH	CN
3	NHCONH	N ₃	3	NRCONR	N ₃	3	NHCNHNH	N ₃	3	NRCNHNH	N ₃
3	NHCONH	CONH ₂	3	NRCONR	CONH ₂	3	NHCNHNH	CONH ₂	3	NRCNHNH	CONH ₂
3	NHCONH	CH=CH ₂	3	NRCONR	CH=CH ₂	3	NHCNHNH	CH=CH ₂	3	NRCNHNH	CH=CH ₂
3	NHCONH	C≡CH	3	NRCONR	C≡CH	3	NHCNHNH	C≡CH	3	NRCNHNH	C≡CH
3	NHCONH	NH ₂	3	NRCONR	NH ₂	3	NHCNHNH	NH ₂	3	NRCNHNH	NH ₂
3	NHCONH	NHR	3	NRCONR	NHR	3	NHCNHNH	NHR	3	NRCNHNH	NHR
3	NHCONH	COH	3	NRCONR	COH	3	NHCNHNH	COH	3	NRCNHNH	COH
3	NHCONH	COR	3	NRCONR	COR	3	NHCNHNH	COR	3	NRCNHNH	COR
3	NHCOO	OH	3	NRCOO	OH	3	C≡C	OH	3	CH ₂ =CH ₂	OH
3	NHCOO	SH	3	NRCOO	SH	3	C≡C	SH	3	CH ₂ =CH ₂	SH
3	NHCOO	COOH	3	NRCOO	COOH	3	C≡C	COOH	3	CH ₂ =CH ₂	COOH
3	NHCOO	SO ₂ H	3	NRCOO	SO ₂ H	3	C≡C	SO ₂ H	3	CH ₂ =CH ₂	SO ₂ H
3	NHCOO	Cl	3	NRCOO	Cl	3	C≡C	Cl	3	CH ₂ =CH ₂	Cl
3	NHCOO	Br	3	NRCOO	Br	3	C≡C	Br	3	CH ₂ =CH ₂	Br
3	NHCOO	I	3	NRCOO	I	3	C≡C	I	3	CH ₂ =CH ₂	I
3	NHCOO	F	3	NRCOO	F	3	C≡C	F	3	CH ₂ =CH ₂	F
3	NHCOO	CN	3	NRCOO	CN	3	C≡C	CN	3	CH ₂ =CH ₂	CN
3	NHCOO	N ₃	3	NRCOO	N ₃	3	C≡C	N ₃	3	CH ₂ =CH ₂	N ₃
3	NHCOO	CONH ₂	3	NRCOO	CONH ₂	3	C≡C	CONH ₂	3	CH ₂ =CH ₂	CONH ₂
3	NHCOO	CH=CH ₂	3	NRCOO	CH=CH ₂	3	C≡C	CH=CH ₂	3	CH ₂ =CH ₂	CH=CH ₂
3	NHCOO	C≡CH	3	NRCOO	C≡CH	3	C≡C	C≡CH	3	CH ₂ =CH ₂	C≡CH
3	NHCOO	NH ₂	3	NRCOO	NH ₂	3	C≡C	NH ₂	3	CH ₂ =CH ₂	NH ₂
3	NHCOO	NHR	3	NRCOO	NHR	3	C≡C	NHR	3	CH ₂ =CH ₂	NHR
3	NHCOO	COH	3	NRCOO	COH	3	C≡C	COH	3	CH ₂ =CH ₂	COH
3	NHCOO	COR	3	NRCOO	COR	3	C≡C	COR	3	CH ₂ =CH ₂	COR
4	O	OH	4	S	OH	4	NH	OH	4	NR	OH
4	O	SH	4	S	SH	4	NH	SH	4	NR	SH
4	O	COOH	4	S	COOH	4	NH	COOH	4	NR	COOH
4	O	SO ₂ H	4	S	SO ₂ H	4	NH	SO ₂ H	4	NR	SO ₂ H
4	O	Cl	4	S	Cl	4	NH	Cl	4	NR	Cl
4	O	Br	4	S	Br	4	NH	Br	4	NR	Br
4	O	I	4	S	I	4	NH	I	4	NR	I
4	O	F	4	S	F	4	NH	F	4	NR	F
4	O	CN	4	S	CN	4	NH	CN	4	NR	CN
4	O	N ₃	4	S	N ₃	4	NH	N ₃	4	NR	N ₃

4	O	CONH ₂	4	S	CONH ₂	4	NH	CONH ₂	4	NR	CONH ₂
4	O	CH=CH ₂	4	S	CH=CH ₂	4	NH	CH=CH ₂	4	NR	CH=CH ₂
4	O	C≡CH	4	S	C≡CH	4	NH	C≡CH	4	NR	C≡CH
4	O	NH ₂	4	S	NH ₂	4	NH	NH ₂	4	NR	NH ₂
4	O	NHR	4	S	NHR	4	NH	NHR	4	NR	NHR
4	O	COH	4	S	COH	4	NH	COH	4	NR	COH
4	O	COR	4	S	COR	4	NH	COR	4	NR	COR
4	CH ₂	OH	4	COR ₁ R ₂	OH	4	CONH	OH	4	CONR	OH
4	CH ₂	SH	4	COR ₁ R ₂	SH	4	CONH	SH	4	CONR	SH
4	CH ₂	COOH	4	COR ₁ R ₂	COOH	4	CONH	COOH	4	CONR	COOH
4	CH ₂	SO ₂ H	4	COR ₁ R ₂	SO ₂ H	4	CONH	SO ₂ H	4	CONR	SO ₂ H
4	CH ₂	Cl	4	COR ₁ R ₂	Cl	4	CONH	Cl	4	CONR	Cl
4	CH ₂	Br	4	COR ₁ R ₂	Br	4	CONH	Br	4	CONR	Br
4	CH ₂	I	4	COR ₁ R ₂	I	4	CONH	I	4	CONR	I
4	CH ₂	F	4	COR ₁ R ₂	F	4	CONH	F	4	CONR	F
4	CH ₂	CN	4	COR ₁ R ₂	CN	4	CONH	CN	4	CONR	CN
4	CH ₂	N ₃	4	COR ₁ R ₂	N ₃	4	CONH	N ₃	4	CONR	N ₃
4	CH ₂	CONH ₂	4	COR ₁ R ₂	CONH ₂	4	CONH	CONH ₂	4	CONR	CONH ₂
4	CH ₂	CH=CH ₂	4	COR ₁ R ₂	CH=CH ₂	4	CONH	CH=CH ₂	4	CONR	CH=CH ₂
4	CH ₂	C≡CH	4	COR ₁ R ₂	C≡CH	4	CONH	C≡CH	4	CONR	C≡CH
4	CH ₂	NH ₂	4	COR ₁ R ₂	NH ₂	4	CONH	NH ₂	4	CONR	NH ₂
4	CH ₂	NHR	4	COR ₁ R ₂	NHR	4	CONH	NHR	4	CONR	NHR
4	CH ₂	COH	4	COR ₁ R ₂	COH	4	CONH	COH	4	CONR	COH
4	CH ₂	COR	4	COR ₁ R ₂	COR	4	CONH	COR	4	CONR	COR
4	SO ₂ NH	OH	4	SO ₂ NR	OH	4	NHCONH	OH	4	NRCONR	OH
4	SO ₂ NH	SH	4	SO ₂ NR	SH	4	NHCONH	SH	4	NRCONR	SH
4	SO ₂ NH	COOH	4	SO ₂ NR	COOH	4	NHCONH	COOH	4	NRCONR	COOH
4	SO ₂ NH	SO ₂ H	4	SO ₂ NR	SO ₂ H	4	NHCONH	SO ₂ H	4	NRCONR	SO ₂ H
4	SO ₂ NH	Cl	4	SO ₂ NR	Cl	4	NHCONH	Cl	4	NRCONR	Cl
4	SO ₂ NH	Br	4	SO ₂ NR	Br	4	NHCONH	Br	4	NRCONR	Br
4	SO ₂ NH	I	4	SO ₂ NR	I	4	NHCONH	I	4	NRCONR	I
4	SO ₂ NH	F	4	SO ₂ NR	F	4	NHCONH	F	4	NRCONR	F
4	SO ₂ NH	CN	4	SO ₂ NR	CN	4	NHCONH	CN	4	NRCONR	CN
4	SO ₂ NH	N ₃	4	SO ₂ NR	N ₃	4	NHCONH	N ₃	4	NRCONR	N ₃
4	SO ₂ NH	CONH ₂	4	SO ₂ NR	CONH ₂	4	NHCONH	CONH ₂	4	NRCONR	CONH ₂
4	SO ₂ NH	CH=CH ₂	4	SO ₂ NR	CH=CH ₂	4	NHCONH	CH=CH ₂	4	NRCONR	CH=CH ₂
4	SO ₂ NH	C≡CH	4	SO ₂ NR	C≡CH	4	NHCONH	C≡CH	4	NRCONR	C≡CH
4	SO ₂ NH	NH ₂	4	SO ₂ NR	NH ₂	4	NHCONH	NH ₂	4	NRCONR	NH ₂


4	SO ₂ NH	NHR	4	SO ₂ NR	NHR	4	NHCONH	NHR	4	NRCNHR	NHR
4	SO ₂ NH	COH	4	SO ₂ NR	COH	4	NHCONH	COH	4	NRCNHR	COH
4	SO ₂ NH	COR	4	SO ₂ NR	COR	4	NHCONH	COR	4	NRCNHR	COR
4	NHCNHNH	OH	4	NRCNHNH	OH	4	NHCOO	OH	4	NRCOO	OH
4	NHCNHNH	SH	4	NRCNHNH	SH	4	NHCOO	SH	4	NRCOO	SH
4	NHCNHNH	COOH	4	NRCNHNH	COOH	4	NHCOO	COOH	4	NRCOO	COOH
4	NHCNHNH	SO ₂ H	4	NRCNHNH	SO ₂ H	4	NHCOO	SO ₂ H	4	NRCOO	SO ₂ H
4	NHCNHNH	Cl	4	NRCNHNH	Cl	4	NHCOO	Cl	4	NRCOO	Cl
4	NHCNHNH	Br	4	NRCNHNH	Br	4	NHCOO	Br	4	NRCOO	Br
4	NHCNHNH	I	4	NRCNHNH	I	4	NHCOO	I	4	NRCOO	I
4	NHCNHNH	F	4	NRCNHNH	F	4	NHCOO	F	4	NRCOO	F
4	NHCNHNH	CN	4	NRCNHNH	CN	4	NHCOO	CN	4	NRCOO	CN
4	NHCNHNH	N ₃	4	NRCNHNH	N ₃	4	NHCOO	N ₃	4	NRCOO	N ₃
4	NHCNHNH	CONH ₂	4	NRCNHNH	CONH ₂	4	NHCOO	CONH ₂	4	NRCOO	CONH ₂
4	NHCNHNH	CH=CH ₂	4	NRCNHNH	CH=CH ₂	4	NHCOO	CH=CH ₂	4	NRCOO	CH=CH ₂
4	NHCNHNH	C≡CH	4	NRCNHNH	C≡CH	4	NHCOO	C≡CH	4	NRCOO	C≡CH
4	NHCNHNH	NH ₂	4	NRCNHNH	NH ₂	4	NHCOO	NH ₂	4	NRCOO	NH ₂
4	NHCNHNH	NHR	4	NRCNHNH	NHR	4	NHCOO	NHR	4	NRCOO	NHR
4	NHCNHNH	COH	4	NRCNHNH	COH	4	NHCOO	COH	4	NRCOO	COH
4	NHCNHNH	COR	4	NRCNHNH	COR	4	NHCOO	COR	4	NRCOO	COR
4	C≡C	OH	4	CH ₂ =CH ₂	OH	5	O	OH	5	S	OH
4	C≡C	SH	4	CH ₂ =CH ₂	SH	5	O	SH	5	S	SH
4	C≡C	COOH	4	CH ₂ =CH ₂	COOH	5	O	COOH	5	S	COOH
4	C≡C	SO ₂ H	4	CH ₂ =CH ₂	SO ₂ H	5	O	SO ₂ H	5	S	SO ₂ H
4	C≡C	Cl	4	CH ₂ =CH ₂	Cl	5	O	Cl	5	S	Cl
4	C≡C	Br	4	CH ₂ =CH ₂	Br	5	O	Br	5	S	Br
4	C≡C	I	4	CH ₂ =CH ₂	I	5	O	I	5	S	I
4	C≡C	F	4	CH ₂ =CH ₂	F	5	O	F	5	S	F
4	C≡C	CN	4	CH ₂ =CH ₂	CN	5	O	CN	5	S	CN
4	C≡C	N ₃	4	CH ₂ =CH ₂	N ₃	5	O	N ₃	5	S	N ₃
4	C≡C	CONH ₂	4	CH ₂ =CH ₂	CONH ₂	5	O	CONH ₂	5	S	CONH ₂
4	C≡C	CH=CH ₂	4	CH ₂ =CH ₂	CH=CH ₂	5	O	CH=CH ₂	5	S	CH=CH ₂
4	C≡C	C≡CH	4	CH ₂ =CH ₂	C≡CH	5	O	C≡CH	5	S	C≡CH
4	C≡C	NH ₂	4	CH ₂ =CH ₂	NH ₂	5	O	NH ₂	5	S	NH ₂
4	C≡C	NHR	4	CH ₂ =CH ₂	NHR	5	O	NHR	5	S	NHR
4	C≡C	COH	4	CH ₂ =CH ₂	COH	5	O	COH	5	S	COH

4	C≡C	COR	4	CH ₂ =CH ₂	COR	5	O	COR	5	S	COR
5	NH	OH	5	NR	OH	5	CH ₂	OH	5	COR ₁ R ₂	OH
5	NH	SH	5	NR	SH	5	CH ₂	SH	5	COR ₁ R ₂	SH
5	NH	COOH	5	NR	COOH	5	CH ₂	COOH	5	COR ₁ R ₂	COOH
5	NH	SO ₂ H	5	NR	SO ₂ H	5	CH ₂	SO ₂ H	5	COR ₁ R ₂	SO ₂ H
5	NH	Cl	5	NR	Cl	5	CH ₂	Cl	5	COR ₁ R ₂	Cl
5	NH	Br	5	NR	Br	5	CH ₂	Br	5	COR ₁ R ₂	Br
5	NH	I	5	NR	I	5	CH ₂	I	5	COR ₁ R ₂	I
5	NH	F	5	NR	F	5	CH ₂	F	5	COR ₁ R ₂	F
5	NH	CN	5	NR	CN	5	CH ₂	CN	5	COR ₁ R ₂	CN
5	NH	N ₃	5	NR	N ₃	5	CH ₂	N ₃	5	COR ₁ R ₂	N ₃
5	NH	CONH ₂	5	NR	CONH ₂	5	CH ₂	CONH ₂	5	COR ₁ R ₂	CONH ₂
5	NH	CH=CH ₂	5	NR	CH=CH ₂	5	CH ₂	CH=CH ₂	5	COR ₁ R ₂	CH=CH ₂
5	NH	C≡CH	5	NR	C≡CH	5	CH ₂	C≡CH	5	COR ₁ R ₂	C≡CH
5	NH	NH ₂	5	NR	NH ₂	5	CH ₂	NH ₂	5	COR ₁ R ₂	NH ₂
5	NH	NHR	5	NR	NHR	5	CH ₂	NHR	5	COR ₁ R ₂	NHR
5	NH	COH	5	NR	COH	5	CH ₂	COH	5	COR ₁ R ₂	COH
5	NH	COR	5	NR	COR	5	CH ₂	COR	5	COR ₁ R ₂	COR
5	CONH	OH	5	CONR	OH	5	SO ₂ NH	OH	5	SO ₂ NR	OH
5	CONH	SH	5	CONR	SH	5	SO ₂ NH	SH	5	SO ₂ NR	SH
5	CONH	COOH	5	CONR	COOH	5	SO ₂ NH	COOH	5	SO ₂ NR	COOH
5	CONH	SO ₂ H	5	CONR	SO ₂ H	5	SO ₂ NH	SO ₂ H	5	SO ₂ NR	SO ₂ H
5	CONH	Cl	5	CONR	Cl	5	SO ₂ NH	Cl	5	SO ₂ NR	Cl
5	CONH	Br	5	CONR	Br	5	SO ₂ NH	Br	5	SO ₂ NR	Br
5	CONH	I	5	CONR	I	5	SO ₂ NH	I	5	SO ₂ NR	I
5	CONH	F	5	CONR	F	5	SO ₂ NH	F	5	SO ₂ NR	F
5	CONH	CN	5	CONR	CN	5	SO ₂ NH	CN	5	SO ₂ NR	CN
5	CONH	N ₃	5	CONR	N ₃	5	SO ₂ NH	N ₃	5	SO ₂ NR	N ₃
5	CONH	CONH ₂	5	CONR	CONH ₂	5	SO ₂ NH	CONH ₂	5	SO ₂ NR	CONH ₂
5	CONH	CH=CH ₂	5	CONR	CH=CH ₂	5	SO ₂ NH	CH=CH ₂	5	SO ₂ NR	CH=CH ₂
5	CONH	C≡CH	5	CONR	C≡CH	5	SO ₂ NH	C≡CH	5	SO ₂ NR	C≡CH
5	CONH	NH ₂	5	CONR	NH ₂	5	SO ₂ NH	NH ₂	5	SO ₂ NR	NH ₂
5	CONH	NHR	5	CONR	NHR	5	SO ₂ NH	NHR	5	SO ₂ NR	NHR
5	CONH	COH	5	CONR	COH	5	SO ₂ NH	COH	5	SO ₂ NR	COH
5	CONH	COR	5	CONR	COR	5	SO ₂ NH	COR	5	SO ₂ NR	COR
5	NHCONH	OH	5	NRCONR	OH	5	NHCNHNH	OH	5	NRCNHNH	OH
5	NHCONH	SH	5	NRCONR	SH	5	NHCNHNH	SH	5	NRCNHNH	SH
5	NHCONH	COOH	5	NRCONR	COOH	5	NHCNHNH	COOH	5	NRCNHNH	COOH

5	NHCONH	SO ₂ H	5	NRCONR	SO ₂ H	5	NHCNHNH	SO ₂ H	5	NRCNHNH	SO ₂ H
5	NHCONH	Cl	5	NRCONR	Cl	5	NHCNHNH	Cl	5	NRCNHNH	Cl
5	NHCONH	Br	5	NRCONR	Br	5	NHCNHNH	Br	5	NRCNHNH	Br
5	NHCONH	I	5	NRCONR	I	5	NHCNHNH	I	5	NRCNHNH	I
5	NHCONH	F	5	NRCONR	F	5	NHCNHNH	F	5	NRCNHNH	F
5	NHCONH	CN	5	NRCONR	CN	5	NHCNHNH	CN	5	NRCNHNH	CN
5	NHCONH	N ₃	5	NRCONR	N ₃	5	NHCNHNH	N ₃	5	NRCNHNH	N ₃
5	NHCONH	CONH ₂	5	NRCONR	CONH ₂	5	NHCNHNH	CONH ₂	5	NRCNHNH	CONH ₂
5	NHCONH	CH=CH ₂	5	NRCONR	CH=CH ₂	5	NHCNHNH	CH=CH ₂	5	NRCNHNH	CH=CH ₂
5	NHCONH	C≡CH	5	NRCONR	C≡CH	5	NHCNHNH	C≡CH	5	NRCNHNH	C≡CH
5	NHCONH	NH ₂	5	NRCONR	NH ₂	5	NHCNHNH	NH ₂	5	NRCNHNH	NH ₂
5	NHCONH	NHR	5	NRCONR	NHR	5	NHCNHNH	NHR	5	NRCNHNH	NHR
5	NHCONH	COH	5	NRCONR	COH	5	NHCNHNH	COH	5	NRCNHNH	COH
5	NHCONH	COR	5	NRCONR	COR	5	NHCNHNH	COR	5	NRCNHNH	COR
5	NRCNHNH	OH	5	NHCOO	OH	5	NRCOO	OH	5	C≡C	OH
5	NRCNHNH	SH	5	NHCOO	SH	5	NRCOO	SH	5	C≡C	SH
5	NRCNHNH	COOH	5	NHCOO	COOH	5	NRCOO	COOH	5	C≡C	COOH
5	NRCNHNH	SO ₂ H	5	NHCOO	SO ₂ H	5	NRCOO	SO ₂ H	5	C≡C	SO ₂ H
5	NRCNHNH	Cl	5	NHCOO	Cl	5	NRCOO	Cl	5	C≡C	Cl
5	NRCNHNH	Br	5	NHCOO	Br	5	NRCOO	Br	5	C≡C	Br
5	NRCNHNH	I	5	NHCOO	I	5	NRCOO	I	5	C≡C	I
5	NRCNHNH	F	5	NHCOO	F	5	NRCOO	F	5	C≡C	F
5	NRCNHNH	CN	5	NHCOO	CN	5	NRCOO	CN	5	C≡C	CN
5	NRCNHNH	N ₃	5	NHCOO	N ₃	5	NRCOO	N ₃	5	C≡C	N ₃
5	NRCNHNH	CONH ₂	5	NHCOO	CONH ₂	5	NRCOO	CONH ₂	5	C≡C	CONH ₂
5	NRCNHNH	CH=CH ₂	5	NHCOO	CH=CH ₂	5	NRCOO	CH=CH ₂	5	C≡C	CH=CH ₂
5	NRCNHNH	C≡CH	5	NHCOO	C≡CH	5	NRCOO	C≡CH	5	C≡C	C≡CH
5	NRCNHNH	NH ₂	5	NHCOO	NH ₂	5	NRCOO	NH ₂	5	C≡C	NH ₂
5	NRCNHNH	NHR	5	NHCOO	NHR	5	NRCOO	NHR	5	C≡C	NHR
5	NRCNHNH	COH	5	NHCOO	COH	5	NRCOO	COH	5	C≡C	COH
5	NRCNHNH	COR	5	NHCOO	COR	5	NRCOO	COR	5	C≡C	COR
5	CH ₂ =CH ₂	OH	5	CH ₂ =CH ₂	Br	5	CH ₂ =CH ₂	N ₃	5	CH ₂ =CH ₂	NH ₂

5	CH ₂ =CH ₂	SH	5	CH ₂ =CH ₂	I	5	CH ₂ =CH ₂	CONH ₂	5	CH ₂ =CH ₂	NHR
5	CH ₂ =CH ₂	COOH	5	CH ₂ =CH ₂	F	5	CH ₂ =CH ₂	CH=CH ₂	5	CH ₂ =CH ₂	COH
5	CH ₂ =CH ₂	SO ₂ H	5	CH ₂ =CH ₂	CN	5	CH ₂ =CH ₂	C≡CH	5	CH ₂ =CH ₂	COR
5	CH ₂ =CH ₂	Cl	R, R ₁ , and R ₂ = H, alkyl, alkenyl, alkynyl, aryl, and heterocycle								

TABLE 8



10081989.022102

n	E	F	Y	n	E	F	Y
0	O	O	OH	0	O	S	OH
0	O	O	NH ₂	0	O	S	NH ₂
0	O	CONR	I	0	O	SO ₂ NR	I
0	O	NRCONR	COH	0	O	NRCNHNR	COH
0	O	NRCONR	COR	0	O	NRCNHNR	COR
0	O	NRCOO	CH=CH ₂	0	O	C≡C	CH=CH ₂
0	O	CH=CH	NHR	0	S	O	NHR
0	O	CH=CH	COH	0	S	O	COH
0	S	S	NHR	0	S	NR	NHR
0	S	S	COH	0	S	NR	COH
0	S	S	COR	0	S	NR	COR
0	S	CR ₁ R ₂	COH	0	S	CONR	COH
0	S	CR ₁ R ₂	COR	0	S	CONR	COR
0	S	SO ₂ NR	OH	0	S	NRCONR	OH
0	S	SO ₂ NR	SO ₂ H	0	S	NRCONR	SO ₂ H
0	S	NRCNHNR	CONH ₂	0	S	NRCOO	CONH ₂
0	S	NRCNHNR	CH=CH ₂	0	S	NRCOO	CH=CH ₂
0	NR	O	C≡CH	0	NR	S	C≡CH
0	NR	CONR	Cl	0	NR	SO ₂ NR	Cl
0	NR	CONR	COR	0	NR	SO ₂ NR	COR
0	NR	NRCONR	OH	0	NR	NRCNHNR	OH
0	NR	NRCONR	SH	0	NR	NRCNHNR	SH
0	NR	NRCONR	CONH ₂	0	NR	NRCNHNR	CONH ₂
0	NR	NRCOO	COR	0	NR		COR
0	NR	CH=CH	OH	0	CR ₁ R ₂	O	OH
0	NR	CH=CH	N ₃	0	CR ₁ R ₂	O	N ₃
0	NR	CH=CH	CONH ₂	0	CR ₁ R ₂	O	CONH ₂
0	NR	CH=CH	CH=CH ₂	0	CR ₁ R ₂	O	CH=CH ₂
0	CR ₁ R ₂	S	COH	0	CR ₁ R ₂	NR	COH
0	CR ₁ R ₂	S	COR	0	CR ₁ R ₂	NR	COR
0	CR ₁ R ₂	CR ₁ R ₂	SH	0	CR ₁ R ₂	CONR	SH
0	CR ₁ R ₂	CR ₁ R ₂	COOH	0	CR ₁ R ₂	CONR	COOH
0	CR ₁ R ₂	CR ₁ R ₂	NH ₂	0	CR ₁ R ₂	CONR	NH ₂
0	CR ₁ R ₂	SO ₂ NR	Cl	0	CR ₁ R ₂	NRCONR	Cl
0	CR ₁ R ₂	SO ₂ NR	CN	0	CR ₁ R ₂	NRCONR	CN
0	CR ₁ R ₂	SO ₂ NR	N ₃	0	CR ₁ R ₂	NRCONR	N ₃
0	CR ₁ R ₂	NRCNHNR	NHR	0	CR ₁ R ₂	NRCOO	NHR
0	CR ₁ R ₂	NRCNHNR	COR	0	CR ₁ R ₂	NRCOO	COR
0	CR ₁ R ₂	C≡C	OH	0	CR ₁ R ₂	CH=CH	OH
0	CR ₁ R ₂	C≡C	Br	0	CR ₁ R ₂	CH=CH	Br
0	CONR	O	OH	0	CONR	S	OH
0	CONR	O	SH	0	CONR	S	SH
0	CONR	O	COR	0	CONR	S	COR
0	CONR	NR	OH	0	CONR	CR ₁ R ₂	OH
0	CONR	NR	COR	0	CONR	CR ₁ R ₂	COR
0	CONR	CONR	OH	0	CONR	SO ₂ NR	OH
0	CONR	CONR	SH	0	CONR	SO ₂ NR	SH
0	CONR	CONR	COOH	0	CONR	SO ₂ NR	COOH
0	CONR	NRCOO	Br	0	CONR	C≡C	Br
0	CONR	NRCOO	CONH ₂	0	CONR	C≡C	CONH ₂
0	CONR	CH=CH	CONH ₂	0	SO ₂ NR	O	CONH ₂
0	CONR	CH=CH	CH=CH ₂	0	SO ₂ NR	O	CH=CH ₂

0	CONR	CH=CH	NH ₂	0	SO ₂ NR	O	NH ₂
0	SO ₂ NR	S	SH	0	SO ₂ NR	NR	SH
0	SO ₂ NR	S	COOH	0	SO ₂ NR	NR	COOH
0	SO ₂ NR	S	F	0	SO ₂ NR	NR	F
0	SO ₂ NR	CR ₁ R ₂	CONH ₂	0	SO ₂ NR	CONR	CONH ₂
0	SO ₂ NR	SO ₂ NR	F	0	SO ₂ NR	NRCONR	F
0	SO ₂ NR	SO ₂ NR	N ₃	0	SO ₂ NR	NRCONR	N ₃
0	SO ₂ NR	SO ₂ NR	CH=CH ₂	0	SO ₂ NR	NRCONR	CH=CH ₂
0	SO ₂ NR	NRCNHNR	SH	0	SO ₂ NR	NRCOO	SH
0	SO ₂ NR	NRCNHNR	SO ₂ H	0	SO ₂ NR	NRCOO	SO ₂ H
0	SO ₂ NR	NRCNHNR	Cl	0	SO ₂ NR	NRCOO	Cl
0	SO ₂ NR	C≡C	NHR	0	SO ₂ NR	CH=CH	NHR
0	SO ₂ NR	C≡C	COR	0	SO ₂ NR	CH=CH	COR
0	NRCONR	O	OH	0	NRCONR	S	OH
0	NRCONR	O	SH	0	NRCONR	S	SH
0	NRCONR	O	COOH	0	NRCONR	S	COOH
0	NRCONR	NR	SO ₂ H	0	NRCONR	CR ₁ R ₂	SO ₂ H
0	NRCONR	NR	COH	0	NRCONR	CR ₁ R ₂	COH
0	NRCONR	NR	COR	0	NRCONR	CR ₁ R ₂	COR
0	NRCONR	CONR	F	0	NRCONR	SO ₂ NR	F
0	NRCONR	CONR	CH=CH ₂	0	NRCONR	SO ₂ NR	CH=CH ₂
0	NRCONR	CONR	C≡CH	0	NRCONR	SO ₂ NR	C≡CH
0	NRCONR	NRCONR	COR	0	NRCONR	NRCNHNR	COR
0	NRCONR	NRCOO	OH	0	NRCONR	C≡C	OH
0	NRCONR	NRCOO	COH	0	NRCONR	C≡C	COH
0	NRCONR	NRCOO	COR	0	NRCONR		COR
0	NRCONR	CH=CH	OH	0	NRCNHNR	O	OH
0	NRCONR	CH=CH	SH	0	NRCNHNR	O	SH
0	NRCONR	CH=CH	COOH	0	NRCNHNR	O	COOH
0	NRCNHNR	S	C≡CH	0	NRCNHNR	NR	C≡CH
0	NRCNHNR	S	NH ₂	0	NRCNHNR	NR	NH ₂
0	NRCNHNR	S	NHR	0	NRCNHNR	NR	NHR
0	NRCNHNR	CR ₁ R ₂	Br	0	NRCNHNR	CONR	Br
0	NRCNHNR	CR ₁ R ₂	NH ₂	0	NRCNHNR	CONR	NH ₂
0	NRCNHNR	CR ₁ R ₂	NHR	0	NRCNHNR	CONR	NHR
0	NRCNHNR	SO ₂ NR	SH	0	NRCNHNR	NRCONR	SH
0	NRCNHNR	SO ₂ NR	COOH	0	NRCNHNR	NRCONR	COOH
0	NRCNHNR	NRCNHNR	CN	0	NRCNHNR	NRCOO	CN
0	NRCNHNR	NRCNHNR	N ₃	0	NRCNHNR	NRCOO	N ₃
0	NRCNHNR	NRCNHNR	CONH ₂	0	NRCNHNR	NRCOO	CONH ₂
0	NRCNHNR	C≡C	SH	0	NRCNHNR	CH=CH	SH
0	NRCNHNR	C≡C	COOH	0	NRCNHNR	CH=CH	COOH
0	NRCOO	O	CN	0	NRCOO	S	CN
0	NRCOO	O	N ₃	0	NRCOO	S	N ₃
0	NRCOO	O	CONH ₂	0	NRCOO	S	CONH ₂
0	NRCOO	CONR	CN	0	NRCOO	SO ₂ NR	CN
0	NRCOO	CONR	N ₃	0	NRCOO	SO ₂ NR	N ₃
0	NRCOO	NRCONR	COH	0	NRCOO	NRCNHNR	COH
0	NRCOO	NRCONR	COR	0	NRCOO	NRCNHNR	COR
0	NRCOO	NRCOO	OH	0	NRCOO	C≡C	OH
0	NRCOO	NRCOO	SH	0	NRCOO	C≡C	SH
0	NRCOO	CH=CH	F	0	C≡C	O	F

0	C≡C	S	COOH	0	C≡C	NR	COOH
0	C≡C	S	SO ₂ H	0	C≡C	NR	SO ₂ H
0	C≡C	CR ₁ R ₂	NH ₂	0	C≡C	CONR	NH ₂
0	C≡C	CR ₁ R ₂	NHR	0	C≡C	CONR	NHR
0	C≡C	CR ₁ R ₂	COH	0	C≡C	CONR	COH
0	C≡C	SO ₂ NR	COH	0	C≡C	NRCONR	COH
0	C≡C	SO ₂ NR	COR	0	C≡C	NRCONR	COR
0	C≡C	NRCNHNR	OH	0	C≡C	NRCOO	OH
0	C≡C	NRCNHNR	SO ₂ H	0	C≡C	NRCOO	SO ₂ H
0	C≡C	NRCNHNR	Cl	0	C≡C	NRCOO	Cl
0	C≡C	C≡C	OH	0	C≡C	CH=CH	OH
0	C≡C	C≡C	CN	0	C≡C	CH=CH	CN
0	CH=CH	O	CH=CH ₂	0	CH=CH	S	CH=CH ₂
0	CH=CH	O	C≡CH	0	CH=CH	S	C≡CH
0	CH=CH	O	COR	0	CH=CH	S	COR
0	CH=CH	NR	OH	0	CH=CH	CR ₁ R ₂	OH
0	CH=CH	NR	SH	0	CH=CH	CR ₁ R ₂	SH
0	CH=CH	NRCONR	COH	0	CH=CH	NRCNHNR	COH
0	CH=CH	NRCONR	COR	0	CH=CH	NRCNHNR	COR
0	CH=CH	NRCOO	SH	0	CH=CH	C≡C	SH
0	CH=CH	NRCOO	NHR	0	CH=CH	C≡C	NHR
0	CH=CH	NRCOO	COH	0	CH=CH	C≡C	COH
0	CH=CH	CH=CH	OH	0	CH=CH	CH=CH	N ₃
0	CH=CH	CH=CH	SH	0	CH=CH	CH=CH	CONH ₂
1	O	O	C≡CH	1	O	S	C≡CH
1	O	O	NH ₂	1	O	S	NH ₂
1	O	O	NHR	1	O	S	NHR
1	O	NR	NHR	1	O	CR ₁ R ₂	NHR
1	O	NR	COH	1	O	CR ₁ R ₂	COH
1	O	CONR	SH	1	O	SO ₂ NR	SH
1	O	CONR	SO ₂ H	1	O	SO ₂ NR	SO ₂ H
1	O	NRCONR	OH	1	O	NRCNHNR	OH
1	O	NRCONR	SH	1	O	NRCNHNR	SH
1	O	NRCOO	SH	1	O	C≡C	SH
1	O	NRCOO	COOH	1	O	C≡C	COOH
1	O	CH=CH	OH	1	S	O	OH
1	O	CH=CH	COH	1	S	O	COH
1	O	CH=CH	COR	1	S	O	COR
1	S	S	OH	1	S	NR	OH
1	S	S	CH=CH ₂	1	S	NR	CH=CH ₂
1	S	S	NH ₂	1	S	NR	NH ₂
1	S	CR ₁ R ₂	Cl	1	S	CONR	Cl
1	S	CR ₁ R ₂	Br	1	S	CONR	Br
1	S	SO ₂ NR	Br	1	S	NRCONR	Br
1	S	SO ₂ NR	COH	1	S	NRCONR	COH
1	S	NRCNHNR	COOH	1	S	NRCOO	COOH
1	S	NRCNHNR	F	1	S	NRCOO	F
1	S	C≡C	OH	1	S	CH=CH	OH
1	S	C≡C	SH	1	S	CH=CH	SH
1	S	C≡C	COOH	1	S	CH=CH	COOH

1	S	C≡C	C≡CH	1	S	CH=CH	C≡CH
1	NR	O	SO ₂ H	1	NR	S	SO ₂ H
1	NR	O	Cl	1	NR	S	Cl
1	NR	O	CN	1	NR	S	CN
1	NR	NR	CONH ₂	1	NR	CR ₁ R ₂	CONH ₂
1	NR	NR	CH=CH ₂	1	NR	CR ₁ R ₂	CH=CH ₂
1	NR	CONR	CONH ₂	1	NR	SO ₂ NR	CONH ₂
1	NR	CONR	COR	1	NR	SO ₂ NR	COR
1	NR	NRCNR	NHR	1	NR	NRCNHR	NHR
1	NR	NRCNR	COH	1	NR	NRCNHR	COH
1	NR	NRCOO	OH	1	NR	C≡C	OH
1	NR	NRCOO	N ₃	1	NR	C≡C	N ₃
1	NR	NRCOO	CONH ₂	1	NR	C≡C	CONH ₂
1	NR	CH=CH	N ₃	1	CR ₁ R ₂	O	N ₃
1	NR	CH=CH	CONH ₂	1	CR ₁ R ₂	O	CONH ₂
1	NR	CH=CH	CH=CH ₂	1	CR ₁ R ₂	O	CH=CH ₂
1	CR ₁ R ₂	S	Br	1	CR ₁ R ₂	NR	Br
1	CR ₁ R ₂	S	N ₃	1	CR ₁ R ₂	NR	N ₃
1	CR ₁ R ₂	S	NHR	1	CR ₁ R ₂	NR	NHR
1	CR ₁ R ₂	S	COH	1	CR ₁ R ₂	NR	COH
1	CR ₁ R ₂	CR ₁ R ₂	SO ₂ H	1	CR ₁ R ₂	CONR	SO ₂ H
1	CR ₁ R ₂	SO ₂ NR	COOH	1	CR ₁ R ₂	NRCNR	COOH
1	CR ₁ R ₂	SO ₂ NR	SO ₂ H	1	CR ₁ R ₂	NRCNR	SO ₂ H
1	CR ₁ R ₂	NRCNHR	CN	1	CR ₁ R ₂	NRCOO	CN
1	CR ₁ R ₂	NRCNHR	COH	1	CR ₁ R ₂	NRCOO	COH
1	CR ₁ R ₂	NRCNHR	COR	1	CR ₁ R ₂	NRCOO	COR
1	CR ₁ R ₂	C≡C	SH	1	CR ₁ R ₂	CH=CH	SH
1	CR ₁ R ₂	C≡C	COOH	1	CR ₁ R ₂	CH=CH	COOH
1	CONR	O	OH	1	CONR	S	OH
1	CONR	O	SH	1	CONR	S	SH
1	CONR	O	COOH	1	CONR	S	COOH
1	CONR	NR	CN	1	CONR	CR ₁ R ₂	CN
1	CONR	NR	N ₃	1	CONR	CR ₁ R ₂	N ₃
1	CONR	NR	COH	1	CONR	CR ₁ R ₂	COH
1	CONR	NR	COR	1	CONR	CR ₁ R ₂	COR
1	CONR	CONR	OH	1	CONR	SO ₂ NR	OH
1	CONR	CONR	F	1	CONR	SO ₂ NR	F
1	CONR	CONR	NHR	1	CONR	SO ₂ NR	NHR
1	CONR	CONR	COR	1	CONR	SO ₂ NR	COR
1	CONR	NRCNR	OH	1	CONR	NRCNHR	OH
1	CONR	NRCNR	SO ₂ H	1	CONR	NRCNHR	SO ₂ H
1	CONR	NRCOO	SH	1	CONR	C≡C	SH
1	CONR	NRCOO	COOH	1	CONR	C≡C	COOH
1	CONR	NRCOO	COH	1	CONR	C≡C	COH
1	CONR	CH=CH	Cl	1	SO ₂ NR	O	Cl
1	CONR	CH=CH	Br	1	SO ₂ NR	O	Br
1	SO ₂ NR	S	N ₃	1	SO ₂ NR	NR	N ₃
1	SO ₂ NR	S	CONH ₂	1	SO ₂ NR	NR	CONH ₂
1	SO ₂ NR	S	COR	1	SO ₂ NR	NR	COR
1	SO ₂ NR	CR ₁ R ₂	SH	1	SO ₂ NR	CONR	SH
1	SO ₂ NR	CR ₁ R ₂	COOH	1	SO ₂ NR	CONR	COOH
1	SO ₂ NR	SO ₂ NR	SO ₂ H	1	SO ₂ NR	NRCNR	SO ₂ H

1	SO ₂ NR	SO ₂ NR	Cl	1	SO ₂ NR	NRCONR	Cl
1	SO ₂ NR	SO ₂ NR	Br	1	SO ₂ NR	NRCONR	Br
1	SO ₂ NR	SO ₂ NR	COH	1	SO ₂ NR	NRCONR	COH
1	SO ₂ NR	NRCNHNR	OH	1	SO ₂ NR	NRCOO	OH
1	SO ₂ NR	NRCNHNR	NH ₂	1	SO ₂ NR	NRCOO	NH ₂
1	SO ₂ NR	C≡C	Br	1	SO ₂ NR	CH=CH	Br
1	SO ₂ NR	C≡C	COR	1	SO ₂ NR	CH=CH	COR
1	NRCONR	O	SH	1	NRCONR	S	SH
1	NRCONR	O	NH ₂	1	NRCONR	S	NH ₂
1	NRCONR	NR	Cl	1	NRCONR	CR ₁ R ₂	Cl
1	NRCONR	NR	I	1	NRCONR	CR ₁ R ₂	I
1	NRCONR	CONR	F	1	NRCONR	SO ₂ NR	F
1	NRCONR	CONR	N ₃	1	NRCONR	SO ₂ NR	N ₃
1	NRCONR	NRCNHNR	OH	1	NRCONR	NRCNHNR	OH
1	NRCONR	NRCNHNR	COR	1	NRCONR	NRCNHNR	COR
1	NRCONR	NRCOO	OH	1	NRCONR	C≡C	OH
1	NRCONR	NRCOO	COR	1	NRCONR		COR
1	NRCONR	CH=CH	OH	1	NRCNHNR	O	OH
1	NRCONR	CH=CH	COOH	1	NRCNHNR	O	COOH
1	NRCNHNR	S	NH ₂	1	NRCNHNR	NR	NH ₂
1	NRCNHNR	S	NHR	1	NRCNHNR	NR	NHR
1	NRCNHNR	S	COH	1	NRCNHNR	NR	COH
1	NRCNHNR	CR ₁ R ₂	F	1	NRCNHNR	CONR	F
1	NRCNHNR	CR ₁ R ₂	CN	1	NRCNHNR	CONR	CN
1	NRCNHNR	SO ₂ NR	CN	1	NRCNHNR	NRCONR	CN
1	NRCNHNR	SO ₂ NR	NHR	1	NRCNHNR	NRCONR	NHR
1	NRCNHNR	SO ₂ NR	COH	1	NRCNHNR	NRCONR	COH
1	NRCNHNR	NRCNHNR	Cl	1	NRCNHNR	NRCOO	Cl
1	NRCNHNR	NRCNHNR	Br	1	NRCNHNR	NRCOO	Br
1	NRCNHNR	NRCNHNR	CH=CH ₂	1	NRCNHNR	NRCOO	CH=CH ₂
1	NRCNHNR	C≡C	OH	1	NRCNHNR	CH=CH	OH
1	NRCNHNR	C≡C	SO ₂ H	1	NRCNHNR	CH=CH	SO ₂ H
1	NRCNHNR	C≡C	COR	1	NRCNHNR	CH=CH	COR
1	NRCOO	O	F	1	NRCOO	S	F
1	NRCOO	O	N ₃	1	NRCOO	S	N ₃
1	NRCOO	O	CONH ₂	1	NRCOO	S	CONH ₂
1	NRCOO	NR	OH	1	NRCOO	CR ₁ R ₂	OH
1	NRCOO	NR	SH	1	NRCOO	CR ₁ R ₂	SH
1	NRCOO	NR	I	1	NRCOO	CR ₁ R ₂	I
1	NRCOO	CONR	OH	1	NRCOO	SO ₂ NR	OH
1	NRCOO	CONR	N ₃	1	NRCOO	SO ₂ NR	N ₃
1	NRCOO	CONR	COR	1	NRCOO	SO ₂ NR	COR
1	NRCOO	NRCONR	OH	1	NRCOO	NRCNHNR	OH
1	NRCOO	NRCONR	N ₃	1	NRCOO	NRCNHNR	N ₃
1	NRCOO	NRCOO	SH	1	NRCOO	C≡C	SH
1	NRCOO	NRCOO	CH=CH ₂	1	NRCOO	C≡C	CH=CH ₂
1	NRCOO	CH=CH	I	1	C≡C	O	I
1	NRCOO	CH=CH	F	1	C≡C	O	F
1	NRCOO	CH=CH	C≡CH	1	C≡C	O	C≡CH
1	C≡C	S	I	1	C≡C	NR	I
1	C≡C	S	F	1	C≡C	NR	F
1	C≡C	S	CH=CH ₂	1	C≡C	NR	CH=CH ₂

1	C≡C	CR ₁ R ₂	OH	1	C≡C	CONR	OH
1	C≡C	CR ₁ R ₂	SH	1	C≡C	CONR	SH
1	C≡C	CR ₁ R ₂	COOH	1	C≡C	CONR	COOH
1	C≡C	CR ₁ R ₂	SO ₂ H	1	C≡C	CONR	SO ₂ H
1	C≡C	SO ₂ NR	NHR	1	C≡C	NRCNR	NHR
1	C≡C	NRCNHNHNR	SH	1	C≡C	NRCOO	SH
1	C≡C	NRCNHNHNR	SO ₂ H	1	C≡C	NRCOO	SO ₂ H
1	C≡C	NRCNHNHNR	COR	1	C≡C	NRCOO	COR
1	C≡C	C≡C	OH	1	C≡C	CH=CH	OH
1	C≡C	C≡C	COH	1	C≡C	CH=CH	COH
1	C≡C	C≡C	COR	1	C≡C	CH=CH	COR
1	CH=CH	O	OH	1	CH=CH	S	OH
1	CH=CH	O	COOH	1	CH=CH	S	COOH
1	CH=CH	O	COH	1	CH=CH	S	COH
1	CH=CH	NR	SO ₂ H	1	CH=CH	CR ₁ R ₂	SO ₂ H
1	CH=CH	NR	F	1	CH=CH	CR ₁ R ₂	F
1	CH=CH	NR	COH	1	CH=CH	CR ₁ R ₂	COH
1	CH=CH	CONR	SH	1	CH=CH	SO ₂ NR	SH
1	CH=CH	CONR	I	1	CH=CH	SO ₂ NR	I
1	CH=CH	CONR	F	1	CH=CH	SO ₂ NR	F
1	CH=CH	NRCNR	CH=CH ₂	1	CH=CH	NRCNHNHNR	CH=CH ₂
1	CH=CH	NRCNR	C≡CH	1	CH=CH	NRCNHNHNR	C≡CH
1	CH=CH	NRCNR	NH ₂	1	CH=CH	NRCNHNHNR	NH ₂
1	CH=CH	NRCOO	COH	1	CH=CH	C≡C	COH
1	CH=CH	NRCOO	COR	1	CH=CH	C≡C	COR
1	CH=CH	CH=CH	OH	1	CH=CH	CH=CH	N ₃
1	CH=CH	CH=CH	Br	1	CH=CH	CH=CH	NHR
1	CH=CH	CH=CH	I	1	CH=CH	CH=CH	COH
2	O	O	F	2	O	S	F
2	O	O	CN	2	O	S	CN
2	O	O	N ₃	2	O	S	N ₃
2	O	NR	Br	2	O	CR ₂ R ₂	Br
2	O	NR	F	2	O	CR ₂ R ₂	F
2	O	NR	COR	2	O	CR ₂ R ₂	COR
2	O	CONR	OH	2	O	SO ₂ NR	OH
2	O	CONR	SH	2	O	SO ₂ NR	SH
2	O	CONR	COOH	2	O	SO ₂ NR	COOH
2	O	NRCNR	N ₃	2	O	NRCNHNHNR	N ₃
2	O	NRCNR	CONH ₂	2	O	NRCNHNHNR	CONH ₂
2	O	NRCOO	Cl	2	O	C≡C	Cl
2	O	NRCOO	CH=CH ₂	2	O	C≡C	CH=CH ₂
2	O	CH=CH	SH	2	S	O	SH
2	O	CH=CH	COOH	2	S	O	COOH
2	O	CH=CH	COH	2	S	O	COH
2	S	S	COOH	2	S	NR	COOH
2	S	S	SO ₂ H	2	S	NR	SO ₂ H
2	S	S	Cl	2	S	NR	Cl
2	S	S	NHR	2	S	NR	NHR
2	S	CR ₂ R ₂	CN	2	S	CONR	CN
2	S	CR ₂ R ₂	C≡CH	2	S	CONR	C≡CH
2	S	CR ₂ R ₂	NH ₂	2	S	CONR	NH ₂

2	S	SO ₂ NR	Cl	2	S	NRCONR	Cl
2	S	SO ₂ NR	Br	2	S	NRCONR	Br
2	S	SO ₂ NR	N ₃	2	S	NRCONR	N ₃
2	S	NRCNHNR	Br	2	S	NRCOO	Br
2	S	NRCNHNR	I	2	S	NRCOO	I
2	S	NRCNHNR	COR	2	S	NRCOO	COR
2	S	C≡C	OH	2	S	CH=CH	OH
2	S	C≡C	SH	2	S	CH=CH	SH
2	S	C≡C	CH=CH ₂	2	S	CH=CH	CH=CH ₂
2	NR	O	C≡CH	2	NR	S	C≡CH
2	NR	O	NH ₂	2	NR	S	NH ₂
2	NR	O	NHR	2	NR	S	NHR
2	NR	NR	Br	2	NR	CR ₂ R ₂	Br
2	NR	NR	F	2	NR	CR ₂ R ₂	F
2	NR	NR	NH ₂	2	NR	CR ₂ R ₂	NH ₂
2	NR	NR	NHR	2	NR	CR ₂ R ₂	NHR
2	NR	CONR	CN	2	NR	SO ₂ NR	CN
2	NR	CONR	COR	2	NR	SO ₂ NR	COR
2	NR	NRCONR	OH	2	NR	NRCNHNR	OH
2	NR	NRCONR	SH	2	NR	NRCNHNR	SH
2	NR	NRCOO	CH=CH ₂	2	NR	C≡C	CH=CH ₂
2	NR	NRCOO	C≡CH	2	NR	C≡C	C≡CH
2	NR	NRCOO	NH ₂	2	NR	C≡C	NH ₂
2	NR	CH=CH	Br	2	CR ₂ R ₂	O	Br
2	NR	CH=CH	NH ₂	2	CR ₂ R ₂	OO	NH ₂
2	NR	CH=CH	COH	2	CR ₂ R ₂	O	COH
2	NR	CH=CH	COR	2	CR ₂ R ₂	O	COR
2	CR ₂ R ₂	S	OH	2	CR ₂ R ₂	NR	OH
2	CR ₂ R ₂	S	SH	2	CR ₂ R ₂	NR	SH
2	CR ₂ R ₂	S	NH ₂	2	CR ₂ R ₂	NR	NH ₂
2	CR ₂ R ₂	CR ₂ R ₂	CN	2	CR ₂ R ₂	CONR	CN
2	CR ₂ R ₂	CR ₂ R ₂	N ₃	2	CR ₂ R ₂	CONR	N ₃
2	CR ₂ R ₂	CR ₂ R ₂	CONH ₂	2	CR ₂ R ₂	CONR	CONH ₂
2	CR ₂ R ₂	CR ₂ R ₂	CH=CH ₂	2	CR ₂ R ₂	CONR	CH=CH ₂
2	CR ₂ R ₂	SO ₂ NR	OH	2	CR ₂ R ₂	NRCONR	OH
2	CR ₂ R ₂	SO ₂ NR	Br	2	CR ₂ R ₂	NRCONR	Br
2	CR ₂ R ₂	SO ₂ NR	I	2	CR ₂ R ₂	NRCONR	I
2	CR ₂ R ₂	SO ₂ NR	F	2	CR ₂ R ₂	NRCONR	F
2	CR ₂ R ₂	NRCNHNR	SH	2	CR ₂ R ₂	NRCOO	SH
2	CR ₂ R ₂	NRCNHNR	COOH	2	CR ₂ R ₂	NRCOO	COOH
2	CR ₂ R ₂	NRCNHNR	SO ₂ H	2	CR ₂ R ₂	NRCOO	SO ₂ H
2	CR ₂ R ₂	C≡C	Cl	2	CR ₂ R ₂	CH=CH	Cl
2	CR ₂ R ₂	C≡C	NH ₂	2	CR ₂ R ₂	CH=CH	NH ₂
2	CR ₂ R ₂	C≡C	COH	2	CR ₂ R ₂	CH=CH	COH
2	CONR	O	SO ₂ H	2	CONR	S	SO ₂ H
2	CONR	O	N ₃	2	CONR	S	N ₃
2	CONR	NR	COOH	2	CONR	CR ₂ R ₂	COOH
2	CONR	NR	SO ₂ H	2	CONR	CR ₂ R ₂	SO ₂ H
2	CONR	NR	Cl	2	CONR	CR ₂ R ₂	Cl
2	CONR	CONR	CH=CH ₂	2	CONR	SO ₂ NR	CH=CH ₂
2	CONR	CONR	C≡CH	2	CONR	SO ₂ NR	C≡CH
2	CONR	CONR	NH ₂	2	CONR	SO ₂ NR	NH ₂

2	CONR	NRCONR	NH ₂	2	CONR	NRCNHNR	NH ₂
2	CONR	NRCONR	NHR	2	CONR	NRCNHNR	NHR
2	CONR	NRCOO	CN	2	CONR	C≡C	CN
2	CONR	NRCOO	COR	2	CONR	C≡C	COR
2	CONR	CH=CH	OH	2	SO ₂ NR	O	OH
2	CONR	CH=CH	Br	2	SO ₂ NR	O	Br
2	CONR	CH=CH	I	2	SO ₂ NR	O	I
2	SO ₂ NR	S	OH	2	SO ₂ NR	NR	OH
2	SO ₂ NR	S	SH	2	SO ₂ NR	NR	SH
2	SO ₂ NR	S	COH	2	SO ₂ NR	NR	COH
2	SO ₂ NR	CR ₂ R ₂	COOH	2	SO ₂ NR	CONR	COOH
2	SO ₂ NR	CR ₂ R ₂	COR	2	SO ₂ NR	CONR	COR
2	SO ₂ NR	SO ₂ NR	OH	2	SO ₂ NR	NRCONR	OH
2	SO ₂ NR	SO ₂ NR	SH	2	SO ₂ NR	NRCONR	SH
2	SO ₂ NR	SO ₂ NR	COOH	2	SO ₂ NR	NRCONR	COOH
2	SO ₂ NR	NRCNHNR	CH=CH ₂	2	SO ₂ NR	NRCOO	CH=CH ₂
2	SO ₂ NR	NRCNHNR	COH	2	SO ₂ NR	NRCOO	COH
2	SO ₂ NR	NRCNHNR	COR	2	SO ₂ NR	NRCOO	COR
2	SO ₂ NR	C≡C	NHR	2	SO ₂ NR	CH=CH	NHR
2	SO ₂ NR	C≡C	COH	2	SO ₂ NR	CH=CH	COH
2	NRCONR	O	COOH	2	NRCONR	S	COOH
2	NRCONR	O	CONH ₂	2	NRCONR	S	CONH ₂
2	NRCONR	O	CH=CH ₂	2	NRCONR	S	CH=CH ₂
2	NRCONR	NR	Cl	2	NRCONR	CR ₂ R ₂	Cl
2	NRCONR	NR	Br	2	NRCONR	CR ₂ R ₂	Br
2	NRCONR	CONR	COH	2	NRCONR	SO ₂ NR	COH
2	NRCONR	CONR	COR	2	NRCONR	SO ₂ NR	COR
2	NRCONR	NRCONR	SH	2	NRCONR	NRCNHNR	SH
2	NRCONR	NRCONR	CN	2	NRCONR	NRCNHNR	CN
2	NRCONR	NRCOO	F	2	NRCONR	C≡C	F
2	NRCONR	NRCOO	CN	2	NRCONR	C≡C	CN
2	NRCONR	CH=CH	I	2	NRCNHNR	O	I
2	NRCONR	CH=CH	F	2	NRCNHNR	O	F
2	NRCONR	CH=CH	CN	2	NRCNHNR	O	CN
2	NRCNHNR	S	F	2	NRCNHNR	NR	F
2	NRCNHNR	S	COH	2	NRCNHNR	NR	COH
2	NRCNHNR	S	COR	2	NRCNHNR	NR	COR
2	NRCNHNR	CR ₂ R ₂	COR	2	NRCNHNR	CONR	COR
2	NRCNHNR	SO ₂ NR	OH	2	NRCNHNR	NRCONR	OH
2	NRCNHNR	SO ₂ NR	N ₃	2	NRCNHNR	NRCONR	N ₃
2	NRCNHNR	NRCNHNR	CONH ₂	2	NRCNHNR	NRCOO	CONH ₂
2	NRCNHNR	NRCNHNR	COH	2	NRCNHNR	NRCOO	COH
2	NRCNHNR	NRCNHNR	COR	2	NRCNHNR	NRCOO	COR
2	NRCNHNR	C≡C	OH	2	NRCNHNR	CH=CH	OH
2	NRCNHNR	C≡C	SH	2	NRCNHNR	CH=CH	SH
2	NRCNHNR	C≡C	NH ₂	2	NRCNHNR	CH=CH	NH ₂
2	NRCOO	O	I	2	NRCOO	S	I
2	NRCOO	O	C≡CH	2	NRCOO	S	C≡CH
2	NRCOO	O	COR	2	NRCOO	S	COR
2	NRCOO	NR	SH	2	NRCOO	CR ₂ R ₂	SH
2	NRCOO	NR	COOH	2	NRCOO	CR ₂ R ₂	COOH
2	NRCOO	CONR	I	2	NRCOO	SO ₂ NR	I

2	NRCOO	CONR	CN	2	NRCOO	SO ₂ NR	CN
2	NRCOO	NRCONR	OH	2	NRCOO	NRCNHNR	OH
2	NRCOO	NRCONR	SH	2	NRCOO	NRCNHNR	SH
2	NRCOO	NRCOO	Br	2	NRCOO	C≡C	Br
2	NRCOO	NRCOO	F	2	NRCOO	C≡C	F
2	NRCOO	NRCOO	N ₃	2	NRCOO	C≡C	N ₃
2	NRCOO	CH=CH	CN	2	C≡C	O	CN
2	NRCOO	CH=CH	C≡CH	2	C≡C	O	C≡CH
2	NRCOO	CH=CH	NH ₂	2	C≡C	O	NH ₂
2	C≡C	S	COOH	2	C≡C	NR	COOH
2	C≡C	S	CONH ₂	2	C≡C	NR	CONH ₂
2	C≡C	S	NHR	2	C≡C	NR	NHR
2	C≡C	CR ₂ R ₂	COOH	2	C≡C	CONR	COOH
2	C≡C	SO ₂ NR	SH	2	C≡C	NRCONR	SH
2	C≡C	SO ₂ NR	N ₃	2	C≡C	NRCONR	N ₃
2	C≡C	SO ₂ NR	CONH ₂	2	C≡C	NRCONR	CONH ₂
2	C≡C	SO ₂ NR	CH=CH ₂	2	C≡C	NRCONR	CH=CH ₂
2	C≡C	NRCNHNR	I	2	C≡C	NRCOO	I
2	C≡C	NRCNHNR	F	2	C≡C	NRCOO	F
2	C≡C	NRCNHNR	NHR	2	C≡C	NRCOO	NHR
2	C≡C	C≡C	CH=CH ₂	2	C≡C	CH=CH	CH=CH ₂
2	C≡C	C≡C	C≡CH	2	C≡C	CH=CH	C≡CH
2	CH=CH	O	CONH ₂	2	CH=CH	S	CONH ₂
2	CH=CH	O	NHR	2	CH=CH	S	NHR
2	CH=CH	O	COR	2	CH=CH	S	COR
2	CH=CH	NR	I	2	CH=CH	CR ₂ R ₂	I
2	CH=CH	NR	F	2	CH=CH	CR ₂ R ₂	F
2	CH=CH	NR	CN	2	CH=CH	CR ₂ R ₂	CN
2	CH=CH	NR	CH=CH ₂	2	CH=CH	CR ₂ R ₂	CH=CH ₂
2	CH=CH	CONR	C≡CH	2	CH=CH	SO ₂ NR	C≡CH
2	CH=CH	CONR	NH ₂	2	CH=CH	SO ₂ NR	NH ₂
2	CH=CH	NRCONR	Cl	2	CH=CH	NRCNHNR	Cl
2	CH=CH	NRCONR	N ₃	2	CH=CH	NRCNHNR	N ₃
2	CH=CH	NRCOO	SH	2	CH=CH	C≡C	SH
2	CH=CH	NRCOO	CONH ₂	2	CH=CH	C≡C	CONH ₂
2	CH=CH	NRCOO	CH=CH ₂	2	CH=CH	C≡C	CH=CH ₂
2	CH=CH	NRCOO	C≡CH	2	CH=CH	C≡C	C≡CH
2	CH=CH	CH=CH	SO ₂ H	2	CH=CH	CH=CH	C≡CH
2	CH=CH	CH=CH	Cl	2	CH=CH	CH=CH	NH ₂
2	CH=CH	CH=CH	Br	2	CH=CH	CH=CH	NHR
3	O	O	Cl	3	O	S	Cl
3	O	O	I	3	O	S	I
3	O	NR	CONH ₂	3	O	CR ₃ R ₂	CONH ₂
3	O	NR	CH=CH ₂	3	O	CR ₃ R ₂	CH=CH ₂
3	O	NR	NH ₂	3	O	CR ₃ R ₂	NH ₂
3	O	CONR	NH ₂	3	O	SO ₂ NR	NH ₂
3	O	CONR	NHR	3	O	SO ₂ NR	NHR
3	O	NRCONR	N ₃	3	O	NRCNHNR	N ₃
3	O	NRCONR	CONH ₂	3	O	NRCNHNR	CONH ₂
3	O	NRCOO	SH	3	O	C≡C	SH

3	O	NRCOO	F	3	O	C≡C	F
3	O	NRCOO	N ₃	3	O	C≡C	N ₃
3	O	NRCOO	C≡CH	3	O	C≡C	C≡CH
3	O	NRCOO	NH ₂	3	O	C≡C	NH ₂
3	O	CH=CH	NH ₂	3	S	O	NH ₂
3	O	CH=CH	COH	3	S	O	COH
3	O	CH=CH	COR	3	S	O	COR
3	S	S	OH	3	S	NR	OH
3	S	S	SH	3	S	NR	SH
3	S	S	NHR	3	S	NR	NHR
3	S	S	COH	3	S	NR	COH
3	S	CR ₃ R ₂	NH ₂	3	S	CONR	NH ₂
3	S	SO ₂ NR	SH	3	S	NRCONR	SH
3	S	SO ₂ NR	COOH	3	S	NRCONR	COOH
3	S	NRCNHNR	I	3	S	NRCOO	I
3	S	NRCNHNR	CONH ₂	3	S	NRCOO	CONH ₂
3	S	NRCNHNR	COR	3	S	NRCOO	COR
3	S	C≡C	OH	3	S	CH=CH	OH
3	S	C≡C	SH	3	S	CH=CH	SH
3	NR	O	CH=CH ₂	3	NR	S	CH=CH ₂
3	NR	O	C≡CH	3	NR	S	C≡CH
3	NR	O	COH	3	NR	S	COH
3	NR	NR	SH	3	NR	CR ₃ R ₂	SH
3	NR	NR	COOH	3	NR	CR ₃ R ₂	COOH
3	NR	NR	SO ₂ H	3	NR	CR ₃ R ₂	SO ₂ H
3	NR	CONR	NH ₂	3	NR	SO ₂ NR	NH ₂
3	NR	CONR	NHR	3	NR	SO ₂ NR	NHR
3	NR	CONR	COH	3	NR	SO ₂ NR	COH
3	NR	NRCONR	COOH	3	NR	NRCNHNR	COOH
3	NR	NRCONR	C≡CH	3	NR	NRCNHNR	C≡CH
3	NR	NRCONR	NH ₂	3	NR	NRCNHNR	NH ₂
3	NR	NRCOO	OH	3	NR	C≡C	OH
3	NR	NRCOO	NHR	3	NR	C≡C	NHR
3	NR	CH=CH	COOH	3	CR ₃ R ₂	O	COOH
3	NR	CH=CH	I	3	CR ₃ R ₂	O	I
3	CR ₃ R ₂	S	Br	3	CR ₃ R ₂	NR	Br
3	CR ₃ R ₂	CR ₃ R ₂	CH=CH ₂	3	CR ₃ R ₂	CONR	CH=CH ₂
3	CR ₃ R ₂	CR ₃ R ₂	C≡CH	3	CR ₃ R ₂	CONR	C≡CH
3	CR ₃ R ₂	SO ₂ NR	NH ₂	3	CR ₃ R ₂	NRCONR	NH ₂
3	CR ₃ R ₂	SO ₂ NR	NHR	3	CR ₃ R ₂	NRCONR	NHR
3	CR ₃ R ₂	SO ₂ NR	COH	3	CR ₃ R ₂	NRCONR	COH
3	CR ₃ R ₂	NRCNHNR	COOH	3	CR ₃ R ₂	NRCOO	COOH
3	CR ₃ R ₂	NRCNHNR	SO ₂ H	3	CR ₃ R ₂	NRCOO	SO ₂ H
3	CR ₃ R ₂	NRCNHNR	COH	3	CR ₃ R ₂	NRCOO	COH
3	CR ₃ R ₂	C≡C	SO ₂ H	3	CR ₃ R ₂	CH=CH	SO ₂ H
3	CR ₃ R ₂	C≡C	CN	3	CR ₃ R ₂	CH=CH	CN
3	CONR	O	SO ₂ H	3	CONR	S	SO ₂ H
3	CONR	O	Cl	3	CONR	S	Cl
3	CONR	O	Br	3	CONR	S	Br
3	CONR	NR	N ₃	3	CONR	CR ₃ R ₂	N ₃
3	CONR	NR	CONH ₂	3	CONR	CR ₃ R ₂	CONH ₂
3	CONR	NR	CH=CH ₂	3	CONR	CR ₃ R ₂	CH=CH ₂

3	CONR	CONR	C≡CH	3	CONR	SO ₂ NR	C≡CH
3	CONR	CONR	NH ₂	3	CONR	SO ₂ NR	NH ₂
3	CONR	NRCONR	I	3	CONR	NRCNHNR	I
3	CONR	NRCONR	N ₃	3	CONR	NRCNHNR	N ₃
3	CONR	NRCOO	COH	3	CONR	C≡C	COH
3	CONR	NRCOO	COR	3	CONR	C≡C	COR
3	CONR	CH=CH	OH	3	SO ₂ NR	O	OH
3	CONR	CH=CH	SH	3	SO ₂ NR	O	SH
3	SO ₂ NR	S	SO ₂ H	3	SO ₂ NR	NR	SO ₂ H
3	SO ₂ NR	S	COH	3	SO ₂ NR	NR	COH
3	SO ₂ NR	S	COR	3	SO ₂ NR	NR	COR
3	SO ₂ NR	CR ₃ R ₂	OH	3	SO ₂ NR	CONR	OH
3	SO ₂ NR	CR ₃ R ₂	SH	3	SO ₂ NR	CONR	SH
3	SO ₂ NR	CR ₃ R ₂	CONH ₂	3	SO ₂ NR	CONR	CONH ₂
3	SO ₂ NR	CR ₃ R ₂	CH=CH ₂	3	SO ₂ NR	CONR	CH=CH ₂
3	SO ₂ NR	SO ₂ NR	SH	3	SO ₂ NR	NRCONR	SH
3	SO ₂ NR	SO ₂ NR	COH	3	SO ₂ NR	NRCONR	COH
3	SO ₂ NR	SO ₂ NR	COR	3	SO ₂ NR	NRCONR	COR
3	SO ₂ NR	NRCNHNR	OH	3	SO ₂ NR	NRCOO	OH
3	SO ₂ NR	NRCNHNR	SH	3	SO ₂ NR	NRCOO	SH
3	SO ₂ NR	C≡C	CH=CH ₂	3	SO ₂ NR	CH=CH	CH=CH ₂
3	SO ₂ NR	C≡C	NH ₂	3	SO ₂ NR	CH=CH	NH ₂
3	SO ₂ NR	C≡C	NHR	3	SO ₂ NR	CH=CH	NHR
3	NRCONR	O	Br	3	NRCONR	S	Br
3	NRCONR	O	I	3	NRCONR	S	I
3	NRCONR	NR	F	3	NRCONR	CR ₃ R ₂	F
3	NRCONR	NR	CN	3	NRCONR	CR ₃ R ₂	CN
3	NRCONR	CONR	SO ₂ H	3	NRCONR	SO ₂ NR	SO ₂ H
3	NRCONR	CONR	Cl	3	NRCONR	SO ₂ NR	Cl
3	NRCONR	NRCONR	SH	3	NRCONR	NRCNHNR	SH
3	NRCONR	NRCONR	CONH ₂	3	NRCONR	NRCNHNR	CONH ₂
3	NRCONR	NRCONR	CH=CH ₂	3	NRCONR	NRCNHNR	CH=CH ₂
3	NRCONR	NRCOO	NH ₂	3	NRCONR	C≡C	NH ₂
3	NRCONR	NRCOO	COH	3	NRCONR	C≡C	COH
3	NRCONR	CH=CH	OH	3	NRCNHNR	O	OH
3	NRCONR	CH=CH	CONH ₂	3	NRCNHNR	O	CONH ₂
3	NRCONR	CH=CH	CH=CH ₂	3	NRCNHNR	O	CH=CH ₂
3	NRCNHNR	S	SH	3	NRCNHNR	NR	SH
3	NRCNHNR	S	COOH	3	NRCNHNR	NR	COOH
3	NRCNHNR	S	SO ₂ H	3	NRCNHNR	NR	SO ₂ H
3	NRCNHNR	SO ₂ NR	Br	3	NRCNHNR	NRCONR	Br
3	NRCNHNR	SO ₂ NR	C≡CH	3	NRCNHNR	NRCONR	C≡CH
3	NRCNHNR	SO ₂ NR	NH ₂	3	NRCNHNR	NRCONR	NH ₂
3	NRCNHNR	NRCNHNR	COOH	3	NRCNHNR	NRCOO	COOH
3	NRCNHNR	NRCNHNR	SO ₂ H	3	NRCNHNR	NRCOO	SO ₂ H
3	NRCNHNR	C≡C	Cl	3	NRCNHNR	CH=CH	Cl
3	NRCNHNR	C≡C	Br	3	NRCNHNR	CH=CH	Br
a3	NRCOO	O	SH	3	NRCOO	S	SH
3	NRCOO	O	COOH	3	NRCOO	S	COOH
3	NRCOO	O	SO ₂ H	3	NRCOO	S	SO ₂ H
3	NRCOO	NR	F	3	NRCOO	CR ₃ R ₂	F
3	NRCOO	NR	CN	3	NRCOO	CR ₃ R ₂	CN

3	NRCOO	NR	COR	3	NRCOO	CR ₃ R ₂	COR
3	NRCOO	CONR	C≡CH	3	NRCOO	SO ₂ NR	C≡CH
3	NRCOO	CONR	COH	3	NRCOO	SO ₂ NR	COH
3	NRCOO	CONR	COR	3	NRCOO	SO ₂ NR	COR
3	NRCOO	NRCONR	OH	3	NRCOO	NRCNHNR	OH
3	NRCOO	NRCONR	COR	3	NRCOO	NRCNHNR	COR
3	NRCOO	NRCOO	Br	3	NRCOO	C≡C	Br
3	NRCOO	CH=CH	CONH ₂	3	C≡C	O	CONH ₂
3	NRCOO	CH=CH	CH=CH ₂	3	C≡C	O	CH=CH ₂
3	C≡C	S	OH	3	C≡C	NR	OH
3	C≡C	CR ₃ R ₂	I	3	C≡C	CONR	I
3	C≡C	CR ₃ R ₂	F	3	C≡C	CONR	F
3	C≡C	CR ₃ R ₂	NH ₂	3	C≡C	CONR	NH ₂
3	C≡C	SO ₂ NR	N ₃	3	C≡C	NRCONR	N ₃
3	C≡C	SO ₂ NR	CONH ₂	3	C≡C	NRCONR	CONH ₂
3	C≡C	SO ₂ NR	CH=CH ₂	3	C≡C	NRCONR	CH=CH ₂
3	C≡C	NRCNHNR	CH=CH ₂	3	C≡C	NRCOO	CH=CH ₂
3	C≡C	NRCNHNR	C≡CH	3	C≡C	NRCOO	C≡CH
3	C≡C	C≡C	I	3	C≡C	CH=CH	I
3	C≡C	C≡C	C≡CH	3	C≡C	CH=CH	C≡CH
3	C≡C	C≡C	NH ₂	3	C≡C	CH=CH	NH ₂
3	C≡C	C≡C	NHR	3	C≡C	CH=CH	NHR
3	CH=CH	O	COOH	3	CH=CH	S	COOH
3	CH=CH	O	CN	3	CH=CH	S	CN
3	CH=CH	NR	I	3	CH=CH	CR ₃ R ₂	I
3	CH=CH	NR	F	3	CH=CH	CR ₃ R ₂	F
3	CH=CH	CONR	CN	3	CH=CH	SO ₂ NR	CN
3	CH=CH	CONR	N ₃	3	CH=CH	SO ₂ NR	N ₃
3	CH=CH	CONR	C≡CH	3	CH=CH	SO ₂ NR	C≡CH
3	CH=CH	NRCONR	NHR	3	CH=CH	NRCNHNR	NHR
3	CH=CH	NRCOO	Br	3	CH=CH	C≡C	Br
3	CH=CH	NRCOO	I	3	CH=CH	C≡C	I
3	CH=CH	CH=CH	Cl	3	CH=CH	CH=CH	NH ₂
3	O	O	OH	3	O	S	OH
3	O	O	SH	3	O	S	SH
3	O	NR	CH=CH ₂	3	O	CR ₃ R ₂	CH=CH ₂
3	O	NR	C≡CH	3	O	CR ₃ R ₂	C≡CH
3	O	NR	NH ₂	3	O	CR ₃ R ₂	NH ₂
3	O	CONR	Br	3	O	SO ₂ NR	Br
3	O	NRCONR	Br	3	O	NRCNHNR	Br
3	O	NRCONR	CONH ₂	3	O	NRCNHNR	CONH ₂
3	O	NRCOO	COH	3	O	C≡C	COH
3	O	NRCOO	COR	3	O	C≡C	COR
3	O	CH=CH	CONH ₂	3	S	O	CONH ₂
3	O	CH=CH	CH=CH ₂	3	S	O	CH=CH ₂
3	O	CH=CH	C≡CH	3	S	O	C≡CH
3	S	S	CONH ₂	3	S	NR	CONH ₂
3	S	S	CH=CH ₂	3	S	NR	CH=CH ₂
3	S	S	C≡CH	3	S	NR	C≡CH
3	S	S	NH ₂	3	S	NR	NH ₂

3	S	CR ₃ R ₂	N ₃	3	S	CONR	N ₃
3	S	CR ₃ R ₂	C≡CH	3	S	CONR	C≡CH
3	S	SO ₂ NR	Br	3	S	NRCONR	Br
3	S	SO ₂ NR	NHR	3	S	NRCONR	NHR
3	S	SO ₂ NR	COH	3	S	NRCONR	COH
3	S	NRCNHNR	N ₃	3	S	NRCOO	N ₃
3	S	NRCNHNR	COR	3	S	NRCOO	COR
3	S	C≡C	OH	3	S	CH=CH	OH
3	S	C≡C	SH	3	S	CH=CH	SH
3	S	C≡C	Br	3	S	CH=CH	Br
3	NR	O	SH	3	NR	S	SH
3	NR	O	COOH	3	NR	S	COOH
3	NR	O	CONH ₂	3	NR	S	CONH ₂
3	NR	O	COR	3	NR	S	COR
3	NR	NR	OH	3	NR	CR ₃ R ₂	OH
3	NR	NR	I	3	NR	CR ₃ R ₂	I
3	NR	NR	F	3	NR	CR ₃ R ₂	F
3	NR	CONR	F	3	NR	SO ₂ NR	F
3	NR	CONR	CONH ₂	3	NR	SO ₂ NR	CONH ₂
3	NR	NRCONR	Br	3	NR	NRCNHNR	Br
3	NR	NRCONR	I	3	NR	NRCNHNR	I
3	NR	NRCOO	CN	3	NR	C≡C	CN
3	NR	NRCOO	N ₃	3	NR	C≡C	N ₃
3	NR	NRCOO	CONH ₂	3	NR	C≡C	CONH ₂
3	NR	CH=CH	Cl	3	CR ₃ R ₂	O	Cl
3	NR	CH=CH	Br	3	CR ₃ R ₂	O	Br
3	CR ₃ R ₂	S	COOH	3	CR ₃ R ₂	NR	COOH
3	CR ₃ R ₂	S	SO ₂ H	3	CR ₃ R ₂	NR	SO ₂ H
3	CR ₃ R ₂	S	Cl	3	CR ₃ R ₂	NR	Cl
3	CR ₃ R ₂	CR ₃ R ₂	COOH	3	CR ₃ R ₂	CONR	COOH
3	CR ₃ R ₂	CR ₃ R ₂	I	3	CR ₃ R ₂	CONR	I
3	CR ₃ R ₂	CR ₃ R ₂	CH=CH ₂	3	CR ₃ R ₂	CONR	CH=CH ₂
3	CR ₃ R ₂	CR ₃ R ₂	C≡CH	3	CR ₃ R ₂	CONR	C≡CH
3	CR ₃ R ₂	SO ₂ NR	F	3	CR ₃ R ₂	NRCONR	F
3	CR ₃ R ₂	SO ₂ NR	CH=CH ₂	3	CR ₃ R ₂	NRCONR	CH=CH ₂
3	CR ₃ R ₂	SO ₂ NR	C≡CH	3	CR ₃ R ₂	NRCONR	C≡CH
3	CR ₃ R ₂	SO ₂ NR	NH ₂	3	CR ₃ R ₂	NRCONR	NH ₂
3	CR ₃ R ₂	NRCNHNR	OH	3	CR ₃ R ₂	NRCOO	OH
3	CR ₃ R ₂	NRCNHNR	SH	3	CR ₃ R ₂	NRCOO	SH
3	CR ₃ R ₂	C≡C	C≡CH	3	CR ₃ R ₂	CH=CH	C≡CH
3	CR ₃ R ₂	C≡C	NH ₂	3	CR ₃ R ₂	CH=CH	NH ₂
3	CONR	O	SH	3	CONR	S	SH
3	CONR	O	COOH	3	CONR	S	COOH
3	CONR	O	CONH ₂	3	CONR	S	CONH ₂
3	CONR	NR	I	3	CONR	CR ₃ R ₂	I
3	CONR	NR	F	3	CONR	CR ₃ R ₂	F
3	CONR	CONR	OH	3	CONR	SO ₂ NR	OH
3	CONR	CONR	SH	3	CONR	SO ₂ NR	SH
3	CONR	CONR	COOH	3	CONR	SO ₂ NR	COOH
3	CONR	NRCONR	NHR	3	CONR	NRCNHNR	NHR
3	CONR	NRCONR	COH	3	CONR	NRCNHNR	COH
3	CONR	NRCOO	I	3	CONR	C≡C	I

3	CONR	NRCOO	F	3	CONR	C≡C	F
3	CONR	CH=CH	F	3	SO ₂ NR	O	F
3	CONR	CH=CH	COR	3	SO ₂ NR	O	COR
3	SO ₂ NR	S	OH	3	SO ₂ NR	NR	OH
3	SO ₂ NR	S	SH	3	SO ₂ NR	NR	SH
3	SO ₂ NR	CR ₃ R ₂	N ₃	3	SO ₂ NR	CONR	N ₃
3	SO ₂ NR	CR ₃ R ₂	CONH ₂	3	SO ₂ NR	CONR	CONH ₂
3	SO ₂ NR	SO ₂ NR	COOH	3	SO ₂ NR	NRCONR	COOH
3	SO ₂ NR	SO ₂ NR	CN	3	SO ₂ NR	NRCONR	CN
3	SO ₂ NR	SO ₂ NR	N ₃	3	SO ₂ NR	NRCONR	N ₃
3	SO ₂ NR	SO ₂ NR	CONH ₂	3	SO ₂ NR	NRCONR	CONH ₂
3	SO ₂ NR	NRCNHNR	CN	3	SO ₂ NR	NRCOO	CN
3	SO ₂ NR	NRCNHNR	CH=CH ₂	3	SO ₂ NR	NRCOO	CH=CH ₂
3	SO ₂ NR	C≡C	SO ₂ H	3	SO ₂ NR	CH=CH	SO ₂ H
3	SO ₂ NR	C≡C	Cl	3	SO ₂ NR	CH=CH	Cl
3	SO ₂ NR	C≡C	Br	3	SO ₂ NR	CH=CH	Br
3	NRCONR	O	C≡CH	3	NRCONR	S	C≡CH
3	NRCONR	O	NH ₂	3	NRCONR	S	NH ₂
3	NRCONR	NR	Cl	3	NRCONR	CR ₃ R ₂	Cl
3	NRCONR	NR	Br	3	NRCONR	CR ₃ R ₂	Br
3	NRCONR	NR	CONH ₂	3	NRCONR	CR ₃ R ₂	CONH ₂
3	NRCONR	CONR	OH	3	NRCONR	SO ₂ NR	OH
3	NRCONR	CONR	F	3	NRCONR	SO ₂ NR	F
3	NRCONR	CONR	CN	3	NRCONR	SO ₂ NR	CN
3	NRCONR	NRCONR	CONH ₂	3	NRCONR	NRCNHNR	CONH ₂
3	NRCONR	NRCONR	CH=CH ₂	3	NRCONR	NRCNHNR	CH=CH ₂
3	NRCONR	NRCOO	CONH ₂	3	NRCONR	C≡C	CONH ₂
3	NRCONR	NRCOO	COH	3	NRCONR	C≡C	COH
3	NRCONR	CH=CH	SO ₂ H	3	NRCNHNR	O	SO ₂ H
3	NRCONR	CH=CH	Cl	3	NRCNHNR	O	Cl
3	NRCONR	CH=CH	F	3	NRCNHNR	O	F
3	NRCNHNR	S	OH	3	NRCNHNR	NR	OH
3	NRCNHNR	S	Br	3	NRCNHNR	NR	Br
3	NRCNHNR	CR ₃ R ₂	OH	3	NRCNHNR	CONR	OH
3	NRCNHNR	CR ₃ R ₂	SH	3	NRCNHNR	CONR	SH
3	NRCNHNR	CR ₃ R ₂	CH=CH ₂	3	NRCNHNR	CONR	CH=CH ₂
3	NRCNHNR	SO ₂ NR	I	3	NRCNHNR	NRCONR	I
3	NRCNHNR	SO ₂ NR	NHR	3	NRCNHNR	NRCONR	NHR
3	NRCNHNR	SO ₂ NR	COH	3	NRCNHNR	NRCONR	COH
3	NRCNHNR	SO ₂ NR	COR	3	NRCNHNR	NRCONR	COR
3	NRCNHNR	NRCNHNR	N ₃	3	NRCNHNR	NRCOO	N ₃
3	NRCNHNR	NRCNHNR	CONH ₂	3	NRCNHNR	NRCOO	CONH ₂
3	NRCNHNR	NRCNHNR	COR	3	NRCNHNR	NRCOO	COR
3	NRCNHNR	C≡C	OH	3	NRCNHNR	CH=CH	OH
3	NRCNHNR	C≡C	COR	3	NRCNHNR	CH=CH	COR
3	NRCOO	O	OH	3	NRCOO	S	OH
a3	NRCOO	O	SH	3	NRCOO	S	SH
3	NRCOO	O	COR	3	NRCOO	S	COR
3	NRCOO	NR	OH	3	NRCOO	CR ₃ R ₂	OH
3	NRCOO	NR	SH	3	NRCOO	CR ₃ R ₂	SH
3	NRCOO	NR	COOH	3	NRCOO	CR ₃ R ₂	COOH
3	NRCOO	CONR	NH ₂	3	NRCOO	SO ₂ NR	NH ₂

3	NRCOO	CONR	NHR	3	NRCOO	SO ₂ NR	NHR
3	NRCOO	NRCONR	CH=CH ₂	3	NRCOO	NRCNHNR	CH=CH ₂
3	NRCOO	NRCONR	NHR	3	NRCOO	NRCNHNR	NHR
3	NRCOO	NRCOO	I	3	NRCOO	C≡C	I
3	NRCOO	CH=CH	OH	3	C≡C	O	OH
3	NRCOO	CH=CH	SH	3	C≡C	O	SH
3	NRCOO	CH=CH	COOH	3	C≡C	O	COOH
3	C≡C	S	C≡CH	3	C≡C	NR	C≡CH
3	C≡C	S	NH ₂	3	C≡C	NR	NH ₂
3	C≡C	S	NHR	3	C≡C	NR	NHR
3	C≡C	CR ₃ R ₂	SO ₂ H	3	C≡C	CONR	SO ₂ H
3	C≡C	CR ₃ R ₂	Cl	3	C≡C	CONR	Cl
3	C≡C	CR ₃ R ₂	Br	3	C≡C	CONR	Br
3	C≡C	SO ₂ NR	OH	3	C≡C	NRCONR	OH
3	C≡C	SO ₂ NR	SH	3	C≡C	NRCONR	SH
3	C≡C	SO ₂ NR	Br	3	C≡C	NRCONR	Br
3	C≡C	NRCNHNR	CONH ₂	3	C≡C	NRCOO	CONH ₂
3	C≡C	NRCNHNR	NHR	3	C≡C	NRCOO	NHR
3	C≡C	C≡C	C≡CH	3	C≡C	CH=CH	C≡CH
3	C≡C	C≡C	NH ₂	3	C≡C	CH=CH	NH ₂
3	C≡C	C≡C	COR	3	C≡C	CH=CH	COR
3	CH=CH	O	OH	3	CH=CH	S	OH
3	CH=CH	O	SH	3	CH=CH	S	SH
3	CH=CH	O	COOH	3	CH=CH	S	COOH
3	CH=CH	O	SO ₂ H	3	CH=CH	S	SO ₂ H
3	CH=CH	O	Cl	3	CH=CH	S	Cl
3	CH=CH	NR	OH	3	CH=CH	CR ₃ R ₂	OH
3	CH=CH	NR	COOH	3	CH=CH	CR ₃ R ₂	COOH
3	CH=CH	NR	F	3	CH=CH	CR ₃ R ₂	F
3	CH=CH	CONR	NH ₂	3	CH=CH	SO ₂ NR	NH ₂
3	CH=CH	CONR	NHR	3	CH=CH	SO ₂ NR	NHR
3	CH=CH	CONR	COH	3	CH=CH	SO ₂ NR	COH
3	CH=CH	CONR	COR	3	CH=CH	SO ₂ NR	COR
3	CH=CH	NRCONR	OH	3	CH=CH	NRCNHNR	OH
3	CH=CH	NRCOO	CH=CH ₂	3	CH=CH	C≡C	CH=CH ₂
3	CH=CH	NRCOO	NHR	3	CH=CH	C≡C	NHR
3	CH=CH	CH=CH	I	3	CH=CH	CH=CH	COH
3	CH=CH	CH=CH	F	3	CH=CH	CH=CH	COR
3	CH=CH	CH=CH	CN				
3	O	O	OH	3	O	S	OH
3	O	O	SH	3	O	S	SH
3	O	O	COOH	3	O	S	COOH
3	O	NR	CONH ₂	3	O	CR ₃ R ₂	CONH ₂
3	O	NR	CH=CH ₂	3	O	CR ₃ R ₂	CH=CH ₂
3	O	NR	C≡CH	3	O	CR ₃ R ₂	C≡CH
3	O	CONR	CONH ₂	3	O	SO ₂ NR	CONH ₂
3	O	CONR	CH=CH ₂	3	O	SO ₂ NR	CH=CH ₂
3	O	NRCONR	CONH ₂	3	O	NRCNHNR	CONH ₂
3	O	NRCONR	CH=CH ₂	3	O	NRCNHNR	CH=CH ₂
3	O	NRCOO	COOH	3	O	C≡C	COOH

3	O	NRCOO	SO ₂ H	3	O	C≡C	SO ₂ H
3	O	NRCOO	Cl	3	O	C≡C	Cl
3	O	CH=CH	SO ₂ H	3	S	O	SO ₂ H
3	O	CH=CH	Cl	3	S	O	Cl
3	O	CH=CH	COR	3	S	O	COR
3	S	S	OH	3	S	NR	OH
3	S	S	SH	3	S	NR	SH
3	S	S	COOH	3	S	NR	COOH
3	S	S	SO ₂ H	3	S	NR	SO ₂ H
3	S	CR ₃ R ₂	CONH ₂	3	S	CONR	CONH ₂
3	S	CR ₃ R ₂	CH=CH ₂	3	S	CONR	CH=CH ₂
3	S	CR ₃ R ₂	NHR	3	S	CONR	NHR
3	S	SO ₂ NR	NHR	3	S	NRCONR	NHR
3	S	SO ₂ NR	COH	3	S	NRCONR	COH
3	S	SO ₂ NR	COR	3	S	NRCONR	COR
3	S	NRCNHNR	OH	3	S	NRCOO	OH
3	S	NRCNHNR	NH ₂	3	S	NRCOO	NH ₂
3	S	NRCNHNR	NHR	3	S	NRCOO	NHR
3	S	C≡C	I	3	S	CH=CH	I
3	S	C≡C	NH ₂	3	S	CH=CH	NH ₂
3	NR	O	SO ₂ H	3	NR	S	SO ₂ H
3	NR	O	F	3	NR	S	F
3	NR	O	CN	3	NR	S	CN
3	NR	O	N ₃	3	NR	S	N ₃
3	NR	O	NH ₂	3	NR	S	NH ₂
3	NR	NR	SH	3	NR	CR ₃ R ₂	SH
3	NR	NR	COOH	3	NR	CR ₃ R ₂	COOH
3	NR	CONR	CN	3	NR	SO ₂ NR	CN
3	NR	CONR	COR	3	NR	SO ₂ NR	COR
3	NR	NRCONR	OH	3	NR	NRCNHNR	OH
3	NR	NRCONR	NHR	3	NR	NRCNHNR	NHR
3	NR	NRCOO	SO ₂ H	3	NR	C≡C	SO ₂ H
3	NR	NRCOO	C≡CH	3	NR	C≡C	C≡CH
3	NR	NRCOO	NH ₂	3	NR	C≡C	NH ₂
3	NR	NRCOO	NHR	3	NR	C≡C	NHR
3	NR	CH=CH	COR	3	CR ₃ R ₂	O	COR
3	CR ₃ R ₂	S	OH	3	CR ₃ R ₂	NR	OH
3	CR ₃ R ₂	S	SH	3	CR ₃ R ₂	NR	SH
3	CR ₃ R ₂	CR ₃ R ₂	SO ₂ H	3	CR ₃ R ₂	CONR	SO ₂ H
3	CR ₃ R ₂	CR ₃ R ₂	Cl	3	CR ₃ R ₂	CONR	Cl
3	CR ₃ R ₂	SO ₂ NR	OH	3	CR ₃ R ₂	NRCONR	OH
3	CR ₃ R ₂	SO ₂ NR	C≡CH	3	CR ₃ R ₂	NRCONR	C≡CH
3	CR ₃ R ₂	SO ₂ NR	NH ₂	3	CR ₃ R ₂	NRCONR	NH ₂
3	CR ₃ R ₂	SO ₂ NR	NHR	3	CR ₃ R ₂	NRCONR	NHR
3	CR ₃ R ₂	NRCNHNR	Cl	3	CR ₃ R ₂	NRCOO	Cl
3	CR ₃ R ₂	NRCNHNR	COR	3	CR ₃ R ₂	NRCOO	COR
3	CR ₃ R ₂	C≡C	Cl	3	CR ₃ R ₂	CH=CH	Cl
3	CR ₃ R ₂	C≡C	Br	3	CR ₃ R ₂	CH=CH	Br
3	CR ₃ R ₂	C≡C	NHR	3	CR ₃ R ₂	CH=CH	NHR
3	CONR	O	COR	3	CONR	S	COR
3	CONR	NR	OH	3	CONR	CR ₃ R ₂	OH
3	CONR	NR	SH	3	CONR	CR ₃ R ₂	SH

3	CONR	NR	C≡CH	3	CONR	CR ₃ R ₂	C≡CH
3	CONR	CONR	Br	3	CONR	SO ₂ NR	Br
3	CONR	CONR	I	3	CONR	SO ₂ NR	I
3	CONR	CONR	F	3	CONR	SO ₂ NR	F
3	CONR	NRCONR	OH	3	CONR	NRCNHNR	OH
3	CONR	NRCOO	COOH	3	CONR	C≡C	COOH
3	CONR	NRCOO	SO ₂ H	3	CONR	C≡C	SO ₂ H
3	CONR	NRCOO	F	3	CONR	C≡C	F
3	CONR	CH=CH	Cl	3	SO ₂ NR	O	Cl
3	CONR	CH=CH	NHR	3	SO ₂ NR	O	NHR
3	SO ₂ NR	S	OH	3	SO ₂ NR	NR	OH
3	SO ₂ NR	S	SH	3	SO ₂ NR	NR	SH
3	SO ₂ NR	S	NH ₂	3	SO ₂ NR	NR	NH ₂
3	SO ₂ NR	S	NHR	3	SO ₂ NR	NR	NHR
3	SO ₂ NR	CR ₃ R ₂	Cl	3	SO ₂ NR	CONR	Cl
3	SO ₂ NR	CR ₃ R ₂	Br	3	SO ₂ NR	CONR	Br
3	SO ₂ NR	SO ₂ NR	Br	3	SO ₂ NR	NRCONR	Br
3	SO ₂ NR	SO ₂ NR	I	3	SO ₂ NR	NRCONR	I
3	SO ₂ NR	NRCNHNR	OH	3	SO ₂ NR	NRCOO	OH
3	SO ₂ NR	NRCNHNR	SH	3	SO ₂ NR	NRCOO	SH
3	SO ₂ NR	NRCNHNR	COR	3	SO ₂ NR	NRCOO	COR
3	SO ₂ NR	C≡C	OH	3	SO ₂ NR	CH=CH	OH
3	SO ₂ NR	C≡C	CN	3	SO ₂ NR	CH=CH	CN
3	NRCONR	O	I	3	NRCONR	S	I
3	NRCONR	O	COH	3	NRCONR	S	COH
3	NRCONR	O	COR	3	NRCONR	S	COR
3	NRCONR	NR	OH	3	NRCONR	CR ₃ R ₂	OH
3	NRCONR	NR	SH	3	NRCONR	CR ₃ R ₂	SH
3	NRCONR	CONR	OH	3	NRCONR	SO ₂ NR	OH
3	NRCONR	CONR	SH	3	NRCONR	SO ₂ NR	SH
3	NRCONR	CONR	SO ₂ H	3	NRCONR	SO ₂ NR	SO ₂ H
3	NRCONR	NRCONR	I	3	NRCONR	NRCNHNR	I
3	NRCONR	NRCONR	N ₃	3	NRCONR	NRCNHNR	N ₃
3	NRCONR	NRCONR	CONH ₂	3	NRCONR	NRCNHNR	CONH ₂
3	NRCONR	NRCOO	SH	3	NRCONR	C≡C	SH
3	NRCONR	NRCOO	COOH	3	NRCONR	C≡C	COOH
3	NRCONR	CH=CH	CN	3	NRCNHNR	O	CN
3	NRCONR	CH=CH	N ₃	3	NRCNHNR	O	N ₃
3	NRCONR	CH=CH	COR	3	NRCNHNR	O	COR
3	NRCNHNR	S	OH	3	NRCNHNR	NR	OH
3	NRCNHNR	S	COH	3	NRCNHNR	NR	COH
3	NRCNHNR	S	COR	3	NRCNHNR	NR	COR
3	NRCNHNR	CR ₃ R ₂	Br	3	NRCNHNR	CONR	Br
3	NRCNHNR	CR ₃ R ₂	N ₃	3	NRCNHNR	CONR	N ₃
3	NRCNHNR	SO ₂ NR	C≡CH	3	NRCNHNR	NRCONR	C≡CH
3	NRCNHNR	SO ₂ NR	COH	3	NRCNHNR	NRCONR	COH
3	NRCNHNR	NRCNHNR	NHR	3	NRCNHNR	NRCOO	NHR
3	NRCNHNR	NRCNHNR	COH	3	NRCNHNR	NRCOO	COH
3	NRCNHNR	NRCNHNR	COR	3	NRCNHNR	NRCOO	COR
3	NRCNHNR	C≡C	OH	3	NRCNHNR	CH=CH	OH
3	NRCNHNR	C≡C	Br	3	NRCNHNR	CH=CH	Br
3	NRCNHNR	C≡C	I	3	NRCNHNR	CH=CH	I

3	NRCOO	O	COH	3	NRCOO	S	COH
3	NRCOO	O	COR	3	NRCOO	S	COR
3	NRCOO	NR	CONH ₂	3	NRCOO	CR ₃ R ₂	CONH ₂
3	NRCOO	NR	CH=CH ₂	3	NRCOO	CR ₃ R ₂	CH=CH ₂
3	NRCOO	NR	COH	3	NRCOO	CR ₃ R ₂	COH
3	NRCOO	NR	COR	3	NRCOO	CR ₃ R ₂	COR
3	NRCOO	CONR	OH	3	NRCOO	SO ₂ NR	OH
3	NRCOO	CONR	Cl	3	NRCOO	SO ₂ NR	Cl
3	NRCOO	CONR	CONH ₂	3	NRCOO	SO ₂ NR	CONH ₂
3	NRCOO	NRCONR	Cl	3	NRCOO	NRCNHNR	Cl
3	NRCOO	NRCONR	N ₃	3	NRCOO	NRCNHNR	N ₃
3	NRCOO	NRCONR	CONH ₂	3	NRCOO	NRCNHNR	CONH ₂
3	NRCOO	NRCONR	CH=CH ₂	3	NRCOO	NRCNHNR	CH=CH ₂
3	NRCOO	NRCOO	Cl	3	NRCOO	C≡C	Cl
3	NRCOO	NRCOO	NH ₂	3	NRCOO	C≡C	NH ₂
3	NRCOO	CH=CH	I	3	C≡C	O	I
3	NRCOO	CH=CH	F	3	C≡C	O	F
3	C≡C	S	CN	3	C≡C	NR	CN
3	C≡C	S	NHR	3	C≡C	NR	NHR
3	C≡C	CR ₃ R ₂	COOH	3	C≡C	CONR	COOH
3	C≡C	CR ₃ R ₂	SO ₂ H	3	C≡C	CONR	SO ₂ H
3	C≡C	CR ₃ R ₂	CN	3	C≡C	CONR	CN
3	C≡C	SO ₂ NR	Cl	3	C≡C	NRCONR	Cl
3	C≡C	SO ₂ NR	COR	3	C≡C	NRCONR	COR
3	C≡C	NRCNHNR	OH	3	C≡C	NRCOO	OH
3	C≡C	NRCNHNR	F	3	C≡C	NRCOO	F
3	C≡C	NRCNHNR	NH ₂	3	C≡C	NRCOO	NH ₂
3	C≡C	C≡C	I	3	C≡C	CH=CH	I
3	C≡C	C≡C	F	3	C≡C	CH=CH	F
3	C≡C	C≡C	CN	3	C≡C	CH=CH	CN
3	CH=CH	O	F	3	CH=CH	S	F
3	CH=CH	O	CN	3	CH=CH	S	CN
3	CH=CH	NR	CONH ₂	3	CH=CH	CR ₃ R ₂	CONH ₂
3	CH=CH	NR	CH=CH ₂	3	CH=CH	CR ₃ R ₂	CH=CH ₂
3	CH=CH	NR	C≡CH	3	CH=CH	CR ₃ R ₂	C≡CH
3	CH=CH	NR	NH ₂	3	CH=CH	CR ₃ R ₂	NH ₂
3	CH=CH	CONR	C≡CH	3	CH=CH	SO ₂ NR	C≡CH
3	CH=CH	CONR	NH ₂	3	CH=CH	SO ₂ NR	NH ₂
3	CH=CH	NRCONR	I	3	CH=CH	NRCNHNR	I
3	CH=CH	NRCONR	F	3	CH=CH	NRCNHNR	F
3	CH=CH	NRCOO	OH	3	CH=CH	C≡C	OH
3	CH=CH	NRCOO	COOH	3	CH=CH	C≡C	COOH
3	CH=CH	NRCOO	SO ₂ H	3	CH=CH	C≡C	SO ₂ H
3	CH=CH	CH=CH	OH	3	CH=CH	CH=CH	N ₃
3	CH=CH	CH=CH	COOH	3	CH=CH	CH=CH	CH=CH ₂
3	CH=CH	CH=CH	CN				
4	O	O	OH	4	O	S	OH
4	O	O	SH	4	O	S	SH
4	O	O	CONH ₂	4	O	S	CONH ₂
4	O	NR	SH	4	O	CR ₄ R ₂	SH

4	O	NR	Cl	4	O	CR ₄ R ₂	Cl
4	O	NR	NHR	4	O	CR ₄ R ₂	NHR
4	O	CONR	F	4	O	SO ₂ NR	F
4	O	CONR	CH=CH ₂	4	O	SO ₂ NR	CH=CH ₂
4	O	CONR	COR	4	O	SO ₂ NR	COR
4	O	NRCONR	OH	4	O	NRCNHNHR	OH
4	O	NRCONR	NHR	4	O	NRCNHNHR	NHR
4	O	NRCOO	CN	4	O	C≡C	CN
4	O	NRCOO	NHR	4	O	C≡C	NHR
4	O	CH=CH	Br	4	S	O	Br
4	O	CH=CH	C≡CH	4	S	O	C≡CH
4	O	CH=CH	NH ₂	4	S	O	NH ₂
4	S	S	Br	4	S	NR	Br
4	S	S	N ₃	4	S	NR	N ₃
4	S	S	NH ₂	4	S	NR	NH ₂
4	S	S	NHR	4	S	NR	NHR
4	S	CR ₄ R ₂	OH	4	S	CONR	OH
4	S	CR ₄ R ₂	COR	4	S	CONR	COR
4	S	SO ₂ NR	COOH	4	S	NRCONR	COOH
4	S	SO ₂ NR	I	4	S	NRCONR	I
4	S	SO ₂ NR	F	4	S	NRCONR	F
4	S	SO ₂ NR	COR	4	S	NRCONR	COR
4	S	NRCNHNHR	OH	4	S	NRCOO	OH
4	S	NRCNHNHR	I	4	S	NRCOO	I
4	S	NRCNHNHR	F	4	S	NRCOO	F
4	S	C≡C	SH	4	S	CH=CH	SH
4	NR	O	OH	4	NR	S	OH
4	NR	O	SH	4	NR	S	SH
4	NR	O	NH ₂	4	NR	S	NH ₂
4	NR	NR	SO ₂ H	4	NR	CR ₄ R ₂	SO ₂ H
4	NR	NR	Cl	4	NR	CR ₄ R ₂	Cl
4	NR	NR	NHR	4	NR	CR ₄ R ₂	NHR
4	NR	NR	COR	4	NR	CR ₄ R ₂	COR
4	NR	CONR	OH	4	NR	SO ₂ NR	OH
4	NR	CONR	NH ₂	4	NR	SO ₂ NR	NH ₂
4	NR	CONR	NHR	4	NR	SO ₂ NR	NHR
4	NR	NRCONR	I	4	NR	NRCNHNHR	I
4	NR	NRCONR	F	4	NR	NRCNHNHR	F
4	NR	NRCOO	OH	4	NR	C≡C	OH
4	NR	NRCOO	CONH ₂	4	NR	C≡C	CONH ₂
4	NR	CH=CH	NH ₂	4	CR ₄ R ₂	OO	NH ₂
4	NR	CH=CH	NHR	4	CR ₄ R ₂	O	NHR
4	NR	CH=CH	COR	4	CR ₄ R ₂	O	COR
4	CR ₄ R ₂	S	OH	4	CR ₄ R ₂	NR	OH
4	CR ₄ R ₂	S	Br	4	CR ₄ R ₂	NR	Br
4	CR ₄ R ₂	CR ₄ R ₂	SO ₂ H	4	CR ₄ R ₂	CONR	SO ₂ H
4	CR ₄ R ₂	CR ₄ R ₂	CH=CH ₂	4	CR ₄ R ₂	CONR	CH=CH ₂
4	CR ₄ R ₂	CR ₄ R ₂	C≡CH	4	CR ₄ R ₂	CONR	C≡CH
4	CR ₄ R ₂	SO ₂ NR	F	4	CR ₄ R ₂	NRCONR	F
4	CR ₄ R ₂	SO ₂ NR	CN	4	CR ₄ R ₂	NRCONR	CN
4	CR ₄ R ₂	SO ₂ NR	N ₃	4	CR ₄ R ₂	NRCONR	N ₃
4	CR ₄ R ₂	NRCNHNHR	CONH ₂	4	CR ₄ R ₂	NRCOO	CONH ₂
4	CR ₄ R ₂	NRCNHNHR	CH=CH ₂	4	CR ₄ R ₂	NRCOO	CH=CH ₂

4	CR ₄ R ₂	NRCNHNR	C≡CH	4	CR ₄ R ₂	NRCOO	C≡CH
4	CR ₄ R ₂	C≡C	Cl	4	CR ₄ R ₂	CH=CH	Cl
4	CR ₄ R ₂	C≡C	Br	4	CR ₄ R ₂	CH=CH	Br
4	CR ₄ R ₂	C≡C	I	4	CR ₄ R ₂	CH=CH	I
4	CONR	O	COH	4	CONR	S	COH
4	CONR	O	COR	4	CONR	S	COR
4	CONR	NR	OH	4	CONR	CR ₄ R ₂	OH
4	CONR	NR	Br	4	CONR	CR ₄ R ₂	Br
4	CONR	NR	N ₃	4	CONR	CR ₄ R ₂	N ₃
4	CONR	CONR	Br	4	CONR	SO ₂ NR	Br
4	CONR	CONR	N ₃	4	CONR	SO ₂ NR	N ₃
4	CONR	CONR	C≡CH	4	CONR	SO ₂ NR	C≡CH
4	CONR	NRCONR	OH	4	CONR	NRCNHNR	OH
4	CONR	NRCONR	SH	4	CONR	NRCNHNR	SH
4	CONR	NRCONR	COH	4	CONR	NRCNHNR	COH
4	CONR	NRCOO	F	4	CONR	C≡C	F
4	CONR	NRCOO	CN	4	CONR	C≡C	CN
4	CONR	NRCOO	COR	4	CONR	C≡C	COR
4	CONR	CH=CH	OH	4	SO ₂ NR	O	OH
4	CONR	CH=CH	CN	4	SO ₂ NR	O	CN
4	CONR	CH=CH	COR	4	SO ₂ NR	O	COR
4	SO ₂ NR	S	OH	4	SO ₂ NR	NR	OH
4	SO ₂ NR	S	SH	4	SO ₂ NR	NR	SH
4	SO ₂ NR	CR ₄ R ₂	N ₃	4	SO ₂ NR	CONR	N ₃
4	SO ₂ NR	CR ₄ R ₂	NHR	4	SO ₂ NR	CONR	NHR
4	SO ₂ NR	CR ₄ R ₂	COH	4	SO ₂ NR	CONR	COH
4	SO ₂ NR	SO ₂ NR	COOH	4	SO ₂ NR	NRCONR	COOH
4	SO ₂ NR	SO ₂ NR	NHR	4	SO ₂ NR	NRCONR	NHR
4	SO ₂ NR	SO ₂ NR	COH	4	SO ₂ NR	NRCONR	COH
4	SO ₂ NR	NRCNHNR	SH	4	SO ₂ NR	NRCOO	SH
4	SO ₂ NR	NRCNHNR	COOH	4	SO ₂ NR	NRCOO	COOH
4	SO ₂ NR	NRCNHNR	SO ₂ H	4	SO ₂ NR	NRCOO	SO ₂ H
4	SO ₂ NR	NRCNHNR	Cl	4	SO ₂ NR	NRCOO	Cl
4	SO ₂ NR	C≡C	I	4	SO ₂ NR	CH=CH	I
4	SO ₂ NR	C≡C	F	4	SO ₂ NR	CH=CH	F
4	SO ₂ NR	C≡C	CN	4	SO ₂ NR	CH=CH	CN
4	NRCONR	O	F	4	NRCONR	S	F
4	NRCONR	O	CN	4	NRCONR	S	CN
4	NRCONR	O	N ₃	4	NRCONR	S	N ₃
4	NRCONR	NR	CONH ₂	4	NRCONR	CR ₄ R ₂	CONH ₂
4	NRCONR	NR	CH=CH ₂	4	NRCONR	CR ₄ R ₂	CH=CH ₂
4	NRCONR	NR	C≡CH	4	NRCONR	CR ₄ R ₂	C≡CH
4	NRCONR	CONR	SH	4	NRCONR	SO ₂ NR	SH
4	NRCONR	CONR	COOH	4	NRCONR	SO ₂ NR	COOH
4	NRCONR	NRCONR	CH=CH ₂	4	NRCONR	NRCNHNR	CH=CH ₂
4	NRCONR	NRCOO	SH	4	NRCONR	C≡C	SH
4	NRCONR	NRCOO	COOH	4	NRCONR	C≡C	COOH
4	NRCONR	CH=CH	SO ₂ H	4	NRCNHNR	O	SO ₂ H
4	NRCONR	CH=CH	Cl	4	NRCNHNR	O	Cl
4	NRCNHNR	S	Br	4	NRCNHNR	NR	Br
4	NRCNHNR	S	I	4	NRCNHNR	NR	I
4	NRCNHNR	CR ₄ R ₂	N ₃	4	NRCNHNR	CONR	N ₃

4	NRCNHNR	CR ₄ R ₂	CONH ₂	4	NRCNHNR	CONR	CONH ₂
4	NRCNHNR	SO ₂ NR	SO ₂ H	4	NRCNHNR	NRCONR	SO ₂ H
4	NRCNHNR	SO ₂ NR	Cl	4	NRCNHNR	NRCONR	Cl
4	NRCNHNR	SO ₂ NR	Br	4	NRCNHNR	NRCONR	Br
4	NRCNHNR	NRCNHNR	COR	4	NRCNHNR	NRCOO	COR
4	NRCNHNR	C≡C	Br	4	NRCNHNR	CH=CH	Br
4	NRCOO	O	COH	4	NRCOO	S	COH
4	NRCOO	O	COR	4	NRCOO	S	COR
4	NRCOO	NR	OH	4	NRCOO	CR ₄ R ₂	OH
4	NRCOO	NR	COH	4	NRCOO	CR ₄ R ₂	COH
4	NRCOO	NR	COR	4	NRCOO	CR ₄ R ₂	COR
4	NRCOO	CONR	OH	4	NRCOO	SO ₂ NR	OH
4	NRCOO	CONR	SH	4	NRCOO	SO ₂ NR	SH
4	NRCOO	NRCONR	NH ₂	4	NRCOO	NRCNHNR	NH ₂
4	NRCOO	NRCOO	SH	4	NRCOO	C≡C	SH
4	NRCOO	NRCOO	COOH	4	NRCOO	C≡C	COOH
4	NRCOO	CH=CH	COH	4	C≡C	O	COH
4	NRCOO	CH=CH	COR	4	C≡C	O	COR
4	C≡C	S	OH	4	C≡C	NR	OH
4	C≡C	CR ₄ R ₂	COOH	4	C≡C	CONR	COOH
4	C≡C	CR ₄ R ₂	SO ₂ H	4	C≡C	CONR	SO ₂ H
4	C≡C	SO ₂ NR	SO ₂ H	4	C≡C	NRCONR	SO ₂ H
4	C≡C	SO ₂ NR	COR	4	C≡C	NRCONR	COR
4	C≡C	NRCNHNR	OH	4	C≡C	NRCOO	OH
4	C≡C	NRCNHNR	SH	4	C≡C	NRCOO	SH
4	C≡C	C≡C	CONH ₂	4	C≡C	CH=CH	CONH ₂
4	C≡C	C≡C	COR	4	C≡C	CH=CH	COR
4	CH=CH	O	OH	4	CH=CH	S	OH
4	CH=CH	O	NH ₂	4	CH=CH	S	NH ₂
4	CH=CH	O	COR	4	CH=CH	S	COR
4	CH=CH	NR	OH	4	CH=CH	CR ₄ R ₂	OH
4	CH=CH	NR	COH	4	CH=CH	CR ₄ R ₂	COH
4	CH=CH	CONR	OH	4	CH=CH	SO ₂ NR	OH
4	CH=CH	CONR	CH=CH ₂	4	CH=CH	SO ₂ NR	CH=CH ₂
4	CH=CH	CONR	C≡CH	4	CH=CH	SO ₂ NR	C≡CH
4	CH=CH	CONR	NH ₂	4	CH=CH	SO ₂ NR	NH ₂
4	CH=CH	NRCONR	C≡CH	4	CH=CH	NRCNHNR	C≡CH
4	CH=CH	NRCONR	NH ₂	4	CH=CH	NRCNHNR	NH ₂
4	CH=CH	NRCOO	I	4	CH=CH	C≡C	I
4	CH=CH	NRCOO	C≡CH	4	CH=CH	C≡C	C≡CH
4	CH=CH	CH=CH	OH	4	CH=CH	CH=CH	N ₃
4	CH=CH	CH=CH	SH	4	CH=CH	CH=CH	CONH ₂
4	CH=CH	CH=CH	Br	4	CH=CH	CH=CH	NHR
5	O	O	CN	5	O	S	CN
5	O	O	N ₃	5	O	S	N ₃
5	O	NR	Br	5	O	CR ₅ R ₂	Br
5	O	NR	I	5	O	CR ₅ R ₂	I
5	O	CONR	CONH ₂	5	O	SO ₂ NR	CONH ₂
5	O	CONR	CH=CH ₂	5	O	SO ₂ NR	CH=CH ₂
5	O	NRCONR	NHR	5	O	NRCNHNR	NHR
5	O	NRCONR	COH	5	O	NRCNHNR	COH

5	O	NRCOO	OH	5	O	C≡C	OH
5	O	NRCOO	COOH	5	O	C≡C	COOH
5	O	CH=CH	OH	5	S	O	OH
5	O	CH=CH	C≡CH	5	S	O	C≡CH
5	S	S	Cl	5	S	NR	Cl
5	S	S	Br	5	S	NR	Br
5	S	S	I	5	S	NR	I
5	S	S	NH ₂	5	S	NR	NH ₂
5	S	CR ₅ R ₂	COOH	5	S	CONR	COOH
5	S	CR ₅ R ₂	NHR	5	S	CONR	NHR
5	S	CR ₅ R ₂	COH	5	S	CONR	COH
5	S	CR ₅ R ₂	COR	5	S	CONR	COR
5	S	SO ₂ NR	Cl	5	S	NRCONR	Cl
5	S	SO ₂ NR	CN	5	S	NRCONR	CN
5	S	SO ₂ NR	N ₃	5	S	NRCONR	N ₃
5	S	SO ₂ NR	COR	5	S	NRCONR	COR
5	S	NRCNHNR	OH	5	S	NRCOO	OH
5	S	NRCNHNR	COR	5	S	NRCOO	COR
5	S	C≡C	OH	5	S	CH=CH	OH
5	S	C≡C	SH	5	S	CH=CH	SH
5	NR	O	SH	5	NR	S	SH
5	NR	O	COOH	5	NR	S	COOH
5	NR	O	SO ₂ H	5	NR	S	SO ₂ H
5	NR	NR	OH	5	NR	CR ₅ R ₂	OH
5	NR	NR	SH	5	NR	CR ₅ R ₂	SH
5	NR	CONR	OH	5	NR	SO ₂ NR	OH
5	NR	CONR	COR	5	NR	SO ₂ NR	COR
5	NR	NRCONR	OH	5	NR	NRCNHNR	OH
5	NR	NRCONR	SH	5	NR	NRCNHNR	SH
5	NR	NRCOO	NH ₂	5	NR	C≡C	NH ₂
5	NR	NRCOO	NHR	5	NR	C≡C	NHR
5	NR	CH=CH	COOH	5	CR ₅ R ₂	O	COOH
5	NR	CH=CH	SO ₂ H	5	CR ₅ R ₂	O	SO ₂ H
5	CR ₅ R ₂	S	SO ₂ H	5	CR ₅ R ₂	NR	SO ₂ H
5	CR ₅ R ₂	S	NH ₂	5	CR ₅ R ₂	NR	NH ₂
5	CR ₅ R ₂	S	NHR	5	CR ₅ R ₂	NR	NHR
5	CR ₅ R ₂	S	COH	5	CR ₅ R ₂	NR	COH
5	CR ₅ R ₂	CR ₅ R ₂	COOH	5	CR ₅ R ₂	CONR	COOH
5	CR ₅ R ₂	CR ₅ R ₂	F	5	CR ₅ R ₂	CONR	F
5	CR ₅ R ₂	SO ₂ NR	NH ₂	5	CR ₅ R ₂	NRCONR	NH ₂
5	CR ₅ R ₂	SO ₂ NR	NHR	5	CR ₅ R ₂	NRCONR	NHR
5	CR ₅ R ₂	SO ₂ NR	COH	5	CR ₅ R ₂	NRCONR	COH
5	CR ₅ R ₂	NRCNHNR	COH	5	CR ₅ R ₂	NRCOO	COH
5	CR ₅ R ₂	NRCNHNR	COR	5	CR ₅ R ₂	NRCOO	COR
5	CR ₅ R ₂	C≡C	OH	5	CR ₅ R ₂	CH=CH	OH
5	CR ₅ R ₂	C≡C	Cl	5	CR ₅ R ₂	CH=CH	Cl
5	CONR	O	N ₃	5	CONR	S	N ₃
5	CONR	O	COH	5	CONR	S	COH
5	CONR	O	COR	5	CONR	S	COR
5	CONR	NR	OH	5	CONR	CR ₅ R ₂	OH
5	CONR	NR	NHR	5	CONR	CR ₅ R ₂	NHR
5	CONR	CONR	COOH	5	CONR	SO ₂ NR	COOH

20220927 10081989 02402


5	CONR	CONR	NHR	5	CONR	SO ₂ NR	NHR
5	CONR	NRCONR	F	5	CONR	NRCNHNR	F
5	CONR	NRCONR	CN	5	CONR	NRCNHNR	CN
5	CONR	NRCOO	OH	5	CONR	C≡C	OH
5	CONR	NRCOO	COH	5	CONR	C≡C	COH
5	CONR	CH=CH	I	5	SO ₂ NR	O	I
5	CONR	CH=CH	F	5	SO ₂ NR	O	F
5	CONR	CH=CH	COR	5	SO ₂ NR	O	COR
5	SO ₂ NR	S	OH	5	SO ₂ NR	NR	OH
5	SO ₂ NR	S	SO ₂ H	5	SO ₂ NR	NR	SO ₂ H
5	SO ₂ NR	S	Cl	5	SO ₂ NR	NR	Cl
5	SO ₂ NR	CR ₅ R ₂	F	5	SO ₂ NR	CONR	F
5	SO ₂ NR	CR ₅ R ₂	NHR	5	SO ₂ NR	CONR	NHR
5	SO ₂ NR	SO ₂ NR	COOH	5	SO ₂ NR	NRCONR	COOH
5	SO ₂ NR	SO ₂ NR	SO ₂ H	5	SO ₂ NR	NRCONR	SO ₂ H
5	SO ₂ NR	SO ₂ NR	Cl	5	SO ₂ NR	NRCONR	Cl
5	SO ₂ NR	SO ₂ NR	Br	5	SO ₂ NR	NRCONR	Br
5	SO ₂ NR	NRCNHNR	NH ₂	5	SO ₂ NR	NRCOO	NH ₂
5	SO ₂ NR	NRCNHNR	NHR	5	SO ₂ NR	NRCOO	NHR
5	SO ₂ NR	C≡C	COOH	5	SO ₂ NR	CH=CH	COOH
5	SO ₂ NR	C≡C	COH	5	SO ₂ NR	CH=CH	COH
5	SO ₂ NR	C≡C	COR	5	SO ₂ NR	CH=CH	COR
5	NRCONR	O	OH	5	NRCONR	S	OH
5	NRCONR	O	SH	5	NRCONR	S	SH
5	NRCONR	O	COOH	5	NRCONR	S	COOH
5	NRCONR	O	CONH ₂	5	NRCONR	S	CONH ₂
5	NRCONR	NR	CN	5	NRCONR	CR ₅ R ₂	CN
5	NRCONR	NR	NHR	5	NRCONR	CR ₅ R ₂	NHR
5	NRCONR	NR	COH	5	NRCONR	CR ₅ R ₂	COH
5	NRCONR	CONR	CONH ₂	5	NRCONR	SO ₂ NR	CONH ₂
5	NRCONR	CONR	COH	5	NRCONR	SO ₂ NR	COH
5	NRCONR	CONR	COR	5	NRCONR	SO ₂ NR	COR
5	NRCONR	NRCONR	OH	5	NRCONR	NRCNHNR	OH
5	NRCONR	NRCONR	SH	5	NRCONR	NRCNHNR	SH
5	NRCONR	NRCONR	COOH	5	NRCONR	NRCNHNR	COOH
5	NRCONR	NRCOO	F	5	NRCONR	C≡C	F
5	NRCONR	NRCOO	CN	5	NRCONR	C≡C	CN
5	NRCONR	CH=CH	Cl	5	NRCNHNR	O	Cl
5	NRCONR	CH=CH	Br	5	NRCNHNR	O	Br
5	NRCONR	CH=CH	NH ₂	5	NRCNHNR	OO	NH ₂
5	NRCNHNR	S	CONH ₂	5	NRCNHNR	NR	CONH ₂
5	NRCNHNR	S	CH=CH ₂	5	NRCNHNR	NR	CH=CH ₂
5	NRCNHNR	S	C≡CH	5	NRCNHNR	NR	C≡CH
5	NRCNHNR	S	NH ₂	5	NRCNHNR	NR	NH ₂
5	NRCNHNR	S	NHR	5	NRCNHNR	NR	NHR
5	NRCNHNR	S	COH	5	NRCNHNR	NR	COH
5	NRCNHNR	CR ₅ R ₂	SO ₂ H	5	NRCNHNR	CONR	SO ₂ H
5	NRCNHNR	CR ₅ R ₂	Cl	5	NRCNHNR	CONR	Cl
5	NRCNHNR	SO ₂ NR	SO ₂ H	5	NRCNHNR	NRCONR	SO ₂ H
5	NRCNHNR	SO ₂ NR	Cl	5	NRCNHNR	NRCONR	Cl
5	NRCNHNR	SO ₂ NR	Br	5	NRCNHNR	NRCONR	Br
5	NRCNHNR	SO ₂ NR	I	5	NRCNHNR	NRCONR	I

5	NRCNHNR	SO ₂ NR	F	5	NRCNHNR	NRCNHR	F
5	NRCNHNR	SO ₂ NR	CN	5	NRCNHNR	NRCNHR	CN
5	NRCNHNR	NRCNHNR	NH ₂	5	NRCNHNR	NRCOO	NH ₂
5	NRCNHNR	NRCNHNR	NHR	5	NRCNHNR	NRCOO	NHR
5	NRCNHNR	NRCNHNR	COH	5	NRCNHNR	NRCOO	COH
5	NRCNHNR	NRCNHNR	COR	5	NRCNHNR	NRCOO	COR
5	NRCNHNR	C≡C	OH	5	NRCNHNR	CH=CH	OH
5	NRCNHNR	C≡C	SH	5	NRCNHNR	CH=CH	SH
5	NRCNHNR	C≡C	I	5	NRCNHNR	CH=CH	I
5	NRCNHNR	C≡C	NHR	5	NRCNHNR	CH=CH	NHR
5	NRCOO	O	COOH	5	NRCOO	S	COOH
5	NRCOO	O	SO ₂ H	5	NRCOO	S	SO ₂ H
5	NRCOO	O	NHR	5	NRCOO	S	NHR
5	NRCOO	O	COH	5	NRCOO	S	COH
5	NRCOO	O	COR	5	NRCOO	S	COR
5	NRCOO	NR	OH	5	NRCOO	CR ₅ R ₂	OH
5	NRCOO	NR	SH	5	NRCOO	CR ₅ R ₂	SH
5	NRCOO	NR	COOH	5	NRCOO	CR ₅ R ₂	COOH
5	NRCOO	NR	SO ₂ H	5	NRCOO	CR ₅ R ₂	SO ₂ H
5	NRCOO	CONR	NHR	5	NRCOO	SO ₂ NR	NHR
5	NRCOO	CONR	COH	5	NRCOO	SO ₂ NR	COH
5	NRCOO	CONR	COR	5	NRCOO	SO ₂ NR	COR
5	NRCOO	NRCNHR	OH	5	NRCOO	NRCNHR	OH
5	NRCOO	NRCNHR	SH	5	NRCOO	NRCNHR	SH
5	NRCOO	NRCNHR	COOH	5	NRCOO	NRCNHR	COOH
5	NRCOO	NRCNHR	COR	5	NRCOO	NRCNHR	COR
5	NRCOO	NRCOO	OH	5	NRCOO	C≡C	OH
5	NRCOO	NRCOO	SH	5	NRCOO	C≡C	SH
5	NRCOO	NRCOO	COH	5	NRCOO	C≡C	COH
5	NRCOO	NRCOO	COR	5	NRCOO	C≡C	COR
5	NRCOO	CH=CH	N ₃	5	C≡C	O	N ₃
5	NRCOO	CH=CH	CONH ₂	5	C≡C	O	CONH ₂
5	NRCOO	CH=CH	COH	5	C≡C	O	COH
5	NRCOO	CH=CH	COR	5	C≡C	O	COR
5	C≡C	S	OH	5	C≡C	NR	OH
5	C≡C	S	SH	5	C≡C	NR	SH
5	C≡C	S	COOH	5	C≡C	NR	COOH
5	C≡C	S	NH ₂	5	C≡C	NR	NH ₂
5	C≡C	CR ₅ R ₂	SH	5	C≡C	CONR	SH
5	C≡C	CR ₅ R ₂	SO ₂ H	5	C≡C	CONR	SO ₂ H
5	C≡C	CR ₅ R ₂	N ₃	5	C≡C	CONR	N ₃
5	C≡C	CR ₅ R ₂	COR	5	C≡C	CONR	COR
5	C≡C	SO ₂ NR	NHR	5	C≡C	NRCNHR	NHR
5	C≡C	SO ₂ NR	COH	5	C≡C	NRCNHR	COH
5	C≡C	SO ₂ NR	COR	5	C≡C	NRCNHR	COR
5	C≡C	NRCNHR	CN	5	C≡C	NRCOO	CN
5	C≡C	NRCNHR	CH=CH ₂	5	C≡C	NRCOO	CH=CH ₂
5	C≡C	NRCNHR	C≡CH	5	C≡C	NRCOO	C≡CH
5	C≡C	C≡C	COOH	5	C≡C	CH=CH	COOH
5	CH=CH	O	OH	5	CH=CH	S	OH

5	CH=CH	O	C≡CH	5	CH=CH	S	C≡CH
5	CH=CH	O	NH ₂	5	CH=CH	S	NH ₂
5	CH=CH	O	NHR	5	CH=CH	S	NHR
5	CH=CH	NR	NHR	5	CH=CH	CR ₅ R ₂	NHR
5	CH=CH	NR	COH	5	CH=CH	CR ₅ R ₂	COH
5	CH=CH	NR	COR	5	CH=CH	CR ₅ R ₂	COR
5	CH=CH	CONR	Br	5	CH=CH	SO ₂ NR	Br
5	CH=CH	CONR	COR	5	CH=CH	SO ₂ NR	COR
5	CH=CH	NRCONR	Br	5	CH=CH	NRCNHR	Br
5	CH=CH	NRCONR	OH	5	CH=CH	C≡C	OH
5	CH=CH	CH=CH	COOH	5	CH=CH	CH=CH	CH=CH ₂
5	CH=CH	CH=CH	SO ₂ H	5	CH=CH	CH=CH	C≡CH


R, R₁, and R₂ = hydrogen, alkyl, alkenyl, alkynyl, aryl, and heterocyclic

TABLE 9



The variables E, Y, and n can have the values provided in Table 7 above. R in the compounds is alkyl, alkenyl, alkynyl, aromatic, or heterocyclic.

TABLE 10




5

The variables E, F, Y, and n can have the values provided in Table 8 above.

10

2017-02-20 10:58:58

TABLE 11




The variables E, F, Y, and n can have the values provided in Table 8 above.

10

TABLE 12

15



The variables E, F, Y, and n can have the values provided in Table 8 above.

EXAMPLE 23

5 **Preparation of [2-(4-oxo-2-thioxo-thiazolidin-3-yl)-ethyl]-carbamic acid tert-butyl ester (compound 35)**

This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 10. Compound numbers correspond to the numbers in the figure.

10 The compound N-(2-aminoethyl)carbamic acid tert-butyl ester (compound 33, 5.03 g, 31.4 mmol) was dissolved in THF (120 ml), followed by the addition of diisopropylethylamine (5.47 ml, 31.4 mmol). Carbon disulfide (2.08 ml, 34.5 mmol) in THF (10 ml) was added
15 to the reaction mixture at a temperature of 0°C. The reaction mixture was stirred at room temperature for 1 hour. The reaction then was cooled to a temperature of -78 °C. Pyridine (5.08 ml, 62.8 mmol) and bromoacetyl bromide (3.01 ml, 34.5 mmol) were added successively to
20 the reaction mixture, which then was stirred at -78 °C for 30 minutes, followed by stirring at room temperature for an additional 2 hours. The precipitate formed was filtered and washed with ethyl acetate.

25 The filtrate was concentrated *in vacuo*, and was quickly diluted with saturated sodium bicarbonate solution, followed by extraction with ethyl acetate. The

10081989-022402

combined organic layers were quickly washed twice with 0.4 N HCl and then once with brine. The organic layer was dried over MgSO₄, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (gradient 9:1 to 2:1 hexane/ethyl acetate) to give [2-(4-oxo-2-thioxo-thiazolidin-3-yl)-ethyl]-carbamic acid tert-butyl ester (Compound 35, 2.45 g, 29%).

¹H NMR (300 MHz, CDCl₃) δ 1.39 (s, 9H), 3.42 (m, 2H), 3.95 (s, 2H), 4.15 (s, *J* = 5.4, 2H); ¹³C NMR (300 MHz, CDCl₃) δ 28.2, 35.1, 37.9, 44.4, 79.5, 156.0, 174.2, 201.8.

EXAMPLE 24

Preparation of 4-{5-[3-(2-tert-butoxycarbonylamino-ethyl)-4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl]-furan-2-yl}-benzoic acid (compound 38)

This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 10. Compound numbers correspond to the numbers in the figure.

The compounds [2-(4-oxo-2-thioxo-thiazolidin-3-yl)-ethyl]-carbamic acid tert-butyl ester (compound 35, 652 mg, 3.02 mmol) and 4-(5-formyl-furan-2-yl)-benzoic acid (compound 37, 1.0 g, 3.62 mmol) were mixed in ethanol (10 ml). Piperidine (2 drops) was added, and the reaction was stirred at 75 °C for 1 hour, followed by stirring at room temperature for an additional 18 hours.

The resulting orange precipitate was collected on a fritted filter funnel. The solid was washed with ethyl acetate and then with ethyl ether to give pure 4-{5-[3-(2-tert-butoxycarbonylamino-ethyl)-4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl]-furan-2-yl}-benzoic acid (compound 38, 1.05 g, 73%).

^1H NMR (300 MHz, DMSO- d_6) δ 1.34 (s, 9H), 3.29 (m, 2H), 4.12 (t, J = 5.0, 2H), 6.94 (t, J = 5.8, 1H), 7.39 (d, J = 3.7, 1H), 7.48 (d, J = 3.7, 1H), 7.69 (s, 1H), 7.95 (d, J = 8.3, 2H), 8.10 (d, J = 8.3, 2H).

EXAMPLE 25

Preparation of 2-{5-[5-(4-carboxy-phenyl)-furan-2-ylmethylene]-4-oxo-2-thioxo-thiazolidin-3-yl}-ethyl-ammonium trifluoroacetate (compound 40)

This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 10. Compound numbers correspond to the numbers in the figure.

The compound 4-{5-[3-(2-tert-butoxycarbonylamino-ethyl)-4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl]-furan-2-yl}-benzoic acid (compound 38, 500 mg, 1.05 mmol) was dissolved in a mixture of dichloromethane (7 ml) and trifluoroacetic acid (3 ml) at room temperature. The reaction mixture was stirred at room temperature for 1 hour, and the volatiles were

removed *in vacuo*. The residue was washed with ethyl acetate and then with ethyl ether on a fritted filter funnel to give pure 2-{5-[5-(4-carboxy-phenyl)-furan-2-ylmethylene]-4-oxo-2-thioxo-thiazolidin-3-yl}-ethyl-ammonium trifluoroacetate (compound 40, 475 mg, 92%).

MS m/z 374.97 ($M+1$).

EXAMPLE 26

Preparation of [4-(4-oxo-2-thioxo-thiazolidin-3-yl)-butyl]-carbamic acid tert-butyl ester (compound 36)

This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 10. Compound numbers correspond to the numbers in the figure.

The compound (4-amino-butyl)-carbamic acid tert-butyl ester (compound 34, 12.5 g, 66.3 mmol) was dissolved in THF (180 ml), followed by the addition of diisopropylethylamine (11.6 ml, 66.3 mmol). Carbon disulfide (4.4 ml, 73 mmol) in THF (20 ml) was added dropwise to the reaction mixture over 10 minutes at a temperature of 0°C. The reaction mixture was stirred at room temperature for 1 hour and then cooled to a temperature of 0°C. Pyridine (10.7 ml, 133 mmol) and bromoacetyl bromide (6.94 ml, 79.7 mmol) were added successively to the reaction mixture, which was then stirred at room temperature for 6 hours.

The precipitate formed was filtered and washed with ethyl acetate. The filtrate was concentrated *in vacuo* and was quickly diluted with saturated sodium bicarbonate solution, followed by extraction with ethyl ether. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude product was purified by flash chromatography (gradient 5:1 to 2:1 hexane/ethyl acetate) to give [2-(4-oxo-2-thioxo-thiazolidin-3-yl)-ethyl]-carbamic acid tert-butyl ester (Compound 36, 7.53 g, 37%).

EXAMPLE 27

Preparation of 4-{5-[3-(2-tert-butoxycarbonylamino-ethyl)-4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl]-furan-2-yl}-benzoic acid (compound 39)

This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 10. Compound numbers correspond to the numbers in the figure.

The compounds [2-(4-oxo-2-thioxo-thiazolidin-3-yl)-ethyl]-carbamic acid tert-butyl ester (Compound 36, 387 mg, 1.27 mmol) and 4-(5-formyl-furan-2-yl)-benzoic acid (compound 37, 250 mg, 1.16 mmol) were mixed in ethanol (5 ml). Piperidine (2 drops) was added and the reaction was stirred at 75°C for 1 hour, followed by stirring at room temperature for an additional 18 hours. The resulting orange precipitate was collected on a fritted filter funnel and washed with ethyl acetate,

followed by ethyl ether to give pure 4-{5-[3-(4-tert-butoxycarbonylamino-butyl)-4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl]-furan-2-yl}-benzoic acid (compound 39, 410 mg, 71%).

5 ^1H NMR (300 MHz, DMSO- d_6) δ 1.37 (s, 9H), 1.37 (m, 2H), 1.61 (m, 2H), 2.93 (m, 2H), 4.02 (t, $J = 6.7$, 2H), 6.79 (m, 1H), 7.38 (d, $J = 3.6$, 1H), 7.46 (d, $J = 3.6$, 1H), 7.66 (s, 1H), 7.93 (d, $J = 8.2$, 2H), 8.08 (d, $J = 8.2$, 2H).

10

EXAMPLE 28

Preparation of 4-{5-[5-(4-carboxy-phenyl)-furan-2-ylmethylene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butylammonium trifluoroacetate (compound 41)

15 This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 10. Compound numbers correspond to the numbers in the figure.

20 The compound 4-{5-[3-(4-tert-butoxycarbonylamino-butyl)-4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl]-furan-2-yl}-benzoic acid (compound 39, 380 mg, 0.756 mmol) was dissolved in a mixture of dichloromethane (7 ml) and trifluoroacetic acid (3 ml) at room temperature. The reaction was stirred at room temperature for 1 hour, and then the volatiles were removed *in vacuo*. The residue was washed with ethyl acetate and then with ethyl ether on a fritted filter

25

funnel to give pure 4-{5-[5-(4-carboxy-phenyl)-furan-2-ylmethylene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyl-ammonium trifluoroacetate (compound 41, 147 mg, 38%).

EXAMPLE 29

5 **Preparation of 5-(4-{3-[3-(4-fluoro-phenyl)-5-oxo-1,5-dihydro-[1,2,4]triazol-4-yl]-propenyl}-phenyl)-furan-2-carbaldehyde (compound 44)**

10 This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 11. Compound numbers correspond to the numbers in the figure.

15 The compounds 4-allyl-5-(4-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one (compound 42, 500 mg, 2.28 mmol) and 5-(4-bromo-phenyl)-furfural were mixed in dioxane (10 ml), followed by the addition of diisopropylethylamine (0.795 ml, 4.56 mmol). Bis(tri-tert-butylphosphine) palladium (56 mg, 0.109 mmol) was added to the reaction mixture, which then was stirred at a temperature of 90°C for a period of 1 hour. Volatiles were removed in vacuo, and the residue was diluted in 0.2 N HCl solution, followed by extraction with ethyl acetate. Combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (gradient 7:3 to 9:1 ethyl acetate/hexanes + 0.5 % MeOH) to give 5-(4-{3-[3-(4-fluoro-phenyl)-5-oxo-1,5-dihydro-[1,2,4]triazol-4-yl]-

20

25

propenyl}-phenyl)-furan-2-carbaldehyde (compound 44, 375 mg, 42%).

¹H NMR (300 MHz, CDCl₃) δ 4.55 (d, J = 4.7, 2 H), 6.31 (td, J = 3.2, 16.0, 1H), 6.44 (d, J = 16.0, 1H), 6.84 (d, J = 3.7, 1H), 7.18 (dd, J = 8.5, J_{HF} = 8.5, 2H), 7.32 (d, J = 3.7, 1H), 7.40 (d, J = 8.3, 2H), 7.61 (dd, J = 8.5, J_{HF} = 5.2, 2H), 7.76 (d, J = 8.3, 2H), 9.64 (s, 1H), 10.56 (s, 1H); ¹³C NMR (300 MHz, CDCl₃) δ 43.8, 107.9, 116.3 (d, J_{CF} = 22), 123.2, 124.4, 125.6, 127.1, 128.7, 130.3 (d, J_{CF} = 9), 132.3, 137.1, 147.0, 152.2, 155.7, 158.9, 164.1 (d, J_{CF} = 250), 206.6; MS m/s 389.96 (M+1).

EXAMPLE 30

Preparation of 5-[5-(4-{3-[3-(4-fluoro-phenyl)-5-oxo-1,5-dihydro-[1,2,4]triazol-4-yl]-propenyl}-phenyl)-furan-2-ylmethylenel]-thiazolidine-2,4-dione (compound 45)

This example describes the synthesis of common ligand mimics of the invention containing a linker group following the reaction scheme shown in Figure 10. Compound numbers correspond to the numbers in the figure.

The compounds 5-(4-{3-[3-(4-fluoro-phenyl)-5-oxo-1,5-dihydro-[1,2,4]triazol-4-yl]-propenyl}-phenyl)-furan-2-carbaldehyde (compound 44, 70 mg, 0.181 mmol) and 2,4-thiazolidinedione (23 mg, 0.199 mmol) were mixed in ethanol (2 ml). Piperidine (0.20 ml) was added, and the reaction was stirred at 75°C for 2 hours, followed by

stirring at room temperature for an additional 18 hours.

The resulting yellow precipitate was collected on a
fritted filter funnel. The solid was washed with cold
ethanol and then with ethyl ether to give pure 5-[5-(4-
5 {3-[3-(4-fluoro-phenyl)-5-oxo-1,5-dihydro-[1,2,4]triazol-
4-yl]-propenyl}-phenyl)-furan-2-ylmethylene]-
thiazolidine-2,4-dione (compound 45, 10.6 mg, 12%).

¹H NMR (300 MHz, DMSO-*d*₆) δ 4.48 (bs, 2H), 6.35 (bs, 2H),
6.44 (d, *J* = 16.0, 1H), 7.21 (d, 1H), 7.27 (d, 1H), 7.32
10 (dd, *J* = 8.5, *J*_{HF} = 8.5, 2H), 7.53 (d, *J* = 8.3, 2H), 7.61
(s, 1H), 7.73 (m, 4H), 12.05 (s, 1H); ¹³C NMR (300 MHz,
DMSO-*d*₆) δ 43.8, 107.9, 116.3 (d, *J*_{CF} = 22), 123.2, 124.4,
125.6, 127.1, 128.7, 130.3 (d, *J*_{CF} = 9), 132.3, 137.1,
147.0, 152.2, 155.7, 158.9, 164.1 (d, *J*_{CF} = 250), 206.6;
15 MS *m/z* 389.96 (M+1).

EXAMPLE 31

Preparation of Bi-ligand Libraries of the present invention

This example provides a general procedure for
20 preparing bi-ligand libraries from common ligand mimics
of the invention according to the reaction scheme
presented in Figure 12a. Compound numbers correspond to
the numbers in the figure.

HOBt resin (40mg, 1.41mmol/g, Argonaut) was
25 swelled in a mixture of 150 μl dry THF and 50 μl of dry

DMF. The resin then was added to a solution of compound 21 (2eq, 0.226mmol) dissolved in a mixture of 153 μ l of dry DMF and 10eq, 0.564 mmol, of DIC (N,N'-diisopropylcarbodiimide). The solution was shaken at room temperature overnight and then washed three times with dry DMF and three times with dry THF.

The resin was added to a solution of the amine (0.4eq, 0.0226 mmol) dissolved in 200 μ l dry DMF. The mixture was again shaken at room temperature overnight. The resin was filtered and washed once with 500 μ l of dry DMF. The filtrate was collected and vacuum dried. Amines that have been used for the development of bi-ligand libraries of the invention using this reaction are provided in Table 1.

EXAMPLE 32

Preparation of Bi-ligand Libraries of the present invention

This example provides a general procedure for preparing bi-ligand libraries from common ligand mimics of the invention according to the reaction scheme presented in Figure 12b. Compound numbers correspond to the numbers in the figure.

HOBt resin (40mg; 1.41mmol/g, Argonaut) was swelled in 200 μ l dry THF. The resin (4eq, 0.226mmol) was added to a solution of carboxylic acid (1-

5 The resin was added to a solution of compound
23 (0.4eq, 0.0226 mmol) dissolved in 200 µl dry DMF. The
solution was again shaken at room temperature overnight.
The resin was filtered and washed once with 500 µl of dry
DMF. The filtrate was collected and vacuum dried.
10 Carboxylic acids that have been used for the development
of bi-ligand libraries of the invention using this
reaction are provided in Table 2.

Preparation of Bi-ligand Libraries of the present invention

Three equivalents of an isocyanate (0.070 ml, 0.49 M in DMSO) were added to a solution of compound 23 (4 mg, 0.0112 mmol) in 0.200 ml of DMSO. The reaction was allowed to proceed overnight. Then, 20 to 30 mg of aminomethylated polystyrene Resin (NovaBiochem, Cat. No.

01-64-0383) was added to the solution. The mixture was shaken for 4 hours at room temperature. The resin was filtered off, and the solution was dried under reduced pressure to yield the desired product. Isocyanates that have been used for the development of bi-ligand libraries of the invention using this reaction are provided in Table 3.

EXAMPLE 34

Preparation of Bi-ligand Libraries of the present invention

This example provides a general procedure for preparing bi-ligand libraries from common ligand mimics of the invention according to the reaction scheme presented in Figure 13. Compound numbers correspond to the numbers in the figure.

In a 10 ml vial, DBU (1,8-diazabicyclo [5.4.0]undec-7-ene (760 mg, 5 mmol) was added to a mixture of compound 26 (860 mg, 5 mmol) and compound 27 (7.5 mmol) in dioxane. The reaction mixture was agitated under microwave irradiation at a temperature of 170°C for a period of 40 minutes. The solvent was removed from the mixture, and the resultant oil residue was subjected to flash chromatography to provide desired compound 28 (65% yield).

Compound 28 (6.4 mmol) was suspended in a mixture of water (5 ml) and MeOH (15 ml). LiOH (307 mg, 12.8 mmol) was added, and the solution was refluxed for 2 hours. Solvent was removed from the reaction mixture, and the residue was dissolved in water. Dilute hydrochloric acid was added dropwise, forming a white precipitate that then was collected.

HOBt resin (20 mg, 1.41 mmol/g, Argonaut) was swelled in 100 μ l dry THF. The resin was added to a solution of compound 29 (2 eq, 0.056 mmol) dissolved in a mixture 100 μ l of dry DMF and 6 eq (0.168 mmol) of DIC. The solution was shaken at room temperature overnight and washed with 3x dry DMF and 2x dry THF.

The resin then was added to a solution of the amine (0.5 eq, 0.014 mmol), dissolved in 200 μ l dry DMF. The mixture was shaken at room temperature overnight. The resin was filtered and washed twice with 100 μ l of dry DMF to provide compound 30. The filtrate of compound 30 was collected and vacuum dried.

Compound 30 was dissolved in a mixture of TFA (trifluoroacetic acid) and dichloroethane (DCE, 50 %) and was shaken at room temperature for 20 minutes. Solvent was removed from the mixture, and the residue (compound 30) was ready for the next step reaction.

HOBt resin (20 mg; 1.41 mmol/g, Argonaut) was swelled in a mixture of 100 μ l dry THF and 100 μ l of dry

DMF. It was added to CLM 1 (2 eq, 0.056 mmol) dissolved in 200 μ l of dry DMF and 6 eq (0.168 mmol) of DIC. The solution was shaken at room temperature overnight and washed with 3x dry DMF and 3x dry THF.

5 The resin was then added to the residue of the deBoc reaction (compound 30), which was dissolved in 200 μ l dry THF. The mixture was shaken at room temperature overnight, and the resin was filtered and washed twice with 100 μ l of dry DMF. The filtrate, compound 31, was
10 collected and vacuum dried. Amines that have been used for the development of bi-ligand libraries of the invention using this reaction are provided in Table 4.

EXAMPLE 35

Preparation of Bi-ligand Libraries of the present 15 invention

This example provides a general procedure for preparing bi-ligand libraries from common ligand mimics of the invention according to the reaction scheme presented in Figure 14. Compound numbers correspond to
20 the numbers in the figure.

Et₃N resin (53 mg, 3.2 mmol/g, Fluka) was added to a mixture of 4-mercaptobenzoic acid (0.056 mmol, 8.6 mg) and alkyl bromide (0.067 mmol) in CH₃CN. The mixture was shaken at room temperature overnight, after which the

resin was filtered and washed twice with 100 μ l of CH_3CN . The filtrate was collected and vacuum dried.

5 HOBt resin (10 mg, 1.41mmol/g, Argonaut) was swelled in 100 μ l dry THF and was added to the residue of the last step reaction, which was dissolved in a mixture of 100 μ l of dry DMF and 6 eq (0.084 mmol) of DIC. The solution was shaken at room temperature overnight and washed with 3x dry DMF and 2x dry THF.

10 The resin then was added to CLM 4 (0.5 eq, 0.007 mmol) dissolved in 200 μ l dry DMF. The solution was shaken at room temperature overnight. The resin was filtered and washed twice with 100 μ l of dry DMF. The filtrate was collected and vacuum dried. Alkylhalides that have been used for the development of bi-ligand
15 libraries of the invention using this reaction are provided in Table 5.

EXAMPLE 36

Screening of Selected Thiazolidinediones for Binding to Dehydrogenases and Oxidoreductases

20 This example describes the screening of two thiazolidinedione common ligand mimics for binding activity to a variety of dehydrogenases and oxidoreductases.

The thiazolidinedione compounds 4-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid and 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoic acid were produced following the method of Examples 1 and 5. The compounds were screened for binding to the following enzymes: dihydrodipicolinate reductase (DHPR), lactate dehydrogenase (LDH), alcohol dehydrogenase (ADH), dihydrofolate reductase (DHFR), 1-deoxy-D-xylulose-5-phosphate reductase (DOXPR), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 3-isopropylmalate (IPMDH), inosine-5'-monophosphate dehydrogenase (IMPDH), aldose reductase (AR), and HMG CoA reductase (HMGCoAR).

DHPR

For DHPR analysis, the compounds were screened using a kinetic protocol that spectrophotometrically evaluates oxidation of NADPH.

Stock solutions of each of the reagents were prepared in the following concentrations. Dilutions of the stock solutions were prepared prior to running the assay in the concentrations indicated below. DHPR was diluted in 10 mM HEPES at a pH of 7.4. DHPS (dihydrodipicolinate synthase) was not diluted and was stored in eppendorf tubes.

	Stock	Final	Volume needed
ddH ₂ O			798 μ l
HEPES (pH 7.8)	1 M	0.1 M	100 μ l
Pyruvate	50 mM	1 mM	20 μ l
NADPH	1 mM	6 μ M	6 μ l
L-ASA	28.8 mM	40 μ M	13.9 μ l
DHPS	1 mg/ml		7 μ l
DHPR	1:1000 dilution of 1 mg/ml stock		5 μ l
Inhibitor	15 mM	100 μ M	6.7 μ l (0.67 DMSO)
DMSO	100%	5%	43.3 μ l
Total Assay volume = 1000 μ l			

The L-ASA (L-aspartate semialdehyde) solution
 was prepared in the following manner. 180 μ M stock
 solution of ASA was prepared. 100 μ l of the ASA stock
 5 solution was mixed with 150 μ l of concentrated NaHCO₃ and
 375 μ l of H₂O. For use in the assay, 28.8 mM L-ASA was
 equal to 625 μ l of the solution. The L-ASA stock
 solution was kept at a temperature of -20°C. After
 dilution, the pH of the 28.8 mM solution was checked and
 10 maintained between 1 and 2.

The DHPS reaction was monitored at 340 nm prior
 to and after addition of the inhibitor to detect
 background reaction with the inhibitor. The solution for
 background detection was a 945 μ l solution containing 0.1
 15 HEPES (pH 7.8), 1 mM pyruvate, 6 μ M NADPH, 40 μ M L-ASA,
 and 7 μ l of 1 mg/ml DHPS at 25°C in the volumes provided
 above. The sample solution was then mixed and incubated

20081999.022102

for 10 minutes. Next, 500 nM solutions of the inhibitors and enough DMSO to provide a final DMSO concentration of 5% of the total assay volume were added. The solution was mixed and incubated for an additional 6 minutes.

5 In DHPR samples, 5 μ l of the diluted DHPR enzyme were added. The sample was mixed for 20 seconds and then the reaction was run for 10 minutes. After a 50 second lag, the samples were read in a Cary spectrophotometer at 340 nm. Reading of the samples was
10 continued until 300 seconds. Cuvette #1 contained the control reaction (no inhibitor), and cuvette #2 contained the positive control reaction in which Cibacron Blue at 2.58 μ M was substituted for inhibitor to yield 70 to 80% inhibition. The substrate was kept at a level at least
15 10 times the K_m . The final concentration of L-ASA was about 1 mM.

LDH

For LDH analysis, the compounds were screened using a kinetic protocol that spectrophotometrically
20 evaluates oxidation of NADH.

Stock solutions of each of the reagents were prepared in the following concentrations. Dilutions of the stock solutions were prepared prior to running the assay in the concentrations indicated below.

	Stock	Final	Volume needed
ddH ₂ O			780 μ l
HEPES (pH 7.4)	1 M	0.1 M	100 μ l
Pyruvate	50 mM	2.5 mM	50 μ l
NADH	1 mM	10 μ M	10 μ l
LDH	1:2000 dilution of 1 mg/ml stock		10 μ l
Inhibitor	15 mM	100 μ M	6.7 μ l (0.67% DMSO)
DMSO	100%	5%	43.3 μ l
Total Assay volume = 1000 μ l			

The LDH reaction was monitored at 340 nm prior
 to and after addition of the inhibitor to detect
 background reaction with the inhibitor. Solutions of 100
 5 μ l of the inhibitors in DMSO were prepared to provide a
 final DMSO concentration of 5% of the total assay volume.
 These solutions were incubated for 6 minutes at 25°C in a
 990 μ l of a solution containing 0.1 M HEPES, pH 7.4, 10
 μ M NADH, and 2.5 mM of pyruvate. The reaction was then
 10 initiated with 10 μ l of LDH from Rabbit Muscle (0.5
 μ g/ml; 1:2000 dilution of 1.0 mg/ml). After the enzyme
 was added, the solution was mixed for 20 seconds, and the
 reaction was run for 10 minutes. After a 50 second lag,
 the samples were read in a Cary spectrophotometer at 340
 15 nm. Reading of the samples was continued until 300
 seconds. Cuvette #1 contained the control reaction (no
 inhibitor), and cuvette #2 contained the positive control
 reaction in which Cibacron Blue at 10.3 μ M was
 substituted for inhibitor to yield 50 to 70% inhibition.

The substrate was kept at a level at least 10 times the Km.

ADH

For ADH analysis, the compounds were screened using a kinetic protocol that spectrophotometrically evaluates reduction of NAD⁺.

Stock solutions of each of the reagents were prepared in the following concentrations. Dilutions of the stock solutions were prepared prior to running the assay in the concentrations indicated below.

	Stock	Final	Volume needed
DdH ₂ O			787 µl
HEPES (pH 8.0)	1 M	0.1 M	100 µl
EtOH	10 M	130 mM	13 µl
NAD ⁺	2 mM	80 µM	40 µl
ADH	1:400 dilution of 1 mg/ml stock		10 µl
Inhibitor	15 mM	100 µM	6.7 µl (0.67% DMSO)
DMSO	100%	5%	43.3 µl
Total Assay volume = 1000 µl			

The ADH reaction was monitored at 340 nm prior to and after addition of the inhibitor to detect background reaction with the inhibitor. Solutions of 100 µl of the inhibitors in DMSO were prepared to provide a final DMSO concentration of 5% of the total assay volume. These solutions were incubated for 6 minutes at 25°C in a

990 μ l of a solution containing 0.1 M HEPES, pH 8.0, 80 μ M NAD⁺, and 130 mM of ethanol. The reaction was then initiated with 10 μ l of ADH from Bakers Yeast (3.3 μ g/ml; 1:400 dilution of 1.0 mg/ml). After the enzyme was added, the solution was mixed for 20 seconds, and the reaction was run for 10 minutes. After a 50 second lag, the samples were read in a Cary spectrophotometer at 340 nm. Reading of the samples was continued until 300 seconds. Cuvette #1 contained the control reaction (no inhibitor), and cuvette #2 contained the positive control reaction in which Cibacron Blue at 15.5 μ M was substituted for inhibitor to yield 50 to 60% inhibition. The substrate was kept at a level at least 10 times the K_m . The final concentration of pyruvate was about 2.5 mM.

Where only a simple read was desired, as in the case of NAD⁺ concentration determination, 13 μ l (10 M stock) of ethanol was used to drive the reaction, and 10 μ l of pure enzyme (1 mg/ml) was used. NAD⁺ was soluble at 2 mM, which allowed the concentration determination step to be skipped. In this situation, the procedure was as follows. All of the ingredients except for the enzyme were mixed together. The solution was mixed well and the absorbance at 340 nm read. The enzyme was added and read again at OD 340 after the absorbance stopped changing, generally 10 to 15 minutes after the enzyme was added.

DHFR

For DHFR analysis, the compounds were screened using a kinetic protocol that spectrophotometrically evaluates oxidation of NADH.

5 Stock solutions of each of the reagents were prepared in the following concentrations. Dilutions of the stock solutions were prepared prior to running the assay in the concentrations indicated below. H₂ folate was dissolved in DMSO to about 10 mM and then diluted
10 with water to a concentration of 0.1 mM.

	Stock	Final	Volume needed
ddH ₂ O			616 µl
Tris-HCl (pH 7.0)	1 M	0.1 M	100 µl
KCl	1 mM	0.15 M	150 µl
H ₂ Folate	0.1 mM	5 µM	50 µl
NADPH	2 mM	52 µM	26 µl
DHFR	1:85 dilution of 4 mg/ml stock		8 µl
Inhibitor	15 mM	100 µM	6.7 µl (0.67% DMSO)
DMSO	100%	5%	43.3 µl
Total Assay volume = 1000 µl			

The DHFR reaction was monitored at 340 nm prior to and after addition of the inhibitor to detect background reaction with the inhibitor. Solutions of 100
15 µl of the inhibitors in DMSO were prepared to provide a final DMSO concentration of 5% of the total assay volume. These solutions were incubated for 6 minutes at 25°C in a 992 µl of a solution containing 0.1 M Tris-HCl, pH 7.0,

20081989, 022102

150 mM KCl, 5 μ M H₂ folate, and 52 μ M NADH. The
oxidation reaction was then initiated with 8 μ l of DHFR
(0.047 mg/ml). After the enzyme was added, the solution
was mixed for 20 seconds, and the reaction was run for 10
5 minutes. After a 50 second lag, the samples were read
in a **Cary** spectrophotometer at 340 nm. Reading of the
samples was continued until 300 seconds. Cuvette #1
always contained the control reaction (no inhibitor), and
cuvette #2 always contained the positive control reaction
10 in which Cibacron Blue at 3 μ M was substituted for
inhibitor to yield 50 to 70% inhibition. The substrate
was kept at a level at least 10 times the K_m.

DOXPR

For DOXPR analysis, the compounds were screened
15 using a kinetic protocol that spectrophotometrically
evaluates oxidation of NADPH.

Stock solutions of each of the reagents were
prepared in the following concentrations. Dilutions of
the stock solutions were prepared prior to running the
20 assay in the concentrations indicated below. DOXPR was
diluted in 10 mM HEPES at a pH of 7.4.

20081989-022102

	Stock	Final	Volume needed
ddH ₂ O			707 μ l
HEPES (pH 7.4)	1 M	0.1 M	100 μ l
DOXP	10 mM	1.15 mM	115 μ l
NADPH	1 mM	8 μ M	8 μ l
MnCl ₂	100 mM	1 mM	10 μ l
DOXPR	1:200 dilution of 2 mg/ml stock		10 μ l
Inhibitor	15 mM	100 μ M	6.7 μ l (0.67% DMSO)
DMSO	100%	5%	43.3 μ l
Total Assay volume = 1000 μ l			

The DOXPR reaction was monitored at 340 nm
 prior to and after addition of the inhibitor to detect
 background reaction with the inhibitor. Solutions of the
 5 inhibitors in DMSO were prepared to provide a final DMSO
 concentration of 5% of the total assay volume. These
 solutions were incubated for 6 minutes at 25°C in a 990
 μ l of a solution containing 0.1 M HEPES, pH 7.4, 1 mM
 MnCl₂, 1.15 mM DOXP, and 8 μ M NADPH. The oxidation
 10 reaction was then initiated with 10 μ l of DOXP
 reductoisomerase (10 μ g/ml). After the enzyme was added,
 the solution was mixed for 20 seconds, and the reaction
 was run for 10 minutes. After a 50 second lag, the
 samples were read in a Cary spectrophotometer at 340 nm.
 15 Reading of the samples was continued until 300 seconds.
 Cuvette #1 contained the control reaction (no inhibitor),
 and cuvette #2 contained the positive control reaction in
 which Cibacron Blue at 10.32 μ M was substituted for
 inhibitor to yield 70 to 80% inhibition. The substrate
 20 was kept at a level at least 10 times the Km.

GAPDH

For GAPDH analysis, the compounds were screened using a kinetic protocol that spectrophotometrically evaluates reduction of NAD⁺.

- 5 Stock solutions of each of the reagents were prepared in the following concentrations. Dilutions of the stock solutions were prepared prior to running the assay in the concentrations indicated below.

	Stock	Final	Volume needed
ddH ₂ O			739 µl
Triethanolamine (pH 7.5)	1 M	25 mM	125 µl
GAP	50 mM	145 µM	3 µl
NAD ⁺	5 mM	0.211 mM	42 µl
Sodium Arsenate	200 mM	5 mM	25 µl
2-BME	500 mM	3 mM	6 µl
GAPDH	1:200 dilution of 1 mg/ml stock		10 µl
Inhibitor	12.5 mM	100 µM	8 µl (total 5% DMSO)
DMSO	100%	5%	42 µl
Total Assay volume = 1000 µl			

- 10 The GAPDH reaction was monitored at 340 nm prior to and after addition of the inhibitor to detect background reaction with the inhibitor. Solutions of 100 µl of the inhibitors incubated for 6 minutes at 25°C in a 990 µl of a solution containing 125 mM triethanolamine,
- 15 pH 7.5, 145 µM glyceraldehyde 3-phosphate (GAP), 0.211 mM

NAD, 5 mM sodium arsenate, and 3mM β -metcaptoethanol (2-BME). The reaction was then initiated with 10 μ l of E. coli GAPDH (1:200 dilution of 1.0 mg/ml). After the enzyme was added, the solution was mixed for 20 seconds, and the reaction was run for 10 minutes. After a 50 second lag, the samples were read in a Cary spectrophotometer at 340 nm. Reading of the samples was continued until 300 seconds. The final concentration of DMSO in a cuvette was about 5% of the total assay volume. Cuvette #1 contained the control reaction (no inhibitor).

GAP for use in this experiment was deprotected from the diethyl acetal in the following manner. Water was boiled in recrystallizing dish. Dowex (1.5 mg) and GAP (200 mg; SIGMA G-5376) were weighed and placed in a 15 ml conical tube. The Dowex and GAP were resuspended in 2 ml dH₂O, followed by shaking of the tube until the GAP dissolved. The tube was then immersed, while shaking, in the boiling water for 3 minutes. Next, the tube was placed in an ice bath to cool for 5 minutes. As the sample cooled, a resin settled to the bottom of the test tube, allowing removal of the supernatant with a pasteur pipette. The supernatant was filtered through a 0.45 or 0.2 μ M cellulose acetate syringe filter.

The filtered supernatant was retained, and another 1 ml of dH₂O was added to the resin tube. The tube was then shaken and centrifuged for 5 minutes at 3,000 rpm. The supernatant was again removed with a pasteur pipette and passed through a 0.45 or 0.2 μ M

cellulose acetate syringe filter. The two supernatant aliquots were then pooled to provide a total GAP concentration of about 50 mM. The GAP was then divided into 100 μ l aliquots and stored at -20°C until use.

5 IMPDH

For IMPDH analysis, the compounds were screened using a kinetic protocol that spectrophotometrically evaluates reduction of NAD^{+} .

10 Stock solutions of each of the reagents were prepared in the following concentrations. Dilutions of the stock solutions were prepared prior to running the assay in the concentrations indicated below.

	Stock	Final	Volume needed
ddH ₂ O			447 μ l
Tris-HCl (pH 8.0)	1 M	0.1 M	100 μ l
KCl	1 M	0.25 M	250 μ l
NAD ⁺	2 mM	30 μ M	15 μ l
IMP	6 mM	600 μ M	100 μ l
Glycerol	10%	0.3%	30 μ l
IMPDH	0.75 mg/ml, undiluted		8 μ l
Inhibitor	15 mM	100 μ M	6.7 μ l (0.67% DMSO)
DMSO	100%	5%	43.3 μ l
Total Assay volume = 1000 μ l			

15 The IMPDH reaction was monitored at 340 nm prior to and after addition of the inhibitor to detect background reaction with the inhibitor. Solutions of 100

10081989-023102

10081989.022102
5 μ l of the inhibitors in DMSO were prepared to provide a final DMSO concentration of 5% of the total assay volume. These solutions were incubated for 6 minutes at 37°C in a 992 μ l of a solution containing 0.1 M Tris-HCl, pH 8.0, 0.25 M KCl, 0.3% glycerol, 30 μ M NAD⁺, and 600 μ M IMP (inosine monophosphate). The reaction was then initiated with 8 μ l of IMPDH (0.75 μ g/ml). After the enzyme was added, the solution was mixed for 20 seconds, and the reaction was run for 10 minutes. After a 50 second lag, 10 the samples were read in a Cary spectrophotometer at 340 nm. Reading of the samples was continued until 300 seconds. Cuvette #1 contained the control reaction (no inhibitor), and cuvette #2 contained the positive control reaction in which Cibacron Blue was substituted for 15 inhibitor. The substrate was kept at a level at least 10 times the K_m .

HMGCoAR

For HMGCoAR analysis, the compounds were screened using a kinetic protocol that 20 spectrophotometrically evaluates oxidation of NADPH.

Stock solutions of each of the reagents were prepared in the following concentrations. Dilutions of the stock solutions were prepared prior to running the assay in the concentrations indicated below. The enzyme 25 was diluted in 1 M NaCl. To prepare the dilution buffer, 10 μ l of HMGCoAR (1 mg/ml) was mixed with 133 μ l of 3 M NaCl solution and 257 μ l of 25 mM KH₂PO₄ buffer (pH 7.5;

containing 50 mM NaCl, μ l mM EDTA
(ethylenediaminetetraacetic acid), and 5 mM DTT
(dithiothreitol).

	Stock	Final	Volume needed
ddH ₂ O			841 μ l
KH ₂ PO ₄ (pH 7.5)	1 M	25 mM	25 μ l
HMGCoA	10 mM	160 mM	16 μ l
NADPH	1 mM	13 μ M	13 μ l
NaCl	1 M	50 mM	50 μ l
EDTA	50 mM	1 mM	20 μ l
DTT	500 mM	5 mM	10 μ l
HMGCoAR	1:40 dilution of 0.65 mg/ml stock		5 μ l
Inhibitor	10 mM	100 μ M	10 μ l
DMSO	100%	2%	10 μ l
Total Assay volume = 1000 μ l			

- 5 The HMGCoAR reaction was monitored at 340 nm
prior to and after addition of the inhibitor to detect
background reaction with the inhibitor. Solutions of 500
nM of the inhibitors in DMSO were prepared to provide a
final DMSO concentration of 2% of the total assay volume.
- 10 These solutions were incubated for 6 minutes at 25°C in a
994 μ l of a solution containing 25 mM KH₂PO₄, pH 7.5, 160
 μ M HMGCoA, 13 μ M NADPH, 50 mM NaCl, 1 mM EDTA, and 5mM
DTT. The reaction was then initiated with 5 μ l of
HMGCoAR enzyme (1:40 dilution of 0.65 mg/ml). After the
- 15 enzyme was added, the solution was mixed for 20 seconds,
and the reaction was run for 10 minutes. After a 50
second lag, the samples were read in a Cary
spectrophotometer at 340 nm. Reading of the samples was

continued until 300 seconds. Cuvette #1 contained the control reaction (no inhibitor), and cuvette #2 contained the positive control reaction in which Cibacron Blue at 2.05 μM was substituted for inhibitor to yield 50 to 70% inhibition. The substrate was kept at a level at least 10 times the K_m .

IPMDH

For IPMDH analysis, the compounds were screened using a kinetic protocol that spectrophotometrically evaluates reduction of NAD.

Stock solutions of each of the reagents were prepared in the following concentrations. Dilutions of the stock solutions were prepared prior to running the assay in the concentrations indicated below.

	Stock	Final	Volume needed
ddH ₂ O			407 μl
KH ₂ PO ₄ (pH 7.6)	1 M	20 mM	20 μl
KCl	1 M	0.3 M	300 μl
MNCl ₂	20 mM	0.2 mM	10 μl
NAD	3.3 mM	109 μM	33 μl
IPM	2 mM	340 μM	170 μl
E. coli IPMDH	1:300 dilution of 2.57 mg/ml stock		10 μl
Inhibitor	16 mM	200 μM	12.5 μl
DMSO	100%	5%	37.5 μl
15	Total Assay volume = 1000 μl		

20130909 09:40

10081989-022102

The IPMDH reaction was monitored at 340 nm prior to and after addition of the inhibitor to detect background reaction with the inhibitor. Inhibitor was incubated for 5 minutes at 37°C in a 990 µl of a solution containing 20 mM potassium phosphate, pH 7.6, 0.3 M potassium chloride, 0.2 mM manganese chloride, 109 µM NAD, and 340 µM DL-threo-3-isopropylmalic acid (IPM). The reaction was then initiated with 10 µl of E. coli isopropylmalate dehydrogenase (1:300 dilution of 2.57 mg/ml). After the enzyme was added, the solution was mixed for 20 seconds, and the reaction was run for 10 minutes. After a 50 second lag, the samples were read in a Cary spectrophotometer at 340 nm. Reading of the samples was continued until 300 seconds. The final concentration of DMSO in the cuvette was 5% of the total assay volume. Cuvette #1 contained the control reaction (no inhibitor), and cuvette #2 contained the positive control reaction in which Cibacron Blue was substituted for inhibitor to yield 30 to 70% inhibition. The substrate was kept at a level at least 10 times the Km.

AR

For AR analysis, the compounds were screened using a kinetic protocol that spectrophotometrically measures enzyme activity.

25 Stock solutions of each of the reagents were prepared in the following concentrations. Dilutions of

the stock solutions were prepared prior to running the assay in the concentrations indicated below.

	Stock	Final	Volume needed
ddH ₂ O			565.5 μ l
KH ₂ PO ₄ (pH 7.5)	1 M	100 mM	100 μ l
Ammonium Sulfate	1 M	0.3 M	300 μ l
EDTA	500 mM	1 mM	2 μ l
NADPH	1 mM	3.8 μ M	3.8 μ l
Glyceraldehyde	100 mM	171 μ M	1.7 μ l
DTT	100 mM	0.1 mM	1 μ l
Human ALDR	1:5 dilution of 0.55 mg/ml stock		10 μ l
Inhibitor	12.5 mM	200 μ M	16 μ l
Total Assay volume = 1000 μ l			

5 The AR reaction was monitored at 340 nm prior to and after addition of the inhibitor to detect background reaction with the inhibitor. Solutions of 100 μ l of the inhibitors in DMSO were prepared to provide a final DMSO concentration of 5% of the total assay volume. These solutions were incubated for 5 minutes at 25°C in a

10 990 μ l of a solution containing 100 mM potassium phosphate, pH 7.5, 0.3 M ammonium sulfate, 1.0 mM ethylenediaminetetraacetic acid (EDTA), 3.8 μ M B-Nicotinamide adenine dinucleotide phosphate (NADPH), 171 μ M DL-glyceraldehyde and 0.1 mM DL-dithiothreitol. The

15 reaction was then initiated with 10 μ l of Human Aldose Reductase (1:5 dilution of 0.55 mg/ml). After the enzyme was added, the solution was mixed for 20 seconds, and the reaction was run for 10 minutes. After a 50 second lag, the samples were read in a Cary spectrophotometer at 340

nm. Reading of the samples was continued until 300 seconds. The final DMSO concentration in the cuvette was 5%. Cuvette #1 contained the control reaction (no inhibitor), and cuvette #2 contained the positive control reaction in which Cibacron Blue was substituted for inhibitor to yield 30 to 70% inhibition. The substrate was kept at a level at least 10 times the K_m .

IC₅₀ data for these compounds are presented in Figure 16. The compound 4-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (compound 5a) exhibited IC₅₀ values of 116 μ M for ADH, 49.3 μ M for HMGC_oAR, and 2.26 μ M for AR, respectively. The IC₅₀ values for DHPR, DOXPR, GAPDH, and IMPDH were greater than 200 μ M, and the IC₅₀ value for DHFR was greater than 75 μ M.

The compound 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoic acid (compound 5e) exhibited IC₅₀ values of 46 μ M for LDH, 21 μ M for ADH, 2.15 μ M for IMPDH, and 245 nM for HMGC_oAR, respectively. The IC₅₀ values for DHPR and GAPDH were greater than 200 μ M. The IC₅₀ value for DOXPR was greater than 100 μ M, while the IC₅₀ value for IPMDH was greater than 50 μ M. No inhibition of AR was seen.

EXAMPLE 37

**Screening of Selected Thiazolidinediones and Rhodanines
for Binding to Dehydrogenases and Oxidoreductases**

5 This example describes the screening of
thiazolidinedione and rhodanine common ligand mimics for
binding activity to a variety of dehydrogenases and
oxidoreductases.

10 The following compounds were produced by the
methods of Examples 1, 5, 2, and 12, respectively: 4-[5-
(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-
benzoic acid; 5-[5-(2,4-dioxo-thiazolidin-5-
ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoic acid; 3-[5-
(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-
benzoic acid; 2-hydroxy-5-[5-(4-oxo-2-thioxo-thiazolidin-
15 5-ylidenemethyl)-furan-2-yl]-benzoic acid. The compounds
were screened for binding to the following enzymes: HMG
CoA reductase (HMGCoAR), inosine-5'-monophosphate
dehydrogenase (IMPDH), 1-deoxy-D-xylulose-5-phosphate
reductase (DOXPR), dihydrodipicolinate reductase (DHPR),
20 dihydrofolate reductase (DHFR), 3-isopropylmalate
(IPMDH), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), aldose reductase (AR), alcohol dehydrogenase
(ADH), and lactate dehydrogenase (LDH). The assay
procedures employed were those described in Example 36.

25 IC₅₀ data for these compounds are presented in
Figure 17. The compound 4-[5-(2,4-dioxo-thiazolidin-5-
ylidenemethyl)-furan-2-yl]-benzoic acid exhibited IC₅₀

values of 1.75 μM for HMGCAR, 4.1 μM for AR, 52.2 μM for DOXPR, 58.8 μM for IMPDH, and 140 μM for ADH, respectively. The IC_{50} values for GAPDH, DHPR, and IPMDH were greater than 100 μM , greater than 150 μM , and greater than 200 μM , respectively. No inhibition of DHFR was seen.

No inhibition of DHFR or AR was seen with 5-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-2-hydroxy-benzoic acid. However, the compound exhibited IC_{50} values of 245 μM for HMGCAR, 2.15 μM for IMPDH, 21 μM for ADH, and 46 μM for LDH, respectively. The IC_{50} values for DHPR and GAPDH were greater than 200 μM , and the IC_{50} value for IPMDH was greater than 50 μM .

No inhibition of IMPDH seen with 3-[5-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid. The IC_{50} values for HMGCAR, DOXPR, DHPR, DHFR, and GAPDH with this compound were greater than 400 μM .

The compound 2-hydroxy-5-[5-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid exhibited IC_{50} values of 143 nM for HMGCAR, 340 nM for LDH, 1.6 μM for DOXPR, 2.1 μM for DHPR, 3.4 μM for ADH, and 4.3 μM for DHFR, respectively.

EXAMPLE 38

Screening of Biligands for Binding to Dihydrodipicolinate
Reductase (DHPR)

5 This example describes the screening of bi-
ligands having thiazolidinedione or rhodanine common
ligand mimics for binding activity to dihydrodipicolinate
reductase (DHPR).

10 Bi-ligands were produced by the methods of
Examples 14 to 18. The bi-ligands were screened for
binding to E. coli DHPR. The bi-ligands were screened
using a kinetic protocol that spectrophotometrically
evaluates oxidation of NADPH.

15 Stock solutions of each of the reagents were
prepared in the following concentrations. Dilutions of
the stock solutions were prepared prior to running the
assay in the concentrations indicated below. Dilution of
DHPR was prepared in 10 mM HEPES at a pH of 7.4. DHPS
was not diluted and was stored in eppendorf tubes.

20081969.022102

	Stock	Final	Volume needed
ddH ₂ O			798 μ l
HEPES (pH 7.8)	1 M	0.1 M	100 μ l
Pyruvate	50 mM	1 mM	20 μ l
NADPH	1 mM	6 μ M	6 μ l
L-ASA	28.8 mM	40 μ M	13.9 μ l
DHPS	1 mg/ml		7 μ l
DHPR	1:1000 dilution of 1 mg/ml stock		5 μ l
Inhibitor	10 μ M	500 nM	50 μ l
DMSO	100%	5%	0 μ l
Total Assay volume = 1000 μ l			

5 The L-ASA solution was prepared in the following manner. 180 μ M stock solution of ASA was prepared. 100 μ l of the ASA stock was mixed with 150 μ l of concentrated NaHCO₃ and 375 μ l of H₂O. For use in the assay, 28.8 mM L-ASA equal 625 μ l of the solution. The L-ASA stock solution was kept at a temperature of -20°C. After dilution, the pH of the 28.8 mM solution was checked and maintained between 1 and 2.

10 First, the DHPS reaction was monitored at 340 nm prior to and after addition of the inhibitor to detect background reaction with the inhibitor. The solution for background detection was a 945 μ l solution containing 0.1 HEPES (pH 7.8), 1 mM pyruvate, 6 μ M NADPH, 40 μ M L-ASA, and 7 μ l of 1 mg/ml DHPS at 25°C in the volumes provided
15 above. The sample solution was then mixed and incubated for 10 minutes. Next, 500 nM solutions of the inhibitors

and enough DMSO to provide a final DMSO concentration of 5% of the total assay volume were added. The solution was mixed and incubated for an additional 6 minutes.

In DHPR samples, 5 μ l of the diluted DHPR enzyme were added. The sample was mixed for 20 seconds and then the reaction was run for 10 minutes. After a 50 second lag, the samples were read in Cary spectrophotometer at 340 nm. Reading of the samples was continued until 300 seconds. Cuvette #1 contained the control reaction (no inhibitor), and cuvette #2 contained the positive control reaction in which Cibacron Blue at 2.58 μ M was substituted for inhibitor to yield 70 to 80% inhibition. The substrate and NADPH or NAHD were kept near their K_m values.

IC_{50} data for these compounds are presented in Figure 18. The rhodanine and thiazolidinedione derivative bi-ligands 13a, 13b, 13c, 13d and 13f exhibited IC_{50} values for dihydrodipicolinate reductase (DHPR) of about 0.536 μ M, 7.1 μ M, 13 μ M, 0.254 μ M, and 4.91 μ M respectively.